

Champion Health Plan of California

Formulario 2024 (Lista de medicamentos cubiertos)

POR FAVOR, LEA: ESTE DOCUMENTO CONTIENE INFORMACIÓN
ACERCA DE LOS MEDICAMENTOS QUE CUBRIMOS EN ESTE PLAN

Formulario 00024131, número de versión 19

Este formulario se actualizó el 12/01/2024. Para obtener información más reciente o si tiene pregunta, comuníquese con Servicios para Miembros de Champion Health Plan al 1-844-282-5341 (los usuarios de TTY deben llamar al 711), de 8:00 a. m. a 8:00 p. m., los 7 días de la semana, desde el 1 de octubre hasta el 31 de marzo. Desde el 1 de abril hasta el 30 de septiembre, el horario es de 8:00 a. m. a 8:00 p. m., de lunes a Viernes (los mensajes recibidos en días festivos y fuera del horario de atención se responderán en el plazo de un día hábil). También puede visitar www.championhmo.com.

Nota a los miembros existentes: Esta lista de medicamentos es diferente al del año anterior. Por favor revise este documento para asegurarse de que todavía contenga los medicamentos que usted toma.

Cuando esta lista de medicamentos (formulario) se refiere a “nosotros” o a “nuestro”, se estará refiriendo a Champion. Cuando se refiere al “plan” o a “nuestro plan”, significa Champion.

Este documento incluye una lista de los medicamentos (formulario) de nuestro plan, que entrará en vigencia el 12/01/2024. Para obtener un formulario actualizado, por favor póngase en contacto con nosotros. Nuestra información de contacto, junto con la fecha en la que se actualizó el formulario por última vez, aparecen en la portada y contraportada.

De forma general debe usar las farmacias de la red para utilizar su beneficio de medicamentos controlados. Los beneficios, el formulario, la red de farmacias, y/o los copagos/coaseguros pueden cambiar el 12/01/2024, y

también de vez en cuando durante el año.

¿Qué es el Formulario de Champion?

Un formulario es una lista de medicamentos seleccionados que están cubiertos por Champion en consulta con un equipo de proveedores de atención médica, que representa los medicamentos controlados que se cree son una parte necesaria de un programa de tratamiento de calidad. Por lo general, Champion cubrirá los medicamentos descritos en nuestro formulario siempre que el medicamento sea médicamente necesario, y la receta se surta en una farmacia de la red y se cumplan otras reglas del plan. Para obtener más información sobre cómo surtir sus recetas, favor de revisar la Evidencia de Cobertura.

¿Puede cambiar el formulario (la lista de medicamentos)?

La mayoría de los cambios en la cobertura de medicamentos ocurren el 1 de enero, pero Champion puede agregar o eliminar medicamentos de la Lista de medicamentos durante el año, moverlos a diferentes niveles de costo compartido o agregar nuevas restricciones. Debemos seguir las reglas de Medicare al hacer estos cambios.

Cambios que pueden afectarlo este año: En los siguientes casos, usted se verá afectado por cambios de cobertura durante el año:

- **Nuevos medicamentos genéricos.** Podemos eliminar inmediatamente un medicamento de marca de nuestra Lista de medicamentos si lo reemplazamos por un nuevo medicamento genérico que aparecerá en el mismo nivel de costo compartido o en un nivel más bajo y con las mismas o menos restricciones. Además, cuando agregamos el nuevo medicamento genérico, podemos decidir mantener el medicamento de marca en nuestra Lista de medicamentos, pero inmediatamente lo movemos a otro nivel de costo compartido o agregamos nuevas restricciones. Si actualmente toma el medicamento de marca, es posible que no le informemos con anticipación antes de hacer ese cambio, pero posteriormente le proporcionaremos información sobre los cambios específicos que hayamos hecho.
 - Si hacemos dicho cambio, usted o su recetador pueden solicitarnos que hagamos una excepción y que continuemos cubriendo el medicamento de marca para usted. El aviso que le proporcionamos también incluye información sobre cómo solicitar una excepción, y puede encontrar información en la siguiente sección titulada “¿Cómo solicito una excepción al Formulario de Champion?”

Medicamentos retirados del mercado. Si la Administración de Alimentos y Medicamentos (FDA por sus siglas en inglés) considera que alguno de los medicamento de nuestro formulario es inseguro o si el fabricante del mismo lo retira del mercado, inmediatamente retiraremos el medicamento de nuestro formulario y daremos aviso a los miembros que toman dicho medicamento.

- **Otros cambios.** Podríamos hacer otros cambios que afecten a los miembros que actualmente toman un medicamento. Por ejemplo, podemos agregar un nuevo medicamento genérico para reemplazar un medicamento de marca que se encuentra actualmente en el formulario o agregar nuevas restricciones al medicamento de marca o moverlo a otro nivel de costo compartido, o las dos cosas. O bien, podemos hacer cambios con base en nuevos lineamientos clínicos. Si quitamos medicamentos de nuestro formulario [o] agregamos una autorización previa, o límites de cantidad y/o restricciones de tratamiento por pasos de algún medicamento o si movemos un medicamento a un nivel más alto de costo compartido, debemos notificarle a los miembros afectados sobre dicho cambio al menos 30 días

antes de que el cambio sea efectivo, o en el momento en que el miembro solicite una reposición del medicamento, en cuyo caso el miembro recibirá un suministro de 30 días del medicamento.

- Si hacemos estos u otros cambios, usted o su recetador pueden solicitarnos que hagamos una excepción y que continuemos cubriendo el medicamento de marca para usted. El aviso que le proporcionamos también incluye información sobre cómo solicitar una excepción, y también puede encontrar información en la siguiente sección titulada “¿Cómo solicito una excepción al Formulario de Champion?”

Cambios que no lo afectarán si toma actualmente el medicamento. Por lo general, si está tomando un medicamento de nuestro formulario 2024 que estaba cubierto a principios de año, no interrumpiremos ni reduciremos la cobertura del medicamento durante el año de cobertura 2024, excepto en las condiciones descritas anteriormente. Esto significa que estos medicamentos permanecerán disponibles al mismo costo compartido y sin nuevas restricciones para aquellos miembros que los toman por el resto del año de cobertura. No recibirá una notificación directa este año sobre los cambios que no le afecten. Sin embargo, el 1 de enero del próximo año, dichos cambios le afectarán y es importante que revise la Lista de medicamentos para el nuevo año de beneficios para conocer cualquier cambio en los medicamentos.

El formulario adjunto está actualizado a partir del 12/01/2024. Para obtener información actualizada acerca de los medicamentos cubiertos por Champion, póngase en contacto con nosotros. Nuestra información de contacto aparece en la portada y contraportada.

¿Cómo puedo utilizar el formulario?

Existen dos maneras de encontrar su medicamento dentro del formulario:

Padecimiento médico

El formulario comienza en la página 1. Los medicamentos de este formulario se agrupan en categorías según el tipo de padecimiento médico que tratan. Por ejemplo, los medicamentos utilizados para tratar una afección del corazón aparecen bajo la categoría de Agentes cardiovasculares. Si sabe para qué se utiliza su medicamento, busque el nombre de la categoría en la lista que comienza en la página 1. Luego, busque en la categoría el nombre de su medicamento.

Lista alfabética

Si no está seguro de en qué categoría buscar, busque su medicamento en el Índice. El índice proporciona una lista alfabética de todos los medicamentos incluidos en este documento. Ambos medicamentos, tanto de marca como genéricos, están enlistados en el índice. Busque en el Índice y encuentre su medicamento. Al lado de su medicamento, verá el número de la página donde podrá encontrar la información de cobertura. Vaya a la página que aparece en el Índice y encuentre el nombre de su medicamento en la primera columna de la lista.

¿Qué son los medicamentos genéricos?

Champion cubre medicamentos de marca y medicamentos genéricos. Un medicamento genérico está aprobado por la Administración de Alimentos y Medicamentos (FDA por sus siglas en inglés), ya que contiene el mismo ingrediente activo que el medicamento de marca. Por lo general, los medicamentos genéricos cuestan menos que los medicamentos de marca.

¿Existen restricciones en mi cobertura?

Algunos medicamentos cubiertos pueden tener requisitos adicionales o límites de cobertura. Estos requisitos y límites pueden incluir:

- **Autorización previa:** Champion requiere que usted [o su médico] obtenga una autorización previa para ciertos medicamentos. Esto significa que deberá obtener la aprobación de Champion antes de surtir sus recetas. Si no obtiene la aprobación, Champion podría no cubrir el medicamento.
- **Límites de cantidad:** Para ciertos medicamentos, Champion limita la cantidad del medicamento que Champion cubrirá. Por ejemplo, nuestro Plan proporciona 18 comprimidos de succinato de sumatriptán oral por receta para 28 días. Esto puede ser adicional al suministro estándar para un mes o tres meses.
- **Tratamiento por pasos:** En algunos casos, Champion requiere que primero pruebe ciertos medicamentos para tratar su afección médica antes de cubrir otro medicamento para dicha afección. Por ejemplo, si tanto el medicamento A como el medicamento B tratan su afección médica, Champion podría no cubrir el medicamento B a menos que primero pruebe el medicamento A. Si el medicamento A no funciona para usted, Champion cubrirá el medicamento B.

Para averiguar si su medicamento tiene requisitos o límites adicionales, revise el formulario que comienza en la página 1. También puede obtener más información sobre las restricciones que se aplican a medicamentos específicos cubiertos si visita nuestro sitio web. Hemos publicado documentos en línea que explican nuestras restricciones en cuanto a autorizaciones previas y tratamiento por pasos. También puede solicitar que le enviemos una copia. Nuestra información de contacto, junto con la fecha en la que se actualizó el formulario por última vez, aparecen en la portada y contraportada.

Puede solicitarle a Champion una excepción a estas restricciones o límites, o una lista de otros medicamentos similares, que pudieran tratar la misma afección médica. Consulte la sección "¿Cómo solicito una excepción al Formulario de Champion?" en la página 1 para obtener información sobre cómo solicitar una excepción.

¿Qué sucede si mi medicamento no está en el Formulario?

Si su medicamento no está incluido en este formulario (lista de medicamentos cubiertos), primero debe comunicarse con el Servicio a Miembros y preguntar si su medicamento está cubierto. Para obtener más información, comuníquese con nosotros. Nuestra información de contacto, junto con la fecha en la que se actualizó el formulario por última vez, aparecen en la portada y contraportada.

Si Champion no cubre su medicamento, usted tiene dos opciones:

- Puede solicitar a Servicio a Miembros una lista de medicamentos similares que estén cubiertos por Champion. Cuando usted reciba la lista, muéstresela a su médico y pídale que le recete un medicamento similar que esté cubierto por Champion.
- Usted puede solicitarle a Champion que haga una excepción y cubra su medicamento. Consulte lo siguiente para obtener información sobre cómo solicitar una excepción.

¿Cómo solicito una excepción al formulario de Champion?

Usted puede solicitarle a Champion que haga una excepción a nuestras reglas de cobertura. Existen varios tipos de excepciones que puede solicitarnos.

- Puede pedirnos que cubramos un medicamento incluso si no está en nuestro formulario. Si se aprueba, este medicamento estará cubierto a un nivel predeterminado de costo compartido, y usted no podría pedirnos que suministremos el medicamento a un nivel inferior de costo compartido.
- Puede pedirnos que cubramos un medicamento del formulario a un nivel inferior de costo compartido, a menos que el medicamento esté en el nivel de especialidades. Si se aprueba, esto disminuiría la cantidad que usted debe pagar por su medicamento.
- Puede solicitarnos que exoneremos las restricciones de cobertura o los límites de su medicamento. Por ejemplo, para algunos medicamentos, Champion limita la cantidad del medicamento que cubriremos. Si su medicamento tiene un límite de cantidad, puede solicitarnos que exoneremos el límite y cubramos una cantidad mayor.

Por lo general, Champion solo aprobará su solicitud de excepción si los medicamentos alternativos incluidos en el formulario del plan, el medicamento de costo compartido inferior o las restricciones adicionales de uso pudieran no ser tan efectivos para tratar su afección o pudieran provocarle efectos médicos adversos.

Debe contactarnos para solicitarnos una decisión inicial de cobertura con respecto a alguna excepción del formulario o restricción de uso. **Cuando solicite alguna excepción al formulario o a alguna restricción de uso, deberá ingresar una declaración de quién se lo haya recetado o de su médico quien apoya su solicitud.** Por lo general, debemos emitir una decisión dentro de las siguientes 72 horas a partir de recibir la declaración de apoyo de su médico. Puede solicitar una excepción expedita (rápida) si usted o su médico consideran que su salud podría verse seriamente comprometida si espera hasta 72 horas para obtener una decisión. Si se autoriza su solicitud expedita, debemos proporcionarle una decisión a más tardar 24 horas después de haber recibido la declaración de apoyo de su médico u otra persona autorizada para recetar.

Qué debo hacer antes de que pueda hablar con mi médico sobre un cambio en mis medicamentos o de solicitar una excepción?

Como un miembro nuevo o uno que continúa en nuestro plan, es posible que esté tomando medicamentos que no se encuentren en nuestro formulario. O bien, es posible que esté tomando un medicamento que no esté en nuestro formulario, pero su capacidad para obtenerlo sea limitada. Por ejemplo, puede ser que necesite una autorización previa de nuestra parte antes de poder surtir su receta médica. Usted deberá hablar con su médico para decidir si deben cambiar a un medicamento apropiado que sí cubramos o solicitar una excepción al formulario para que cubramos el medicamento que toma. En el transcurso antes de hablar con su médico para determinar el curso correcto de acción para usted, podemos cubrir su medicamento en ciertos casos durante los primeros 90 días a partir de que se afilie a nuestro plan.

Para cada uno de sus medicamentos que no estén incluidos en nuestro formulario, o si su capacidad de obtener los medicamentos es limitada, cubriremos un suministro temporal para 30 días. Si su receta está escrita para menos días, permitiremos resurtidos para proporcionar hasta un suministro máximo para 30 días del medicamento. Después de su primer suministro de 30 días, no pagaremos por dichos medicamentos, incluso si usted lleva menos de 90 días siendo miembro del plan.

Si usted es residente de un centro de cuidados a largo plazo y necesita un medicamento que no esté incluido en nuestro formulario, o si su capacidad de obtener los medicamentos es limitada, pero usted lleva más de 90 días afiliado a nuestro plan, cubriremos un suministro de emergencia de 31 días de ese medicamento mientras tramita una excepción al formulario.

Los miembros que cambian de lugar de tratamiento debido a cambios en el nivel de atención también se consideran en transición. Estos miembros recibirán un resurtido de transición adecuado.

Para obtener más información

Para obtener información más detallada acerca de su cobertura de medicamentos controlados por Champion, consulte su Evidencia de Cobertura y otros materiales del plan.

Si tiene preguntas sobre Champion, comuníquese con nosotros. Nuestra información de contacto, junto con la fecha en la que se actualizó el formulario por última vez, aparecen en la portada y contraportada.

Si tiene preguntas generales sobre la cobertura de medicamentos controlados por Medicare, llame a Medicare al 1-800-MEDICARE (1-800-633-4227) 24 horas del día / 7 días de la semana. Los usuarios de TTY deben llamar al 1-877-486-2048. O visite <http://www.medicare.gov>.

Formulario de Champion

El formulario proporciona información de cobertura sobre los medicamentos cubiertos por Champion. Si tiene problemas para encontrar su medicamento en la lista, consulte el Índice que comienza en la página 107.

La primera columna del cuadro muestra el nombre del medicamento. Los medicamentos de marca están en mayúsculas (por ej., HUMIRA) y los medicamentos genéricos están escritos en minúsculas en bastarda (p. ej., *atorvastatina*).

La información en la columna de Requisitos/Límites indica si Champion tiene algún requisito especial para la cobertura de su medicamento. La siguiente es una lista de abreviaturas que pueden aparecer en las siguientes páginas en la columna de Requisitos/Límites para indicarle si su medicamento está sujeto a algún requisito especial de cobertura.

Lista de Abreviaciones

B/D PA: Este medicamento recetado podría estar cubierto bajo Medicare Parte B o Parte D, dependiendo de las circunstancias. Puede ser necesario que se presente información que describa la utilización y las circunstancias en las que se administrará el medicamento, para que se pueda tomar una determinación.

EX: Medicamento excluido. Este medicamento recetado no se cubre normalmente bajo un plan de medicamentos recetados Medicare. La cantidad que usted paga cuando se surte una receta de este medicamento no se imputa al costo total de sus medicamentos (es decir, la cantidad que pague no le ayudará a calificar para recibir cobertura catastrófica). Además, si recibe asistencia suplementaria para pagar sus medicamentos recetados, no recibirá asistencia suplementaria para pagar este medicamento.

GC: Cobertura durante la Falta de cobertura. Cubrimos este medicamento recetado durante la etapa de Falta de cobertura. Consulte nuestro Folleto explicativo de la cobertura (EOC), para obtener más información acerca de esta cobertura.

LA: Disponibilidad limitada. Esta receta puede estar disponible solo en ciertas farmacias. Para obtener más

información, llame al Servicio de atención al cliente de Express Scripts.

MO: Medicamento obtenido por correo. Este medicamento recetado está disponible a través de nuestro servicio de pedido por correo, así como en las farmacias minoristas de nuestra red. Considere utilizar el servicio de farmacia por correo para obtener sus medicamentos de uso continuo, o de mantenimiento (por ejemplo, los medicamentos para la presión sanguínea elevada). Las farmacias minoristas de la red pueden ser más adecuadas para obtener medicamentos de uso a corto plazo (por ejemplo, los antibióticos).

NEDS: Medicamentos con suministro de día no extendido. Este medicamento solo está disponible como suministro de 30 días o menos.

PA: Autorización previa. El Plan requiere que usted o su médico obtengan autorización previa para obtener ciertos medicamentos. Esto significa que deberá obtener aprobación antes de que se surtan sus recetas. Si no obtiene aprobación, podríamos no cubrir el medicamento.

QL: Límite de cantidad. En el caso de ciertos medicamentos, el Plan limita la cantidad del medicamento que cubriremos.

ST: Terapia de paso. En algunos casos, el Plan requiere que primero pruebe ciertos medicamentos para el tratamiento de su afección médica antes de que podamos cubrir otro medicamento para tratar esa afección. Por ejemplo, si puede utilizarse tanto un medicamento A como un medicamento B en el tratamiento de la misma afección médica, es posible que no cubramos el medicamento B a menos que usted pruebe primero el medicamento A. Si el medicamento A no le produce mejoras, cubriremos el medicamento B.

V: Esta vacuna se suministra a los adultos sin costo alguno cuando se usa según las recomendaciones del Comité Asesor sobre Prácticas de Inmunización (ACIP) de los Centros para el Control y la Prevención de Enfermedades (CDC).

Tabla de Contenido

| | |
|---|-----|
| Agentes Anti Cáncer | 3 |
| Agentes Anti-Adicción/De Tratamiento De Abuso De Sustancias | 19 |
| Agentes Antiansiedad | 20 |
| Agentes Antidemencia | 21 |
| Agentes Antidiabetico | 22 |
| Agentes Antigota | 26 |
| Agentes Antimigraña | 27 |
| Agentes Antinausea | 28 |
| Agentes Antiparasitarios | 30 |
| Agentes Antiparkinson | 31 |
| Agentes Antipsicóticos | 33 |
| Agentes Calóricos | 39 |
| Agentes Cardiovasculares | 40 |
| Agentes De Enfermedad Intestinal Inflamatoria | 52 |
| Agentes De Enfermedad Ósea Metabólica | 53 |
| Agentes De Trastorno De Sueño | 54 |
| Agentes Del Sistema Nervioso Central | 55 |
| Agentes Del Tracto Respiratorio | 60 |
| Agentes Dentales Y Orales | 65 |
| Agentes Dermatológicos | 66 |
| Agentes Gastrointestinales | 71 |
| Agentes Genitourinarios | 75 |
| Agentes Hormonales, Estimulante/Reemplazo/Modificador | 76 |
| Agentes Inmunológicos | 82 |
| Agentes Oftálmicos | 93 |
| Agentes Para Los Ojos, Oídos, Nariz, Garganta | 94 |
| Agentes Terapeuticos Misceláneos | 99 |
| Agentes Vasodilatadores | 101 |
| Analgésicos | 102 |
| Anestésicos | 107 |
| Antagonistas De Metales Pesados | 107 |
| Anti Infecciosos (Membrana Cutánea Y Mucosa) | 108 |
| Antibacterianos | 108 |
| Anticonceptivos | 116 |
| Anticonvulsivos | 125 |
| Antidepresivos | 130 |
| Antifúngicos | 133 |
| Antihistamínicos | 135 |

| | |
|---|-----|
| Antimicrobacteriales..... | 135 |
| Antivirales (Sistémico)..... | 136 |
| Dispositivos..... | 142 |
| Non-Frf..... | 185 |
| Preparaciones De Reemplazo..... | 185 |
| Productos Para La Tos Y Resfriado..... | 187 |
| Productos Sanguíneos/Modificadores/Expansores De Volumen..... | 187 |
| Reemplazo/Modificadores De Enzima..... | 191 |
| Relajantes Musculares Esqueléticos..... | 192 |
| Vitaminas Y Minerales..... | 193 |

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|-----------------------------------|
| Agentes Anti Cáncer | | |
| Agentes Anti Cáncer | | |
| <i>abiraterone oral tablet 250 mg, 500 mg</i> (Zytiga) | 5 | PA NSO; NDS; QL (120 per 30 days) |
| ABRAXANE INTRAVENOUS SUSPENSION FOR RECONSTITUTION 100 MG (paclitaxel protein-bound) | 5 | PA BvD; NDS |
| <i>adrucil intravenous solution 2.5 gram/50 ml</i> (fluorouracil) | 2 | PA BvD |
| AKEEGA ORAL TABLET 100-500 MG, 50-500 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| ALECENSA ORAL CAPSULE 150 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| ALUNBRIG ORAL TABLETS,DOSE PACK 90 MG (7)-180 MG (23) | 5 | PA NSO; NDS |
| <i>anastrozole oral tablet 1 mg</i> (Arimidex) | 1 | GC |
| ANKTIVA INTRAVESICAL SOLUTION 400 MCG/0.4 ML | 5 | PA NSO; NDS; QL (1.6 per 28 days) |
| AUGTYRO ORAL CAPSULE 40 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>azacitidine injection recon soln 100 mg</i> (Vidaza) | 5 | NDS |
| BALVERSA ORAL TABLET 3 MG | 5 | PA NSO; NDS; QL (84 per 28 days) |
| BALVERSA ORAL TABLET 4 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| BALVERSA ORAL TABLET 5 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |
| <i>bendamustine intravenous recon soln 100 mg, 25 mg</i> (Treanda) | 5 | PA NSO; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|--------------------------------------|
| BENDAMUSTINE (Bendeka) INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NDS |
| BENDEKA INTRAVENOUS (bendamustine) SOLUTION 25 MG/ML | 5 | PA NSO; NDS |
| <i>bexarotene oral capsule 75 mg</i> (Targretin) | 5 | PA NSO; NDS |
| <i>bexarotene topical gel 1 %</i> (Targretin) | 5 | PA NSO; NDS |
| <i>bicalutamide oral tablet 50 mg</i> (Casodex) | 2 | |
| <i>bleomycin injection recon soln 15 unit, 30 unit</i> | 2 | |
| <i>bortezomib injection recon soln 1 mg</i> | 4 | PA NSO |
| <i>bortezomib injection recon soln 2.5 mg</i> | 5 | PA NSO; NDS |
| <i>bortezomib injection recon soln 3.5 (Velcade) mg</i> | 5 | PA NSO; NDS |
| BOSULIF ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| BOSULIF ORAL CAPSULE 50 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| BOSULIF ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 60 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| CABOMETYX ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| CALQUENCE (ACALABRUTINIB MAL) ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 100 (vandetanib) MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 300 (vandetanib) MG | 5 | PA NSO; NDS; QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|--------------------------------------|
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 60 MG/DAY (20 MG X 3/DAY) | 5 | PA NSO; NDS |
| COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3) | 5 | PA NSO; NDS; QL (112 per 28 days) |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| COTELLIC ORAL TABLET 20 MG | 5 | PA NSO; LA; NDS; QL (63 per 28 days) |
| <i>cyclophosphamide intravenous recon soln 1 gram, 2 gram, 500 mg</i> | 5 | PA BvD; NDS |
| <i>cyclophosphamide intravenous solution 100 mg/ml, 200 mg/ml, 500 mg/ml</i> | 5 | PA BvD; NDS |
| <i>cyclophosphamide oral capsule 25 mg, 50 mg</i> | 2 | PA BvD; ST |
| <i>cyclophosphamide oral tablet 25 mg, 50 mg</i> | 3 | PA BvD; ST |
| CYRAMZA INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NDS |
| DANYELZA INTRAVENOUS SOLUTION 4 MG/ML | 5 | PA NSO; NDS; QL (120 per 28 days) |
| <i>dasatinib oral tablet 100 mg, 140 mg, 50 mg, 70 mg, 80 mg</i> (Sprycel) | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>dasatinib oral tablet 20 mg</i> (Sprycel) | 5 | PA NSO; NDS; QL (90 per 30 days) |
| DAURISMO ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| DAURISMO ORAL TABLET 25 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>decitabine intravenous recon soln 50 mg</i> (Dacogen) | 5 | NDS |
| <i>doxorubicin intravenous solution 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml</i> | 2 | PA BvD |
| <i>doxorubicin, peg-liposomal intravenous suspension 2 mg/ml</i> (Caelyx) | 5 | PA BvD; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|--------------------------------------|
| ELIGARD (3 MONTH) SUBCUTANEOUS SYRINGE 22.5 MG | 4 | PA NSO |
| ELIGARD (4 MONTH) SUBCUTANEOUS SYRINGE 30 MG | 4 | PA NSO |
| ELIGARD (6 MONTH) SUBCUTANEOUS SYRINGE 45 MG | 4 | PA NSO |
| ELIGARD SUBCUTANEOUS SYRINGE 7.5 MG (1 MONTH) | 4 | PA NSO |
| ELREXFIO 44 MG/1.1 ML VIAL OUTER, SUV, P/F 40 MG/ML | 5 | PA NSO; NDS |
| ELREXFIO SUBCUTANEOUS SOLUTION 40 MG/ML | 5 | PA NSO; NDS; QL (9.5 per 28 days) |
| EMCYT ORAL CAPSULE 140 MG | 5 | NDS |
| EPKINLY SUBCUTANEOUS SOLUTION 4 MG/0.8 ML, 48 MG/0.8 ML | 5 | PA NSO; NDS |
| ERBITUX INTRAVENOUS SOLUTION 100 MG/50 ML, 200 MG/100 ML | 5 | PA NSO; NDS |
| ERIVEDGE ORAL CAPSULE 150 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |
| ERLEADA ORAL TABLET 240 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ERLEADA ORAL TABLET 60 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| <i>erlotinib oral tablet 100 mg</i> (Tarceva) | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>erlotinib oral tablet 150 mg</i> (Tarceva) | 5 | PA NSO; NDS; QL (90 per 30 days) |
| <i>erlotinib oral tablet 25 mg</i> | 5 | PA NSO; NDS; QL (60 per 30 days) |
| ETOPOPHOS INTRAVENOUS RECON SOLN 100 MG | 4 | |
| <i>etoposide intravenous solution 20 mg/ml</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|-----------------------------------|
| <i>everolimus (antineoplastic) oral tablet 10 mg</i> (Torpenz) | 5 | PA NSO; NDS; QL (56 per 28 days) |
| <i>everolimus (antineoplastic) oral tablet 2.5 mg, 5 mg, 7.5 mg</i> (Torpenz) | 5 | PA NSO; NDS; QL (28 per 28 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg</i> (Afinitor Disperz) | 5 | PA NSO; NDS; QL (112 per 28 days) |
| <i>exemestane oral tablet 25 mg</i> (Aromasin) | 2 | |
| EXKIVITY ORAL CAPSULE 40 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG | 5 | PA BvD; NDS |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG | 4 | PA BvD |
| <i>floxuridine injection recon soln 0.5 gram</i> | 2 | PA BvD |
| <i>fluorouracil intravenous solution 1 gram/20 ml, 5 gram/100 ml, 500 mg/10 ml</i> | 2 | PA BvD |
| FOTIVDA ORAL CAPSULE 0.89 MG, 1.34 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| FRUZAQLA ORAL CAPSULE 1 MG | 5 | PA NSO; NDS; QL (84 per 28 days) |
| FRUZAQLA ORAL CAPSULE 5 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| <i>fulvestrant intramuscular syringe 250 mg/5 ml</i> (Faslodex) | 5 | NDS |
| FYARRO INTRAVENOUS SUSPENSION FOR RECONSTITUTION 100 MG | 5 | PA NSO; NDS |
| GAVRETO ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| <i>gefitinib oral tablet 250 mg</i> (Iressa) | 5 | PA NSO; NDS; QL (60 per 30 days) |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|--------------------------------------|
| GLEOSTINE ORAL CAPSULE 10 (lomustine) MG, 100 MG, 40 MG | 4 | |
| HERCEPTIN HYLECTA SUBCUTANEOUS SOLUTION 600 MG-10,000 UNIT/5 ML | 5 | PA NSO; NDS; QL (5 per 21 days) |
| HERZUMA INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NDS |
| <i>hydroxyurea oral capsule 500 mg</i> (Hydrea) | 2 | |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| IDHIFA ORAL TABLET 100 MG, 50 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>ifosfamide intravenous recon soln 1 gram</i> (Ifex) | 2 | |
| <i>ifosfamide intravenous solution 1 gram/20 ml, 3 gram/60 ml</i> | 2 | |
| <i>imatinib oral tablet 100 mg</i> (Gleevec) | 2 | PA NSO; QL (180 per 30 days) |
| <i>imatinib oral tablet 400 mg</i> (Gleevec) | 2 | PA NSO; QL (60 per 30 days) |
| IMBRUVICA ORAL CAPSULE 140 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| IMBRUVICA ORAL CAPSULE 70 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |
| IMBRUVICA ORAL SUSPENSION 70 MG/ML | 5 | PA NSO; NDS; QL (240 per 30 days) |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG | 5 | PA NSO; NDS; QL (28 per 28 days) |
| IMBRUVICA ORAL TABLET 560 MG | 5 | NDS; QL (28 per 28 days) |
| IMDELLTRA INTRAVENOUS RECON SOLN 1 MG, 10 MG | 5 | PA NSO; NDS |
| IMJUDO INTRAVENOUS SOLUTION 20 MG/ML | 5 | PA NSO; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|--------------------------------------|
| IMLYGIC INJECTION SUSPENSION 10EXP6 (1 MILLION) PFU/ML | 4 | PA NSO; QL (4 per 365 days) |
| INLYTA ORAL TABLET 1 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| INLYTA ORAL TABLET 5 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| INQOVI ORAL TABLET 35-100 MG | 5 | PA NSO; NDS; QL (5 per 28 days) |
| INREBIC ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| IWILFIN ORAL TABLET 192 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| JEMPERLI INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NDS |
| JYLAMVO ORAL SOLUTION 2 MG/ML | 4 | PA BvD; ST |
| KEYTRUDA INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NDS |
| KIMMTRAK INTRAVENOUS SOLUTION 100 MCG/0.5 ML | 5 | PA NSO; NDS; QL (2 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG | 5 | PA NSO; NDS; QL (49 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG | 5 | PA NSO; NDS; QL (70 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG | 5 | PA NSO; NDS; QL (91 per 28 days) |
| KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1) | 5 | PA NSO; NDS; QL (21 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2) | 5 | PA NSO; NDS; QL (42 per 28 days) |
| KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3) | 5 | PA NSO; NDS; QL (63 per 28 days) |
| KOSELUGO ORAL CAPSULE 10 MG | 5 | PA NSO; NDS; QL (300 per 30 days) |
| KOSELUGO ORAL CAPSULE 25 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| KRAZATI ORAL TABLET 200 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>lapatinib oral tablet 250 mg</i> (Tykerb) | 5 | PA NSO; NDS |
| LAZCLUZE ORAL TABLET 240 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| LAZCLUZE ORAL TABLET 80 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>lenalidomide oral capsule 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg</i> (Revlimid) | 5 | PA NSO; NDS; QL (28 per 28 days) |
| LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2) | 5 | PA NSO; NDS |
| <i>letrozole oral tablet 2.5 mg</i> (Femara) | 1 | GC |
| LEUKERAN ORAL TABLET 2 MG | 5 | NDS |
| <i>leuprolide (3 month) intramuscular suspension for reconstitution 22.5 mg</i> | 4 | PA NSO |
| <i>leuprolide subcutaneous kit 1 mg/0.2 ml</i> | 2 | PA NSO |
| LONSURF ORAL TABLET 15-6.14 MG | 5 | PA NSO; NDS; QL (100 per 28 days) |
| LONSURF ORAL TABLET 20-8.19 MG | 5 | PA NSO; NDS; QL (80 per 28 days) |
| LOQTORZI INTRAVENOUS SOLUTION 240 MG/6 ML (40 MG/ML) | 5 | PA NSO; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| LORBRENA ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| LORBRENA ORAL TABLET 25 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| LUMAKRAS ORAL TABLET 120 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| LUMAKRAS ORAL TABLET 320 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| LUNSUMIO INTRAVENOUS SOLUTION 1 MG/ML | 5 | PA NSO; NDS |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 22.5 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT (4 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT (6 MONTH) INTRAMUSCULAR SYRINGE KIT 45 MG | 5 | PA NSO; NDS |
| LYNPARZA ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| LYSODREN ORAL TABLET 500 MG | 5 | NDS |
| LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5) | 5 | PA NSO; NDS; QL (140 per 28 days) |
| MARGENZA INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NDS |
| MATULANE ORAL CAPSULE 50 MG | 5 | NDS |
| <i>megestrol oral tablet 20 mg, 40 mg</i> | 2 | PA NSO-HRM; AGE (Max 64 Years) |
| MEKINIST ORAL RECON SOLN 0.05 MG/ML | 5 | PA NSO; NDS; QL (1260 per 30 days) |
| MEKINIST ORAL TABLET 0.5 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| MEKINIST ORAL TABLET 2 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| MEKTOVI ORAL TABLET 15 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>mercaptapurine oral tablet 50 mg</i> | 2 | |
| <i>methotrexate sodium (pf) injection recon soln 1 gram</i> | 2 | |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i> | 2 | |
| <i>methotrexate sodium injection solution 25 mg/ml</i> | 2 | |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | 2 | PA BvD; ST |
| <i>mitoxantrone intravenous concentrate 2 mg/ml</i> | 2 | |
| MVASI INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NDS |
| NERLYNX ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>nilutamide oral tablet 150 mg</i> (Nilandron) | 5 | NDS |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG | 5 | PA NSO; NDS; QL (3 per 28 days) |
| NUBEQA ORAL TABLET 300 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG | 5 | PA NSO; LA; NDS |
| OGIVRI INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NDS |
| OGSIVEO ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| OGSIVEO ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| OJEMDA ORAL SUSPENSION FOR RECONSTITUTION 25 MG/ML | 5 | PA NSO; NDS; QL (96 per 28 days) |
| OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500 MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6) | 5 | PA NSO; NDS; QL (24 per 28 days) |
| OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|--------------------------------------|
| ONTRUZANT INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NDS |
| ONUREG ORAL TABLET 200 MG, 300 MG | 5 | PA NSO; NDS; QL (14 per 28 days) |
| OPDIVO INTRAVENOUS SOLUTION 100 MG/10 ML, 120 MG/12 ML, 240 MG/24 ML, 40 MG/4 ML | 5 | PA NSO; NDS |
| OPDUALAG INTRAVENOUS SOLUTION 240-80 MG/20 ML | 5 | PA NSO; NDS |
| ORSERDU ORAL TABLET 345 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ORSERDU ORAL TABLET 86 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| <i>paclitaxel protein-bound intravenous suspension for reconstitution 100 mg</i> (Abraxane) | 5 | PA BvD; NDS |
| <i>pazopanib oral tablet 200 mg</i> (Votrient) | 5 | PA NSO; NDS; QL (120 per 30 days) |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>pemetrexed disodium intravenous recon soln 1,000 mg, 750 mg</i> | 5 | NDS |
| <i>pemetrexed disodium intravenous solution 25 mg/ml</i> | 5 | NDS |
| <i>pemetrexed intravenous recon soln 100 mg, 500 mg</i> | 5 | NDS |
| PEMRYDI RTU INTRAVENOUS SOLUTION 10 MG/ML | 5 | NDS |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1) | 5 | PA NSO; NDS; QL (28 per 28 days) |
| PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) | 5 | PA NSO; NDS; QL (56 per 28 days) |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 5 | PA NSO; NDS; QL (21 per 28 days) |
| PURIXAN ORAL SUSPENSION 20 MG/ML | 5 | NDS |
| QINLOCK ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| RETEVMO ORAL CAPSULE 40 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| RETEVMO ORAL TABLET 120 MG, 160 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| RETEVMO ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| RETEVMO ORAL TABLET 80 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| REZLIDHIA ORAL CAPSULE 150 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| RIABNI INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NDS |
| RITUXAN HYCELA SUBCUTANEOUS SOLUTION 1400 MG/11.7 ML (120 MG/ML), 1600 MG/13.4 ML (120 MG/ML) | 5 | PA NSO; NDS |
| ROZLYTREK ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| ROZLYTREK ORAL PELLETS IN PACKET 50 MG | 5 | PA NSO; NDS; QL (360 per 30 days) |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| RUXIENCE INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NDS |
| RYBREVANT INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NDS |
| RYDAPT ORAL CAPSULE 25 MG | 5 | PA NSO; NDS; QL (224 per 28 days) |
| RYTELO INTRAVENOUS RECON SOLN 188 MG, 47 MG | 5 | PA NSO; NDS |
| SCEMBLIX ORAL TABLET 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| SCEMBLIX ORAL TABLET 20 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|--------------------------------------|
| SCEMBLIX ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (300 per 30 days) |
| SOLTAMOX ORAL SOLUTION 20 MG/10 ML | 5 | NDS |
| <i>sorafenib oral tablet 200 mg</i> (Nexavar) | 5 | PA NSO; NDS; QL (120 per 30 days) |
| SPRYCEL ORAL TABLET 100 MG, 140 MG, 50 MG, 70 MG, 80 MG (dasatinib) | 5 | PA NSO; NDS; QL (30 per 30 days) |
| SPRYCEL ORAL TABLET 20 MG (dasatinib) | 5 | PA NSO; NDS; QL (90 per 30 days) |
| STIVARGA ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (84 per 28 days) |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> (Sutent) | 5 | PA NSO; NDS; QL (28 per 28 days) |
| SYNRIBO SUBCUTANEOUS RECON SOLN 3.5 MG | 5 | PA NSO; NDS |
| TABLOID ORAL TABLET 40 MG (thioguanine) | 4 | |
| TABRECTA ORAL TABLET 150 MG, 200 MG | 5 | PA NSO; NDS; QL (112 per 28 days) |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| TAFINLAR ORAL TABLET FOR SUSPENSION 10 MG | 5 | PA NSO; NDS; QL (900 per 30 days) |
| TAGRISSO ORAL TABLET 40 MG, 80 MG | 5 | PA NSO; LA; NDS; QL (30 per 30 days) |
| TALVEY SUBCUTANEOUS SOLUTION 2 MG/ML, 40 MG/ML | 5 | PA NSO; NDS |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>tamoxifen oral tablet 10 mg, 20 mg</i> | 2 | |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG | 5 | PA NSO; NDS; QL (112 per 28 days) |
| TASIGNA ORAL CAPSULE 50 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| TAZVERIK ORAL TABLET 200 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| TECVAYLI SUBCUTANEOUS SOLUTION 10 MG/ML, 90 MG/ML | 5 | PA NSO; NDS |
| TEPMETKO ORAL TABLET 225 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| TEVIMBRA INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NDS |
| TIBSOVO ORAL TABLET 250 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| TICE BCG INTRAVESICAL SUSPENSION FOR RECONSTITUTION 50 MG | 4 | |
| TIVDAK INTRAVENOUS RECON SOLN 40 MG | 5 | PA NSO; NDS; QL (5 per 21 days) |
| <i>toposar intravenous solution 20 mg/ml</i> (etoposide) | 2 | |
| <i>toremifene oral tablet 60 mg</i> (Fareston) | 5 | NDS |
| <i>torpenz oral tablet 10 mg</i> (everolimus (antineoplastic)) | 5 | PA NSO; NDS; QL (60 per 30 days) |
| <i>torpenz oral tablet 2.5 mg, 5 mg, 7.5 mg</i> (everolimus (antineoplastic)) | 5 | PA NSO; NDS; QL (30 per 30 days) |
| TRAZIMERA INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NDS |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 11.25 MG, 22.5 MG, 3.75 MG | 3 | PA NSO |
| <i>tretinoin (antineoplastic) oral capsule 10 mg</i> | 5 | NDS |
| TRUQAP ORAL TABLET 160 MG, 200 MG | 5 | PA NSO; NDS; QL (64 per 28 days) |
| TRUXIMA INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NDS |
| TUKYSA ORAL TABLET 150 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| TUKYSA ORAL TABLET 50 MG | 5 | PA NSO; NDS; QL (300 per 30 days) |
| TURALIO ORAL CAPSULE 125 MG, 200 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|---------------------------------------|
| VANFLYTA ORAL TABLET 17.7 MG, 26.5 MG | 5 | PA NSO; NDS |
| VEGZELMA INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NDS |
| VELCADE INJECTION RECON SOLN 3.5 MG (bortezomib) | 5 | PA NSO; NDS |
| VENCLEXTA ORAL TABLET 10 MG | 3 | PA NSO; LA; QL (60 per 30 days) |
| VENCLEXTA ORAL TABLET 100 MG | 5 | PA NSO; LA; NDS; QL (180 per 30 days) |
| VENCLEXTA ORAL TABLET 50 MG | 5 | PA NSO; LA; NDS; QL (30 per 30 days) |
| VENCLEXTA STARTING PACK ORAL TABLETS,DOSE PACK 10 MG-50 MG- 100 MG | 5 | PA NSO; LA; NDS |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| <i>vinorelbine intravenous solution 10 mg/ml, 50 mg/5 ml</i> | 2 | |
| VITRAKVI ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| VITRAKVI ORAL CAPSULE 25 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| VITRAKVI ORAL SOLUTION 20 MG/ML | 5 | PA NSO; NDS; QL (300 per 30 days) |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| VONJO ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| VORANIGO ORAL TABLET 10 MG, 40 MG | 5 | PA NSO; NDS |
| VYLOY INTRAVENOUS RECON SOLN 100 MG | 5 | PA NSO; NDS |
| WELIREG ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| XALKORI ORAL PELLETT 150 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| XALKORI ORAL PELLETT 20 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| XALKORI ORAL PELLETT 50 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 4 | PA BvD; ST |
| XOSPATA ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2) | 5 | PA NSO; NDS; QL (8 per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1) | 5 | PA NSO; NDS; QL (4 per 28 days) |
| XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK) | 5 | PA NSO; NDS; QL (24 per 28 days) |
| XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK) | 5 | PA NSO; NDS; QL (32 per 28 days) |
| XTANDI ORAL CAPSULE 40 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 40 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 80 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| YERVOY INTRAVENOUS SOLUTION 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML) | 5 | PA NSO; NDS |
| YONSA ORAL TABLET 125 MG | 5 | PA NSO; NDS; QL (120 per 30 days) |
| ZEJULA ORAL CAPSULE 100 MG | 5 | PA NSO; NDS; QL (90 per 30 days) |
| ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| ZELBORAF ORAL TABLET 240 MG | 5 | PA NSO; NDS; QL (240 per 30 days) |
| ZIRABEV INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG, 3.6 MG | 4 | PA NSO |
| ZOLINZA ORAL CAPSULE 100 MG | 5 | NDS |
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| ZYKADIA ORAL TABLET 150 MG | 5 | PA NSO; NDS; QL (84 per 28 days) |
| ZYNLONTA INTRAVENOUS RECON SOLN 10 MG | 5 | PA NSO; NDS |
| ZYNYZ INTRAVENOUS SOLUTION 500 MG/20 ML | 5 | PA NSO; NDS; QL (20 per 28 days) |
| Agentes Anti-Adicción/De Tratamiento De Abuso De Sustancias | | |
| Agentes Anti-Adicción/De Tratamiento De Abuso De Sustancias | | |
| <i>acamprosate oral tablet, delayed release (dr/ec) 333 mg</i> | 2 | |
| <i>buprenorphine hcl sublingual tablet 2 mg, 8 mg</i> | 2 | QL (90 per 30 days) |
| <i>buprenorphine-naloxone sublingual film 12-3 mg</i> (Suboxone) | 2 | QL (60 per 30 days) |
| <i>buprenorphine-naloxone sublingual film 2-0.5 mg, 4-1 mg, 8-2 mg</i> (Suboxone) | 2 | QL (90 per 30 days) |
| <i>buprenorphine-naloxone sublingual tablet 2-0.5 mg, 8-2 mg</i> | 2 | QL (90 per 30 days) |
| <i>bupropion hcl (smoking deter) oral tablet extended release 12 hr 150 mg</i> | 2 | |
| <i>disulfiram oral tablet 250 mg, 500 mg</i> | 2 | |
| KLOXXADO NASAL SPRAY, NON-AEROSOL 8 MG/ACTUATION | 3 | QL (4 per 30 days) |
| <i>naloxone injection solution 0.4 mg/ml</i> | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>naloxone injection syringe 0.4 mg/ml, 0.4 mg/ml (prefilled syringe), 1 mg/ml</i> | 2 | |
| <i>naloxone nasal spray, non-aerosol 4 mg/actuation</i> (Narcan) | 2 | QL (4 per 30 days) |
| <i>naltrexone oral tablet 50 mg</i> | 2 | |
| NICOTROL INHALATION CARTRIDGE 10 MG | 4 | ST; QL (2688 per 365 days) |
| NICOTROL NS NASAL SPRAY, NON-AEROSOL 10 MG/ML | 4 | ST; QL (240 per 180 days) |
| <i>varenicline oral tablet 0.5 mg, 1 mg (56 pack)</i> | 2 | QL (336 per 365 days) |
| <i>varenicline oral tablet 1 mg</i> (Chantix) | 2 | QL (336 per 365 days) |
| <i>varenicline oral tablets, dose pack 0.5 mg (11)- 1 mg (42)</i> (Chantix Starting Month Box) | 2 | |
| Agentes Antiansiedad | | |
| Benzodiacepinas | | |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg</i> (Xanax) | 1 | GC; NDS; QL (120 per 30 days) |
| <i>alprazolam oral tablet 2 mg</i> (Xanax) | 1 | GC; NDS; QL (150 per 30 days) |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | 1 | GC; NDS; QL (120 per 30 days) |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i> (Klonopin) | 1 | GC; QL (90 per 30 days) |
| <i>clonazepam oral tablet 2 mg</i> (Klonopin) | 1 | GC; QL (300 per 30 days) |
| <i>clonazepam oral tablet, disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i> | 2 | QL (90 per 30 days) |
| <i>clonazepam oral tablet, disintegrating 2 mg</i> | 2 | QL (300 per 30 days) |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | 2 | QL (180 per 30 days) |
| <i>diazepam injection solution 5 mg/ml</i> | 2 | QL (10 per 28 days) |
| <i>diazepam injection syringe 5 mg/ml</i> | 2 | |
| <i>diazepam intensol oral concentrate 5 mg/ml</i> (diazepam) | 2 | QL (1200 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|-------------------------------|
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i> | 2 | QL (1200 per 30 days) |
| <i>diazepam oral tablet 10 mg, 2 mg, 5 mg</i> (Valium) | 1 | GC; QL (120 per 30 days) |
| <i>lorazepam 2 mg/ml vial 25's, outer</i> (Ativan) | 1 | GC |
| <i>lorazepam 4 mg/ml vial inner</i> (Ativan) | 1 | GC |
| <i>lorazepam injection solution 2 mg/ml</i> (Ativan) | 2 | QL (2 per 30 days) |
| <i>lorazepam injection solution 4 mg/ml</i> (Ativan) | 4 | QL (2 per 30 days) |
| <i>lorazepam injection syringe 2 mg/ml</i> | 1 | GC; QL (2 per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg</i> (Ativan) | 1 | GC; NDS; QL (90 per 30 days) |
| <i>lorazepam oral tablet 2 mg</i> (Ativan) | 1 | GC; NDS; QL (150 per 30 days) |
| <i>oxazepam oral capsule 10 mg, 15 mg, 30 mg</i> | 2 | NDS; QL (120 per 30 days) |
| <i>temazepam oral capsule 15 mg, 30 mg</i> (Restoril) | 1 | GC; NDS; QL (30 per 30 days) |
| Agentes Antidemencia | | |
| Agentes Antidemencia | | |
| <i>donepezil oral tablet 10 mg, 5 mg</i> (Aricept) | 1 | GC; QL (30 per 30 days) |
| <i>donepezil oral tablet, disintegrating 10 mg, 5 mg</i> | 2 | QL (30 per 30 days) |
| <i>ergoloid oral tablet 1 mg</i> | 2 | |
| <i>galantamine oral capsule, ext rel. pellets 24 hr 16 mg, 24 mg, 8 mg</i> | 2 | QL (30 per 30 days) |
| <i>galantamine oral solution 4 mg/ml</i> | 2 | QL (200 per 30 days) |
| <i>galantamine oral tablet 12 mg, 4 mg, 8 mg</i> | 2 | QL (60 per 30 days) |
| <i>memantine oral capsule, sprinkle, er 24hr 14 mg, 21 mg, 28 mg, 7 mg</i> (Namenda XR) | 2 | ST; QL (30 per 30 days) |
| <i>memantine oral solution 2 mg/ml</i> | 2 | QL (300 per 30 days) |
| <i>memantine oral tablet 10 mg, 5 mg</i> | 2 | QL (60 per 30 days) |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | 2 | QL (60 per 30 days) |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour</i> (Exelon Patch) | 2 | QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|-------------------------------|
| Agentes Antidiabetico | | |
| Agentes Antidiabeticos, Varios | | |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> (Precose) | 2 | QL (90 per 30 days) |
| FARXIGA ORAL TABLET 10 MG, 5 MG (dapagliflozin propanediol) | 3 | QL (30 per 30 days) |
| GLYXAMBI ORAL TABLET 10-5 MG, 25-5 MG | 3 | QL (30 per 30 days) |
| JANUMET ORAL TABLET 50-1,000 MG, 50-500 MG | 3 | QL (60 per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG | 3 | QL (30 per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG, 50-500 MG | 3 | QL (60 per 30 days) |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG | 3 | QL (30 per 30 days) |
| JARDIANCE ORAL TABLET 10 MG, 25 MG | 3 | QL (30 per 30 days) |
| JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG, 2.5-850 MG | 3 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG | 3 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG | 3 | QL (30 per 30 days) |
| <i>metformin oral tablet 1,000 mg</i> | 6 | GC; QL (75 per 30 days) |
| <i>metformin oral tablet 500 mg</i> | 6 | GC; QL (150 per 30 days) |
| <i>metformin oral tablet 850 mg</i> | 6 | GC; QL (90 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 500 mg</i> | 6 | GC; QL (120 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 750 mg</i> | 6 | GC; QL (60 per 30 days) |
| <i>mifepristone oral tablet 300 mg</i> (Korlym) | 5 | PA; NDS; QL (112 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| MOUNJARO SUBCUTANEOUS PEN INJECTOR 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML | 3 | PA NSO; QL (2 per 28 days) |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | 6 | GC; QL (90 per 30 days) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) | 3 | PA NSO; QL (3 per 28 days) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG(2 MG/1.5 ML) | 3 | PA NSO; QL (1.5 per 28 days) |
| <i>pioglitazone oral tablet 15 mg, 30 mg, 45 mg</i> (Actos) | 6 | GC; QL (30 per 30 days) |
| <i>pioglitazone-metformin oral tablet 15-500 mg</i> | 6 | GC; QL (90 per 30 days) |
| <i>pioglitazone-metformin oral tablet 15-850 mg</i> (Actoplus MET) | 6 | GC; QL (90 per 30 days) |
| <i>repaglinide oral tablet 0.5 mg, 1 mg</i> | 6 | GC; QL (120 per 30 days) |
| <i>repaglinide oral tablet 2 mg</i> | 6 | GC; QL (240 per 30 days) |
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG | 3 | PA NSO; QL (30 per 30 days) |
| SYMLINPEN 120 SUBCUTANEOUS PEN INJECTOR 2,700 MCG/2.7 ML | 5 | PA; NDS; QL (10.8 per 28 days) |
| SYMLINPEN 60 SUBCUTANEOUS PEN INJECTOR 1,500 MCG/1.5 ML | 5 | PA; NDS; QL (10.8 per 28 days) |
| SYNJARDY ORAL TABLET 12.5-1,000 MG, 12.5-500 MG, 5-1,000 MG, 5-500 MG | 3 | QL (60 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 25-1,000 MG | 3 | QL (30 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-1,000 MG, 5-1,000 MG | 3 | QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|--|
| TRADJENTA ORAL TABLET 5 MG | 3 | QL (30 per 30 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG | 3 | QL (30 per 30 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG | 3 | QL (60 per 30 days) |
| TRULICITY SUBCUTANEOUS PEN INJECTOR 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML | 3 | PA NSO; QL (2 per 28 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG | 3 | QL (30 per 30 days) |
| (dapaglifloz propaned-metformin) | | |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-500 MG | 3 | QL (30 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-500 MG | 3 | QL (60 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG | 3 | QL (60 per 30 days) |
| (dapaglifloz propaned-metformin) | | |
| Insulinas | | |
| FIASP FLEXTOUCH U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| FIASP PENFILL U-100 INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| FIASP U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| HUMULIN R U-500 (CONC) INSULIN SUBCUTANEOUS SOLUTION 500 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| HUMULIN R U-500 (CONC) KWIKPEN SUBCUTANEOUS INSULIN PEN 500 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (24 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|----------------------------------|--|
| <i>insulin asp prt-insulin aspart subcutaneous insulin pen 100 unit/ml (70-30)</i> | (Novolog Mix 70-30FlexPen U-100) | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin asp prt-insulin aspart subcutaneous solution 100 unit/ml (70-30)</i> | (Novolog Mix 70-30 U-100 Insuln) | max \$35 copay per month supply; QL (40 per 28 days) |
| <i>insulin aspart u-100 subcutaneous cartridge 100 unit/ml</i> | (Novolog PenFill U-100 Insulin) | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin aspart u-100 subcutaneous insulin pen 100 unit/ml (3 ml)</i> | (Novolog FlexPen U-100 Insulin) | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin aspart u-100 subcutaneous solution 100 unit/ml</i> | (Novolog U-100 Insulin aspart) | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70-30) | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN 70-30 FLEXPEN U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN N FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN N NPH U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN R FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN R REGULAR U100 INSULIN INJECTION SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| SEMGLEE(INSULIN GLARGINE-YFGN) SUBCUTANEOUS SOLUTION 100 UNIT/ML | (insulin glargine-yfgn) | max \$35 copay per month supply; QL (40 per 28 days) |
| SEMGLEE(INSULIN GLARG-YFGN)PEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | (insulin glargine-yfgn) | max \$35 copay per month supply; QL (30 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|----------------------------------|--|
| SOLQUA 100/33 SUBCUTANEOUS INSULIN PEN 100 UNIT-33 MCG/ML | 3 | max \$35 copay per month supply; QL (30 per 30 days) |
| TOUJEO MAX U-300 SOLOSTAR SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (3 ML) | (insulin glargine u-300 conc) | 3 |
| TOUJEO SOLOSTAR U-300 INSULIN SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (1.5 ML) | (insulin glargine u-300 conc) | 3 |
| XULTOPHY 100/3.6 SUBCUTANEOUS INSULIN PEN 100 UNIT-3.6 MG /ML (3 ML) | | 3 |
| Sulfonilureas | | |
| <i>glimepiride oral tablet 1 mg, 2 mg</i> | | 6 |
| <i>glimepiride oral tablet 4 mg</i> | | 6 |
| <i>glipizide oral tablet 10 mg</i> | | 6 |
| <i>glipizide oral tablet 2.5 mg</i> | | 6 |
| <i>glipizide oral tablet 5 mg</i> | | 6 |
| <i>glipizide oral tablet extended release 24hr 10 mg</i> | (Glucotrol XL) | 6 |
| <i>glipizide oral tablet extended release 24hr 2.5 mg, 5 mg</i> | (Glucotrol XL) | 6 |
| <i>glipizide-metformin oral tablet 2.5- 250 mg</i> | | 6 |
| <i>glipizide-metformin oral tablet 2.5- 500 mg, 5-500 mg</i> | | 6 |
| <i>glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg</i> | | 6 |
| <i>glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg</i> | | 6 |
| <i>glyburide-metformin oral tablet 1.25- 250 mg, 2.5-500 mg, 5-500 mg</i> | | 6 |
| Agentes Antigota | | |
| Agentes Antigota, Otros | | |
| <i>allopurinol oral tablet 100 mg</i> | (Zyloprim) | 1 |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|-----------------------------|
| <i>allopurinol oral tablet 300 mg</i> | 1 | GC |
| <i>colchicine oral capsule 0.6 mg</i> (Mitigare) | 2 | QL (60 per 30 days) |
| <i>colchicine oral tablet 0.6 mg</i> (Colcryst) | 2 | QL (120 per 30 days) |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> (Uloric) | 2 | ST; QL (30 per 30 days) |
| <i>probenecid oral tablet 500 mg</i> | 2 | |
| <i>probenecid-colchicine oral tablet 500-0.5 mg</i> | 2 | |
| Agentes Antimigraña | | |
| Agentes Antimigraña | | |
| AJOVY AUTOINJECTOR SUBCUTANEOUS AUTO- INJECTOR 225 MG/1.5 ML | 3 | PA; QL (1.5 per 30 days) |
| AJOVY SYRINGE SUBCUTANEOUS SYRINGE 225 MG/1.5 ML | 3 | PA; QL (1.5 per 30 days) |
| <i>dihydroergotamine injection solution 1 mg/ml</i> | 5 | NDS; QL (24 per 28 days) |
| <i>dihydroergotamine nasal spray, non-aerosol 0.5 mg/pump act. (4 mg/ml)</i> (Migranal) | 5 | ST; NDS; QL (8 per 28 days) |
| EMGALITY PEN SUBCUTANEOUS PEN INJECTOR 120 MG/ML | 3 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML | 3 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3) | 3 | PA; QL (3 per 30 days) |
| <i>naratriptan oral tablet 1 mg, 2.5 mg</i> | 2 | QL (9 per 30 days) |
| NURTEC ODT ORAL TABLET, DISINTEGRATING 75 MG | 3 | PA; QL (18 per 30 days) |
| QULIPTA ORAL TABLET 10 MG, 30 MG, 60 MG | 3 | PA; QL (30 per 30 days) |
| <i>rizatriptan oral tablet 10 mg</i> (Maxalt) | 2 | QL (12 per 30 days) |
| <i>rizatriptan oral tablet 5 mg</i> | 2 | QL (12 per 30 days) |
| <i>rizatriptan oral tablet, disintegrating 10 mg</i> (Maxalt-MLT) | 2 | QL (12 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>rizatriptan oral tablet, disintegrating 5 mg</i> | 2 | QL (12 per 30 days) |
| <i>sumatriptan 4 mg/0.5 ml inject outer, suv</i> (Imitrex STATdose Pen) | 2 | QL (4 per 28 days) |
| <i>sumatriptan nasal spray, non-aerosol 20 mg/actuation</i> | 2 | QL (12 per 30 days) |
| <i>sumatriptan nasal spray, non-aerosol 5 mg/actuation</i> | 2 | QL (18 per 30 days) |
| <i>sumatriptan succinate oral tablet 100 mg</i> (Imitrex) | 1 | GC; QL (9 per 30 days) |
| <i>sumatriptan succinate oral tablet 25 mg, 50 mg</i> (Imitrex) | 1 | GC; QL (18 per 30 days) |
| <i>sumatriptan succinate subcutaneous cartridge 6 mg/0.5 ml</i> (Imitrex STATdose Refill) | 2 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml</i> (Imitrex STATdose Pen) | 4 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml</i> (Imitrex STATdose Pen) | 2 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5 ml</i> (Imitrex) | 2 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous syringe 6 mg/0.5 ml</i> | 2 | QL (4 per 28 days) |
| <i>sumatriptan-naproxen oral tablet 85-500 mg</i> (Treximet) | 2 | QL (9 per 27 days) |
| UBRELVY ORAL TABLET 100 MG, 50 MG | 3 | PA; QL (16 per 30 days) |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i> (Zomig) | 2 | QL (6 per 30 days) |
| <i>zolmitriptan oral tablet, disintegrating 2.5 mg, 5 mg</i> | 2 | QL (6 per 30 days) |
| Agentes Antinausea | | |
| Agentes Antinausea | | |
| AKYNZEO (FOSNETUPITANT) INTRAVENOUS RECON SOLN 235-0.25 MG | 4 | |
| AKYNZEO (FOSNETUPITANT) INTRAVENOUS SOLUTION 235 MG-0.25 MG /20 ML | 4 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|---------------------------------|
| AKYNZEO (NETUPITANT) ORAL CAPSULE 300-0.5 MG | 4 | PA BvD |
| APONVIE INTRAVENOUS EMULSION 32 MG/4.4 ML (7.2 MG/ML) | 4 | QL (4.4 per 28 days) |
| <i>aprepitant oral capsule 125 mg</i> | 2 | PA BvD; QL (2 per 28 days) |
| <i>aprepitant oral capsule 40 mg</i> | 2 | PA BvD; QL (1 per 28 days) |
| <i>aprepitant oral capsule 80 mg</i> (Emend) | 2 | PA BvD; QL (4 per 28 days) |
| <i>aprepitant oral capsule, dose pack 125 mg (1)- 80 mg (2)</i> (Emend) | 2 | PA BvD |
| <i>compro rectal suppository 25 mg</i> (prochlorperazine) | 2 | |
| <i>dimenhydrinate injection solution 50 mg/ml</i> | 2 | |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> (Marinol) | 2 | PA; QL (60 per 30 days) |
| <i>droperidol injection solution 2.5 mg/ml</i> | 2 | |
| EMEND ORAL SUSPENSION FOR RECONSTITUTION 125 MG (25 MG/ ML FINAL CONC.) | 5 | PA BvD; NDS; QL (6 per 28 days) |
| <i>fosaprepitant intravenous recon soln 150 mg</i> (Emend (fosaprepitant)) | 2 | QL (2 per 28 days) |
| <i>granisetron (pf) intravenous solution 1 mg/ml (1 ml), 100 mcg/ml</i> | 2 | |
| <i>granisetron hcl intravenous solution 1 mg/ml</i> | 2 | |
| <i>granisetron hcl oral tablet 1 mg</i> | 2 | PA BvD |
| <i>meclizine oral tablet 12.5 mg</i> | 2 | |
| <i>meclizine oral tablet 25 mg</i> (Dramamine (meclizine)) | 2 | |
| <i>ondansetron hcl (pf) injection solution 4 mg/2 ml</i> | 2 | |
| <i>ondansetron hcl (pf) injection syringe 4 mg/2 ml</i> | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---|
| <i>ondansetron hcl intravenous solution 2 mg/ml</i> | 2 | |
| <i>ondansetron hcl oral solution 4 mg/5 ml</i> | 2 | PA BvD |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | 2 | PA BvD |
| <i>ondansetron oral tablet, disintegrating 4 mg, 8 mg</i> | 2 | PA BvD |
| <i>prochlorperazine edisylate injection solution 10 mg/2 ml (5 mg/ml)</i> | 2 | |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> (Compazine) | 2 | |
| <i>prochlorperazine rectal suppository 25 mg</i> (Compro) | 2 | |
| <i>promethazine injection solution 25 mg/ml</i> (Phenergan) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>promethazine injection solution 50 mg/ml</i> (Phenergan) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>promethazine oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | PA-HRM; GC; AGE (Max 64 Years) |
| <i>promethazine rectal suppository 12.5 mg, 25 mg, 50 mg</i> (Promethegan) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>promethegan rectal suppository 12.5 mg, 25 mg</i> (promethazine) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>scopolamine base transdermal patch 3 day 1 mg over 3 days</i> (Transderm-Scop) | 2 | PA-HRM; QL (10 per 30 days); AGE (Max 64 Years) |
| Agentes Antiparasitarios | | |
| Agentes Antiparasitarios | | |
| <i>albendazole oral tablet 200 mg</i> | 5 | NDS |
| <i>atovaquone oral suspension 750 mg/5 ml</i> (Mepron) | 2 | |
| <i>atovaquone-proguanil oral tablet 250-100 mg</i> (Malarone) | 2 | |
| <i>atovaquone-proguanil oral tablet 62.5-25 mg</i> (Malarone Pediatric) | 2 | |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|------------------------------|
| COARTEM ORAL TABLET 20-120 MG | 4 | |
| <i>hydroxychloroquine oral tablet 200 mg</i> (Plaquenil) | 2 | QL (90 per 30 days) |
| IMPAVIDO ORAL CAPSULE 50 MG | 5 | PA; NDS; QL (84 per 28 days) |
| <i>ivermectin oral tablet 3 mg</i> (Stromectol) | 2 | |
| KRINTAFEL ORAL TABLET 150 MG | 4 | |
| <i>mefloquine oral tablet 250 mg</i> | 2 | |
| <i>nitazoxanide oral tablet 500 mg</i> (Alinia) | 5 | NDS |
| <i>paromomycin oral capsule 250 mg</i> (Humatin) | 2 | |
| <i>pentamidine inhalation recon soln 300 mg</i> (Nebupent) | 2 | PA BvD |
| <i>pentamidine injection recon soln 300 mg</i> (Pentam) | 2 | |
| PRIMAQUINE ORAL TABLET 26.3 MG (15 MG BASE) | 4 | |
| <i>pyrimethamine oral tablet 25 mg</i> (Daraprim) | 5 | PA; NDS |
| <i>quinine sulfate oral capsule 324 mg</i> (Qualaquin) | 2 | PA; QL (42 per 7 days) |
| Agentes Antiparkinson | | |
| Agentes Antiparkinson | | |
| <i>amantadine hcl oral capsule 100 mg</i> | 2 | |
| <i>amantadine hcl oral solution 50 mg/5 ml</i> | 1 | GC |
| <i>apomorphine subcutaneous cartridge 10 mg/ml</i> (APOKYN) | 5 | PA; NDS; QL (60 per 30 days) |
| <i>benztropine oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | |
| <i>bromocriptine oral capsule 5 mg</i> (Parlodel) | 2 | |
| <i>bromocriptine oral tablet 2.5 mg</i> (Parlodel) | 2 | |
| <i>cabergoline oral tablet 0.5 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet 10-100 mg</i> (Sinemet) | 2 | |
| <i>carbidopa-levodopa oral tablet 25-100 mg</i> (Dhivy) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>carbidopa-levodopa oral tablet 25-250 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet extended release 25-100 mg, 50-200 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet, disintegrating 10-100 mg, 25-100 mg, 25-250 mg</i> | 2 | |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 2 | |
| <i>entacapone oral tablet 200 mg</i> | 2 | |
| INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE 42 MG | 5 | PA; NDS; QL (300 per 30 days) |
| KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; NDS; QL (150 per 30 days) |
| KYNMOBI SUBLINGUAL FILM 10-15-20-25-30 MG | 5 | PA; NDS |
| OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 129 MG, 193 MG, 258 MG | 4 | ST; QL (30 per 30 days) |
| OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 322 MG/DAY(129 MG X1-193MG X1) | 4 | ST; QL (60 per 30 days) |
| <i>pramipexole oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | 1 | GC |
| <i>rasagiline oral tablet 0.5 mg, 1 mg</i> (Azilect) | 2 | |
| <i>ropinirole oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | 2 | |
| <i>ropinirole oral tablet extended release 24 hr 12 mg, 2 mg, 4 mg, 6 mg, 8 mg</i> | 2 | |
| <i>selegiline hcl oral capsule 5 mg</i> | 2 | |
| <i>selegiline hcl oral tablet 5 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|-------------------------------|
| <i>trihexyphenidyl oral elixir 0.4 mg/ml</i> | 2 | |
| <i>trihexyphenidyl oral tablet 2 mg, 5 mg</i> | 1 | GC |
| VYALEV CONTIN. SUBCUTANEOUS INFUSION SOLUTION 12-240 MG/ML | 5 | PA; NDS; QL (560 per 28 days) |
| Agentes Antipsicóticos | | |
| Agentes Antipsicóticos | | |
| ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 720 MG/2.4 ML | 5 | NDS; QL (2.4 per 42 days) |
| ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 960 MG/3.2 ML | 5 | NDS; QL (3.2 per 42 days) |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 300 MG, 400 MG | 5 | NDS; QL (1 per 26 days) |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 300 MG, 400 MG | 5 | NDS; QL (1 per 26 days) |
| <i>aripiprazole oral solution 1 mg/ml</i> | 2 | |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i> (Abilify) | 2 | |
| <i>aripiprazole oral tablet, disintegrating 10 mg</i> | 2 | ST; QL (90 per 30 days) |
| <i>aripiprazole oral tablet, disintegrating 15 mg</i> | 2 | ST; QL (60 per 30 days) |
| ARISTADA INITIO INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 675 MG/2.4 ML | 5 | NDS; QL (4.8 per 365 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 1,064 MG/3.9 ML | 5 | NDS; QL (3.9 per 14 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 441 MG/1.6 ML | 5 | NDS; QL (1.6 per 14 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 662 MG/2.4 ML | 5 | NDS; QL (2.4 per 14 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 882 MG/3.2 ML | 5 | NDS; QL (3.2 per 14 days) |
| <i>asenapine maleate sublingual tablet</i> (Saphris) <i>10 mg, 2.5 mg, 5 mg</i> | 2 | QL (60 per 30 days) |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG | 5 | ST; NDS; QL (30 per 30 days) |
| <i>chlorpromazine injection solution 25 mg/ml</i> | 2 | |
| <i>chlorpromazine oral concentrate 100 mg/ml, 30 mg/ml</i> | 2 | |
| <i>chlorpromazine oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | 2 | |
| <i>clozapine oral tablet 100 mg, 200</i> (Clozaril) <i>mg, 25 mg, 50 mg</i> | 2 | |
| <i>clozapine oral tablet,disintegrating 100 mg, 12.5 mg, 25 mg</i> | 2 | ST; QL (90 per 30 days) |
| <i>clozapine oral tablet,disintegrating 150 mg</i> | 2 | ST; QL (180 per 30 days) |
| <i>clozapine oral tablet,disintegrating 200 mg</i> | 5 | ST; NDS; QL (120 per 30 days) |
| COBENFY ORAL CAPSULE 100- 20 MG, 125-30 MG, 50-20 MG | 5 | ST; NDS; QL (60 per 30 days) |
| COBENFY STARTER PACK ORAL CAPSULE,DOSE PACK 50 MG-20 MG /100 MG-20 MG | 5 | ST; NDS |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 5 | ST; NDS; QL (60 per 30 days) |
| FANAPT ORAL TABLETS,DOSE PACK 1MG(2)-2MG(2)- 4MG(2)- 6MG(2) | 4 | ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | 2 | |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | 2 | |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 2 | |
| <i>fluphenazine hcl oral elixir 2.5 mg/5 ml</i> | 2 | |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml (1 ml), 50 mg/ml(1ml)</i> | 2 | |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 50 mg/ml</i> (Haldol Decanoate) | 2 | |
| <i>haloperidol lactate injection solution 5 mg/ml</i> | 2 | |
| <i>haloperidol lactate intramuscular syringe 5 mg/ml</i> | 2 | |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 2 | |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 2 | |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML | 5 | NDS; QL (3.5 per 166 days) |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML | 5 | NDS; QL (5 per 166 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | 5 | NDS; QL (0.75 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML | 5 | NDS; QL (1 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | 5 | NDS; QL (1.5 per 21 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------------|
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | 3 | QL (0.25 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | 5 | NDS; QL (0.5 per 21 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML | 5 | NDS; QL (0.88 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML | 5 | NDS; QL (1.32 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML | 5 | NDS; QL (1.75 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML | 5 | NDS; QL (2.63 per 70 days) |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |
| <i>lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg</i> (Latuda) | 2 | QL (30 per 30 days) |
| <i>lurasidone oral tablet 80 mg</i> (Latuda) | 2 | QL (60 per 30 days) |
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>molindone oral tablet 10 mg</i> | 2 | QL (240 per 30 days) |
| <i>molindone oral tablet 25 mg</i> | 2 | QL (270 per 30 days) |
| <i>molindone oral tablet 5 mg</i> | 2 | QL (120 per 30 days) |
| NUPLAZID ORAL CAPSULE 34 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| NUPLAZID ORAL TABLET 10 MG | 5 | PA NSO; NDS; QL (30 per 30 days) |
| <i>olanzapine intramuscular recon soln 10 mg</i> (Zyprexa) | 2 | QL (30 per 30 days) |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg</i> (Zyprexa) | 2 | |
| <i>olanzapine oral tablet, disintegrating 10 mg, 15 mg, 20 mg, 5 mg</i> (Zyprexa Zydis) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|-------------------------------|
| <i>paliperidone oral tablet extended release 24hr 1.5 mg</i> | 2 | QL (30 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr 3 mg, 9 mg</i> (Invega) | 2 | QL (30 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr 6 mg</i> (Invega) | 2 | QL (60 per 30 days) |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i> | 2 | |
| PERSERIS SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 120 MG, 90 MG | 5 | NDS; QL (1 per 30 days) |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>prochlorperazine 10 mg/2 ml vl outer 10 mg/2 ml (5 mg/ml)</i> | 2 | |
| <i>quetiapine oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg</i> (Seroquel) | 2 | |
| <i>quetiapine oral tablet 150 mg</i> | 2 | QL (30 per 30 days) |
| <i>quetiapine oral tablet extended release 24 hr 150 mg, 200 mg, 300 mg, 400 mg, 50 mg</i> (Seroquel XR) | 2 | |
| REXULTI ORAL TABLET 0.25 MG | 5 | ST; NDS; QL (120 per 30 days) |
| REXULTI ORAL TABLET 0.5 MG | 5 | ST; NDS; QL (60 per 30 days) |
| REXULTI ORAL TABLET 1 MG, 2 MG, 3 MG, 4 MG | 5 | ST; NDS; QL (30 per 30 days) |
| <i>risperidone microspheres intramuscular suspension,extended rel recon 12.5 mg/2 ml, 25 mg/2 ml</i> (Risperdal Consta) | 2 | QL (2 per 28 days) |
| <i>risperidone microspheres intramuscular suspension,extended rel recon 37.5 mg/2 ml, 50 mg/2 ml</i> (Risperdal Consta) | 5 | NDS; QL (2 per 28 days) |
| <i>risperidone oral solution 1 mg/ml</i> (Risperdal) | 2 | |
| <i>risperidone oral tablet 0.25 mg</i> | 2 | |
| <i>risperidone oral tablet 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> (Risperdal) | 2 | |
| <i>risperidone oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR | 5 | ST; NDS; QL (30 per 30 days) |
| <i>thioridazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | |
| <i>trifluoperazine oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 100 MG/0.28 ML | 5 | NDS; QL (0.28 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 125 MG/0.35 ML | 5 | NDS; QL (0.35 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 150 MG/0.42 ML | 5 | NDS; QL (0.42 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 200 MG/0.56 ML | 5 | NDS; QL (0.56 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 250 MG/0.7 ML | 5 | NDS; QL (0.7 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 50 MG/0.14 ML | 5 | NDS; QL (0.14 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 75 MG/0.21 ML | 5 | NDS; QL (0.21 per 28 days) |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML | 5 | ST; NDS; QL (540 per 30 days) |
| VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG | 5 | ST; NDS; QL (30 per 30 days) |
| VRAYLAR ORAL CAPSULE,DOSE PACK 1.5 MG (1)- 3 MG (6) | 4 | ST |
| <i>ziprasidone hcl oral capsule 20 mg, (Geodon) 40 mg, 60 mg, 80 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| <i>ziprasidone mesylate intramuscular recon soln 20 mg/ml (final conc.)</i> (Geodon) | 2 | QL (6 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG | 4 | QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 300 MG | 5 | NDS; QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 405 MG | 5 | NDS; QL (1 per 28 days) |
| Agentes Calóricos | | |
| Agentes Calóricos | | |
| CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX 4.25%/D10W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX 4.25%/D5W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX 5%-D20W(SULFITE- FREE) INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX 6%-D5W (SULFITE- FREE) INTRAVENOUS PARENTERAL SOLUTION 6-5 % | 4 | PA BvD |
| CLINIMIX 8%-D10W(SULFITE- FREE) INTRAVENOUS PARENTERAL SOLUTION 8-10 % | 4 | PA BvD |
| CLINIMIX 8%-D14W(SULFITE- FREE) INTRAVENOUS PARENTERAL SOLUTION 8-14 % | 4 | PA BvD |
| CLINIMIX E 2.75%/D5W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 2.75 % | 4 | PA BvD |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| CLINIMIX E 4.25%/D10W SUL FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX E 4.25%/D5W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX E 5%/D15W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX E 5%/D20W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX E 8%-D10W SULFITEFREE INTRAVENOUS PARENTERAL SOLUTION 8-10 % | 4 | PA BvD |
| <i>dextrose 10 % in water (d10w) intravenous parenteral solution 10 %</i> | 2 | PA BvD |
| <i>dextrose 5 % in water (d5w) intravenous parenteral solution</i> | 4 | |
| <i>dextrose 5 % in water (d5w) intravenous piggyback 5 %</i> | 2 | |
| <i>dextrose 5%-water iv soln single use</i> | 2 | |
| INTRALIPID INTRAVENOUS EMULSION 20 %, 30 % | 4 | PA BvD |
| NUTRILIPID INTRAVENOUS EMULSION 20 % | 4 | PA BvD |
| PROSOL 20 % INTRAVENOUS PARENTERAL SOLUTION | 4 | PA BvD |
| TRAVASOL 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | PA BvD |
| TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | PA BvD |
| Agentes Cardiovasculares | | |
| Agentes Alfa-Adrenérgicos | | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | 1 | GC |
| <i>clonidine transdermal patch weekly (Catapres-TTS-1) 0.1 mg/24 hr</i> | 2 | QL (4 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>clonidine transdermal patch weekly 0.2 mg/24 hr</i> (Catapres-TTS-2) | 2 | QL (4 per 28 days) |
| <i>clonidine transdermal patch weekly 0.3 mg/24 hr</i> (Catapres-TTS-3) | 2 | QL (8 per 28 days) |
| <i>doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> (Cardura) | 2 | |
| <i>droxidopa oral capsule 100 mg, 200 mg, 300 mg</i> (Northera) | 5 | PA; NDS; QL (180 per 30 days) |
| <i>guanfacine oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>methyldopa oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>midodrine oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>phenylephrine hcl injection solution 10 mg/ml</i> (Vazculep) | 2 | |
| <i>prazosin oral capsule 1 mg, 2 mg, 5 mg</i> | 2 | |
| Agentes Antiarrítmicos | | |
| <i>amiodarone oral tablet 100 mg, 400 mg</i> (Pacerone) | 2 | |
| <i>amiodarone oral tablet 200 mg</i> (Pacerone) | 1 | GC |
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i> (Norpace) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> (Tikosyn) | 2 | |
| <i>flecainide oral tablet 100 mg, 150 mg, 50 mg</i> | 2 | |
| <i>lidocaine (pf) injection syringe 100 mg/5 ml (2 %)</i> | 1 | GC |
| <i>lidocaine (pf) intravenous syringe 100 mg/5 ml (2 %), 50 mg/5 ml (1 %)</i> | 1 | GC |
| <i>mexiletine oral capsule 150 mg, 200 mg, 250 mg</i> | 2 | |
| MULTAQ ORAL TABLET 400 MG | 3 | |
| <i>pacerone oral tablet 100 mg, 200 mg, 400 mg</i> (amiodarone) | 2 | |
| <i>procainamide injection solution 100 mg/ml, 500 mg/ml</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>procainamide intravenous syringe 100 mg/ml</i> | 2 | |
| <i>propafenone oral capsule, extended release 12 hr 225 mg, 325 mg, 425 mg</i> | 2 | |
| <i>propafenone oral tablet 150 mg, 225 mg, 300 mg</i> | 2 | |
| <i>quinidine gluconate oral tablet extended release 324 mg</i> | 2 | |
| <i>quinidine sulfate oral tablet 200 mg</i> | 1 | GC |
| <i>quinidine sulfate oral tablet 300 mg</i> | 2 | |
| Agentes Bloqueadores Beta-Adrenérgicos | | |
| <i>acebutolol oral capsule 200 mg, 400 mg</i> | 2 | |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> (Tenormin) | 1 | GC |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg</i> (Tenoretic 100) | 2 | |
| <i>atenolol-chlorthalidone oral tablet 50-25 mg</i> (Tenoretic 50) | 2 | |
| <i>betaxolol oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | 2 | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> (Coreg) | 1 | GC |
| <i>labetalol intravenous solution 5 mg/ml</i> | 2 | |
| <i>labetalol intravenous syringe 10 mg/2 ml (5 mg/ml), 20 mg/4 ml (5 mg/ml)</i> | 2 | |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | 2 | |
| <i>metoprolol succinate oral tablet extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg</i> (Toprol XL) | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>metoprolol ta-hydrochlorothiaz oral tablet 100-25 mg, 100-50 mg, 50-25 mg</i> | 2 | |
| <i>metoprolol tartrate intravenous solution 5 mg/5 ml</i> | 2 | |
| <i>metoprolol tartrate oral tablet 100 mg, 50 mg</i> (Lopressor) | 1 | GC |
| <i>metoprolol tartrate oral tablet 25 mg</i> | 1 | GC |
| <i>nebivolol oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> (Bystolic) | 2 | |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>propranolol intravenous solution 1 mg/ml</i> | 2 | |
| <i>propranolol oral capsule, extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> (Inderal LA) | 2 | |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | 2 | |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | 2 | |
| <i>propranolol-hydrochlorothiazid oral tablet 40-25 mg, 80-25 mg</i> | 2 | |
| <i>sorine oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> (sotalol) | 2 | |
| <i>sotalol af oral tablet 120 mg, 160 mg, 80 mg</i> (sotalol) | 2 | |
| <i>sotalol oral tablet 120 mg, 160 mg, 80 mg</i> (Sotalol AF) | 2 | |
| <i>sotalol oral tablet 240 mg</i> (Betapace) | 2 | |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | |
| Agentes Bloqueadores Da Canal De Calcio | | |
| <i>cartia xt oral capsule, extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> (diltiazem hcl) | 2 | |
| <i>diltiazem 24hr er 360 mg cap once-a-day dosage</i> (Tiadylt ER) | 2 | |
| <i>diltiazem 24hr er 420 mg cap</i> (Tiadylt ER) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>diltiazem hcl intravenous solution 5 mg/ml</i> | 2 | |
| <i>diltiazem hcl oral capsule, extended release 12 hr 120 mg, 60 mg, 90 mg</i> | 2 | |
| <i>diltiazem hcl oral capsule, extended release 24 hr 360 mg, 420 mg</i> (Tiadylt ER) | 2 | |
| <i>diltiazem hcl oral capsule, extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> (Cartia XT) | 2 | |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg</i> (Cardizem) | 2 | |
| <i>diltiazem hcl oral tablet 90 mg</i> | 2 | |
| <i>dilt-xr oral capsule, ext. rel 24h degradable 120 mg, 180 mg, 240 mg</i> (diltiazem hcl) | 2 | |
| <i>taztia xt oral capsule, extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg</i> (diltiazem hcl) | 2 | |
| <i>tiadylt er oral capsule, extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> (diltiazem hcl) | 2 | |
| <i>verapamil intravenous syringe 2.5 mg/ml</i> | 2 | |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i> (Verelan PM) | 2 | |
| <i>verapamil oral capsule, ext rel. pellets 24 hr 120 mg, 180 mg, 240 mg</i> | 2 | |
| <i>verapamil oral capsule, ext rel. pellets 24 hr 360 mg</i> | 4 | |
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | 1 | GC |
| <i>verapamil oral tablet extended release 120 mg, 240 mg</i> | 2 | |
| <i>verapamil oral tablet extended release 180 mg</i> | 2 | |
| Agentes Cardiovasculares, Varios | | |
| CORLANOR ORAL SOLUTION 5 MG/5 ML | 3 | QL (600 per 30 days) |
| <i>digitek oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> (digoxin) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>digox oral tablet 125 mcg (0.125 mg)</i> (digoxin) | 2 | |
| <i>digoxin injection solution 250 mcg/ml (0.25 mg/ml)</i> (Lanoxin) | 2 | |
| <i>digoxin injection syringe 250 mcg/ml (0.25 mg/ml)</i> | 2 | |
| <i>digoxin oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> (Digitek) | 2 | |
| <i>epinephrine injection auto-injector 0.15 mg/0.15 ml, 0.3 mg/0.3 ml</i> (Auvi-Q) | 2 | QL (4 per 30 days) |
| <i>epinephrine injection auto-injector 0.15 mg/0.3 ml</i> (EpiPen Jr) | 2 | QL (4 per 30 days) |
| <i>epinephrine injection solution 1 mg/ml</i> (Adrenalin) | 1 | GC |
| <i>hydralazine injection solution 20 mg/ml</i> | 2 | |
| <i>hydralazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>icatibant subcutaneous syringe 30 mg/3 ml</i> (Sajazir) | 5 | PA; NDS; QL (18 per 30 days) |
| <i>ivabradine oral tablet 5 mg, 7.5 mg</i> (Corlanor) | 3 | QL (60 per 30 days) |
| <i>metyrosine oral capsule 250 mg</i> (Demser) | 5 | NDS |
| <i>ranolazine oral tablet extended release 12 hr 1,000 mg</i> | 2 | QL (60 per 30 days) |
| <i>ranolazine oral tablet extended release 12 hr 500 mg</i> | 2 | QL (120 per 30 days) |
| <i>sajazir subcutaneous syringe 30 mg/3 ml</i> (icatibant) | 5 | PA; NDS; QL (18 per 30 days) |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG | 4 | PA; QL (30 per 30 days) |
| Antagonistas De Receptores De Angiotensina Ii | | |
| <i>candesartan oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> (Atacand) | 6 | GC |
| <i>candesartan-hydrochlorothiazid oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> (Atacand HCT) | 6 | GC |
| EDARBI ORAL TABLET 40 MG, 80 MG | 3 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| EDARBYCLOR ORAL TABLET 40-12.5 MG, 40-25 MG | 3 | |
| ENTRESTO ORAL TABLET 24-26 MG | 3 | QL (180 per 30 days) |
| ENTRESTO ORAL TABLET 49-51 MG, 97-103 MG | 3 | QL (60 per 30 days) |
| ENTRESTO SPRINKLE ORAL PELLET 15-16 MG, 6-6 MG | 3 | QL (240 per 30 days) |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> (Avapro) | 6 | GC |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> (Avalide) | 6 | GC |
| <i>losartan oral tablet 100 mg, 25 mg, 50 mg</i> (Cozaar) | 6 | GC |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> (Hyzaar) | 6 | GC |
| <i>olmesartan oral tablet 20 mg, 40 mg, 5 mg</i> (Benicar) | 6 | GC |
| <i>olmesartan-amlodipin-hcthiiazid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> (Tribenzor) | 6 | GC |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> (Benicar HCT) | 6 | GC |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> (Micardis) | 6 | GC |
| <i>telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> (Micardis HCT) | 6 | GC |
| <i>valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg</i> (Diovan) | 6 | GC |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> (Diovan HCT) | 6 | GC |
| Dihidropiridinas | | |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i> (Norvasc) | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>amlodipine-benazepril oral capsule</i> (Lotrel) 10-20 mg, 10-40 mg, 5-10 mg, 5-20 mg | 6 | GC |
| <i>amlodipine-benazepril oral capsule</i> 2.5-10 mg, 5-40 mg | 6 | GC |
| <i>amlodipine-olmesartan oral tablet</i> (Azor) 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg | 6 | GC |
| <i>amlodipine-valsartan oral tablet</i> 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg (Exforge) | 6 | GC |
| <i>amlodipine-valsartan-hcthiazyd oral tablet</i> 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg (Exforge HCT) | 6 | GC |
| <i>isradipine oral capsule</i> 2.5 mg, 5 mg | 2 | |
| <i>nicardipine oral capsule</i> 20 mg, 30 mg | 2 | |
| <i>nifedipine oral capsule</i> 10 mg, 20 mg | 2 | |
| <i>nifedipine oral tablet extended release</i> 24hr 30 mg, 60 mg, 90 mg (Procardia XL) | 2 | |
| <i>nifedipine oral tablet extended release</i> 30 mg, 60 mg, 90 mg | 2 | |
| Dislipidémicos | | |
| <i>amlodipine-atorvastatin oral tablet</i> 10-10 mg, 5-10 mg (Caduet) | 6 | GC |
| <i>amlodipine-atorvastatin oral tablet</i> 10-20 mg, 10-40 mg, 10-80 mg, 5-20 mg, 5-40 mg, 5-80 mg (Caduet) | 6 | GC; QL (30 per 30 days) |
| <i>amlodipine-atorvastatin oral tablet</i> 2.5-10 mg, 2.5-20 mg, 2.5-40 mg | 6 | GC |
| <i>atorvastatin oral tablet</i> 10 mg, 20 mg, 40 mg, 80 mg (Lipitor) | 6 | GC; QL (30 per 30 days) |
| <i>cholestyramine (with sugar) oral powder in packet</i> 4 gram (Questran) | 2 | |
| <i>cholestyramine light oral powder in packet</i> 4 gram (cholestyramine-aspartame) | 2 | |
| <i>colesevelam oral powder in packet</i> 3.75 gram (WelChol) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>colesevelam oral tablet 625 mg</i> (WelChol) | 2 | |
| <i>colestipol oral packet 5 gram</i> | 2 | |
| <i>colestipol oral tablet 1 gram</i> (Colestid) | 2 | |
| <i>ezetimibe oral tablet 10 mg</i> (Zetia) | 1 | GC; QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg</i> (Vytorin 10-10) | 6 | GC; QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-20 mg</i> (Vytorin 10-20) | 6 | GC; QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-40 mg</i> (Vytorin 10-40) | 6 | GC; QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-80 mg</i> (Vytorin 10-80) | 6 | GC; QL (30 per 30 days) |
| <i>fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 67 mg</i> | 2 | |
| <i>fenofibrate nanocrystallized oral tablet 145 mg, 48 mg</i> (Tricor) | 2 | |
| <i>fenofibrate oral tablet 160 mg, 54 mg</i> | 2 | |
| <i>fenofibric acid (choline) oral capsule, delayed release(dr/ec) 135 mg, 45 mg</i> (Trilipix) | 2 | |
| <i>fluvastatin oral capsule 20 mg, 40 mg</i> | 6 | GC; QL (60 per 30 days) |
| <i>fluvastatin oral tablet extended release 24 hr 80 mg</i> (Lescol XL) | 6 | GC |
| <i>gemfibrozil oral tablet 600 mg</i> (Lopid) | 1 | GC |
| JUXTAPID ORAL CAPSULE 10 MG, 5 MG | 5 | PA; NDS; QL (28 per 28 days) |
| JUXTAPID ORAL CAPSULE 20 MG, 30 MG | 5 | PA; NDS; QL (56 per 28 days) |
| LIVALO ORAL TABLET 1 MG, 2 MG, 4 MG (pitavastatin calcium) | 2 | QL (30 per 30 days) |
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i> | 6 | GC |
| NEXLETOL ORAL TABLET 180 MG | 3 | QL (30 per 30 days) |
| NEXLIZET ORAL TABLET 180-10 MG | 3 | QL (30 per 30 days) |
| <i>niacin oral tablet 500 mg</i> (Niacor) | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>niacin oral tablet extended release 24 hr 1,000 mg, 500 mg, 750 mg</i> | 2 | |
| <i>niacor oral tablet 500 mg</i> (niacin) | 2 | |
| <i>omega-3 acid ethyl esters oral capsule 1 gram</i> (Lovaza) | 2 | ST; QL (120 per 30 days) |
| PRALUENT PEN SUBCUTANEOUS PEN INJECTOR 150 MG/ML, 75 MG/ML | 3 | QL (2 per 28 days) |
| <i>pravastatin oral tablet 10 mg, 80 mg</i> | 6 | GC |
| <i>pravastatin oral tablet 20 mg, 40 mg</i> | 6 | GC; QL (30 per 30 days) |
| <i>prevalite oral powder in packet 4 gram</i> (cholestyramine-aspartame) | 2 | |
| REPATHA PUSHTRONEX SUBCUTANEOUS WEARABLE INJECTOR 420 MG/3.5 ML | 3 | QL (7 per 28 days) |
| REPATHA SURECLICK SUBCUTANEOUS PEN INJECTOR 140 MG/ML | 3 | QL (6 per 28 days) |
| REPATHA SYRINGE SUBCUTANEOUS SYRINGE 140 MG/ML | 3 | QL (6 per 28 days) |
| <i>rosuvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> (Crestor) | 6 | GC; QL (30 per 30 days) |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg</i> (Zocor) | 6 | GC; QL (30 per 30 days) |
| <i>simvastatin oral tablet 5 mg, 80 mg</i> | 6 | GC; QL (30 per 30 days) |
| VASCEPA ORAL CAPSULE 0.5 GRAM (icosapent ethyl) | 2 | QL (240 per 30 days) |
| VASCEPA ORAL CAPSULE 1 GRAM (icosapent ethyl) | 2 | QL (120 per 30 days) |
| Diuréticos | | |
| <i>amiloride oral tablet 5 mg</i> | 2 | |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i> | 2 | |
| <i>bumetanide injection solution 0.25 mg/ml</i> | 2 | |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>chlorothiazide sodium intravenous recon soln 500 mg</i> | 2 | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 2 | |
| <i>furosemide injection solution 10 mg/ml</i> | 2 | |
| <i>furosemide injection syringe 10 mg/ml</i> | 1 | GC |
| <i>furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)</i> | 1 | GC |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> (Lasix) | 1 | GC |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 1 | GC |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | GC |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 1 | GC |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> (Aldactone) | 1 | GC |
| <i>toremide oral tablet 10 mg, 100 mg, 5 mg</i> | 2 | |
| <i>toremide oral tablet 20 mg</i> (Soaanz) | 2 | |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i> | 1 | GC |
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg</i> | 1 | GC |
| Inhibidores De Enzima Convertidoras De Angiotensina | | |
| <i>benazepril oral tablet 10 mg, 20 mg, 40 mg</i> (Lotensin) | 6 | GC |
| <i>benazepril oral tablet 5 mg</i> | 6 | GC |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> (Lotensin HCT) | 6 | GC |
| <i>benazepril-hydrochlorothiazide oral tablet 5-6.25 mg</i> | 6 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 6 | GC |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> (Vasotec) | 6 | GC |
| <i>enalaprilat intravenous solution 1.25 mg/ml</i> | 2 | |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg</i> (Vaseretic) | 6 | GC |
| <i>enalapril-hydrochlorothiazide oral tablet 5-12.5 mg</i> | 6 | GC |
| <i>fosinopril oral tablet 10 mg, 20 mg, 40 mg</i> | 6 | GC |
| <i>fosinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg</i> | 6 | GC |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> (Zestril) | 6 | GC |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> (Zestoretic) | 6 | GC |
| <i>moexipril oral tablet 15 mg, 7.5 mg</i> | 6 | GC |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 6 | GC |
| <i>quinapril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> (Accupril) | 6 | GC |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> (Accuretic) | 6 | GC |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> (Altace) | 6 | GC |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 6 | GC |
| <i>trandolapril-verapamil oral tablet, ir - er, biphasic 24hr 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg</i> | 6 | GC |
| Inhibidores Del Sistema De Renina-Angiotensina-Aldosterona | | |
| <i>aliskiren oral tablet 150 mg, 300 mg</i> (Tekturna) | 2 | |
| <i>eplerenone oral tablet 25 mg, 50 mg</i> (Inspra) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| KERENDIA ORAL TABLET 10 MG, 20 MG | 3 | PA; QL (30 per 30 days) |
| Vasodilatadores | | |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg</i> | 2 | |
| <i>isosorbide dinitrate oral tablet 5 mg</i> (Isordil Titradose) | 2 | |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>isosorbide mononitrate oral tablet extended release 24 hr 120 mg, 30 mg, 60 mg</i> | 1 | GC |
| <i>isosorbide-hydralazine oral tablet 20-37.5 mg</i> (BiDil) | 2 | |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | 2 | |
| <i>nitroglycerin intravenous solution 50 mg/10 ml (5 mg/ml)</i> | 2 | |
| <i>nitroglycerin sublingual tablet 0.3 mg, 0.4 mg, 0.6 mg</i> (Nitrostat) | 2 | |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> (Nitro-Dur) | 2 | |
| Agentes De Enfermedad Intestinal Inflamatoria | | |
| Agentes De Enfermedad Intestinal Inflamatoria | | |
| <i>alose tron oral tablet 0.5 mg</i> (Lotronex) | 2 | |
| <i>alose tron oral tablet 1 mg</i> (Lotronex) | 5 | NDS |
| <i>balsalazide oral capsule 750 mg</i> (Colazal) | 2 | |
| <i>budesonide oral capsule, delayed, extend. release 3 mg</i> | 2 | |
| <i>budesonide rectal foam 2 mg/actuation</i> (Uceris) | 2 | |
| DIPENTUM ORAL CAPSULE 250 MG | 5 | ST; NDS |
| <i>hydrocortisone rectal enema 100 mg/60 ml</i> (Cortenema) | 2 | |
| <i>mesalamine oral capsule (with del rel tablets) 400 mg</i> (Delzicol) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|-----------------------------|
| <i>mesalamine oral capsule, extended release 24hr 0.375 gram</i> (Apriso) | 2 | |
| <i>mesalamine oral tablet, delayed release (dr/ec) 1.2 gram</i> (Lialda) | 2 | QL (120 per 30 days) |
| <i>mesalamine oral tablet, delayed release (dr/ec) 800 mg</i> | 2 | |
| <i>mesalamine rectal suppository 1,000 mg</i> (Canasa) | 2 | |
| <i>sulfasalazine oral tablet 500 mg</i> (Azulfidine) | 2 | |
| <i>sulfasalazine oral tablet, delayed release (dr/ec) 500 mg</i> (Azulfidine EN-tabs) | 4 | |
| Agentes De Enfermedad Ósea Metabólica | | |
| Agentes De Enfermedad Ósea Metabólica | | |
| <i>alendronate oral solution 70 mg/75 ml</i> | 2 | QL (300 per 28 days) |
| <i>alendronate oral tablet 10 mg, 5 mg</i> | 1 | GC; QL (30 per 30 days) |
| <i>alendronate oral tablet 35 mg</i> | 1 | GC; QL (4 per 28 days) |
| <i>alendronate oral tablet 70 mg</i> (Fosamax) | 1 | GC; QL (4 per 28 days) |
| <i>calcitonin (salmon) nasal spray, non-aerosol 200 unit/actuation</i> | 2 | QL (3.7 per 28 days) |
| <i>calcitriol intravenous solution 1 mcg/ml</i> | 2 | |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> (Rocaltrol) | 2 | |
| <i>calcitriol oral solution 1 mcg/ml</i> (Rocaltrol) | 2 | |
| <i>cinacalcet oral tablet 30 mg, 60 mg</i> (Sensipar) | 2 | QL (60 per 30 days) |
| <i>cinacalcet oral tablet 90 mg</i> (Sensipar) | 2 | QL (120 per 30 days) |
| <i>ibandronate intravenous solution 3 mg/3 ml</i> | 2 | QL (3 per 84 days) |
| <i>ibandronate intravenous syringe 3 mg/3 ml</i> | 2 | QL (3 per 84 days) |
| <i>ibandronate oral tablet 150 mg</i> | 1 | GC; QL (1 per 28 days) |
| NATPARA SUBCUTANEOUS CARTRIDGE 100 MCG/DOSE, 25 MCG/DOSE, 50 MCG/DOSE, 75 MCG/DOSE | 5 | PA; NDS; QL (2 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>paricalcitol oral capsule 1 mcg, 2 mcg</i> (Zemplar) | 2 | |
| <i>paricalcitol oral capsule 4 mcg</i> | 2 | |
| PROLIA SUBCUTANEOUS SYRINGE 60 MG/ML | 3 | QL (1 per 180 days) |
| RAYALDEE ORAL CAPSULE,EXTENDED RELEASE 24 HR 30 MCG | 3 | QL (60 per 30 days) |
| <i>risedronate oral tablet 150 mg</i> (Actonel) | 2 | QL (1 per 28 days) |
| <i>risedronate oral tablet 30 mg, 5 mg</i> | 2 | QL (30 per 30 days) |
| <i>risedronate oral tablet 35 mg</i> (Actonel) | 2 | QL (4 per 28 days) |
| <i>risedronate oral tablet 35 mg (12 pack), 35 mg (4 pack)</i> | 2 | QL (4 per 28 days) |
| <i>risedronate oral tablet, delayed release (dr/ec) 35 mg</i> (Atelvia) | 2 | QL (4 per 28 days) |
| <i>teriparatide subcutaneous pen injector 20 mcg/dose (620mcg/2.48ml)</i> | 2 | QL (2.48 per 28 days) |
| TYMLOS SUBCUTANEOUS PEN INJECTOR 80 MCG (3,120 MCG/1.56 ML) | 3 | QL (1.56 per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML) | 5 | PA; NDS |
| <i>zoledronic acid intravenous recon soln 4 mg</i> | 2 | |
| <i>zoledronic acid intravenous solution 4 mg/5 ml</i> | 2 | |
| <i>zoledronic acid-mannitol-water intravenous piggyback 5 mg/100 ml</i> (Reclast) | 2 | QL (100 per 300 days) |
| Agentes De Trastorno De Sueño | | |
| Agentes De Trastorno De Sueño | | |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> (Nuvigil) | 2 | PA; QL (30 per 30 days) |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | 3 | QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>eszopiclone oral tablet 1 mg, 2 mg, 3 mg</i> (Lunesta) | 2 | QL (30 per 30 days) |
| <i>modafinil oral tablet 100 mg</i> (Provigil) | 2 | PA; QL (30 per 30 days) |
| <i>modafinil oral tablet 200 mg</i> (Provigil) | 2 | PA; QL (60 per 30 days) |
| <i>sodium oxybate oral solution 500 mg/ml</i> (Xyrem) | 5 | PA; LA; NDS; QL (540 per 30 days) |
| SUNOSI ORAL TABLET 150 MG, 75 MG | 4 | PA; QL (30 per 30 days) |
| <i>tasimelteon oral capsule 20 mg</i> (Hetlioz) | 5 | PA; NDS; QL (30 per 30 days) |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | 1 | GC; QL (30 per 30 days) |
| <i>zolpidem oral tablet 10 mg, 5 mg</i> (Ambien) | 1 | GC; QL (30 per 30 days) |
| Agentes Del Sistema Nervioso Central | | |
| Agentes Del Sistema Nervioso Central | | |
| <i>atomoxetine oral capsule 10 mg, 18 mg, 25 mg, 40 mg</i> (Strattera) | 2 | QL (60 per 30 days) |
| <i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i> (Strattera) | 2 | QL (30 per 30 days) |
| AUSTEDO ORAL TABLET 12 MG, 9 MG | 5 | PA; NDS; QL (120 per 30 days) |
| AUSTEDO ORAL TABLET 6 MG | 5 | PA; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG | 5 | PA; NDS; QL (90 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 18 MG, 24 MG | 5 | PA; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 30 MG, 36 MG, 42 MG, 48 MG | 5 | PA; NDS; QL (30 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 6 MG | 5 | PA; NDS; QL (210 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|---------------------------------|
| AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24- 30 MG, 6 MG (14)-12 MG (14)-24 MG (14) | 5 | PA; NDS |
| AVONEX INTRAMUSCULAR PEN INJECTOR KIT 30 MCG/0.5 ML | 5 | PA; NDS; QL (1 per 28 days) |
| AVONEX INTRAMUSCULAR SYRINGE KIT 30 MCG/0.5 ML | 5 | PA; NDS; QL (1 per 28 days) |
| BETASERON SUBCUTANEOUS KIT 0.3 MG | 5 | PA; NDS; QL (15 per 30 days) |
| <i>caffeine citrate intravenous solution</i> (Cafcit) <i>60 mg/3 ml (20 mg/ml)</i> | 2 | PA BvD |
| <i>caffeine citrate oral solution 60 mg/3 ml (20 mg/ml)</i> | 2 | |
| COPAXONE SUBCUTANEOUS (glatiramer) SYRINGE 20 MG/ML | 5 | PA; NDS; QL (30 per 30 days) |
| COPAXONE SUBCUTANEOUS (glatiramer) SYRINGE 40 MG/ML | 5 | PA; NDS; QL (12 per 28 days) |
| <i>dalfampridine oral tablet extended release 12 hr 10 mg</i> (Ampyra) | 2 | PA; QL (60 per 30 days) |
| <i>dexmethylphenidate oral tablet 10 mg, 2.5 mg, 5 mg</i> (Focalin) | 2 | QL (60 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 10 mg</i> (Zenzedi) | 2 | QL (180 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 15 mg, 5 mg</i> (Zenzedi) | 2 | QL (90 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 20 mg, 30 mg</i> (Zenzedi) | 2 | QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 10 mg, 15 mg, 5 mg</i> (Adderall XR) | 2 | QL (30 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 20 mg, 25 mg, 30 mg</i> (Adderall XR) | 2 | QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg</i> (Adderall) | 2 | QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg</i> (Tecfidera) | 5 | PA; NDS; QL (14 per 7 days) |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg (14)- 240 mg (46)</i> (Tecfidera) | 5 | PA; NDS |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 240 mg</i> (Tecfidera) | 5 | PA; NDS; QL (60 per 30 days) |
| <i> fingolimod oral capsule 0.5 mg</i> (Gilenya) | 5 | PA; NDS; QL (30 per 30 days) |
| <i>flumazenil intravenous solution 0.1 mg/ml</i> | 2 | |
| GILENYA ORAL CAPSULE 0.25 MG | 5 | PA; NDS; QL (60 per 30 days) |
| <i>glatiramer subcutaneous syringe 20 mg/ml</i> (Copaxone) | 5 | PA; NDS; QL (30 per 30 days) |
| <i>glatiramer subcutaneous syringe 40 mg/ml</i> (Copaxone) | 5 | PA; NDS; QL (12 per 28 days) |
| <i>glatopa subcutaneous syringe 20 mg/ml</i> (glatiramer) | 5 | PA; NDS; QL (30 per 30 days) |
| <i>glatopa subcutaneous syringe 40 mg/ml</i> (glatiramer) | 5 | PA; NDS; QL (12 per 28 days) |
| <i>guanfacine oral tablet extended release 24 hr 1 mg, 2 mg, 3 mg, 4 mg</i> (Intuniv ER) | 2 | |
| INGREZZA INITIATION PK(TARDIV) ORAL CAPSULE,DOSE PACK 40 MG (7)- 80 MG (21) | 5 | PA; NDS |
| INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG | 5 | PA; NDS; QL (30 per 30 days) |
| INGREZZA SPRINKLE ORAL CAPSULE, SPRINKLE 40 MG, 60 MG, 80 MG | 5 | PA; NDS; QL (30 per 30 days) |
| KESIMPTA PEN SUBCUTANEOUS PEN INJECTOR 20 MG/0.4 ML | 5 | PA; NDS; QL (1.2 per 28 days) |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>lithium carbonate oral tablet 300 mg</i> | 2 | |
| <i>lithium carbonate oral tablet extended release 300 mg</i> (Lithobid) | 2 | |
| <i>lithium carbonate oral tablet extended release 450 mg</i> | 2 | |
| <i>lithium citrate oral solution 8 meq/5 ml</i> | 2 | |
| MAVENCLAD (10 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NDS |
| MAVENCLAD (4 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NDS |
| MAVENCLAD (5 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NDS |
| MAVENCLAD (6 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NDS |
| MAVENCLAD (7 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NDS |
| MAVENCLAD (8 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NDS |
| MAVENCLAD (9 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NDS |
| MAYZENT ORAL TABLET 0.25 MG | 5 | PA; NDS; QL (112 per 28 days) |
| MAYZENT ORAL TABLET 1 MG, 2 MG | 5 | PA; NDS; QL (30 per 30 days) |
| MAYZENT STARTER(FOR 1MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (7 TABS) | 4 | PA |
| MAYZENT STARTER(FOR 2MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (12 TABS) | 5 | PA; NDS |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 10 mg, 20 mg, 40 mg, 50 mg, 60 mg</i> (Metadate CD) | 2 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 30 mg</i> (Metadate CD) | 2 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 10 mg, 20 mg, 40 mg</i> (Ritalin LA) | 2 | QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 30 mg</i> (Ritalin LA) | 2 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 60 mg</i> | 2 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral solution 10 mg/5 ml, 5 mg/5 ml</i> (Methylin) | 2 | QL (900 per 30 days) |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> (Ritalin) | 2 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 10 mg</i> | 2 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 20 mg</i> (Metadate ER) | 2 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg (bx rating), 54 mg (bx rating)</i> | 2 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg, 27 mg, 54 mg</i> (Concerta) | 2 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 36 mg</i> (Concerta) | 2 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 36 mg (bx rating)</i> | 2 | QL (60 per 30 days) |
| OCREVUS INTRAVENOUS SOLUTION 30 MG/ML | 5 | PA; NDS; QL (20 per 180 days) |
| OCREVUS ZUNOVO SUBCUTANEOUS SOLUTION 920 MG-23,000 UNIT/23 ML | 5 | PA; NDS; QL (23 per 180 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML | 5 | PA; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 63 MCG/0.5 ML- 94 MCG/0.5 ML | 5 | PA; NDS |
| PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML | 5 | PA; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS SYRINGE 63 MCG/0.5 ML- 94 MCG/0.5 ML | 5 | PA; NDS |
| <i>riluzole oral tablet 50 mg</i> (Rilutek) | 2 | QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG | 3 | QL (60 per 30 days) |
| SAVELLA ORAL TABLETS,DOSE PACK 12.5 MG (5)-25 MG(8)-50 MG(42) | 3 | |
| TASCENSO ODT ORAL TABLET,DISINTEGRATING 0.25 MG, 0.5 MG | 5 | PA; NDS; QL (30 per 30 days) |
| <i>teriflunomide oral tablet 14 mg, 7 mg</i> (Aubagio) | 5 | PA; NDS; QL (30 per 30 days) |
| <i>tetrabenazine oral tablet 12.5 mg, 25 mg</i> (Xenazine) | 5 | PA; NDS; QL (112 per 28 days) |
| VUMERITY ORAL CAPSULE,DELAYED RELEASE(DR/EC) 231 MG | 5 | PA; NDS; QL (120 per 30 days) |
| Agentes Del Tracto Respiratorio | | |
| Agentes Del Tracto Respiratorio, Otros | | |
| <i>acetylcysteine intravenous solution 200 mg/ml (20 %)</i> (Acetadote) | 2 | |
| <i>acetylcysteine solution 100 mg/ml (10 %), 200 mg/ml (20 %)</i> | 2 | PA BvD |
| BRONCHITOL INHALATION CAPSULE, W/INHALATION DEVICE 40 MG | 5 | NDS; QL (560 per 28 days) |
| CINQAIR INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA; NDS |
| <i>cromolyn inhalation solution for nebulization 20 mg/2 ml</i> | 2 | PA BvD |
| FASENRA PEN SUBCUTANEOUS AUTO-INJECTOR 30 MG/ML | 5 | PA; NDS; QL (1 per 28 days) |
| FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML | 5 | PA; NDS; QL (1 per 28 days) |
| KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG | 5 | PA; NDS; QL (56 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| KALYDECO ORAL TABLET 150 MG | 5 | PA; NDS; QL (56 per 28 days) |
| NUCALA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 5 | PA; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS RECON SOLN 100 MG | 5 | PA; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML | 5 | PA; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML | 5 | PA; LA; NDS; QL (0.4 per 28 days) |
| OFEV ORAL CAPSULE 100 MG, 150 MG | 5 | PA; NDS; QL (60 per 30 days) |
| ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG, 75-94 MG | 5 | PA; NDS; QL (56 per 28 days) |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 5 | PA; NDS; QL (112 per 28 days) |
| <i>pirfenidone oral capsule 267 mg</i> (Esbriet) | 5 | PA; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 267 mg</i> (Esbriet) | 5 | PA; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 534 mg</i> | 5 | PA; NDS; QL (90 per 30 days) |
| <i>pirfenidone oral tablet 801 mg</i> (Esbriet) | 5 | PA; NDS; QL (90 per 30 days) |
| PROLASTIN-C INTRAVENOUS SOLUTION 1,000 MG (+/-)/20 ML | 5 | PA BvD; NDS |
| <i>roflumilast oral tablet 250 mcg</i> (Daliresp) | 2 | QL (28 per 28 days) |
| <i>roflumilast oral tablet 500 mcg</i> (Daliresp) | 2 | QL (30 per 30 days) |
| SYMDEKO ORAL TABLETS, SEQUENTIAL 100-150 MG (D)/150 MG (N), 50-75 MG (D)/75 MG (N) | 5 | PA; NDS; QL (56 per 28 days) |
| TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75 MG(D)/150 MG (N), 50-25-37.5 MG (D)/75 MG (N) | 5 | PA; NDS; QL (84 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|------------------------------|
| WINREVAIR SUBCUTANEOUS KIT 45 MG, 45 MG (2 PACK), 60 MG, 60 MG (2 PACK) | 5 | PA; NDS; QL (1 per 21 days) |
| XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML | 5 | PA; NDS |
| XOLAIR SUBCUTANEOUS RECON SOLN 150 MG | 5 | PA; NDS |
| XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML | 5 | PA; NDS |
| Antiinflamatorios, Corticoesteroides Inhalados | | |
| ADVAIR HFA INHALATION HFA AEROSOL INHALER 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION (fluticasone propion-salmeterol) | 3 | QL (12 per 30 days) |
| AIRSUPRA 90-80 MCG INHALER 90-80 MCG/ACTUATION | 3 | QL (32.1 per 30 days) |
| ARNUITY ELLIPTA INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION | 3 | QL (30 per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE (fluticasone furoate-vilanterol) | 3 | QL (60 per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 50-25 MCG/DOSE | 3 | QL (60 per 30 days) |
| <i>breyndra inhalation hfa aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> (budesonide-formoterol) | 2 | QL (30.9 per 30 days) |
| <i>budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml</i> (Pulmicort) | 2 | PA BvD; QL (120 per 30 days) |
| <i>budesonide inhalation suspension for nebulization 1 mg/2 ml</i> (Pulmicort) | 2 | PA BvD; QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>budesonide-formoterol inhalation hfa</i> (Breyna) <i>aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> | 2 | QL (30.6 per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 110 mcg/actuation</i> | 2 | QL (12 per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 220 mcg/actuation</i> | 2 | QL (24 per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 44 mcg/actuation</i> | 2 | QL (21.2 per 30 days) |
| <i>fluticasone propion-salmeterol</i> (Wixela Inhub) <i>inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | 2 | QL (60 per 30 days) |
| <i>wixela inhub inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> (fluticasone propion- salmeterol) | 2 | QL (60 per 30 days) |
| Antileucotrinos | | |
| <i>montelukast oral tablet 10 mg</i> (Singulair) | 1 | GC |
| <i>montelukast oral tablet, chewable 4 mg, 5 mg</i> (Singulair) | 1 | GC |
| <i>zafirlukast oral tablet 10 mg, 20 mg</i> (Accolate) | 2 | |
| Broncodilatadores | | |
| AIRSUPRA INHALATION HFA AEROSOL INHALER 90-80 MCG/ACTUATION | 3 | QL (32.1 per 30 days) |
| <i>albuterol sulfate inhalation hfa</i> (Ventolin HFA) <i>aerosol inhaler 90 mcg/actuation</i> | 2 | QL (17 per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)</i> | 2 | QL (13.4 per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020983)</i> | 2 | QL (36 per 30 days) |
| <i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %)</i> | 2 | PA BvD; QL (360 per 30 days) |
| <i>albuterol sulfate inhalation solution for nebulization 2.5 mg/0.5 ml</i> | 2 | PA BvD; QL (120 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>albuterol sulfate oral syrup 2 mg/5 ml</i> | 2 | |
| <i>albuterol sulfate oral tablet extended release 12 hr 4 mg, 8 mg</i> | 2 | |
| ANORO ELLIPTA INHALATION BLISTER WITH DEVICE 62.5-25 MCG/ACTUATION | 3 | QL (60 per 30 days) |
| ATROVENT HFA INHALATION HFA AEROSOL INHALER 17 MCG/ACTUATION | 4 | QL (25.8 per 28 days) |
| BREZTRI AEROSPHERE INHALATION HFA AEROSOL INHALER 160-9-4.8 MCG/ACTUATION | 3 | QL (10.7 per 30 days) |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION | 3 | QL (8 per 30 days) |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | 2 | PA BvD; QL (312.5 per 30 days) |
| <i>ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml</i> | 2 | PA BvD; QL (540 per 30 days) |
| SEREVENT DISKUS INHALATION BLISTER WITH DEVICE 50 MCG/DOSE | 3 | QL (60 per 30 days) |
| SPIRIVA RESPIMAT INHALATION MIST 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION | 3 | QL (4 per 30 days) |
| SPIRIVA WITH HANDIHALER (tiotropium bromide) INHALATION CAPSULE, W/INHALATION DEVICE 18 MCG | 2 | QL (30 per 30 days) |
| STIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION | 3 | QL (4 per 30 days) |
| STRIVERDI RESPIMAT INHALATION MIST 2.5 MCG/ACTUATION | 3 | QL (4 per 28 days) |
| <i>terbutaline oral tablet 2.5 mg, 5 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>theophylline oral solution 80 mg/15 ml</i> | 2 | |
| <i>theophylline oral tablet extended release 12 hr 100 mg, 200 mg, 300 mg, 450 mg</i> | 2 | |
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i> | 2 | |
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG, 200- 62.5-25 MCG | 3 | QL (60 per 30 days) |
| Agentes Dentales Y Orales | | |
| Agentes Dentales Y Orales | | |
| <i>cevimeline oral capsule 30 mg</i> (Evoxac) | 2 | |
| <i>chlorhexidine gluconate mucous membrane mouthwash 0.12 %</i> (Paroex Oral Rinse) | 1 | GC |
| <i>denta 5000 plus dental cream 1.1 %</i> (fluoride (sodium)) | 1 | GC |
| <i>dentagel dental gel 1.1 %</i> (fluoride (sodium)) | 1 | GC |
| <i>fluoride (sodium) dental solution 0.2 %</i> (PreviDent) | 1 | GC |
| KOURZEQ DENTAL PASTE 0.1 % (triamcinolone acetonide) | 2 | |
| <i>oralone dental paste 0.1 %</i> (triamcinolone acetonide) | 2 | |
| <i>paroex oral rinse mucous membrane mouthwash 0.12 %</i> (chlorhexidine gluconate) | 1 | GC |
| <i>perio gard mucous membrane mouthwash 0.12 %</i> (chlorhexidine gluconate) | 1 | GC |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i> (Salagen (pilocarpine)) | 2 | |
| <i>sf 5000 plus dental cream 1.1 %</i> (fluoride (sodium)) | 1 | GC |
| <i>sodium fluoride-pot nitrate dental paste 1.1-5 %</i> (Denta 5000 Plus Sensitive) | 1 | GC |
| <i>triamcinolone acetonide dental paste 0.1 %</i> (Kourzeq) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| Agentes Dermatológicos | | |
| Agentes Antiinflamatorios Dermatológicos | | |
| <i>ala-cort topical cream 1 %</i> (hydrocortisone) | 2 | |
| <i>alclometasone topical cream 0.05 %</i> | 2 | |
| <i>alclometasone topical ointment 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate topical cream 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate topical lotion 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate topical ointment 0.05 %</i> | 2 | |
| <i>betamethasone valerate topical cream 0.1 %</i> | 2 | |
| <i>betamethasone valerate topical lotion 0.1 %</i> | 2 | |
| <i>betamethasone valerate topical ointment 0.1 %</i> | 2 | |
| <i>betamethasone, augmented topical cream 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical gel 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical lotion 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical ointment 0.05 %</i> (Diprolene (augmented)) | 2 | |
| <i>clobetasol scalp solution 0.05 %</i> | 2 | |
| <i>clobetasol topical cream 0.05 %</i> | 2 | |
| <i>clobetasol topical gel 0.05 %</i> | 2 | |
| <i>clobetasol topical ointment 0.05 %</i> | 2 | |
| <i>clobetasol topical shampoo 0.05 %</i> (Clobex) | 2 | |
| <i>clobetasol-emollient topical cream 0.05 %</i> | 2 | |
| <i>desoximetasone topical cream 0.25 %</i> (Topicort) | 2 | QL (120 per 30 days) |
| <i>desoximetasone topical ointment 0.25 %</i> (Topicort) | 2 | QL (120 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| EUCRISA TOPICAL OINTMENT 2 % | 3 | |
| <i>fluocinolone topical cream 0.01 %</i> | 2 | |
| <i>fluocinolone topical cream 0.025 %</i> (Synalar) | 2 | |
| <i>fluocinolone topical ointment 0.025 %</i> (Synalar) | 2 | |
| <i>fluocinonide topical cream 0.05 %</i> | 2 | |
| <i>fluocinonide topical solution 0.05 %</i> | 2 | |
| <i>fluocinonide-emollient topical cream 0.05 %</i> (Fluocinonide-E) | 2 | |
| <i>fluticasone propionate topical cream 0.05 %</i> | 2 | |
| <i>fluticasone propionate topical ointment 0.005 %</i> | 2 | |
| <i>halobetasol propionate topical cream 0.05 %</i> | 2 | |
| <i>halobetasol propionate topical ointment 0.05 %</i> | 2 | |
| <i>hydrocortisone 2.5% cream</i> | 1 | GC |
| <i>hydrocortisone butyrate topical solution 0.1 %</i> | 2 | QL (120 per 30 days) |
| <i>hydrocortisone topical cream 1 %</i> (Ala-Cort) | 1 | GC |
| <i>hydrocortisone topical cream with perineal applicator 2.5 %</i> (Proctosol HC) | 1 | GC |
| <i>hydrocortisone topical lotion 2.5 %</i> | 2 | |
| <i>hydrocortisone topical ointment 1 %</i> (Anti-Itch (HC)) | 1 | GC |
| <i>hydrocortisone topical ointment 2.5 %</i> | 1 | GC |
| <i>hydrocortisone valerate topical cream 0.2 %</i> | 2 | |
| <i>mometasone topical cream 0.1 %</i> | 2 | |
| <i>mometasone topical ointment 0.1 %</i> | 2 | |
| <i>mometasone topical solution 0.1 %</i> | 2 | |
| <i>pimecrolimus topical cream 1 %</i> (Elidel) | 2 | QL (100 per 30 days) |
| <i>prednicarbate topical ointment 0.1 %</i> | 2 | |
| <i>procto-pak topical cream with perineal applicator 1 %</i> (hydrocortisone) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------|------------------------------|------------------------------------|
| <i>proctosol hc topical cream with perineal applicator 2.5 %</i> | (hydrocortisone) | 2 | |
| <i>proctozone-hc topical cream with perineal applicator 2.5 %</i> | (hydrocortisone) | 2 | |
| <i>tacrolimus topical ointment 0.03 %, 0.1 %</i> | | 2 | QL (100 per 30 days) |
| <i>triamcinolone acetonide topical cream 0.025 %</i> | | 1 | GC |
| <i>triamcinolone acetonide topical cream 0.1 %, 0.5 %</i> | (Triderm) | 1 | GC |
| <i>triamcinolone acetonide topical lotion 0.025 %, 0.1 %</i> | | 2 | |
| <i>triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %</i> | | 2 | |
| Agentes Dermatológicos, Otros | | | |
| <i>accutane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | (isotretinoin) | 2 | |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i> | | 2 | |
| <i>acyclovir topical ointment 5 %</i> | (Zovirax) | 2 | QL (30 per 30 days) |
| ALCOHOL 70% SWABS | (Alcohol Pads) | 1 | GC |
| ALCOHOL PADS TOPICAL PADS, MEDICATED | (alcohol swabs) | 1 | GC |
| ALCOHOL PREP SWABS TOPICAL PADS, MEDICATED | (alcohol swabs) | 1 | GC |
| ALCOHOL WIPES TOPICAL PADS, MEDICATED | (alcohol swabs) | 1 | GC |
| <i>ammonium lactate topical cream 12 %</i> | | 2 | |
| <i>ammonium lactate topical lotion 12 %</i> | (AmLactin) | 2 | |
| BD SINGLE USE SWAB | (alcohol swabs) | 1 | GC |
| <i>calcipotriene scalp solution 0.005 %</i> | | 2 | QL (120 per 30 days) |
| <i>calcipotriene topical cream 0.005 %</i> | | 2 | QL (120 per 30 days) |
| <i>calcipotriene topical ointment 0.005 %</i> | | 2 | QL (120 per 30 days) |
| CARETOUCH ALCOHOL 70% PREP PAD | (alcohol swabs) | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| CURITY ALCOHOL PREPS 2 PLY,MEDIUM (alcohol swabs) | 1 | GC |
| DROPSAFE ALCOHOL 70% PREP PADS (alcohol swabs) | 1 | GC |
| EASY COMFORT ALCOHOL 70% PAD (alcohol swabs) | 1 | GC |
| EASY TOUCH ALCOHOL 70% PADS GAMMA-STERILIZED (alcohol swabs) | 1 | GC |
| <i>fluorouracil topical cream 0.5 %</i> (Carac) | 5 | NDS |
| <i>fluorouracil topical cream 5 %</i> (Efudex) | 2 | |
| <i>fluorouracil topical solution 2 %, 5 %</i> | 2 | |
| HEB INCONTROL ALCOHOL 70% PADS (alcohol swabs) | 1 | GC |
| <i>imiquimod topical cream in packet 5 %</i> | 2 | QL (24 per 30 days) |
| IV ANTISEPTIC WIPES (alcohol swabs) | 1 | GC |
| KENDALL ALCOHOL 70% PREP PAD (alcohol swabs) | 1 | GC |
| KLISYRI TOPICAL OINTMENT IN PACKET 1 % | 3 | QL (5 per 5 days) |
| <i>methoxsalen oral capsule,liq-filled,rapid rel 10 mg</i> | 5 | NDS |
| PANRETIN TOPICAL GEL 0.1 % | 5 | NDS; QL (180 per 30 days) |
| <i>podofilox topical solution 0.5 %</i> | 2 | |
| PRO COMFORT ALCOHOL 70% PADS (alcohol swabs) | 1 | GC |
| PURE COMFORT ALCOHOL 70% PADS (alcohol swabs) | 1 | GC |
| SANTYL TOPICAL OINTMENT 250 UNIT/GRAM | 4 | QL (180 per 30 days) |
| SURE COMFORT ALCOHOL PREP PADS (alcohol swabs) | 1 | GC |
| SURE-PREP ALCOHOL PREP PADS (alcohol swabs) | 1 | GC |
| TRUE COMFORT ALCOHOL 70% PADS (alcohol swabs) | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| TRUE COMFORT PRO ALCOHOL PADS (alcohol swabs) | 1 | GC |
| ULTILET ALCOHOL STERL SWAB (alcohol swabs) | 1 | GC |
| VALCHLOR TOPICAL GEL 0.016 % | 5 | PA NSO; NDS |
| WEBCOL ALCOHOL PREPS 20'S,LARGE (alcohol swabs) | 1 | GC |
| zenatane oral capsule 10 mg, 20 mg, 30 mg, 40 mg (isotretinoin) | 2 | |
| Antibacterianos Dermatológicos | | |
| <i>clindamycin phosphate topical solution 1 %</i> | 2 | QL (180 per 30 days) |
| <i>clindamycin phosphate topical swab 1 %</i> (Clindacin ETZ) | 2 | |
| <i>clindamycin-benzoyl peroxide topical gel 1.2 %(1 % base) -5 %</i> (Neuac) | 2 | |
| <i>ery pads topical swab 2 %</i> (erythromycin with ethanol) | 2 | |
| <i>erythromycin with ethanol topical gel 2 %</i> (Erygel) | 2 | QL (180 per 30 days) |
| <i>erythromycin with ethanol topical solution 2 %</i> | 2 | QL (180 per 30 days) |
| <i>gentamicin topical cream 0.1 %</i> | 2 | QL (120 per 30 days) |
| <i>gentamicin topical ointment 0.1 %</i> | 2 | QL (120 per 30 days) |
| <i>metronidazole topical cream 0.75 %</i> (Rosadan) | 2 | |
| <i>metronidazole topical gel 0.75 %</i> (Rosadan) | 2 | |
| <i>metronidazole topical gel 1 %</i> (Metrogel) | 2 | |
| <i>metronidazole topical lotion 0.75 %</i> (MetroLotion) | 2 | |
| <i>mupirocin topical ointment 2 %</i> (Centany) | 1 | GC; QL (220 per 30 days) |
| <i>neomycin-polymyxin b gu irrigation solution 40 mg-200,000 unit/ml</i> | 2 | |
| <i>rosadan topical cream 0.75 %</i> (metronidazole) | 2 | |
| <i>selenium sulfide topical lotion 2.5 %</i> | 2 | |
| <i>silver sulfadiazine topical cream 1 %</i> (SSD) | 2 | |
| <i>ssd topical cream 1 %</i> (silver sulfadiazine) | 4 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| <i>sulfacetamide sodium (acne) topical suspension 10 %</i> (Klaron) | 2 | |
| Escabicidas Y Pediculicidas | | |
| <i>malathion topical lotion 0.5 %</i> (Ovide) | 2 | |
| <i>permethrin topical cream 5 %</i> (Elimite) | 2 | QL (60 per 30 days) |
| Retinoides Dermatológicos | | |
| <i>adapalene topical cream 0.1 %</i> (Differin) | 2 | |
| <i>adapalene topical gel 0.1 %</i> (Differin) | 2 | |
| ALTRENO TOPICAL LOTION 0.05 % | 4 | PA |
| <i>tazarotene topical cream 0.05 %, 0.1 %</i> (Tazorac) | 2 | |
| TAZORAC TOPICAL CREAM 0.05 % (tazarotene) | 4 | |
| <i>tretinoin topical cream 0.025 %</i> (Avita) | 2 | PA |
| <i>tretinoin topical cream 0.05 %, 0.1 %</i> (Retin-A) | 2 | PA |
| <i>tretinoin topical gel 0.01 %</i> (Retin-A) | 2 | PA |
| <i>tretinoin topical gel 0.025 %</i> (Avita) | 2 | PA |
| <i>tretinoin topical gel 0.05 %</i> (Atralin) | 2 | PA |
| Agentes Gastrointestinales | | |
| Agentes Antiúlceras Y Supresores De Ácidos | | |
| <i>cimetidine hcl oral solution 300 mg/5 ml</i> | 2 | |
| <i>esomeprazole magnesium oral capsule, delayed release(dr/ec) 20 mg</i> (Acid Reducer (esomeprazole)) | 2 | QL (30 per 30 days) |
| <i>esomeprazole magnesium oral capsule, delayed release(dr/ec) 40 mg</i> (Nexium) | 2 | QL (60 per 30 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet 10 mg, 20 mg</i> (Nexium Packet) | 2 | ST; QL (30 per 30 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet 40 mg</i> (Nexium Packet) | 2 | ST; QL (60 per 30 days) |
| <i>esomeprazole sodium intravenous recon soln 20 mg, 40 mg</i> | 2 | |
| <i>famotidine (pf) intravenous solution 20 mg/2 ml</i> | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>famotidine (pf)-nacl (iso-os) intravenous piggyback 20 mg/50 ml</i> | 2 | |
| <i>famotidine intravenous solution 10 mg/ml</i> | 2 | |
| <i>famotidine oral tablet 20 mg</i> (Acid Controller) | 1 | GC |
| <i>famotidine oral tablet 40 mg</i> (Pepcid) | 1 | GC |
| <i>lansoprazole oral capsule, delayed release(dr/ec) 15 mg</i> (Acid Reducer (lansoprazole)) | 1 | GC; QL (30 per 30 days) |
| <i>lansoprazole oral capsule, delayed release(dr/ec) 30 mg</i> (Prevacid) | 1 | GC; QL (60 per 30 days) |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> (Cytotec) | 2 | |
| <i>nizatidine oral capsule 150 mg, 300 mg</i> | 2 | |
| <i>omeprazole oral capsule, delayed release(dr/ec) 10 mg, 20 mg, 40 mg</i> | 1 | GC |
| <i>pantoprazole intravenous recon soln 40 mg</i> (Protonix) | 2 | |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 20 mg</i> (Protonix) | 1 | GC; QL (30 per 30 days) |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 40 mg</i> (Protonix) | 1 | GC; QL (60 per 30 days) |
| <i>rabeprazole oral tablet, delayed release (dr/ec) 20 mg</i> (AcipHex) | 2 | QL (30 per 30 days) |
| <i>sucralfate oral tablet 1 gram</i> (Carafate) | 2 | |
| Agentes Gastrointestinales, Otros | | |
| <i>carglumic acid oral tablet, dispersible 200 mg</i> (Carbaglu) | 5 | PA; NDS |
| <i>constulose oral solution 10 gram/15 ml</i> (lactulose) | 2 | |
| <i>cromolyn oral concentrate 100 mg/5 ml</i> (Gastrocrom) | 2 | |
| <i>dicyclomine oral capsule 10 mg</i> | 2 | |
| <i>dicyclomine oral solution 10 mg/5 ml</i> | 2 | |
| <i>dicyclomine oral tablet 20 mg</i> | 2 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> (Lomotil) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>enulose oral solution 10 gram/15 ml</i> (lactulose) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| GATTEX 30-VIAL SUBCUTANEOUS KIT 5 MG | 5 | PA; NDS |
| <i>generlac oral solution 10 gram/15 ml</i> (lactulose) | 2 | |
| <i>glycopyrrolate oral tablet 1 mg</i> (Robinul) | 2 | |
| <i>glycopyrrolate oral tablet 2 mg</i> (Robinul Forte) | 2 | |
| <i>kionex (with sorbitol) oral suspension 15-19.3 gram/60 ml, 15-20 gram/60 ml</i> | 2 | |
| <i>lactulose oral solution 10 gram/15 ml</i> (Constulose) | 2 | |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG | 3 | QL (30 per 30 days) |
| LOKELMA ORAL POWDER IN PACKET 10 GRAM | 3 | QL (34 per 30 days) |
| LOKELMA ORAL POWDER IN PACKET 5 GRAM | 3 | QL (30 per 30 days) |
| <i>loperamide oral capsule 2 mg</i> (Anti-Diarrheal (loperamide)) | 2 | |
| <i>lubiprostone oral capsule 24 mcg, 8 mcg</i> (Amitiza) | 3 | QL (60 per 30 days) |
| <i>methscopolamine oral tablet 2.5 mg, 5 mg</i> | 2 | |
| <i>metoclopramide hcl injection solution 5 mg/ml</i> | 2 | |
| <i>metoclopramide hcl injection syringe 5 mg/ml</i> | 2 | |
| <i>metoclopramide hcl oral solution 5 mg/5 ml</i> | 2 | |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> (Reglan) | 1 | GC |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG | 3 | QL (30 per 30 days) |
| OCALIVA ORAL TABLET 10 MG, 5 MG | 5 | PA; NDS; QL (30 per 30 days) |
| RAVICTI ORAL LIQUID 1.1 GRAM/ML | 5 | PA; NDS |
| <i>sodium phenylbutyrate oral tablet 500 mg</i> (Buphenyl) | 5 | PA; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>sodium polystyrene sulfonate oral powder</i> | 2 | |
| <i>sps (with sorbitol) oral suspension 15-20 gram/60 ml</i> | 2 | |
| <i>ursodiol oral capsule 300 mg</i> | 2 | |
| <i>ursodiol oral tablet 250 mg</i> | 2 | |
| <i>ursodiol oral tablet 500 mg</i> (URSO Forte) | 2 | |
| VELTASSA ORAL POWDER IN PACKET 16.8 GRAM, 25.2 GRAM, 8.4 GRAM | 3 | QL (30 per 30 days) |
| XERMELO ORAL TABLET 250 MG | 5 | PA; NDS; QL (84 per 28 days) |
| Enlaces De Fosfato | | |
| <i>calcium acetate(phosphat bind) oral capsule 667 mg</i> | 2 | |
| <i>calcium acetate(phosphat bind) oral tablet 667 mg</i> | 2 | |
| <i>sevelamer carbonate oral powder in packet 0.8 gram, 2.4 gram</i> (Renvela) | 2 | |
| <i>sevelamer carbonate oral tablet 800 mg</i> (Renvela) | 2 | |
| <i>sevelamer hcl oral tablet 400 mg, 800 mg</i> | 2 | |
| VELPHORO ORAL TABLET,CHEWABLE 500 MG | 3 | |
| Laxantes | | |
| CLENPIQ ORAL SOLUTION 10 MG-3.5 GRAM- 12 GRAM/160 ML, 10 MG-3.5 GRAM- 12 GRAM/175 ML | 3 | |
| <i>gavilyte-c oral recon soln 240-22.72-6.72 -5.84 gram</i> (peg 3350-electrolytes) | 2 | |
| <i>gavilyte-g oral recon soln 236-22.74-6.74 -5.86 gram</i> (peg 3350-electrolytes) | 2 | |
| <i>gavilyte-n oral recon soln 420 gram</i> (peg-electrolyte soln) | 2 | |
| <i>peg 3350-electrolytes oral recon soln 236-22.74-6.74 -5.86 gram</i> (GaviLyte-G) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| <i>peg-electrolyte soln oral recon soln</i> (GaviLyte-N) 420 gram | 2 | |
| <i>sodium,potassium,mag sulfates oral recon soln</i> (Suprep Bowel Prep Kit) 17.5-3.13-1.6 gram | 3 | |
| <i>sodium,potassium,mag sulfates oral recon soln</i> 17.5-3.13-1.6 gram 2 pack (480ml) | 3 | |
| SUTAB ORAL TABLET 1.479-0.188- 0.225 GRAM | 3 | |
| Agentes Genitourinarios | | |
| Agentes Genitourinarios, Varios | | |
| <i>alfuzosin oral tablet extended release</i> (Uroxatral) 24 hr 10 mg | 1 | GC; QL (30 per 30 days) |
| <i>dutasteride oral capsule</i> 0.5 mg (Avodart) | 2 | |
| <i>finasteride oral tablet</i> 5 mg (Proscar) | 1 | GC |
| <i>tamsulosin oral capsule</i> 0.4 mg (Flomax) | 1 | GC |
| <i>terazosin oral capsule</i> 1 mg, 10 mg, 2 mg, 5 mg | 1 | GC |
| <i>tiopronin oral tablet</i> 100 mg (Thiola) | 5 | NDS |
| Antiespasmódicos, Urinario | | |
| <i>bethanechol chloride oral tablet</i> 10 mg, 25 mg, 5 mg, 50 mg | 2 | |
| <i>fesoterodine oral tablet extended release</i> 24 hr 4 mg, 8 mg (Toviaz) | 2 | |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR 25 MG, 50 MG (mirabegron) | 2 | |
| <i>oxybutynin chloride oral syrup</i> 5 mg/5 ml | 2 | |
| <i>oxybutynin chloride oral tablet</i> 5 mg | 2 | |
| <i>oxybutynin chloride oral tablet extended release</i> 24hr 10 mg, 15 mg, 5 mg | 2 | |
| <i>solifenacin oral tablet</i> 10 mg, 5 mg (Vesicare) | 1 | GC |
| <i>tolterodine oral capsule,extended release</i> 24hr 2 mg, 4 mg (Detrol LA) | 2 | |
| <i>tolterodine oral tablet</i> 1 mg, 2 mg (Detrol) | 2 | |
| <i>tropium oral tablet</i> 20 mg | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|--------------------------|----------------------------|
| Agentes Hormonales, Estimulante/Reemplazo/Modificador | | |
| Agentes Tiroideos Y Antitiroideos | | |
| <i>levothyroxine oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg</i> | (Euthyrox) 1 | GC |
| <i>levothyroxine oral tablet 300 mcg</i> | (Levo-T) 1 | GC |
| <i>liothyronine oral tablet 25 mcg, 5 mcg, 50 mcg</i> | (Cytomel) 2 | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | 1 | GC |
| <i>propylthiouracil oral tablet 50 mg</i> | 2 | |
| Andrógenos | | |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | 2 | |
| <i>oxandrolone oral tablet 10 mg, 2.5 mg</i> | 2 | PA |
| <i>testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml</i> | (Depo-Testosterone) 2 | PA |
| <i>testosterone cypionate intramuscular oil 200 mg/ml (1 ml)</i> | 2 | PA |
| <i>testosterone enanthate intramuscular oil 200 mg/ml</i> | 2 | PA; QL (5 per 28 days) |
| <i>testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %)</i> | (Vogelxo) 2 | PA; QL (300 per 30 days) |
| <i>testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)</i> | (AndroGel) 2 | PA; QL (150 per 30 days) |
| <i>testosterone transdermal gel in packet 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram)</i> | (AndroGel) 2 | PA; QL (300 per 30 days) |
| <i>testosterone transdermal solution in metered pump w/app 30 mg/actuation (1.5 ml)</i> | 2 | PA; QL (180 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|--|
| XYOSTED SUBCUTANEOUS AUTO-INJECTOR 100 MG/0.5 ML, 50 MG/0.5 ML, 75 MG/0.5 ML | 3 | PA; QL (2 per 28 days) |
| Estrógenos Y Antiestrógenos | | |
| <i>amabelz oral tablet 0.5-0.1 mg, 1-0.5 mg</i> (estradiol-norethindrone acet) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>dotti transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> (estradiol) | 2 | PA-HRM; QL (8 per 28 days); AGE (Max 64 Years) |
| DUAVEE ORAL TABLET 0.45-20 MG | 3 | PA-HRM; AGE (Max 64 Years) |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> (Estrace) | 1 | PA-HRM; GC; AGE (Max 64 Years) |
| <i>estradiol transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> (Dotti) | 2 | PA-HRM; QL (8 per 28 days); AGE (Max 64 Years) |
| <i>estradiol transdermal patch weekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> (Climara) | 2 | PA-HRM; QL (4 per 28 days); AGE (Max 64 Years) |
| <i>estradiol vaginal cream 0.01 % (0.1 mg/gram)</i> (Estrace) | 2 | |
| <i>estradiol vaginal tablet 10 mcg</i> (Yuvaferm) | 2 | QL (18 per 28 days) |
| <i>estradiol valerate intramuscular oil 10 mg/ml, 20 mg/ml, 40 mg/ml</i> (Delestrogen) | 2 | |
| <i>estradiol-norethindrone acet oral tablet 0.5-0.1 mg</i> | 2 | PA-HRM; AGE (Max 64 Years) |
| FEMRING VAGINAL RING 0.05 MG/24 HR, 0.1 MG/24 HR | 4 | QL (1 per 84 days) |
| <i>fyavolv oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> (norethindrone ac-eth estradiol) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>jinteli oral tablet 1-5 mg-mcg</i> (norethindrone ac-eth estradiol) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>lyllana transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> (estradiol) | 2 | PA-HRM; QL (8 per 28 days); AGE (Max 64 Years) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|--------------------------------|-----------------------|----------------------------|
| <i>mimvey oral tablet 1-0.5 mg</i> | (estradiol-norethindrone acet) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | (Fyavolv) | 2 | PA-HRM; AGE (Max 64 Years) |
| PREMARIN INJECTION RECON SOLN 25 MG | | 3 | |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.9 MG | | 3 | PA-HRM; AGE (Max 64 Years) |
| PREMARIN ORAL TABLET 0.625 MG, 1.25 MG | (conjugated estrogens) | 3 | PA-HRM; AGE (Max 64 Years) |
| PREMARIN VAGINAL CREAM 0.625 MG/GRAM | | 3 | |
| PREMPHASE ORAL TABLET 0.625 MG (14)/ 0.625MG-5MG(14) | | 3 | PA-HRM; AGE (Max 64 Years) |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | | 3 | PA-HRM; AGE (Max 64 Years) |
| <i>raloxifene oral tablet 60 mg</i> | (Evista) | 2 | |
| <i>yuvafem vaginal tablet 10 mcg</i> | (estradiol) | 2 | QL (18 per 28 days) |
| Glucocorticoides/Mineralocorticoides | | | |
| <i>betamethasone acet,sod phos injection suspension 6 mg/ml</i> | (Celestone Soluspan) | 2 | |
| <i>dexamethasone oral solution 0.5 mg/5 ml</i> | | 2 | |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i> | | 2 | |
| <i>dexamethasone sodium phos (pf) injection solution 10 mg/ml</i> | | 1 | GC |
| <i>dexamethasone sodium phos (pf) injection syringe 10 mg/ml</i> | | 1 | GC |
| <i>dexamethasone sodium phosphate injection solution 10 mg/ml, 4 mg/ml</i> | | 1 | GC |
| <i>dexamethasone sodium phosphate injection syringe 4 mg/ml</i> | | 2 | |
| <i>fludrocortisone oral tablet 0.1 mg</i> | | 2 | |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> | (Cortef) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|------------------------------|
| <i>methylprednisolone acetate injection</i> (Depo-Medrol) <i>suspension 40 mg/ml, 80 mg/ml</i> | 2 | |
| <i>methylprednisolone oral tablet 16 mg, 4 mg, 8 mg</i> (Medrol) | 2 | |
| <i>methylprednisolone oral tablet 32 mg</i> | 2 | |
| <i>methylprednisolone oral tablets, dose pack 4 mg</i> (Medrol (Pak)) | 2 | |
| <i>methylprednisolone sodium succ injection recon soln 125 mg, 40 mg</i> | 2 | |
| <i>methylprednisolone sodium succ intravenous recon soln 1,000 mg</i> (Solu-Medrol) | 1 | GC |
| <i>prednisolone 15 mg/5 ml soln d/f 15 mg/5 ml (3 mg/ml)</i> | 2 | PA BvD |
| <i>prednisolone oral solution 15 mg/5 ml</i> | 2 | PA BvD |
| <i>prednisolone sodium phosphate oral solution 25 mg/5 ml (5 mg/ml)</i> | 2 | PA BvD |
| <i>prednisolone sodium phosphate oral solution 5 mg base/5 ml (6.7 mg/5 ml)</i> (Pediapred) | 2 | PA BvD |
| <i>prednisone oral solution 5 mg/5 ml</i> | 2 | PA BvD |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | 1 | PA BvD; GC |
| <i>prednisone oral tablets, dose pack 10 mg, 10 mg (48 pack), 5 mg, 5 mg (48 pack)</i> | 2 | |
| SOLU-CORTEF ACT-O-VIAL (PF) INJECTION RECON SOLN 100 MG/2 ML | 4 | |
| <i>triamcinolone acetate injection</i> (Kenalog) <i>suspension 40 mg/ml</i> | 2 | |
| Pituitario | | |
| ACTHAR INJECTION GEL 80 UNIT/ML | 5 | PA; NDS; QL (35 per 28 days) |
| ACTHAR SELFJECT SUBCUTANEOUS PEN INJECTOR 40 UNIT/0.5 ML | 5 | PA; NDS; QL (15 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|-----------------------------------|
| ACTHAR SELFJECT SUBCUTANEOUS PEN INJECTOR 80 UNIT/ML | 5 | PA; NDS; QL (30 per 30 days) |
| CORTROPHIN GEL INJECTION GEL 80 UNIT/ML | 5 | PA; NDS; QL (35 per 28 days) |
| <i>desmopressin 10 mcg/0.1 ml spr 10 mcg/spray (0.1 ml)</i> | 2 | |
| <i>desmopressin injection solution 4 mcg/ml</i> (DDAVP) | 2 | |
| <i>desmopressin nasal spray, non-aerosol 10 mcg/spray (0.1 ml)</i> | 2 | |
| <i>desmopressin oral tablet 0.1 mg, 0.2 mg</i> (DDAVP) | 2 | |
| EGRIFTA SV SUBCUTANEOUS RECON SOLN 2 MG | 5 | PA; NDS; QL (30 per 30 days) |
| INCRELEX SUBCUTANEOUS SOLUTION 10 MG/ML | 5 | NDS |
| <i>lanreotide subcutaneous syringe 120 mg/0.5 ml</i> (Somatuline Depot) | 5 | PA NSO; NDS; QL (0.5 per 28 days) |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG | 5 | PA NSO; NDS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG, 7.5 MG | 5 | PA NSO; NDS |
| NORDITROPIN FLEXP SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) | 5 | PA; NDS |
| <i>octreotide acetate injection solution 1,000 mcg/ml, 200 mcg/ml</i> | 2 | |
| <i>octreotide acetate injection solution 100 mcg/ml, 50 mcg/ml</i> (Sandostatin) | 2 | |
| <i>octreotide acetate injection solution 500 mcg/ml</i> (Sandostatin) | 5 | NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|--------------------------------------|
| <i>octreotide acetate injection syringe</i> 100 mcg/ml (1 ml), 50 mcg/ml (1 ml), 500 mcg/ml (1 ml) | 2 | |
| ORGOVYX ORAL TABLET 120 MG | 5 | PA NSO; NDS |
| ORILISSA ORAL TABLET 150 MG | 5 | PA; NDS; QL (28 per 28 days) |
| ORILISSA ORAL TABLET 200 MG | 5 | PA; NDS; QL (56 per 28 days) |
| SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG | 5 | PA; NDS |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) | 5 | PA; NDS; QL (60 per 30 days) |
| SOMATULINE DEPOT (lanreotide) SUBCUTANEOUS SYRINGE 120 MG/0.5 ML | 5 | PA NSO; NDS; QL (0.5 per 28 days) |
| SOMATULINE DEPOT (lanreotide) SUBCUTANEOUS SYRINGE 60 MG/0.2 ML | 5 | PA NSO; NDS; QL (0.2 per 28 days) |
| SOMATULINE DEPOT (lanreotide) SUBCUTANEOUS SYRINGE 90 MG/0.3 ML | 5 | PA NSO; NDS; QL (0.3 per 28 days) |
| SOMAVERT SUBCUTANEOUS RECON SOLN 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; NDS |
| SYNAREL NASAL SPRAY, NON- AEROSOL 2 MG/ML | 5 | PA; NDS |
| Progestinas | | |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SYRINGE 104 MG/0.65 ML | 4 | QL (1 per 84 days) |
| <i>gallifrey oral tablet 5 mg</i> (norethindrone acetate) | 2 | |
| <i>medroxyprogesterone intramuscular</i> <i>suspension 150 mg/ml</i> (Depo-Provera) | 2 | QL (1 per 84 days) |
| <i>medroxyprogesterone intramuscular</i> <i>syringe 150 mg/ml</i> (Depo-Provera) | 2 | QL (1 per 84 days) |
| <i>medroxyprogesterone oral tablet 10</i> <i>mg, 2.5 mg, 5 mg</i> (Provera) | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|---------------------------------|
| <i>megestrol oral suspension 400 mg/10 ml (40 mg/ml)</i> | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>norethindrone acetate oral tablet 5 mg</i> (Gallifrey) | 2 | |
| <i>progesterone intramuscular oil 50 mg/ml</i> | 2 | |
| <i>progesterone micronized oral capsule 100 mg, 200 mg</i> (Prometrium) | 2 | |
| Agentes Inmunológicos | | |
| Agentes Inmunológicos | | |
| ACTEMRA ACTPEN SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML | 5 | PA; NDS |
| ACTEMRA INTRAVENOUS SOLUTION 200 MG/10 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) | 5 | PA; NDS |
| ACTEMRA SUBCUTANEOUS SYRINGE 162 MG/0.9 ML | 5 | PA; NDS |
| ARCALYST SUBCUTANEOUS RECON SOLN 220 MG | 5 | NDS |
| ASTAGRAF XL ORAL CAPSULE, EXTENDED RELEASE 24HR 0.5 MG, 1 MG, 5 MG (tacrolimus) | 4 | PA BvD |
| <i>azathioprine oral tablet 50 mg</i> (Imuran) | 2 | PA BvD |
| <i>azathioprine sodium injection recon soln 100 mg</i> | 2 | PA BvD |
| BENLYSTA SUBCUTANEOUS AUTO-INJECTOR 200 MG/ML | 5 | PA; NDS; QL (8 per 28 days) |
| BENLYSTA SUBCUTANEOUS SYRINGE 200 MG/ML | 5 | PA; NDS; QL (8 per 28 days) |
| BESREMI SUBCUTANEOUS SYRINGE 500 MCG/ML | 5 | PA NSO; NDS; QL (2 per 28 days) |
| COSENTYX (2 SYRINGES) SUBCUTANEOUS SYRINGE 150 MG/ML | 5 | PA; NDS |
| COSENTYX PEN (2 PENS) SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 5 | PA; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML | 5 | PA; NDS |
| COSENTYX UNOREADY PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML (150 MG/ML) | 5 | PA; NDS |
| <i>cyclosporine intravenous solution</i> (Sandimmune) 250 mg/5 ml | 2 | PA BvD |
| <i>cyclosporine modified oral capsule</i> (Gengraf) 100 mg, 25 mg | 2 | PA BvD |
| <i>cyclosporine modified oral capsule</i> 50 mg | 2 | PA BvD |
| <i>cyclosporine modified oral solution</i> (Gengraf) 100 mg/ml | 2 | PA BvD |
| <i>cyclosporine oral capsule</i> 100 mg, 25 mg (Sandimmune) | 2 | PA BvD |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML | 5 | PA; NDS |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML | 5 | PA; NDS |
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML) | 5 | PA; NDS |
| ENBREL SUBCUTANEOUS RECON SOLN 25 MG (1 ML) | 5 | PA; NDS |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML | 5 | PA; NDS |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) | 5 | PA; NDS |
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML) | 5 | PA; NDS |
| <i>everolimus (immunosuppressive) oral tablet</i> 0.25 mg, 0.5 mg, 0.75 mg, 1 mg (Zortress) | 5 | PA BvD; NDS |
| FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 %, 5 % | 5 | PA BvD; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|--|
| GAMIFANT INTRAVENOUS SOLUTION 5 MG/ML | 5 | PA; NDS |
| GAMMAGARD LIQUID INJECTION SOLUTION 10 % | 5 | PA BvD; NDS |
| GAMMAGARD S-D (IGA < 1 MCG/ML) INTRAVENOUS RECON SOLN 10 GRAM, 5 GRAM | 5 | PA BvD; NDS |
| GAMMAPLEX (WITH SORBITOL) INTRAVENOUS SOLUTION 5 % | 5 | PA BvD; NDS |
| GAMMAPLEX INTRAVENOUS SOLUTION 10 %, 10 % (100 ML), 10 % (200 ML) | 5 | PA BvD; NDS |
| <i>gengraf oral capsule 100 mg, 25 mg</i> (cyclosporine modified) | 2 | PA BvD |
| <i>gengraf oral solution 100 mg/ml</i> (cyclosporine modified) | 2 | PA BvD |
| HUMIRA PEN CROHNS-UC-HS START SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA PEN PSOR-UVEITS-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN CROHNS-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN PEDIATRIC UC SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML-40 MG/0.4 ML | 5 | PA; NDS; Only NDCs starting with 00074 |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|---|
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 80 MG/0.8 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML | 5 | PA; NDS; Only NDCs starting with 00074 |
| <i>infliximab intravenous recon soln</i> (Remicade) 100 mg | 5 | PA; NDS |
| KEVZARA SUBCUTANEOUS PEN INJECTOR 150 MG/1.14 ML, 200 MG/1.14 ML | 5 | PA; NDS |
| KEVZARA SUBCUTANEOUS SYRINGE 150 MG/1.14 ML, 200 MG/1.14 ML | 5 | PA; NDS |
| KINERET SUBCUTANEOUS SYRINGE 100 MG/0.67 ML | 5 | PA; NDS |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> (Arava) | 2 | |
| <i>mycophenolate mofetil (hcl)</i> (CellCept Intravenous) <i>intravenous recon soln 500 mg</i> | 2 | PA BvD |
| <i>mycophenolate mofetil oral capsule</i> (CellCept) 250 mg | 2 | PA BvD |
| <i>mycophenolate mofetil oral</i> (CellCept) <i>suspension for reconstitution 200</i> <i>mg/ml</i> | 5 | PA BvD; NDS |
| <i>mycophenolate mofetil oral tablet</i> (CellCept) 500 mg | 2 | PA BvD |
| <i>mycophenolate sodium oral</i> (Myfortic) <i>tablet, delayed release (dr/ec) 180</i> <i>mg, 360 mg</i> | 2 | PA BvD |
| NULOJIX INTRAVENOUS RECON SOLN 250 MG | 5 | PA BvD; NDS |
| OCTAGAM INTRAVENOUS SOLUTION 10 %, 5 % | 5 | PA BvD; NDS |
| OLUMIANT ORAL TABLET 1 MG, 2 MG, 4 MG | 5 | PA; NDS |
| ORENCIA (WITH MALTOSE) INTRAVENOUS RECON SOLN 250 MG | 5 | PA; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| ORENCIA CLICKJECT SUBCUTANEOUS AUTO- INJECTOR 125 MG/ML | 5 | PA; NDS |
| ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML | 5 | PA; NDS |
| OTEZLA ORAL TABLET 20 MG, 30 MG | 5 | PA; NDS |
| OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)- 30 MG (47), 10 MG (4)-20 MG (4)- 30 MG(19) | 5 | PA; NDS |
| PRIVIGEN INTRAVENOUS SOLUTION 10 % | 5 | PA BvD; NDS |
| PROGRAF INTRAVENOUS SOLUTION 5 MG/ML | 4 | PA BvD |
| PROGRAF ORAL GRANULES IN PACKET 0.2 MG, 1 MG | 4 | PA BvD; ST |
| RASUVO (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.2 ML, 12.5 MG/0.25 ML, 15 MG/0.3 ML, 17.5 MG/0.35 ML, 20 MG/0.4 ML, 22.5 MG/0.45 ML, 25 MG/0.5 ML, 30 MG/0.6 ML, 7.5 MG/0.15 ML | 3 | |
| REZUROCK ORAL TABLET 200 MG | 5 | PA NSO; NDS |
| RIDAURA ORAL CAPSULE 3 MG | 5 | NDS |
| RINVOQ LQ ORAL SOLUTION 1 MG/ML | 5 | PA; NDS; QL (360 per 30 days) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG | 5 | PA; NDS |
| <i>sirolimus oral solution 1 mg/ml</i> | 5 | PA BvD; NDS |
| <i>sirolimus oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | PA BvD |
| SKYRIZI INTRAVENOUS SOLUTION 60 MG/ML | 5 | PA; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| SKYRIZI SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 5 | PA; NDS |
| SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.83 ML | 5 | PA; NDS |
| SKYRIZI SUBCUTANEOUS SYRINGE KIT 150MG/1.66ML(75 MG/0.83 ML X2) | 5 | PA; NDS |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML) | 5 | PA; NDS |
| STELARA INTRAVENOUS SOLUTION 130 MG/26 ML | 5 | PA; NDS |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5 ML | 5 | PA; NDS |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML | 5 | PA; NDS |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i> (Prograf) | 2 | PA BvD |
| TALTZ AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML | 5 | PA; NDS |
| TALTZ SYRINGE SUBCUTANEOUS SYRINGE 20 MG/0.25 ML, 40 MG/0.5 ML, 80 MG/ML | 5 | PA; NDS |
| TREMFYA INTRAVENOUS SOLUTION 200 MG/20 ML (10 MG/ML) | 5 | PA; NDS |
| TREMFYA PEN SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML | 5 | PA; NDS |
| TREMFYA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 5 | PA; NDS |
| TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML, 200 MG/2 ML | 5 | PA; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| TYSABRI INTRAVENOUS SOLUTION 300 MG/15 ML | 5 | PA; LA; NDS |
| XELJANZ ORAL SOLUTION 1 MG/ML | 5 | PA; NDS |
| XELJANZ ORAL TABLET 10 MG, 5 MG | 5 | PA; NDS |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG, 22 MG | 5 | PA; NDS |
| Vacunas | | |
| ABRYSVO (PF) INTRAMUSCULAR RECON SOLN 120 MCG/0.5 ML | 6 | GC; \$0 copay |
| ACTHIB (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 6 | GC |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SUSPENSION 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 6 | GC; \$0 copay |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SYRINGE 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 6 | GC; \$0 copay |
| AREXVY (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 120 MCG/0.5 ML | 6 | GC; \$0 copay |
| AREXVY ANTIGEN COMPONENT 120 MCG | 6 | GC; \$0 copay |
| BCG VACCINE, LIVE (PF) PERCUTANEOUS SUSPENSION FOR RECONSTITUTION 50 MG | 6 | GC; \$0 copay |
| BEXSERO INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML | 6 | GC; \$0 copay |
| BOOSTRIX TDAP INTRAMUSCULAR SUSPENSION 2.5-8-5 LF-MCG-LF/0.5ML | 6 | GC; \$0 copay |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---|
| BOOSTRIX TDAP INTRAMUSCULAR SYRINGE 2.5- 8-5 LF-MCG-LF/0.5ML | 6 | GC; \$0 copay |
| DAPTACEL (DTAP PEDIATRIC) (PF) INTRAMUSCULAR SUSPENSION 15-10-5 LF-MCG- LF/0.5ML | 6 | GC |
| DENGVAXIA (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP4.5-6 CCID50/0.5 ML | 6 | GC; QL (3 per 365 days) |
| ENGERIX-B (PF) INTRAMUSCULAR SUSPENSION 20 MCG/ML | 6 | PA BvD; GC; \$0 copay |
| ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML | 6 | PA BvD; GC; \$0 copay |
| ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE 10 MCG/0.5 ML | 6 | PA BvD; GC; \$0 copay |
| GARDASIL 9 (PF) INTRAMUSCULAR SUSPENSION 0.5 ML | 6 | GC; \$0 copay; QL (1.5 per 365 days) |
| GARDASIL 9 (PF) INTRAMUSCULAR SYRINGE 0.5 ML | 6 | GC; \$0 copay; QL (1.5 per 365 days) |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 1,440 ELISA UNIT/ML | 6 | GC; \$0 copay |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT/0.5 ML | 6 | GC |
| HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/0.5 ML | 6 | PA BvD; GC; \$0 copay |
| HIBERIX (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 6 | GC |
| IMOVAX RABIES VACCINE (PF) INTRAMUSCULAR RECON SOLN 2.5 UNIT | 6 | PA BvD; GC; \$0 copay |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE 25- 58-10 LF-MCG-LF/0.5ML | 6 | GC |
| IPOL INJECTION SUSPENSION 40-8-32 UNIT/0.5 ML | 6 | GC; \$0 copay |
| IXCHIQ (PF) INTRAMUSCULAR RECON SOLN 1,000 TCID50/0.5 ML | 6 | GC; \$0 copay |
| IXIARO (PF) INTRAMUSCULAR SYRINGE 6 MCG/0.5 ML | 6 | GC; \$0 copay |
| JYNNEOS (PF) SUBCUTANEOUS SUSPENSION 0.5X TO 3.95X 10EXP8 UNIT/0.5 | 6 | GC; \$0 copay |
| KINRIX (PF) INTRAMUSCULAR SYRINGE 25 LF-58 MCG-10 LF/0.5 ML | 6 | GC |
| MENACTRA (PF) INTRAMUSCULAR SOLUTION 4 MCG/0.5 ML | 6 | GC; \$0 copay |
| MENQUADFI (PF) INTRAMUSCULAR SOLUTION 10 MCG/0.5 ML | 6 | GC; \$0 copay |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT 10-5 MCG/0.5 ML | 6 | GC; \$0 copay |
| M-M-R II (PF) SUBCUTANEOUS RECON SOLN 1,000-12,500 TCID50/0.5 ML | 6 | GC; \$0 copay |
| MRESVIA (PF) INTRAMUSCULAR SYRINGE 50 MCG/0.5 ML | 6 | GC; \$0 copay |
| PEDIARIX (PF) INTRAMUSCULAR SYRINGE 10 MCG-25LF-25 MCG-10LF/0.5 ML | 6 | GC |
| PEDVAX HIB (PF) INTRAMUSCULAR SOLUTION 7.5 MCG/0.5 ML | 6 | GC |
| PENBRAYA (PF) INTRAMUSCULAR KIT 5-120 MCG/0.5 ML | 6 | GC; \$0 copay |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| PENBRAYA MENACWY COMPONENT(PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 5 MCG/0.5 ML | 6 | GC; \$0 copay |
| PENBRAYA MENB COMPONENT (PF) INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML | 6 | GC; \$0 copay |
| PENTACEL (PF) INTRAMUSCULAR KIT 15LF-48MCG-62DU -10 MCG/0.5ML | 6 | GC |
| PREHEVBRIO (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML | 6 | PA BvD; GC; \$0 copay |
| PRIORIX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3.4-4.2-3.3CCID50/0.5ML | 6 | GC; \$0 copay |
| PROQUAD (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3-4.3-3-3.99 TCID50/0.5 | 6 | GC |
| QUADRACEL (PF) INTRAMUSCULAR SUSPENSION 15 LF-48 MCG- 5 LF UNIT/0.5ML, 15 LF-48 MCG- 5 LF UNIT/0.5ML (58 UNT/ML) | 6 | GC |
| QUADRACEL (PF) INTRAMUSCULAR SYRINGE 15 LF-48 MCG- 5 LF UNIT/0.5ML | 6 | GC |
| RABAVERT (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 2.5 UNIT | 6 | PA BvD; GC; \$0 copay |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML | 6 | PA BvD; GC; \$0 copay |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE 10 MCG/ML, 5 MCG/0.5 ML | 6 | PA BvD; GC; \$0 copay |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|---|
| ROTARIX ORAL SUSPENSION 10EXP6 CCID50 /1.5 ML | 6 | GC |
| ROTARIX ORAL SUSPENSION FOR RECONSTITUTION 10EXP6 CCID50/ML | 6 | GC |
| ROTATEQ VACCINE ORAL SOLUTION 2 ML | 6 | GC |
| SHINGRIX (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 50 MCG/0.5 ML | 6 | GC; \$0 copay; QL (2 per 365 days) |
| TDVAX INTRAMUSCULAR (tetanus-diphtheria SUSPENSION 2-2 LF UNIT/0.5 ML toxoids-td) | 6 | GC; \$0 copay |
| TENIVAC (PF) INTRAMUSCULAR SUSPENSION 5 LF UNIT- 2 LF UNIT/0.5ML | 6 | GC; \$0 copay |
| TENIVAC (PF) INTRAMUSCULAR SYRINGE 5-2 LF UNIT/0.5 ML | 6 | GC; \$0 copay |
| TETANUS,DIPHThERIA TOX PED(PF) INTRAMUSCULAR SUSPENSION 5-25 LF UNIT/0.5 ML | 6 | GC |
| TICOVAC INTRAMUSCULAR SYRINGE 1.2 MCG/0.25 ML | 6 | GC; QL (0.75 per 365 days) |
| TICOVAC INTRAMUSCULAR SYRINGE 2.4 MCG/0.5 ML | 6 | GC; \$0 copay; QL (1.5 per 365 days) |
| TRUMENBA INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML | 6 | GC; \$0 copay |
| TWINRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT- 20 MCG/ML | 6 | GC; \$0 copay |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5 ML | 6 | GC; \$0 copay |
| TYPHIM VI INTRAMUSCULAR (typhoid vi polysacch SYRINGE 25 MCG/0.5 ML vaccine) | 6 | GC; \$0 copay |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 25 UNIT/0.5 ML | 6 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---------------------------------------|
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 50 UNIT/ML | 6 | GC; \$0 copay |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 25 UNIT/0.5 ML | 6 | GC |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 50 UNIT/ML | 6 | GC; \$0 copay |
| VARIVAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 1,350 UNIT/0.5 ML | 6 | GC; \$0 copay; QL (2 per 365 days) |
| VAXCHORA VACCINE ORAL SUSPENSION FOR RECONSTITUTION 4X10EXP8 TO 2X 10EXP9 CF UNIT | 6 | GC; \$0 copay |
| YF-VAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10 EXP4.74 UNIT/0.5 ML, 10 EXP4.74 UNIT/0.5 ML(2.5 ML IN 1 VIAL) | 6 | GC; \$0 copay |
| Agentes Oftálmicos | | |
| Agentes Antiglaucoma | | |
| <i>acetazolamide oral capsule, extended release 500 mg</i> | 2 | |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 2 | |
| <i>acetazolamide sodium injection recon soln 500 mg</i> | 2 | |
| <i>brimonidine ophthalmic (eye) drops (Alphagan P) 0.1 %</i> | 2 | |
| <i>brimonidine ophthalmic (eye) drops 0.2 %</i> | 2 | |
| <i>brimonidine-timolol ophthalmic (eye) (Combigan) drops 0.2-0.5 %</i> | 2 | |
| <i>brinzolamide ophthalmic (eye) (Azopt) drops,suspension 1 %</i> | 2 | |
| <i>carteolol ophthalmic (eye) drops 1 %</i> | 2 | |
| <i>dorzolamide ophthalmic (eye) drops 2 %</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>dorzolamide-timolol ophthalmic (eye) (Cosopt) drops 22.3-6.8 mg/ml</i> | 2 | |
| <i>latanoprost ophthalmic (eye) drops 0.005 % (Xalatan)</i> | 1 | GC; QL (2.5 per 25 days) |
| <i>levobunolol ophthalmic (eye) drops 0.5 %</i> | 1 | GC |
| LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 % | 3 | QL (2.5 per 25 days) |
| <i>pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %</i> | 2 | |
| RHOPRESSA OPHTHALMIC (EYE) DROPS 0.02 % | 3 | QL (2.5 per 25 days) |
| ROCKLATAN OPHTHALMIC (EYE) DROPS 0.02-0.005 % | 3 | QL (2.5 per 25 days) |
| SIMBRINZA OPHTHALMIC (EYE) DROPS,SUSPENSION 1-0.2 % | 3 | |
| <i>timolol maleate ophthalmic (eye) drops 0.25 %, 0.5 %</i> | 1 | GC |
| <i>timolol maleate ophthalmic (eye) gel forming solution 0.25 %, 0.5 %</i> | 2 | |
| <i>travoprost ophthalmic (eye) drops 0.004 % (Travatan Z)</i> | 2 | QL (2.5 per 25 days) |
| VYZULTA OPHTHALMIC (EYE) DROPS 0.024 % | 4 | QL (5 per 30 days) |
| Agentes Para Los Ojos, Oídos, Nariz, Garganta | | |
| Agentes Antiinfecciosos De Ojos, Oídos, Nariz Y Garganta | | |
| <i>acetic acid otic (ear) solution 2 %</i> | 2 | |
| <i>bacitracin ophthalmic (eye) ointment 500 unit/gram</i> | 2 | |
| <i>bacitracin-polymyxin b ophthalmic (eye) ointment 500-10,000 unit/gram (Polycin)</i> | 2 | |
| <i>ciprofloxacin hcl ophthalmic (eye) drops 0.3 %</i> | 2 | |
| <i>ciprofloxacin-dexamethasone otic (ear) drops,suspension 0.3-0.1 %</i> | 2 | QL (7.5 per 7 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>erythromycin ophthalmic (eye) ointment 5 mg/gram (0.5 %)</i> | 2 | QL (3.5 per 4 days) |
| <i>gatifloxacin ophthalmic (eye) drops 0.5 %</i> | 2 | |
| <i>gentak ophthalmic (eye) ointment 0.3 % (3 mg/gram)</i> | 2 | |
| <i>gentamicin ophthalmic (eye) drops 0.3 %</i> | 2 | |
| <i>hydrocortisone-acetic acid otic (ear) drops 1-2 %</i> | 2 | |
| <i>levofloxacin ophthalmic (eye) drops 0.5 %</i> | 2 | |
| <i>moxifloxacin ophthalmic (eye) drops 0.5 %</i> (Vigamox) | 2 | |
| NATACYN OPHTHALMIC (EYE) DROPS,SUSPENSION 5 % | 4 | |
| <i>neomycin-bacitracin-poly-hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> (Neo-Polycin HC) | 2 | |
| <i>neomycin-bacitracin-polymyxin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> (Neo-Polycin) | 2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) drops,suspension 3.5mg/ml-10,000 unit/ml-0.1 %</i> (Maxitrol) | 2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) ointment 3.5 mg/g-10,000 unit/g-0.1 %</i> (Maxitrol) | 2 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic (eye) drops 1.75 mg-10,000 unit-0.025mg/ml</i> | 2 | |
| <i>neomycin-polymyxin-hc ophthalmic (eye) drops,suspension 3.5-10,000-10 mg-unit-mg/ml</i> | 2 | |
| <i>neomycin-polymyxin-hc otic (ear) drops,suspension 3.5-10,000-1 mg/ml-unit/ml-%</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|--------------------------------------|------------------------------------|
| <i>neomycin-polymyxin-hc otic (ear) solution 3.5-10,000-1 mg/ml-unit/ml-%</i> | 2 | |
| <i>neo-polycin hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> | (neomycin-bacitracin-poly-hc) 2 | |
| <i>neo-polycin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> | (neomycin-bacitracin-polymyxin) 2 | |
| <i>ofloxacin ophthalmic (eye) drops 0.3 %</i> | (Ocuflox) 2 | |
| <i>ofloxacin otic (ear) drops 0.3 %</i> | 2 | |
| <i>polycin ophthalmic (eye) ointment 500-10,000 unit/gram</i> | (bacitracin-polymyxin b) 2 | |
| <i>polymyxin b sulf-trimethoprim ophthalmic (eye) drops 10,000 unit- 1 mg/ml</i> | 1 | GC |
| <i>sulfacetamide sodium ophthalmic (eye) drops 10 %</i> | 2 | |
| <i>sulfacetamide sodium ophthalmic (eye) ointment 10 %</i> | 2 | |
| <i>sulfacetamide-prednisolone ophthalmic (eye) drops 10 %-0.23 % (0.25 %)</i> | 2 | |
| <i>tobramycin ophthalmic (eye) drops 0.3 %</i> | 2 | |
| <i>tobramycin-dexamethasone ophthalmic (eye) drops,suspension 0.3-0.1 %</i> | 2 | |
| <i>trifluridine ophthalmic (eye) drops 1 %</i> | 2 | |
| ZIRGAN OPHTHALMIC (EYE) GEL 0.15 % | 4 | |
| ZYLET OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3-0.5 % | 3 | |
| Agentes Antiinflamatorios De Ojos, Oídos, Nariz Y Garganta | | |
| <i>bromfenac ophthalmic (eye) drops 0.07 %</i> | (Prolensa) 3 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>bromfenac ophthalmic (eye) drops</i> (BromSite) 0.075 % | 3 | |
| <i>dexamethasone sodium phosphate ophthalmic (eye) drops</i> 0.1 % | 2 | |
| <i>diclofenac sodium ophthalmic (eye) drops</i> 0.1 % | 2 | |
| <i>difluprednate ophthalmic (eye) drops</i> (Durezol) 0.05 % | 2 | |
| EYSUVIS OPHTHALMIC (EYE) DROPS,SUSPENSION 0.25 % | 3 | QL (8.3 per 14 days) |
| <i>flunisolide nasal spray,non-aerosol</i> 25 mcg (0.025 %) | 2 | QL (50 per 25 days) |
| <i>fluocinolone acetonide oil otic (ear) drops</i> 0.01 % (DermOtic Oil) | 2 | |
| <i>fluorometholone ophthalmic (eye) drops,suspension</i> 0.1 % (FML Liquifilm) | 4 | |
| <i>flurbiprofen sodium ophthalmic (eye) drops</i> 0.03 % | 2 | |
| <i>fluticasone propionate nasal spray,suspension</i> 50 mcg/actuation (24 Hour Allergy Relief) | 1 | GC; QL (16 per 30 days) |
| ILEVRO OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3 % | 3 | |
| INVELTYS OPHTHALMIC (EYE) DROPS,SUSPENSION 1 % | 3 | QL (5.6 per 14 days) |
| <i>ketorolac ophthalmic (eye) drops</i> 0.5 % (Acular) | 2 | QL (10 per 25 days) |
| LOTEMAX OPHTHALMIC (EYE) OINTMENT 0.5 % | 3 | QL (3.5 per 14 days) |
| LOTEMAX SM OPHTHALMIC (EYE) DROPS,GEL 0.38 % | 3 | QL (5 per 16 days) |
| <i>loteprednol etabonate ophthalmic (eye) drops,gel</i> 0.5 % (Lotemax) | 2 | QL (10 per 14 days) |
| <i>loteprednol etabonate ophthalmic (eye) drops,suspension</i> 0.2 % (Alrex) | 3 | ST; QL (10 per 25 days) |
| <i>mometasone nasal spray,non-aerosol</i> 50 mcg/actuation (Allergy Nasal (mometasone)) | 2 | QL (34 per 30 days) |
| <i>prednisolone acetate ophthalmic (eye) drops,suspension</i> 1 % (Pred Forte) | 4 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|------------------------------|
| <i>prednisolone sodium phosphate ophthalmic (eye) drops 1 %</i> | 2 | |
| RESTASIS MULTIDOSE OPTHALMIC (EYE) DROPS 0.05 % | 3 | QL (5.5 per 28 days) |
| RESTASIS OPTHALMIC (EYE) (cyclosporine) DROPPERETTE 0.05 % | 2 | QL (60 per 30 days) |
| XHANCE NASAL AEROSOL BREATH ACTIVATED 93 MCG/ACTUATION | 3 | ST; QL (32 per 30 days) |
| XIIDRA OPTHALMIC (EYE) DROPPERETTE 5 % | 3 | QL (60 per 30 days) |
| Agentes De Ojos, Oídos, Nariz Y Garganta, Varios | | |
| <i>apraclonidine ophthalmic (eye) drops 0.5 %</i> | 2 | |
| <i>atropine ophthalmic (eye) drops 1 %</i> (Isopto Atropine) | 2 | |
| <i>azelastine nasal spray, non-aerosol 137 mcg (0.1 %)</i> | 2 | QL (30 per 25 days) |
| <i>azelastine nasal spray, non-aerosol 205.5 mcg (0.15 %)</i> (Astepro Allergy) | 2 | QL (30 per 25 days) |
| <i>azelastine ophthalmic (eye) drops 0.05 %</i> | 2 | |
| <i>cromolyn ophthalmic (eye) drops 4 %</i> | 2 | |
| <i>cyclopentolate ophthalmic (eye) drops 0.5 %, 1 %, 2 %</i> (Cyclogyl) | 2 | |
| CYSTARAN OPTHALMIC (EYE) DROPS 0.44 % | 5 | PA; NDS; QL (60 per 28 days) |
| <i>epinastine ophthalmic (eye) drops 0.05 %</i> | 2 | |
| <i>ipratropium bromide nasal spray, non-aerosol 21 mcg (0.03 %)</i> | 2 | QL (30 per 28 days) |
| <i>ipratropium bromide nasal spray, non-aerosol 42 mcg (0.06 %)</i> | 2 | QL (15 per 10 days) |
| <i>levofloxacin ophthalmic (eye) drops 1.5 %</i> | 2 | |
| <i>olopatadine ophthalmic (eye) drops 0.1 %</i> (Eye Allergy Itch-Redness Rlf) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|-------------------------------|
| <i>olopatadine ophthalmic (eye) drops</i> (Eye Allergy Itch Relief) 0.2 % | 2 | |
| <i>proparacaine ophthalmic (eye) drops</i> (Alcaine) 0.5 % | 2 | |
| Agentes Terapeuticos | | |
| Misceláneos | | |
| Agentes Terapeuticos Misceláneos | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5 ML | 5 | PA; NDS |
| <i>betaine oral powder 1 gram/scoop</i> (Cystadane) | 5 | PA; NDS |
| <i>bupirone oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 2 | |
| COSENTYX INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA; NDS |
| <i>diazoxide oral suspension 50 mg/ml</i> (Proglycem) | 2 | |
| ELMIRON ORAL CAPSULE 100 MG | 4 | QL (90 per 30 days) |
| EVRYSDI ORAL RECON SOLN 0.75 MG/ML | 5 | PA; NDS |
| <i>glutamine (sickle cell) oral powder in packet 5 gram</i> (Endari) | 5 | PA; NDS; QL (180 per 30 days) |
| GVOKE HYPOPEN 2-PACK SUBCUTANEOUS AUTO-INJECTOR 0.5 MG/0.1 ML, 1 MG/0.2 ML | 3 | |
| GVOKE PFS 1-PACK SYRINGE SUBCUTANEOUS SYRINGE 1 MG/0.2 ML | 3 | |
| GVOKE PFS 2-PACK SYRINGE SUBCUTANEOUS SYRINGE 0.5 MG/0.1 ML | 3 | |
| GVOKE SUBCUTANEOUS SOLUTION 1 MG/0.2 ML | 3 | |
| <i>hydroxyzine pamoate oral capsule 100 mg</i> | 2 | |
| <i>hydroxyzine pamoate oral capsule 25 mg</i> (Vistaril) | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>hydroxyzine pamoate oral capsule 50 mg</i> | 1 | GC |
| <i>leucovorin calcium injection recon soln 100 mg, 200 mg, 350 mg, 50 mg, 500 mg</i> | 2 | |
| <i>leucovorin calcium injection solution 10 mg/ml</i> | 2 | |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i> | 2 | |
| <i>levocarnitine (with sugar) oral solution 100 mg/ml</i> (Carnitor) | 2 | |
| <i>levocarnitine oral tablet 330 mg</i> (Carnitor) | 2 | |
| <i>levocarnitine sf 1 g/10 ml sol 100 mg/ml</i> (Carnitor (sugar-free)) | 2 | |
| <i>mesna intravenous solution 100 mg/ml</i> (Mesnex) | 2 | |
| MESNEX ORAL TABLET 400 MG | 5 | NDS |
| <i>nitroglycerin rectal ointment 0.4 % (w/w)</i> (Rectiv) | 2 | QL (30 per 30 days) |
| OXLUMO SUBCUTANEOUS SOLUTION 94.5 MG/0.5 ML | 5 | PA; NDS |
| <i>pyridostigmine bromide oral syrup 60 mg/5 ml</i> (Mestinon) | 2 | |
| <i>pyridostigmine bromide oral tablet 30 mg</i> | 2 | |
| <i>pyridostigmine bromide oral tablet 60 mg</i> (Mestinon) | 2 | |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2 ML (150 MG/ML) | 5 | PA; NDS; QL (4 per 28 days) |
| TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML | 5 | PA; NDS; QL (2 per 28 days) |
| TAKHZYRO SUBCUTANEOUS SYRINGE 300 MG/2 ML (150 MG/ML) | 5 | PA; NDS; QL (4 per 28 days) |
| THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA NSO; NDS; QL (56 per 28 days) |
| TYBOST ORAL TABLET 150 MG | 4 | QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------------|
| VOWST ORAL CAPSULE | 5 | PA; NDS; QL (12 per 30 days) |
| ZEGALOGUE AUTOINJECTOR SUBCUTANEOUS AUTO- INJECTOR 0.6 MG/0.6 ML | 3 | |
| ZEGALOGUE SYRINGE SUBCUTANEOUS SYRINGE 0.6 MG/0.6 ML | 3 | |
| Agentes Vasodilatadores | | |
| Agentes Vasodilatadores | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG | 5 | PA; NDS; QL (90 per 30 days) |
| <i>alyq oral tablet 20 mg</i> (tadalafil (pulm. hypertension)) | 2 | PA; QL (60 per 30 days) |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> (Letairis) | 5 | PA; NDS; QL (30 per 30 days) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> (Tracleer) | 5 | PA; LA; NDS; QL (60 per 30 days) |
| OPSUMIT ORAL TABLET 10 MG | 5 | PA; NDS; QL (30 per 30 days) |
| <i>sildenafil (pulm.hypertension) oral tablet 20 mg</i> (Revatio) | 1 | PA; GC; QL (360 per 30 days) |
| <i>sildenafil oral tablet 100 mg, 25 mg, 50 mg</i> (Viagra) | 1 | GC; EX; CB (6 EA per 30 days) |
| <i>tadalafil (pulm. hypertension) oral tablet 20 mg</i> (Alyq) | 2 | PA; QL (60 per 30 days) |
| TRACLEER ORAL TABLET FOR SUSPENSION 32 MG | 5 | PA; NDS; QL (112 per 28 days) |
| UPTRAVI INTRAVENOUS RECON SOLN 1,800 MCG | 5 | PA; NDS; QL (60 per 30 days) |
| UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG | 5 | PA; NDS; QL (60 per 30 days) |
| UPTRAVI ORAL TABLET 200 MCG | 5 | PA; NDS; QL (240 per 30 days) |
| UPTRAVI ORAL TABLETS,DOSE PACK 200 MCG (140)- 800 MCG (60) | 5 | PA; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|-------------------------------|
| Analgésicos | | |
| Agentes Antiinflamatorios No Esteroides | | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i> (Celebrex) | 2 | QL (60 per 30 days) |
| <i>diclofenac potassium oral tablet 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet extended release 24 hr 100 mg</i> | 2 | QL (60 per 30 days) |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 25 mg</i> | 2 | QL (150 per 30 days) |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 75 mg</i> | 1 | GC; QL (60 per 30 days) |
| <i>diclofenac sodium topical drops 1.5 %</i> | 2 | QL (300 per 30 days) |
| <i>diclofenac sodium topical gel 1 %</i> (Aleve (diclofenac)) | 2 | QL (1000 per 30 days) |
| <i>diclofenac sodium topical gel 3 %</i> | 2 | PA; QL (100 per 28 days) |
| <i>diclofenac sodium topical solution in metered-dose pump 20 mg/gram /actuation(2 %)</i> (Pennsaid) | 5 | PA; NDS; QL (224 per 28 days) |
| <i>diclofenac-misoprostol oral tablet, ir, delayed rel, biphasic 50-200 mg-mcg</i> (Arthrotec 50) | 2 | |
| <i>diclofenac-misoprostol oral tablet, ir, delayed rel, biphasic 75-200 mg-mcg</i> (Arthrotec 75) | 2 | |
| <i>ec-naproxen dr 500 mg tablet</i> (naproxen) | 2 | |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | 2 | |
| <i>etodolac oral tablet 400 mg</i> (Lodine) | 2 | |
| <i>etodolac oral tablet 500 mg</i> | 2 | |
| <i>flurbiprofen oral tablet 100 mg</i> | 2 | |
| <i>ibu oral tablet 400 mg</i> (ibuprofen) | 1 | GC; QL (240 per 30 days) |
| <i>ibu oral tablet 600 mg, 800 mg</i> (ibuprofen) | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|--|
| <i>ibuprofen oral suspension 100 mg/5 ml</i> (Children's Advil) | 2 | |
| <i>ibuprofen oral tablet 400 mg</i> (IBU) | 1 | GC; QL (240 per 30 days) |
| <i>ibuprofen oral tablet 600 mg, 800 mg</i> (IBU) | 1 | GC |
| <i>indomethacin oral capsule 25 mg</i> | 1 | PA-HRM; GC; QL (240 per 30 days); AGE (Max 64 Years) |
| <i>indomethacin oral capsule 50 mg</i> | 1 | PA-HRM; GC; QL (120 per 30 days); AGE (Max 64 Years) |
| <i>indomethacin oral capsule, extended release 75 mg</i> | 2 | PA-HRM; QL (60 per 30 days); AGE (Max 64 Years) |
| <i>ketorolac oral tablet 10 mg</i> | 2 | PA-HRM; QL (20 per 30 days); AGE (Max 64 Years) |
| <i>mefenamic acid oral capsule 250 mg</i> | 2 | |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | 1 | GC |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | 2 | |
| <i>naproxen oral tablet 250 mg, 375 mg</i> | 1 | GC |
| <i>naproxen oral tablet 500 mg</i> (Naprosyn) | 1 | GC |
| <i>naproxen oral tablet, delayed release (dr/ec) 375 mg</i> (EC-Naprosyn) | 2 | |
| <i>naproxen oral tablet, delayed release (dr/ec) 500 mg</i> (EC-Naproxen) | 2 | |
| <i>piroxicam oral capsule 10 mg</i> | 2 | |
| <i>piroxicam oral capsule 20 mg</i> (Feldene) | 2 | |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | 2 | |
| Analgésicos, Varios | | |
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> | 2 | NDS; QL (4500 per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg</i> | 2 | NDS; QL (360 per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-60 mg</i> | 2 | NDS; QL (180 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|---|
| <i>ascomp with codeine oral capsule 30-50-325-40 mg</i> (codeine-butalbital-asa-caff) | 2 | PA-HRM; NDS; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>buprenorphine hcl injection solution 0.3 mg/ml</i> | 2 | |
| <i>buprenorphine hcl injection syringe 0.3 mg/ml</i> | 2 | |
| <i>butalbital-acetaminophen-caff oral tablet 50-325-40 mg</i> (Esgic) | 2 | PA-HRM; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>butalbital-aspirin-caffeine oral capsule 50-325-40 mg</i> | 2 | PA-HRM; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>butalbital-aspirin-caffeine oral tablet 50-325-40 mg</i> | 2 | PA-HRM; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>codeine sulfate oral tablet 30 mg, 60 mg</i> | 2 | NDS; QL (180 per 30 days) |
| <i>codeine-butalbital-asa-caff oral capsule 30-50-325-40 mg</i> (Ascomp with Codeine) | 2 | PA-HRM; NDS; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>endocet oral tablet 10-325 mg</i> (oxycodone-acetaminophen) | 2 | NDS; QL (180 per 30 days) |
| <i>endocet oral tablet 2.5-325 mg, 5-325 mg</i> (oxycodone-acetaminophen) | 2 | NDS; QL (360 per 30 days) |
| <i>endocet oral tablet 7.5-325 mg</i> (oxycodone-acetaminophen) | 2 | NDS; QL (240 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 400 mcg, 600 mcg, 800 mcg</i> | 5 | PA; NDS; QL (120 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 200 mcg</i> | 2 | PA; NDS; QL (120 per 30 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> | 2 | NDS; QL (10 per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml</i> | 2 | NDS; QL (2700 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 7.5-325 mg</i> | 2 | NDS; QL (180 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>hydrocodone-acetaminophen oral tablet 2.5-325 mg, 5-300 mg, 5-325 mg</i> | 2 | NDS; QL (240 per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg, 5-200 mg, 7.5-200 mg</i> | 2 | NDS; QL (150 per 30 days) |
| <i>hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml</i> | 2 | |
| <i>hydromorphone oral liquid 1 mg/ml</i> (Dilaudid) | 2 | NDS; QL (1200 per 30 days) |
| <i>hydromorphone oral tablet 2 mg, 4 mg, 8 mg</i> (Dilaudid) | 2 | NDS; QL (180 per 30 days) |
| <i>methadone injection solution 10 mg/ml</i> | 2 | QL (120 per 30 days) |
| <i>methadone oral solution 10 mg/5 ml</i> | 2 | NDS; QL (600 per 30 days) |
| <i>methadone oral solution 5 mg/5 ml</i> | 2 | NDS; QL (1200 per 30 days) |
| <i>methadone oral tablet 10 mg</i> | 2 | NDS; QL (120 per 30 days) |
| <i>methadone oral tablet 5 mg</i> | 2 | NDS; QL (180 per 30 days) |
| <i>methadose oral tablet, soluble 40 mg</i> (methadone) | 2 | NDS; QL (30 per 30 days) |
| <i>morphine concentrate oral solution 100 mg/5 ml (20 mg/ml)</i> | 2 | PA; NDS; QL (180 per 30 days) |
| <i>morphine oral solution 10 mg/5 ml</i> | 2 | NDS; QL (700 per 30 days) |
| <i>morphine oral solution 20 mg/5 ml (4 mg/ml)</i> | 2 | NDS; QL (300 per 30 days) |
| MORPHINE ORAL TABLET 15 MG | 4 | NDS; QL (180 per 30 days) |
| MORPHINE ORAL TABLET 30 MG | 4 | NDS; QL (120 per 30 days) |
| <i>morphine oral tablet extended release 100 mg, 200 mg, 60 mg</i> (MS Contin) | 2 | NDS; QL (60 per 30 days) |
| <i>morphine oral tablet extended release 15 mg, 30 mg</i> (MS Contin) | 2 | NDS; QL (90 per 30 days) |
| <i>oxycodone oral capsule 5 mg</i> | 2 | NDS; QL (180 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>oxycodone oral solution 5 mg/5 ml</i> | 2 | NDS; QL (1300 per 30 days) |
| <i>oxycodone oral tablet 10 mg, 5 mg</i> | 2 | NDS; QL (180 per 30 days) |
| <i>oxycodone oral tablet 15 mg, 30 mg</i> (Roxicodone) | 2 | NDS; QL (120 per 30 days) |
| <i>oxycodone oral tablet 20 mg</i> | 2 | NDS; QL (120 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet</i> (Endocet) <i>10-325 mg</i> | 2 | NDS; QL (180 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet</i> (Endocet) <i>2.5-325 mg, 5-325 mg</i> | 2 | NDS; QL (360 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet</i> (Endocet) <i>7.5-325 mg</i> | 2 | NDS; QL (240 per 30 days) |
| OXYCONTIN ORAL (oxycodone) TABLET,ORAL ONLY,EXT.REL.12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG | 3 | NDS; QL (60 per 30 days) |
| <i>oxymorphone oral tablet 10 mg</i> | 2 | NDS; QL (120 per 30 days) |
| <i>oxymorphone oral tablet 5 mg</i> | 2 | NDS; QL (180 per 30 days) |
| <i>oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg</i> | 2 | NDS; QL (60 per 30 days) |
| <i>oxymorphone oral tablet extended release 12 hr 40 mg</i> | 5 | NDS; QL (60 per 30 days) |
| <i>tramadol oral tablet 50 mg</i> | 1 | GC; NDS; QL (240 per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i> | 2 | NDS; QL (300 per 30 days) |
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 13.5 MG, 18 MG, 9 MG | 3 | NDS; QL (60 per 30 days) |
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 27 MG | 3 | NDS; QL (120 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|------------------------------|
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 36 MG | 5 | NDS; QL (240 per 30 days) |
| Anestésicos | | |
| Anestesia Local | | |
| <i>glydo mucous membrane jelly in applicator 2 %</i> (lidocaine hcl) | 2 | QL (30 per 30 days) |
| <i>lidocaine (pf) injection solution 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %), 5 mg/ml (0.5 %)</i> (Xylocaine-MPF) | 1 | GC |
| <i>lidocaine (pf) injection solution 40 mg/ml (4 %)</i> | 1 | GC |
| <i>lidocaine hcl 2% 40 mg/2 ml ampule outer,p/f,svd 20 mg/ml (2 %)</i> (Xylocaine-MPF) | 2 | |
| <i>lidocaine hcl injection solution 10 mg/ml (1 %), 20 mg/ml (2 %)</i> (Xylocaine) | 2 | |
| <i>lidocaine hcl injection solution 5 mg/ml (0.5 %)</i> (Xylocaine) | 1 | GC |
| <i>lidocaine hcl mucous membrane jelly in applicator 2 %</i> (Glydo) | 2 | QL (30 per 30 days) |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | 2 | PA |
| <i>lidocaine topical adhesive patch,medicated 5 %</i> (Tridacaine II) | 2 | PA; QL (90 per 30 days) |
| <i>lidocaine topical ointment 5 %</i> | 2 | PA; QL (90 per 30 days) |
| <i>lidocaine viscous mucous membrane solution 2 %</i> (lidocaine hcl) | 2 | |
| <i>lidocaine-prilocaine topical cream 2.5-2.5 %</i> | 2 | PA; QL (30 per 30 days) |
| <i>tridacaine ii topical adhesive patch,medicated 5 %</i> (lidocaine) | 2 | PA; QL (90 per 30 days) |
| ZTLIDO TOPICAL ADHESIVE PATCH,MEDICATED 1.8 % | 3 | PA; QL (90 per 30 days) |
| Antagonistas De Metales Pesados | | |
| <i>deferasirox oral granules in packet 180 mg, 360 mg, 90 mg</i> (Jadenu Sprinkle) | 5 | PA; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|-------------------------------|
| <i>deferasirox oral tablet 180 mg, 360 mg</i> (Jadenu) | 5 | PA; NDS |
| <i>deferasirox oral tablet 90 mg</i> (Jadenu) | 2 | PA |
| <i>deferasirox oral tablet, dispersible 125 mg</i> (Exjade) | 2 | PA |
| <i>deferasirox oral tablet, dispersible 250 mg, 500 mg</i> (Exjade) | 5 | PA; NDS |
| <i>deferiprone oral tablet 1,000 mg, 500 mg</i> (Ferriprox) | 5 | PA; NDS |
| FERRIPROX (2 TIMES A DAY) ORAL TABLET, MODIFIED RELEASE 1,000 MG | 5 | PA; NDS |
| FERRIPROX ORAL SOLUTION 100 MG/ML | 5 | PA; NDS |
| FERRIPROX ORAL TABLET 1,000 MG (deferiprone) | 5 | PA; NDS |
| <i>penicillamine oral tablet 250 mg</i> (Depen Titratabs) | 5 | PA; NDS |
| <i>trientine oral capsule 250 mg</i> (Syprine) | 5 | PA; NDS; QL (240 per 30 days) |
| Anti Infecciosos (Membrana Cutánea Y Mucosa) | | |
| Anti Infecciosos (Membrana Cutánea Y Mucosa) | | |
| <i>clindamycin phosphate vaginal cream 2 %</i> (Cleocin) | 2 | |
| <i>metronidazole vaginal gel 0.75 % (37.5mg/5 gram)</i> (Vandazole) | 2 | |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | 2 | |
| <i>terconazole vaginal suppository 80 mg</i> | 2 | |
| Antibacterianos | | |
| Aminoglicósidos | | |
| <i>gentamicin injection solution 20 mg/2 ml, 40 mg/ml</i> | 2 | |
| <i>gentamicin sulfate (ped) (pf) injection solution 20 mg/2 ml</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>gentamicin sulfate (pf) intravenous solution 100 mg/10 ml, 60 mg/6 ml</i> | 2 | |
| <i>neomycin oral tablet 500 mg</i> | 2 | |
| <i>streptomycin intramuscular recon soln 1 gram</i> | 5 | NDS |
| <i>tobramycin in 0.225 % nacl inhalation solution for nebulization 300 mg/5 ml</i> (Tobi) | 5 | PA BvD; NDS |
| <i>tobramycin inhalation solution for nebulization 300 mg/4 ml</i> (Bethkis) | 5 | PA BvD; NDS |
| <i>tobramycin sulfate injection solution 40 mg/ml</i> | 2 | |
| Antibacteriales, Misceláneos | | |
| <i>chloramphenicol sod succinate intravenous recon soln 1 gram</i> | 2 | |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg, 75 mg</i> (Cleocin HCl) | 1 | GC |
| <i>clindamycin in 5 % dextrose intravenous piggyback 300 mg/50 ml</i> | 2 | |
| <i>clindamycin pediatric oral recon soln 75 mg/5 ml</i> (clindamycin palmitate hcl) | 2 | |
| <i>clindamycin phosphate injection solution 150 mg/ml</i> (Cleocin) | 2 | |
| <i>colistin (colistimethate na) injection recon soln 150 mg</i> (Coly-Mycin M Parenteral) | 5 | NDS |
| <i>daptomycin intravenous recon soln 500 mg</i> | 5 | NDS |
| <i>linezolid in dextrose 5% intravenous piggyback 600 mg/300 ml</i> (Zyvox) | 2 | |
| <i>linezolid oral suspension for reconstitution 100 mg/5 ml</i> (Zyvox) | 5 | NDS |
| <i>linezolid oral tablet 600 mg</i> (Zyvox) | 2 | |
| <i>methenamine hippurate oral tablet 1 gram</i> (Hiprex) | 2 | |
| <i>metronidazole in nacl (iso-os) intravenous piggyback 500 mg/100 ml</i> (Metro I.V.) | 2 | |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|------------------------------|
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 50 mg</i> (Macrochantin) | 2 | QL (120 per 30 days) |
| <i>nitrofurantoin macrocrystal oral capsule 25 mg</i> | 2 | QL (120 per 30 days) |
| <i>nitrofurantoin monohyd/m-cryst oral capsule 100 mg</i> (Macrobid) | 2 | QL (60 per 30 days) |
| <i>polymyxin b sulfate injection recon soln 500,000 unit</i> | 2 | |
| <i>trimethoprim oral tablet 100 mg</i> | 1 | GC |
| <i>vancomycin intravenous recon soln 1,000 mg, 10 gram, 5 gram, 500 mg, 750 mg</i> | 2 | |
| <i>vancomycin oral capsule 125 mg</i> (Vancocin) | 2 | QL (56 per 14 days) |
| <i>vancomycin oral capsule 250 mg</i> (Vancocin) | 2 | QL (112 per 14 days) |
| <i>vancomycin oral recon soln 25 mg/ml</i> (Firvanq) | 4 | |
| XIFAXAN ORAL TABLET 200 MG | 3 | PA; QL (9 per 30 days) |
| XIFAXAN ORAL TABLET 550 MG | 5 | PA; NDS; QL (90 per 30 days) |
| Antibióticos B-Lactam Misceláneos | | |
| <i>aztreonam injection recon soln 1 gram, 2 gram</i> (Azactam) | 2 | |
| CAYSTON INHALATION SOLUTION FOR NEBULIZATION 75 MG/ML | 5 | PA; LA; NDS |
| <i>ertapenem injection recon soln 1 gram</i> | 2 | |
| <i>imipenem-cilastatin intravenous recon soln 250 mg</i> | 2 | |
| <i>imipenem-cilastatin intravenous recon soln 500 mg</i> (Primaxin IV) | 2 | |
| <i>meropenem intravenous recon soln 1 gram, 500 mg</i> | 2 | |
| Cefalosporinas | | |
| <i>cefactor oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>cefactor oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>cefadroxil oral capsule 500 mg</i> | 2 | |
| <i>cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml</i> | 2 | |
| <i>cefadroxil oral tablet 1 gram</i> | 2 | |
| <i>cefazolin in dextrose (iso-os) intravenous piggyback 2 gram/50 ml</i> | 2 | |
| <i>cefazolin injection recon soln 1 gram, 10 gram, 500 mg</i> | 2 | |
| <i>cefazolin intravenous recon soln 3 gram</i> | 4 | |
| <i>cefdinir oral capsule 300 mg</i> | 2 | |
| <i>cefdinir oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>cefepime injection recon soln 1 gram, 2 gram</i> | 2 | |
| <i>cefixime oral capsule 400 mg</i> | 2 | |
| <i>cefotaxime injection recon soln 1 gram</i> | 2 | |
| <i>cefoxitin intravenous recon soln 1 gram, 10 gram, 2 gram</i> | 2 | |
| <i>cefpodoxime oral suspension for reconstitution 100 mg/5 ml, 50 mg/5 ml</i> | 2 | |
| <i>cefpodoxime oral tablet 100 mg, 200 mg</i> | 2 | |
| <i>cefprozil oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>ceftazidime injection recon soln 1 gram, 2 gram, 6 gram</i> (Tazicef) | 2 | |
| <i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg</i> | 2 | |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>cefuroxime sodium injection recon soln 750 mg</i> | 2 | |
| <i>cefuroxime sodium intravenous recon soln 1.5 gram, 7.5 gram</i> | 2 | |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | 1 | GC |
| <i>cephalexin oral capsule 750 mg</i> | 2 | |
| <i>cephalexin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| TEFLARO INTRAVENOUS RECON SOLN 400 MG, 600 MG | 5 | NDS |
| Macrólidos | | |
| <i>azithromycin intravenous recon soln 500 mg</i> (Zithromax) | 2 | |
| <i>azithromycin oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> (Zithromax) | 2 | |
| <i>azithromycin oral tablet 250 mg (6 pack), 500 mg (3 pack)</i> | 1 | GC |
| <i>azithromycin oral tablet 250 mg, 500 mg</i> (Zithromax) | 1 | GC |
| <i>azithromycin oral tablet 600 mg</i> | 2 | |
| <i>clarithromycin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 2 | |
| DIFICID ORAL SUSPENSION FOR RECONSTITUTION 40 MG/ML | 5 | NDS; QL (136 per 10 days) |
| DIFICID ORAL TABLET 200 MG | 5 | NDS; QL (20 per 10 days) |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 200 mg/5 ml</i> (E.E.S. Granules) | 2 | |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 400 mg/5 ml</i> (EryPed 400) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>erythromycin oral tablet 250 mg, 500 mg</i> | 2 | |
| Penicilinas | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 1 | GC |
| <i>amoxicillin oral suspension for reconstitution 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml</i> | 1 | GC |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | 1 | GC |
| <i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 200-28.5 mg/5 ml, 400-57 mg/5 ml</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 250-62.5 mg/5 ml</i> (Augmentin) | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 600-42.9 mg/5 ml</i> (Augmentin ES-600) | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet 500-125 mg</i> (Augmentin) | 1 | GC |
| <i>amoxicillin-pot clavulanate oral tablet 875-125 mg</i> | 1 | GC |
| <i>amoxicillin-pot clavulanate oral tablet, chewable 200-28.5 mg, 400-57 mg</i> | 2 | |
| <i>ampicillin oral capsule 500 mg</i> | 2 | |
| <i>ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg, 2 gram, 250 mg, 500 mg</i> | 2 | |
| <i>ampicillin-sulbactam injection recon soln 1.5 gram, 15 gram, 3 gram</i> (Unasyn) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| BICILLIN L-A INTRAMUSCULAR SYRINGE 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML | 4 | |
| <i>dicloxacillin oral capsule 250 mg, 500 mg</i> | 2 | |
| EXTENCILLINE INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 1.2 MILLION UNIT, 2.4 MILLION UNIT | 4 | |
| LENTOCILIN S INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 1.2 MILLION UNIT | 4 | |
| <i>nafticillin injection recon soln 1 gram, 10 gram, 2 gram</i> | 2 | |
| <i>penicillin g potassium injection recon (Pfizerpen-G) soln 20 million unit</i> | 2 | |
| <i>penicillin g procaine intramuscular syringe 1.2 million unit/2 ml, 600,000 unit/ml</i> | 2 | |
| <i>penicillin v potassium oral recon soln 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 1 | GC |
| <i>pfizerpen-g injection recon soln 20 million unit</i> (penicillin g potassium) | 2 | |
| <i>piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram</i> | 2 | |
| Quinolonas | | |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg</i> (Cipro) | 1 | GC |
| <i>ciprofloxacin hcl oral tablet 750 mg</i> | 1 | GC |
| <i>ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml, 400 mg/200 ml</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>ciprofloxacin oral suspension, microcapsule recon 250 mg/5 ml, 500 mg/5 ml</i> (Cipro) | 2 | |
| <i>levofloxacin in d5w intravenous piggyback 250 mg/50 ml, 500 mg/100 ml, 750 mg/150 ml</i> | 2 | |
| <i>levofloxacin intravenous solution 25 mg/ml</i> | 2 | |
| <i>levofloxacin oral solution 250 mg/10 ml</i> | 2 | |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | GC |
| <i>moxifloxacin 400 mg/250 ml bag</i> | 2 | |
| <i>moxifloxacin oral tablet 400 mg</i> | 2 | |
| <i>moxifloxacin-sod. chloride (iso) intravenous piggyback 400 mg/250 ml</i> (Avelox in NaCl (iso-osmotic)) | 2 | |
| Sulfonamidas | | |
| <i>sulfadiazine oral tablet 500 mg</i> | 2 | |
| <i>sulfamethoxazole-trimethoprim intravenous solution 400-80 mg/5 ml</i> | 2 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5 ml</i> (Sulfatrim) | 2 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg</i> (Bactrim) | 1 | GC |
| <i>sulfamethoxazole-trimethoprim oral tablet 800-160 mg</i> (Bactrim DS) | 1 | GC |
| Tetraciclinas | | |
| <i>doxy-100 intravenous recon soln 100 mg</i> (doxycycline hyclate) | 2 | |
| <i>doxycycline hyclate intravenous recon soln 100 mg</i> (Doxy-100) | 2 | |
| <i>doxycycline hyclate oral capsule 100 mg</i> (Vibramycin) | 2 | |
| <i>doxycycline hyclate oral capsule 50 mg</i> (Morgidox) | 2 | |
| <i>doxycycline hyclate oral tablet 100 mg, 20 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>doxycycline monohydrate oral capsule 100 mg</i> (Mondoxyne NL) | 2 | |
| <i>doxycycline monohydrate oral capsule 50 mg</i> (Monodox) | 2 | |
| <i>doxycycline monohydrate oral suspension for reconstitution 25 mg/5 ml</i> | 2 | |
| <i>doxycycline monohydrate oral tablet 100 mg</i> (Avidoxy) | 2 | |
| <i>doxycycline monohydrate oral tablet 150 mg, 50 mg, 75 mg</i> | 2 | |
| <i>minocycline oral capsule 100 mg, 50 mg, 75 mg</i> | 2 | |
| <i>mondoxyne nl oral capsule 100 mg</i> (doxycycline monohydrate) | 2 | |
| <i>tetracycline oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>tigecycline intravenous recon soln 50 mg</i> (Tygacil) | 5 | NDS |
| Anticonceptivos | | |
| Anticonceptivos | | |
| <i>afirmelle oral tablet 0.1-20 mg-mcg</i> (levonorgestrel-ethinyl estrad) | 2 | |
| <i>altavera (28) oral tablet 0.15-0.03 mg</i> (levonorgestrel-ethinyl estrad) | 2 | |
| <i>alyacen 1/35 (28) oral tablet 1-35 mg-mcg</i> (norethindrone-ethin estradiol) | 2 | |
| <i>alyacen 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 2 | |
| <i>amethia oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> (1 norgest/e.estradiol-e.estrad) | 2 | QL (91 per 84 days) |
| <i>apri oral tablet 0.15-0.03 mg</i> (desogestrel-ethinyl estradiol) | 2 | |
| <i>aranelle (28) oral tablet 0.5/1/0.5-35 mg-mcg</i> | 2 | |
| <i>ashlyna oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> (1 norgest/e.estradiol-e.estrad) | 2 | QL (91 per 84 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|----------------------------------|------------------------------|------------------------------------|
| <i>aubra eq oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>aurovela 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>aurovela 1/20 (21) oral tablet 1-20 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>aurovela 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>aurovela fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>aurovela fe 1-20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 1 | GC |
| <i>aviane oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>ayuna oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>azurette (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>balziva (28) oral tablet 0.4-35 mg-mcg</i> | | 2 | |
| <i>blisovi 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>blisovi fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>blisovi fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 1 | GC |
| <i>briellyn oral tablet 0.4-35 mg-mcg</i> | | 2 | |
| <i>camila oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 1 | GC |
| <i>caziant (28) oral tablet 0.1/.125/.15-25 mg-mcg</i> | | 2 | |
| <i>chateal eq (28) oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>cryselle (28) oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>cyred eq oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|-------------------------------------|------------------------------|--------------------------------|
| <i>dasetta 1/35 (28) oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>dasetta 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | | 2 | |
| <i>daysee oral tablets, dose pack, 3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (1 norgest/e.estradiol-e.estradiol) | 2 | QL (91 per 84 days) |
| <i>deblitane oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 1 | GC |
| <i>desog-e.estradiol/e.estradiol oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (Azurette (28)) | 2 | |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.03 mg</i> | (Enskyce) | 2 | |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg</i> | (Jasmiel (28)) | 2 | |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.03 mg</i> | (Syeda) | 2 | |
| <i>elinest oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| ELLA ORAL TABLET 30 MG | | 4 | QL (6 per 365 days) |
| <i>eluryng vaginal ring 0.12-0.015 mg/24 hr</i> | (etonogestrel-ethinyl estradiol) | 2 | QL (1 per 28 days) |
| <i>emzahh oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 1 | GC |
| <i>enilloring vaginal ring 0.12-0.015 mg/24 hr</i> | (etonogestrel-ethinyl estradiol) | 2 | QL (1 per 28 days) |
| <i>enpresse oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (levonorg-eth estrad triphasic) | 2 | |
| <i>enskyce oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 1 | GC |
| <i>errin oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 1 | GC |
| <i>estarylla oral tablet 0.25-35 mg-mcg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg</i> | (Kelnor 1/35 (28)) | 2 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-50 mg-mcg</i> | (Kelnor 1/50 (28)) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24 hr</i> (EluRyng) | 2 | QL (1 per 28 days) |
| <i>falmina (28) oral tablet 0.1-20 mg-mcg</i> (levonorgestrel-ethinyl estrad) | 2 | |
| <i>hailey 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> (norethindrone-e.estradiol-iron) | 2 | |
| <i>hailey fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> (norethindrone-e.estradiol-iron) | 2 | |
| <i>hailey fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> (norethindrone-e.estradiol-iron) | 2 | |
| <i>hailey oral tablet 1.5-30 mg-mcg</i> (norethindrone ac-eth estradiol) | 2 | |
| <i>haloette vaginal ring 0.12-0.015 mg/24 hr</i> (etonogestrel-ethinyl estradiol) | 2 | QL (1 per 28 days) |
| <i>heather oral tablet 0.35 mg</i> (norethindrone (contraceptive)) | 1 | GC |
| <i>iclevia oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> (levonorgestrel-ethinyl estrad) | 2 | QL (91 per 84 days) |
| <i>incassia oral tablet 0.35 mg</i> (norethindrone (contraceptive)) | 1 | GC |
| <i>isibloom oral tablet 0.15-0.03 mg</i> (desogestrel-ethinyl estradiol) | 1 | GC |
| <i>jaimiess oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> (1 norgest/e.estradiol-e.estrad) | 2 | QL (91 per 84 days) |
| <i>jasmiel (28) oral tablet 3-0.02 mg</i> (drospirenone-ethinyl estradiol) | 2 | |
| <i>jencycla oral tablet 0.35 mg</i> (norethindrone (contraceptive)) | 1 | GC |
| <i>juleber oral tablet 0.15-0.03 mg</i> (desogestrel-ethinyl estradiol) | 2 | |
| <i>junel 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> (norethindrone ac-eth estradiol) | 2 | |
| <i>junel 1/20 (21) oral tablet 1-20 mg-mcg</i> (norethindrone ac-eth estradiol) | 2 | |
| <i>junel fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> (norethindrone-e.estradiol-iron) | 2 | |
| <i>junel fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> (norethindrone-e.estradiol-iron) | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|----------------------------------|------------------------------|--------------------------------|
| <i>junel fe 24 oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>kalliga oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>kariva (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>kelnor 1/35 (28) oral tablet 1-35 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>kelnor 1/50 (28) oral tablet 1-50 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>kurvelo (28) oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>l norgest/e.estradiol-e.estradiol oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7)</i> | (LoJaimiess) | 2 | QL (91 per 84 days) |
| <i>l norgest/e.estradiol-e.estradiol oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (Amethia) | 2 | QL (91 per 84 days) |
| <i>larin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>larin 1/20 (21) oral tablet 1-20 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>larin 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>larin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>larin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 1 | GC |
| <i>lessina oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>levonest (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (levonorg-eth estrad triphasic) | 2 | |
| <i>levonorgest-eth.estradiol-iron oral tablet 0.1 mg-0.02 mg (21)/iron (7)</i> | (Balcoltra) | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg</i> | (Afirmelle) | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.15-0.03 mg</i> | (Altavera (28)) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|----------------------------------|------------------------------|--------------------------------|
| <i>levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (Iclevia) | 2 | QL (91 per 84 days) |
| <i>levonorg-eth estrad triphasic oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (Enpresse) | 2 | |
| <i>levora-28 oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>lojaimiess oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7)</i> | (l norgest/e.estradiol-e.estrad) | 2 | QL (91 per 84 days) |
| <i>loryna (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>low-ogestrel (28) oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>lo-zumandimine (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>luteru (28) oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>lyleq oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 1 | GC |
| <i>lyza oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 1 | GC |
| <i>marlissa (28) oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>merzee oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>microgestin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>mili oral tablet 0.25-35 mg-mcg</i> | (norgestimate-ethinyl estradiol) | 1 | GC |
| <i>mono-linyah oral tablet 0.25-35 mg-mcg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>necon 0.5/35 (28) oral tablet 0.5-35 mg-mcg</i> | | 2 | |
| <i>nikki (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>norelgestromin-ethin.estradiol transdermal patch weekly 150-35 mcg/24 hr</i> | (Xulane) | 2 | QL (3 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|----------------------------------|------------------------------|--------------------------------|
| <i>norethindrone (contraceptive) oral tablet 0.35 mg</i> | (Camila) | 1 | GC |
| <i>norethindrone ac-eth estradiol oral tablet 1.5-30 mg-mcg</i> | (Aurovela 1.5/30 (21)) | 2 | |
| <i>norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg</i> | (Aurovela 1/20 (21)) | 2 | |
| <i>norethindrone-e.estradiol-iron oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | (Merzee) | 2 | |
| <i>norethindrone-e.estradiol-iron oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (Aurovela Fe 1-20 (28)) | 1 | GC |
| <i>norethindrone-e.estradiol-iron oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (Aurovela Fe 1.5/30 (28)) | 2 | |
| <i>norethindrone-e.estradiol-iron oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | (Tri-Legest Fe) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | (Tri-Lo-Estarylla) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | (Tri-Estarylla) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.25-35 mg-mcg</i> | (Mili) | 2 | |
| <i>nortrel 0.5/35 (28) oral tablet 0.5-35 mg-mcg</i> | | 2 | |
| <i>nortrel 1/35 (21) oral tablet 1-35 mg-mcg (21)</i> | | 2 | |
| <i>nortrel 1/35 (28) oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>nortrel 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | | 2 | |
| <i>nylia 1/35 (28) oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>nylia 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | | 2 | |
| <i>nymyo oral tablet 0.25-35 mg-mcg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>philith oral tablet 0.4-35 mg-mcg</i> | | 2 | |
| <i>pimtrea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------------------|------------------------------|--------------------------------|
| <i>pirmella oral tablet 0.5/0.75/1 mg-35 mcg</i> | | 2 | |
| <i>pirmella oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>portia 28 oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>reclipsen (28) oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>setlakin oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 2 | QL (91 per 84 days) |
| <i>sharobel oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 1 | GC |
| <i>simliya (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog- e.estradiol/e.estradiol) | 2 | |
| <i>simpesse oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (l norgest/e.estradiol- e.estrad) | 2 | QL (91 per 84 days) |
| <i>sprintec (28) oral tablet 0.25-35 mg-mcg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>sronyx oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>syeda oral tablet 3-0.03 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>tarina 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone- e.estradiol-iron) | 2 | |
| <i>tarina fe 1-20 eq (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone- e.estradiol-iron) | 1 | GC |
| <i>tri-estarylla oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | (norgestimate-ethinyl estradiol) | 1 | GC |
| <i>tri-legest fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | (norethindrone- e.estradiol-iron) | 2 | |
| <i>tri-linyah oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-estarylla oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | (norgestimate-ethinyl estradiol) | 1 | GC |
| <i>tri-lo-marzia oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | (norgestimate-ethinyl estradiol) | 1 | GC |
| <i>tri-lo-mili oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | (norgestimate-ethinyl estradiol) | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|----------------------------------|------------------------------|------------------------------------|
| <i>tri-lo-sprintec oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-mili oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-nymyo oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-sprintec (28) oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>trivora (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (levonorg-eth estrad triphasic) | 2 | |
| <i>tri-vylibra lo oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | (norgestimate-ethinyl estradiol) | 1 | GC |
| <i>tri-vylibra oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tulana oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 1 | GC |
| <i>turqoz (28) oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>tyblume oral tablet, chewable 0.1 mg-20 mcg</i> | | 4 | |
| <i>velivet triphasic regimen (28) oral tablet 0.1/.125/.15-25 mg-mcg</i> | | 2 | |
| <i>vestura (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>vienna oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>viorele (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>volnea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>vyfemla (28) oral tablet 0.4-35 mg-mcg</i> | | 2 | |
| <i>vylibra oral tablet 0.25-35 mg-mcg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>wera (28) oral tablet 0.5-35 mg-mcg</i> | | 2 | |
| <i>xulane transdermal patch weekly 150-35 mcg/24 hr</i> | (norelgestromin-ethin.estradiol) | 2 | QL (3 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|----------------------------------|-----------------------|-----------------------------------|
| <i>zafemy transdermal patch weekly 150-35 mcg/24 hr</i> | (norelgestromin-ethin.estradiol) | 2 | QL (3 per 28 days) |
| <i>zarah oral tablet 3-0.03 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>zovia 1-35 (28) oral tablet 1-35 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>zumandimine (28) oral tablet 3-0.03 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| Anticonvulsivos | | | |
| Anticonvulsivos | | | |
| APTIOM ORAL TABLET 200 MG, 400 MG | | 5 | ST; NDS; QL (30 per 30 days) |
| APTIOM ORAL TABLET 600 MG, 800 MG | | 5 | ST; NDS; QL (60 per 30 days) |
| BRIVIACT INTRAVENOUS SOLUTION 50 MG/5 ML | | 3 | QL (80 per 30 days) |
| BRIVIACT ORAL SOLUTION 10 MG/ML | | 3 | QL (600 per 30 days) |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG | | 3 | QL (60 per 30 days) |
| <i>carbamazepine oral capsule, er multiphase 12 hr 100 mg, 200 mg, 300 mg</i> | (Carbatrol) | 2 | |
| <i>carbamazepine oral suspension 100 mg/5 ml</i> | (Tegretol) | 2 | |
| <i>carbamazepine oral tablet 200 mg</i> | (Epilex) | 2 | |
| <i>carbamazepine oral tablet extended release 12 hr 100 mg, 200 mg, 400 mg</i> | (Tegretol XR) | 2 | |
| <i>carbamazepine oral tablet, chewable 100 mg, 200 mg</i> | | 2 | |
| <i>clobazam oral suspension 2.5 mg/ml</i> | (Onfi) | 2 | QL (480 per 30 days) |
| <i>clobazam oral tablet 10 mg, 20 mg</i> | (Onfi) | 2 | QL (60 per 30 days) |
| DIACOMIT ORAL CAPSULE 250 MG | | 5 | PA NSO; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL CAPSULE 500 MG | | 5 | PA NSO; NDS; QL (180 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|-----------------------------------|
| DIACOMIT ORAL POWDER IN PACKET 250 MG | 5 | PA NSO; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 500 MG | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>diazepam rectal kit 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg</i> | 4 | |
| <i>divalproex oral capsule, delayed rel sprinkle 125 mg</i> (Depakote Sprinkles) | 2 | |
| <i>divalproex oral tablet extended release 24 hr 250 mg, 500 mg</i> (Depakote ER) | 2 | |
| <i>divalproex oral tablet, delayed release (dr/ec) 125 mg, 250 mg, 500 mg</i> (Depakote) | 2 | |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML | 5 | PA NSO; NDS |
| <i>epitol oral tablet 200 mg</i> (carbamazepine) | 2 | |
| EPRONTIA ORAL SOLUTION 25 MG/ML | 4 | ST; QL (480 per 30 days) |
| <i>ethosuximide oral capsule 250 mg</i> (Zarontin) | 2 | |
| <i>ethosuximide oral solution 250 mg/5 ml</i> (Zarontin) | 2 | |
| <i>felbamate oral suspension 600 mg/5 ml</i> | 2 | |
| <i>felbamate oral tablet 400 mg, 600 mg</i> (Felbatol) | 2 | |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML | 5 | PA NSO; NDS |
| <i>fosphenytoin injection solution 100 mg pe/2 ml, 500 mg pe/10 ml</i> (Cerebyx) | 2 | |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML | 5 | ST; NDS; QL (720 per 30 days) |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 8 MG | 5 | ST; NDS; QL (30 per 30 days) |
| FYCOMPA ORAL TABLET 2 MG | 4 | ST; QL (30 per 30 days) |
| FYCOMPA ORAL TABLET 4 MG, 6 MG | 5 | ST; NDS; QL (60 per 30 days) |
| <i>gabapentin oral capsule 100 mg, 300 mg</i> (Neurontin) | 1 | GC; QL (360 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>gabapentin oral capsule 400 mg</i> (Neurontin) | 1 | GC; QL (270 per 30 days) |
| <i>gabapentin oral solution 250 mg/5 ml</i> (Neurontin) | 2 | QL (2160 per 30 days) |
| <i>gabapentin oral tablet 600 mg</i> (Neurontin) | 2 | QL (180 per 30 days) |
| <i>gabapentin oral tablet 800 mg</i> (Neurontin) | 2 | QL (120 per 30 days) |
| <i>lacosamide intravenous solution 200 mg/20 ml</i> (Vimpat) | 2 | QL (200 per 5 days) |
| <i>lacosamide oral solution 10 mg/ml</i> (Vimpat) | 2 | QL (1200 per 30 days) |
| <i>lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> (Vimpat) | 2 | QL (60 per 30 days) |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> (Subvenite) | 1 | GC |
| <i>lamotrigine oral tablet, chewable dispersible 25 mg, 5 mg</i> (Lamictal) | 2 | |
| <i>lamotrigine oral tablet, disintegrating 100 mg, 200 mg, 25 mg, 50 mg</i> (Lamictal ODT) | 2 | |
| <i>levetiracetam intravenous solution 500 mg/5 ml</i> (Keppra) | 2 | |
| <i>levetiracetam oral solution 100 mg/ml</i> (Keppra) | 2 | |
| <i>levetiracetam oral tablet 1,000 mg, 250 mg, 500 mg, 750 mg</i> (Keppra) | 2 | |
| <i>levetiracetam oral tablet extended release 24 hr 500 mg, 750 mg</i> (Keppra XR) | 2 | |
| LIBERVANT BUCCAL FILM 10 MG, 12.5 MG, 15 MG, 5 MG, 7.5 MG | 4 | QL (10 per 30 days) |
| <i>methsuximide oral capsule 300 mg</i> (Celontin) | 2 | |
| NAYZILAM NASAL SPRAY, NON-AEROSOL 5 MG/SPRAY (0.1 ML) | 4 | QL (10 per 30 days) |
| <i>oxcarbazepine oral suspension 300 mg/5 ml (60 mg/ml)</i> (Trileptal) | 2 | |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> (Trileptal) | 2 | |
| <i>phenobarbital oral elixir 20 mg/5 ml (4 mg/ml)</i> | 2 | PA NSO-HRM; AGE (Max 64 Years) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|----------------------------------|
| <i>phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg</i> | 2 | PA NSO-HRM; AGE (Max 64 Years) |
| <i>phenytoin oral suspension 125 mg/5 ml</i> (Dilantin-125) | 2 | |
| <i>phenytoin oral tablet, chewable 50 mg</i> (Dilantin Infatabs) | 2 | |
| <i>phenytoin sodium extended oral capsule 100 mg</i> (Dilantin Extended) | 2 | |
| <i>phenytoin sodium extended oral capsule 200 mg, 300 mg</i> (Phenytek) | 2 | |
| <i>phenytoin sodium intravenous solution 50 mg/ml</i> | 2 | |
| <i>phenytoin sodium intravenous syringe 50 mg/ml</i> | 2 | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i> (Lyrica) | 2 | QL (90 per 30 days) |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> (Lyrica) | 2 | QL (60 per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> (Lyrica) | 2 | QL (900 per 30 days) |
| <i>primidone oral tablet 125 mg</i> | 2 | |
| <i>primidone oral tablet 250 mg, 50 mg</i> (Mysoline) | 2 | |
| <i>rufinamide oral suspension 40 mg/ml</i> (Banzel) | 5 | ST; NDS |
| <i>rufinamide oral tablet 200 mg</i> (Banzel) | 2 | ST |
| <i>rufinamide oral tablet 400 mg</i> (Banzel) | 5 | ST; NDS |
| SEZABY INTRAVENOUS RECON SOLN 100 MG | 5 | PA BvD; NDS |
| SPRITAM ORAL TABLET FOR SUSPENSION 1,000 MG | 4 | ST; QL (60 per 30 days) |
| SPRITAM ORAL TABLET FOR SUSPENSION 250 MG, 500 MG, 750 MG | 4 | ST; QL (120 per 30 days) |
| <i>subvenite oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> (lamotrigine) | 1 | GC |
| SYMPAZAN ORAL FILM 10 MG, 20 MG | 5 | PA NSO; NDS; QL (60 per 30 days) |
| SYMPAZAN ORAL FILM 5 MG | 4 | PA NSO; QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>tiagabine oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | 2 | |
| <i>topiramate oral capsule, sprinkle 15 mg, 25 mg</i> (Topamax) | 2 | |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> (Topamax) | 1 | GC |
| <i>valproate sodium intravenous solution 500 mg/5 ml (100 mg/ml)</i> | 2 | |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i> | 2 | |
| <i>valproic acid oral capsule 250 mg</i> | 2 | |
| VALTOCO NASAL SPRAY, NON-AEROSOL 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 5 MG/SPRAY (0.1 ML) | 4 | |
| VALTOCO NASAL SPRAY, NON-AEROSOL 20 MG/2 SPRAY (10MG/0.1ML X2) | 5 | NDS |
| <i>vigabatrin oral powder in packet 500 mg</i> (Vigadrone) | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigabatrin oral tablet 500 mg</i> (Vigadrone) | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigadrone oral powder in packet 500 mg</i> (vigabatrin) | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigadrone oral tablet 500 mg</i> (vigabatrin) | 5 | PA NSO; NDS; QL (180 per 30 days) |
| <i>vigpoder oral powder in packet 500 mg</i> (vigabatrin) | 5 | PA NSO; NDS; QL (180 per 30 days) |
| XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) | 4 | ST; QL (56 per 28 days) |
| XCOPRI ORAL TABLET 100 MG, 25 MG, 50 MG | 4 | ST; QL (30 per 30 days) |
| XCOPRI ORAL TABLET 150 MG, 200 MG | 4 | ST; QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|------------------------------------|
| XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 12.5 MG (14)- 25 MG (14), 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) | 4 | ST |
| ZONISADE ORAL SUSPENSION 100 MG/5 ML | 4 | |
| <i>zonisamide oral capsule 100 mg, 25 mg</i> (Zonegran) | 2 | |
| <i>zonisamide oral capsule 50 mg</i> | 2 | |
| ZTALMY ORAL SUSPENSION 50 MG/ML | 5 | PA NSO; NDS; QL (1080 per 30 days) |
| Antidepresivos | | |
| Antidepresivos | | |
| <i>amitriptyline oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 1 | GC |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i> | 2 | |
| AUVELITY ORAL TABLET, IR AND ER, BIPHASIC 45-105 MG | 5 | ST; NDS |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i> | 2 | |
| <i>bupropion hcl oral tablet extended release 24 hr 150 mg, 300 mg</i> (Wellbutrin XL) | 2 | |
| <i>bupropion hcl oral tablet sustained-release 12 hr 100 mg, 150 mg, 200 mg</i> (Wellbutrin SR) | 2 | |
| <i>citalopram oral solution 10 mg/5 ml</i> | 2 | QL (600 per 30 days) |
| <i>citalopram oral tablet 10 mg</i> (Celexa) | 1 | GC; QL (120 per 30 days) |
| <i>citalopram oral tablet 20 mg, 40 mg</i> (Celexa) | 1 | GC; QL (30 per 30 days) |
| <i>clomipramine oral capsule 25 mg, 50 mg, 75 mg</i> (Anafranil) | 2 | |
| <i>desipramine oral tablet 10 mg, 25 mg</i> (Norpramin) | 2 | |
| <i>desipramine oral tablet 100 mg, 150 mg, 50 mg, 75 mg</i> | 2 | |
| <i>desvenlafaxine succinate oral tablet extended release 24 hr 100 mg, 25 mg, 50 mg</i> (Pristiq) | 2 | QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>doxepin oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>doxepin oral concentrate 10 mg/ml</i> | 1 | GC |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 60 MG | 4 | ST; QL (60 per 30 days) |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 40 MG | 4 | ST; QL (30 per 30 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 20 mg, 30 mg, 60 mg</i> (Cymbalta) | 2 | QL (60 per 30 days) |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR | 5 | ST; NDS; QL (30 per 30 days) |
| <i>escitalopram oxalate oral solution 5 mg/5 ml</i> | 2 | |
| <i>escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg</i> (Lexapro) | 1 | GC |
| FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)-40 MG (26) | 4 | ST |
| FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG | 4 | ST; QL (30 per 30 days) |
| <i>fluoxetine oral capsule 10 mg, 20 mg, 40 mg</i> (Prozac) | 1 | GC |
| <i>fluoxetine oral solution 20 mg/5 ml (4 mg/ml)</i> | 2 | |
| <i>fluvoxamine oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | |
| MARPLAN ORAL TABLET 10 MG | 4 | |
| <i>mirtazapine oral tablet 15 mg, 30 mg</i> (Remeron) | 2 | |
| <i>mirtazapine oral tablet 45 mg, 7.5 mg</i> | 2 | |
| <i>mirtazapine oral tablet, disintegrating</i> (Remeron SolTab) <i>15 mg, 30 mg, 45 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>nefazodone oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i> | 2 | |
| <i>nortriptyline oral capsule 10 mg, 25 mg, 50 mg, 75 mg</i> (Pamelor) | 1 | GC |
| <i>nortriptyline oral solution 10 mg/5 ml</i> | 2 | |
| <i>paroxetine hcl oral suspension 10 mg/5 ml</i> (Paxil) | 2 | PA NSO-HRM; AGE (Max 64 Years) |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg, 30 mg, 40 mg</i> (Paxil) | 1 | PA NSO-HRM; GC; AGE (Max 64 Years) |
| <i>phenelzine oral tablet 15 mg</i> (Nardil) | 2 | |
| <i>protriptyline oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>sertraline oral concentrate 20 mg/ml</i> (Zoloft) | 2 | |
| <i>sertraline oral tablet 100 mg, 25 mg, 50 mg</i> (Zoloft) | 1 | GC |
| SPRAVATO NASAL SPRAY, NON-AEROSOL 28 MG | 4 | PA NSO |
| SPRAVATO NASAL SPRAY, NON-AEROSOL 56 MG (28 MG X 2), 84 MG (28 MG X 3) | 5 | PA NSO; NDS |
| <i>tranlycypromine oral tablet 10 mg</i> (Parnate) | 2 | |
| <i>trazodone oral tablet 100 mg, 150 mg, 300 mg, 50 mg</i> | 1 | GC |
| <i>trimipramine oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 3 | QL (30 per 30 days) |
| <i>venlafaxine besylate oral tablet extended release 24hr 112.5 mg</i> | 4 | QL (60 per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 150 mg</i> (Effexor XR) | 1 | GC; QL (30 per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 37.5 mg, 75 mg</i> (Effexor XR) | 2 | QL (90 per 30 days) |
| <i>venlafaxine oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 2 | |
| <i>vilazodone oral tablet 10 mg, 20 mg, 40 mg</i> (Viibryd) | 2 | QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------------|
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG | 5 | PA NSO; NDS; QL (28 per 14 days) |
| ZURZUVAE ORAL CAPSULE 30 MG | 5 | PA NSO; NDS; QL (14 per 14 days) |
| Antifúngicos | | |
| Antifúngicos | | |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | 4 | PA BvD |
| <i>amphotericin b injection recon soln 50 mg</i> | 2 | PA BvD |
| <i>amphotericin b liposome intravenous suspension for reconstitution 50 mg</i> (AmBisome) | 5 | PA BvD; NDS |
| <i>casposfungin intravenous recon soln 50 mg</i> (Cancidas) | 2 | |
| <i>casposfungin intravenous recon soln 70 mg</i> (Cancidas) | 5 | NDS |
| <i>ciclopirox topical cream 0.77 %</i> (Ciclodan) | 2 | QL (180 per 30 days) |
| <i>ciclopirox topical solution 8 %</i> (Ciclodan) | 2 | QL (19.8 per 30 days) |
| <i>clotrimazole mucous membrane troche 10 mg</i> | 2 | |
| <i>clotrimazole topical cream 1 %</i> (Antifungal (clotrimazole)) | 2 | |
| <i>clotrimazole topical solution 1 %</i> | 2 | |
| <i>clotrimazole-betamethasone topical cream 1-0.05 %</i> | 2 | QL (90 per 30 days) |
| <i>econazole topical cream 1 %</i> | 2 | QL (170 per 30 days) |
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 100 mg/50 ml, 200 mg/100 ml, 400 mg/200 ml</i> | 2 | |
| <i>fluconazole oral suspension for reconstitution 10 mg/ml</i> | 2 | |
| <i>fluconazole oral suspension for reconstitution 40 mg/ml</i> (Diflucan) | 2 | |
| <i>fluconazole oral tablet 100 mg, 200 mg</i> (Diflucan) | 2 | |
| <i>fluconazole oral tablet 150 mg, 50 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>flucytosine oral capsule 250 mg, 500 mg</i> (Ancobon) | 5 | NDS |
| <i>griseofulvin microsize oral suspension 125 mg/5 ml</i> | 2 | |
| <i>griseofulvin microsize oral tablet 500 mg</i> | 2 | |
| <i>itraconazole oral capsule 100 mg</i> (Sporanox) | 2 | |
| <i>ketoconazole oral tablet 200 mg</i> | 2 | |
| <i>ketoconazole topical cream 2 %</i> | 2 | QL (180 per 30 days) |
| <i>ketoconazole topical foam 2 %</i> (Extina) | 2 | ST; QL (100 per 30 days) |
| <i>ketoconazole topical shampoo 2 %</i> | 2 | QL (360 per 30 days) |
| <i>miconazole-3 vaginal suppository 200 mg</i> | 2 | |
| NOXAFIL ORAL SUSP,DELAYED RELEASE FOR RECON 300 MG | 5 | PA; NDS |
| <i>nyamyc topical powder 100,000 unit/gram</i> (nystatin) | 2 | QL (60 per 30 days) |
| <i>nystatin oral suspension 100,000 unit/ml</i> | 2 | QL (900 per 30 days) |
| <i>nystatin oral tablet 500,000 unit</i> | 2 | |
| <i>nystatin topical cream 100,000 unit/gram</i> | 2 | QL (60 per 30 days) |
| <i>nystatin topical ointment 100,000 unit/gram</i> | 2 | QL (60 per 30 days) |
| <i>nystatin topical powder 100,000 unit/gram</i> (Nyamyc) | 2 | QL (60 per 30 days) |
| <i>nystatin-triamcinolone topical cream 100,000-0.1 unit/g-%</i> | 2 | |
| <i>nystatin-triamcinolone topical ointment 100,000-0.1 unit/gram-%</i> | 2 | |
| <i>nystop topical powder 100,000 unit/gram</i> (nystatin) | 2 | QL (60 per 30 days) |
| <i>posaconazole oral suspension 200 mg/5 ml (40 mg/ml)</i> (Noxafil) | 5 | PA; NDS |
| <i>posaconazole oral tablet, delayed release (dr/ec) 100 mg</i> (Noxafil) | 5 | PA; NDS |
| <i>terbinafine hcl oral tablet 250 mg</i> | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>voriconazole intravenous recon soln</i> 200 mg (Vfend IV) | 5 | PA BvD; NDS |
| <i>voriconazole oral suspension for reconstitution</i> 200 mg/5 ml (40 mg/ml) (Vfend) | 5 | PA; NDS |
| <i>voriconazole oral tablet</i> 200 mg, 50 mg (Vfend) | 2 | |
| Antihistamínicos | | |
| Antihistamínicos | | |
| <i>cyproheptadine oral syrup</i> 2 mg/5 ml | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>diphenhydramine hcl injection solution</i> 50 mg/ml | 2 | |
| <i>diphenhydramine hcl injection syringe</i> 50 mg/ml | 1 | GC |
| <i>diphenhydramine hcl oral elixir</i> 12.5 mg/5 ml (Diphen) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>hydroxyzine hcl intramuscular solution</i> 25 mg/ml, 50 mg/ml | 2 | |
| <i>hydroxyzine hcl oral solution</i> 10 mg/5 ml | 2 | |
| <i>hydroxyzine hcl oral tablet</i> 10 mg, 25 mg, 50 mg | 1 | GC |
| <i>levocetirizine oral tablet</i> 5 mg (24HR Allergy Relief) | 1 | GC |
| <i>promethazine oral syrup</i> 6.25 mg/5 ml | 2 | PA-HRM; AGE (Max 64 Years) |
| Antimicobacteriales | | |
| Antimicobacteriales | | |
| <i>dapsone oral tablet</i> 100 mg, 25 mg | 2 | |
| <i>ethambutol oral tablet</i> 100 mg, 400 mg | 2 | |
| <i>isoniazid oral solution</i> 50 mg/5 ml | 2 | |
| <i>isoniazid oral tablet</i> 100 mg, 300 mg | 1 | GC |
| PRETOMANID ORAL TABLET 200 MG | 4 | QL (30 per 30 days) |
| PRIFTIN ORAL TABLET 150 MG | 4 | |
| <i>pyrazinamide oral tablet</i> 500 mg | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| <i>rifabutin oral capsule 150 mg</i> (Mycobutin) | 2 | |
| <i>rifampin intravenous recon soln 600 mg</i> (Rifadin) | 2 | |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | 2 | |
| SIRTURO ORAL TABLET 100 MG, 20 MG | 5 | PA; NDS |
| TRECTOR ORAL TABLET 250 MG | 4 | |
| Antivirales (Sitémico) | | |
| Antirretrovirales | | |
| <i>abacavir oral solution 20 mg/ml</i> (Ziagen) | 2 | |
| <i>abacavir oral tablet 300 mg</i> | 2 | |
| <i>abacavir-lamivudine oral tablet 600-300 mg</i> | 2 | |
| APRETUDE INTRAMUSCULAR SUSPENSION, EXTENDED RELEASE 600 MG/3 ML (200 MG/ML) (cabotegravir) | 5 | NDS; QL (24 per 365 days) |
| APTIVUS ORAL CAPSULE 250 MG | 5 | NDS |
| <i>atazanavir oral capsule 150 mg</i> | 2 | |
| <i>atazanavir oral capsule 200 mg, 300 mg</i> (Reyataz) | 2 | |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG | 5 | NDS; QL (30 per 30 days) |
| CABENUVA INTRAMUSCULAR SUSPENSION, EXTENDED RELEASE 400 MG/2 ML- 600 MG/2 ML, 600 MG/3 ML- 900 MG/3 ML | 5 | NDS |
| <i>cabotegravir intramuscular suspension, extended release 400 mg/2 ml (200 mg/ml)</i> | 5 | NDS; QL (24 per 365 days) |
| <i>cabotegravir intramuscular suspension, extended release 600 mg/3 ml (200 mg/ml)</i> (Apretude) | 5 | NDS; QL (24 per 365 days) |
| CIMDUO ORAL TABLET 300-300 MG | 5 | NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| COMPLERA ORAL TABLET 200-25-300 MG | 5 | NDS |
| <i>darunavir oral tablet 600 mg, 800 mg</i> (Prezista) | 5 | NDS |
| DELSTRIGO ORAL TABLET 100-300-300 MG | 5 | NDS |
| DESCOVY ORAL TABLET 120-15 MG, 200-25 MG | 5 | NDS |
| <i>didanosine oral capsule, delayed release(dr/ec) 250 mg, 400 mg</i> | 2 | |
| DOVATO ORAL TABLET 50-300 MG | 5 | NDS |
| EDURANT ORAL TABLET 25 MG | 5 | NDS |
| <i>efavirenz oral capsule 200 mg, 50 mg</i> | 2 | |
| <i>efavirenz oral tablet 600 mg</i> | 2 | |
| <i>efavirenz-emtricitabin-tenofovir oral tablet 600-200-300 mg</i> (Atripla) | 5 | NDS |
| <i>efavirenz-lamivudine-tenofovir disoproxil fumarate oral tablet 400-300-300 mg</i> (Symfi Lo) | 5 | NDS |
| <i>efavirenz-lamivudine-tenofovir disoproxil fumarate oral tablet 600-300-300 mg</i> (Symfi) | 5 | NDS |
| <i>emtricitabine oral capsule 200 mg</i> (Emtriva) | 2 | |
| <i>emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 133-200 mg, 167-250 mg</i> (Truvada) | 5 | NDS |
| <i>emtricitabine-tenofovir (tdf) oral tablet 200-300 mg</i> (Truvada) | 2 | |
| EMTRIVA ORAL SOLUTION 10 MG/ML | 4 | |
| EPIVIR HBV ORAL SOLUTION 25 MG/5 ML (5 MG/ML) | 4 | |
| <i>etravirine oral tablet 100 mg, 200 mg</i> (Intelence) | 5 | NDS |
| EVOTAZ ORAL TABLET 300-150 MG | 5 | NDS |
| <i>fosamprenavir oral tablet 700 mg</i> | 5 | NDS |
| FUZEON SUBCUTANEOUS RECON SOLN 90 MG | 5 | NDS |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 5 | NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| INTELENCE ORAL TABLET 25 MG | 4 | |
| INVIRASE ORAL TABLET 500 MG | 5 | NDS |
| ISENTRESS HD ORAL TABLET 600 MG | 5 | NDS |
| ISENTRESS ORAL POWDER IN PACKET 100 MG | 5 | NDS |
| ISENTRESS ORAL TABLET 400 MG | 5 | NDS |
| ISENTRESS ORAL TABLET,CHEWABLE 100 MG | 5 | NDS |
| ISENTRESS ORAL TABLET,CHEWABLE 25 MG | 4 | |
| JULUCA ORAL TABLET 50-25 MG | 5 | NDS |
| <i>lamivudine oral solution 10 mg/ml</i> (Epivir) | 2 | |
| <i>lamivudine oral tablet 100 mg</i> | 2 | |
| <i>lamivudine oral tablet 150 mg, 300 mg</i> (Epivir) | 2 | |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | 2 | |
| LEXIVA ORAL SUSPENSION 50 MG/ML | 4 | |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5 ml</i> (Kaletra) | 2 | QL (480 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 100-25 mg</i> (Kaletra) | 2 | QL (300 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 200-50 mg</i> (Kaletra) | 2 | QL (120 per 30 days) |
| <i>maraviroc oral tablet 150 mg, 300 mg</i> (Selzentry) | 5 | NDS |
| <i>nevirapine oral suspension 50 mg/5 ml</i> | 2 | |
| <i>nevirapine oral tablet 200 mg</i> | 2 | |
| <i>nevirapine oral tablet extended release 24 hr 100 mg, 400 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| NORVIR ORAL POWDER IN PACKET 100 MG | 4 | |
| NORVIR ORAL SOLUTION 80 MG/ML | 4 | |
| ODEFSEY ORAL TABLET 200-25-25 MG | 5 | NDS |
| PIFELTRO ORAL TABLET 100 MG | 5 | NDS |
| PREZCOBIX ORAL TABLET 800-150 MG-MG | 5 | NDS |
| PREZISTA ORAL SUSPENSION 100 MG/ML | 5 | NDS |
| PREZISTA ORAL TABLET 150 MG, 75 MG | 5 | NDS |
| RETROVIR INTRAVENOUS SOLUTION 10 MG/ML | 4 | |
| REYATAZ ORAL POWDER IN PACKET 50 MG | 5 | NDS |
| <i>rilpivirine intramuscular suspension, extended release 600 mg/2 ml (300 mg/ml), 900 mg/3 ml (300 mg/ml)</i> | 5 | NDS |
| <i>ritonavir oral tablet 100 mg</i> (Norvir) | 2 | |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HR 600 MG | 5 | NDS |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 5 | NDS |
| SELZENTRY ORAL TABLET 25 MG | 3 | |
| SELZENTRY ORAL TABLET 75 MG | 5 | NDS |
| <i>stavudine oral capsule 15 mg, 20 mg, 30 mg, 40 mg</i> | 2 | |
| STRIBILD ORAL TABLET 150-150-200-300 MG | 5 | NDS |
| SUNLENCA ORAL TABLET 300 MG, 300 MG (4-TABLET PACK) | 5 | NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|------------------------------|
| SUNLENCA SUBCUTANEOUS SOLUTION 309 MG/ML | 5 | PA BvD; NDS |
| SYM TUZA ORAL TABLET 800-150-200-10 MG | 5 | NDS |
| TEMIXYS ORAL TABLET 300-300 MG | 5 | NDS |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> (Viread) | 2 | |
| TIVICAY ORAL TABLET 10 MG | 4 | |
| TIVICAY ORAL TABLET 25 MG, 50 MG | 5 | NDS |
| TIVICAY PD ORAL TABLET FOR SUSPENSION 5 MG | 5 | NDS |
| TRIUMEQ ORAL TABLET 600-50-300 MG | 5 | NDS; QL (30 per 30 days) |
| TRIUMEQ PD ORAL TABLET FOR SUSPENSION 60-5-30 MG | 5 | NDS |
| TRIZIVIR ORAL TABLET 300-150-300 MG | 5 | NDS |
| TROGARZO INTRAVENOUS SOLUTION 200 MG/1.33 ML (150 MG/ML) | 5 | NDS |
| VEMLIDY ORAL TABLET 25 MG | 5 | ST; NDS; QL (30 per 30 days) |
| VIRACEPT ORAL TABLET 250 MG, 625 MG | 5 | NDS |
| VIREAD ORAL POWDER 40 MG/SCOOP (40 MG/GRAM) | 5 | NDS |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | 5 | NDS |
| VOCABRIA ORAL TABLET 30 MG | 4 | |
| <i>zidovudine oral capsule 100 mg</i> (Retrovir) | 2 | |
| <i>zidovudine oral syrup 10 mg/ml</i> (Retrovir) | 2 | |
| <i>zidovudine oral tablet 300 mg</i> | 2 | |
| Antivirales Hcv | | |
| EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG | 5 | PA; NDS; QL (28 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|-------------------------------|
| EPCLUSA ORAL PELLETS IN PACKET 200-50 MG | 5 | PA; NDS; QL (56 per 28 days) |
| EPCLUSA ORAL TABLET 200-50 MG | 5 | PA; NDS; QL (28 per 28 days) |
| EPCLUSA ORAL TABLET 400-100 (sofosbuvir-velpatasvir) MG | 5 | PA; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 33.75-150 MG | 5 | PA; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 45-200 MG | 5 | PA; NDS; QL (56 per 28 days) |
| HARVONI ORAL TABLET 45-200 MG | 5 | PA; NDS; QL (28 per 28 days) |
| HARVONI ORAL TABLET 90-400 (ledipasvir-sofosbuvir) MG | 5 | PA; NDS; QL (28 per 28 days) |
| VOSEVI ORAL TABLET 400-100-100 MG | 5 | PA; NDS; QL (28 per 28 days) |
| Antivirales, Varios | | |
| <i>foscarnet intravenous solution 24 mg/ml</i> (Foscavir) | 2 | PA BvD |
| <i>oseltamivir oral capsule 30 mg</i> (Tamiflu) | 2 | QL (84 per 180 days) |
| <i>oseltamivir oral capsule 45 mg</i> (Tamiflu) | 2 | QL (48 per 180 days) |
| <i>oseltamivir oral capsule 75 mg</i> (Tamiflu) | 2 | QL (42 per 180 days) |
| <i>oseltamivir oral suspension for reconstitution 6 mg/ml</i> (Tamiflu) | 2 | QL (540 per 180 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 150-100 MG, 300 MG (150 MG X 2)-100 MG | 3 | \$0 copay; QL (30 per 5 days) |
| PREVYMIS INTRAVENOUS SOLUTION 240 MG/12 ML | 5 | PA; NDS; QL (336 per 28 days) |
| PREVYMIS INTRAVENOUS SOLUTION 480 MG/24 ML | 5 | PA; NDS; QL (672 per 28 days) |
| PREVYMIS ORAL TABLET 240 MG, 480 MG | 5 | PA; NDS; QL (28 per 28 days) |
| RELENZA DISKHALER INHALATION BLISTER WITH DEVICE 5 MG/ACTUATION | 4 | QL (60 per 180 days) |
| <i>rimantadine oral tablet 100 mg</i> (Flumadine) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| XOFLUZA 40 MG TAB (80 MG DOSE) | 4 | QL (4 per 180 days) |
| XOFLUZA ORAL TABLET 20 MG, 40 MG | 4 | QL (4 per 180 days) |
| XOFLUZA ORAL TABLET 80 MG | 4 | QL (2 per 180 days) |
| Interferones | | |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 5 | PA; NDS |
| PEGASYS SUBCUTANEOUS SYRINGE 180 MCG/0.5 ML | 5 | PA; NDS |
| Nucleósidos Y Nucleótidos | | |
| <i>acyclovir oral capsule 200 mg</i> | 2 | |
| <i>acyclovir oral suspension 200 mg/5 ml</i> (Zovirax) | 2 | |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 2 | |
| <i>acyclovir sodium intravenous recon soln 1,000 mg, 500 mg</i> | 2 | PA BvD |
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 2 | PA BvD |
| <i>adefovir oral tablet 10 mg</i> (Hepsera) | 2 | |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> (Baraclude) | 2 | |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 2 | |
| <i>lagevrio (eua) oral capsule 200 mg</i> | 4 | QL (40 per 5 days) |
| <i>ribavirin oral capsule 200 mg</i> | 2 | |
| <i>ribavirin oral tablet 200 mg</i> | 2 | |
| <i>valacyclovir oral tablet 1 gram, 500 mg</i> (Valtrex) | 2 | |
| <i>valganciclovir oral tablet 450 mg</i> (Valcyte) | 2 | |
| Dispositivos | | |
| Dispositivos | | |
| 1ST TIER UNIFINE PENTIP 5MM 31G 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| 1ST TIER UNIFINE PNTIP 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| 1ST TIER UNIFINE PNTIP 6MM 31G 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| 1ST TIER UNIFINE PNTIP 8MM 31G STRL,SINGLE-USE,SHRT 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| 1ST TIER UNIFINE PNTIP 29GX1/2" 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | |
| 1ST TIER UNIFINE PNTIP 31GX3/16 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| 1ST TIER UNIFINE PNTIP 32GX5/32 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| ABOUTTIME PEN NEEDLE 30G X 8MM 30 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| ABOUTTIME PEN NEEDLE 31G X 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| ABOUTTIME PEN NEEDLE 31G X 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| ABOUTTIME PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| ADVOCATE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| ADVOCATE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| ADVOCATE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| ADVOCATE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| ADVOCATE INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| ADVOCATE INS SYR 0.3 ML 29GX1/2 0.3 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| ADVOCATE INS SYR 0.5 ML 29GX1/2 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| ADVOCATE INS SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| ADVOCATE INS SYR 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| ADVOCATE PEN NDL 12.7MM (pen needle, diabetic) 29G 29 GAUGE X 1/2" | 2 | |
| ADVOCATE PEN NEEDLE 32G (pen needle, diabetic) 4MM 32 GAUGE X 5/32" | 2 | |
| ADVOCATE PEN NEEDLE 4MM (pen needle, diabetic) 33G 33 GAUGE X 5/32" | 2 | |
| ADVOCATE PEN NEEDLES 5MM (pen needle, diabetic) 31G 31 GAUGE X 3/16" | 2 | |
| ADVOCATE PEN NEEDLES 8MM (pen needle, diabetic) 31G 31 GAUGE X 5/16" | 2 | |
| AQINJECT PEN NEEDLE 31G (pen needle, diabetic) 5MM 31 GAUGE X 3/16" | 2 | |
| AQINJECT PEN NEEDLE 32G (pen needle, diabetic) 4MM 32 GAUGE X 5/32" | 2 | |
| ASSURE ID DUO PRO NDL 31G (pen needle, diabetic, 5MM 31 GAUGE X 3/16" safety) | 2 | |
| ASSURE ID DUO-SHIELD 30GX3/16" 30 GAUGE X 3/16" | 2 | |
| ASSURE ID DUO-SHIELD 30GX5/16" 30 GAUGE X 5/16" | 2 | |
| ASSURE ID PEN NEEDLE 30GX3/16" 30 GAUGE X 3/16" | 2 | |
| ASSURE ID PEN NEEDLE 30GX5/16" 30 GAUGE X 5/16" | 2 | |
| ASSURE ID PEN NEEDLE (pen needle, diabetic, 31GX3/16" 31 GAUGE X 3/16" safety) | 2 | |
| ASSURE ID PRO PEN NDL 30G 5MM 30 GAUGE X 3/16" | 2 | |
| ASSURE ID SYR 0.5 ML 29GX1/2" (RX) 0.5 ML 29 GAUGE X 1/2" | 2 | |
| ASSURE ID SYR 0.5 ML 31GX15/64" 0.5 ML 31 GAUGE X 15/64" | 2 | |
| ASSURE ID SYR 1 ML 29GX1/2" (RX) 1 ML 29 GAUGE X 1/2" | 2 | |
| ASSURE ID SYR 1 ML 31GX15/64" 1 ML 31 GAUGE X 15/64" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------------------|------------------------------------|
| BD AUTOSHIELD DUO NDL 5MMX30G 30 GAUGE X 3/16" | 2 | |
| BD ECLIPSE 30GX1/2" SYRINGE 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 |
| BD ECLIPSE NEEDLE 30GX1/2" (OTC) 30 X 1/2 " | 2 | |
| BD INS SYR 0.3 ML 8MMX31G(1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | |
| BD INS SYRINGE 1/2 ML 6MMX31G (ONLY FOR 500 UNIT/ML INSULIN) 1/2 ML 31 GAUGE X 15/64" | 2 | |
| BD INS SYRN UF 1 ML 12.7MMX30G NOT FOR RETAIL SALE 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 |
| BD INSULIN SYR 1 ML 25GX1" 1 ML 25 X 1" | 2 | |
| BD INSULIN SYR 1 ML 25GX5/8" 1 ML 25 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 |
| BD INSULIN SYR 1 ML 26GX1/2" 1 ML 26 X 1/2" | 2 | |
| BD INSULIN SYR 1 ML 27GX12.7MM 1 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 |
| BD INSULIN SYR 1 ML 27GX5/8" MICRO-FINE 1 ML 27 GAUGE X 5/8" | 2 | |
| BD INSULIN SYRINGE 1 ML W/O NEEDLE | (insulin syringe needleless) | 2 |
| BD LUER-LOK SYRINGE 1 ML | (Easy Touch Luer Lock Insulin) | 2 |
| BD NANO 2 GEN PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 |
| BD SAFETGLD INS 0.3 ML 29G 13MM 0.3 ML 29 GAUGE X 1/2" | 2 | |
| BD SAFETGLD INS 0.5 ML 13MMX29G 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| BD SAFETYGLD INS 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | 2 | |
| BD SAFETYGLD INS 0.5 ML 30G 8MM 0.5 ML 30 GAUGE X 5/16" | 2 | |
| BD SAFETYGLID INS 1 ML 6MMX31G 1 ML 31 GAUGE X 15/64" | 2 | |
| BD SAFETYGLIDE INSULIN SYRINGE SYRINGE 1 ML 29 GAUGE X 1/2" | 2 | |
| BD SAFETYGLIDE SYRINGE 27GX5/8 1 ML 27 GAUGE X 5/8" | 2 | |
| BD SAFTYGLD INS 0.3 ML 6MMX31G 0.3 ML 31 GAUGE X 15/64" | 2 | |
| BD SAFTYGLD INS 0.5 ML 29G 13MM 0.5 ML 29 GAUGE X 1/2" | 2 | |
| BD SAFTYGLD INS 0.5 ML 6MMX31G 0.5 ML 31 GAUGE X 15/64" | 2 | |
| BD UF MICRO PEN NEEDLE (pen needle, diabetic) 6MMX32G 32 GAUGE X 1/4" | 2 | |
| BD UF MINI PEN NEEDLE (pen needle, diabetic) 5MMX31G 31 GAUGE X 3/16" | 2 | |
| BD UF NANO PEN NEEDLE (pen needle, diabetic) 4MMX32G 32 GAUGE X 5/32" | 2 | |
| BD UF ORIG PEN NDL (pen needle, diabetic) 12.7MMX29G 29 GAUGE X 1/2" | 2 | |
| BD UF SHORT PEN NEEDLE (pen needle, diabetic) 8MMX31G 31 GAUGE X 5/16" | 2 | |
| BD VEO INS 0.3 ML 6MMX31G (1/2) 0.3 ML 31 GAUGE X 15/64" | 2 | |
| BD VEO INS SYRING 1 ML (insulin syringe-needle 6MMX31G 1 ML 31 GAUGE X u-100) 15/64" | 2 | |
| BD VEO INS SYRN 0.3 ML (insulin syringe-needle 6MMX31G 0.3 ML 31 GAUGE X u-100) 15/64" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| BD VEO INS SYRN 0.5 ML 6MMX31G 1/2 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | |
| BORDERED GAUZE 2"X2" 2 X 2 " (gauze bandage) | 1 | GC |
| CAREFINE PEN NEEDLE 12.7MM 29G 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | |
| CAREFINE PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| CAREFINE PEN NEEDLE 5MM 32G 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| CAREFINE PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| CAREFINE PEN NEEDLE 8MM 30G 30 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| CAREFINE PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| CAREFINE PEN NEEDLES 8MM 31G 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| CARETOUCH PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | |
| CARETOUCH PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| CARETOUCH PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| CARETOUCH PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| CARETOUCH PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| CARETOUCH PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| CARETOUCH SYR 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| CARETOUCH SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| CARETOUCH SYR 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| CARETOUCH SYR 1 ML 28GX5/16" 1 ML 28 X 5/16" | 2 | |
| CARETOUCH SYR 1 ML 29GX5/16" 1 ML 29 GAUGE X 5/16" | 2 | |
| CARETOUCH SYR 1 ML (insulin syringe-needle 30GX5/16" 1 ML 30 GAUGE X 5/16 u-100) | 2 | |
| CARETOUCH SYR 1 ML (insulin syringe-needle 31GX5/16" 1 ML 31 GAUGE X 5/16 u-100) | 2 | |
| CLICKFINE 31G X 5/16" (pen needle, diabetic) NEEDLES 8MM, UNIVERSAL 31 GAUGE X 5/16" | 2 | |
| CLICKFINE PEN NEEDLE (pen needle, diabetic) 32GX5/32" 32GX4MM, STERILE 32 GAUGE X 5/32" | 2 | |
| CLICKFINE UNIVERSAL 31G X (pen needle, diabetic) 1/4" 6MM, STORE BRAND 31 GAUGE X 1/4" | 2 | |
| COMFORT EZ 0.3 ML 31G 15/64" (insulin syringe-needle 0.3 ML 31 GAUGE X 15/64" u-100) | 2 | |
| COMFORT EZ 0.5 ML 31G 15/64" (insulin syringe-needle 1/2 ML 31 GAUGE X 15/64" u-100) | 2 | |
| COMFORT EZ INS 0.3 ML (insulin syringe-needle 30GX1/2" 0.3 ML 30 GAUGE X u-100) 1/2" | 2 | |
| COMFORT EZ INS 0.3 ML (insulin syringe-needle 30GX5/16" 0.3 ML 30 GAUGE X u-100) 5/16" | 2 | |
| COMFORT EZ INS 1 ML 31G (insulin syringe-needle 15/64" 1 ML 31 GAUGE X 15/64" u-100) | 2 | |
| COMFORT EZ INS 1 ML (insulin syringe-needle 31GX5/16" 1 ML 31 GAUGE X 5/16 u-100) | 2 | |
| COMFORT EZ INSULIN SYR 0.3 (insulin syringe-needle ML 0.3 ML 31 GAUGE X 5/16" u-100) | 2 | |
| COMFORT EZ INSULIN SYR 0.5 (insulin syringe-needle ML 0.5 ML 30 GAUGE X 5/16", 0.5 u-100) ML 31 GAUGE X 5/16" | 2 | |
| COMFORT EZ PEN NEEDLE (pen needle, diabetic) 12MM 29G 29 GAUGE X 1/2" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------------------|------------------------------|------------------------------------|
| COMFORT EZ PEN NEEDLES 4MM 32G SINGLE USE, MICRO 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | |
| COMFORT EZ PEN NEEDLES 4MM 33G 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | |
| COMFORT EZ PEN NEEDLES 5MM 31G MINI 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | |
| COMFORT EZ PEN NEEDLES 5MM 32G SINGLE USE,MINI,HRI 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | |
| COMFORT EZ PEN NEEDLES 5MM 33G 33 GAUGE X 3/16" | (pen needle, diabetic) | 2 | |
| COMFORT EZ PEN NEEDLES 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | |
| COMFORT EZ PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | |
| COMFORT EZ PEN NEEDLES 6MM 33G 33 GAUGE X 1/4" | (pen needle, diabetic) | 2 | |
| COMFORT EZ PEN NEEDLES 8MM 31G SHORT 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | |
| COMFORT EZ PEN NEEDLES 8MM 32G 32 GAUGE X 5/16" | (pen needle, diabetic) | 2 | |
| COMFORT EZ PEN NEEDLES 8MM 33G 33 GAUGE X 5/16" | | 2 | |
| COMFORT EZ PRO PEN NDL 30G 8MM 30 GAUGE X 5/16" | | 2 | |
| COMFORT EZ PRO PEN NDL 31G 4MM 31 GAUGE X 5/32" | (pen needle, diabetic, safety) | 2 | |
| COMFORT EZ PRO PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | |
| COMFORT EZ SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| COMFORT EZ SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| COMFORT EZ SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| COMFORT EZ SYR 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| COMFORT EZ SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| COMFORT EZ SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| COMFORT EZ SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| COMFORT EZ SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| COMFORT POINT PEN NDL 31GX1/3" 31 GAUGE X 1/3" | 2 | |
| COMFORT POINT PEN NDL 31GX1/6" 31 GAUGE X 1/6" | 2 | |
| COMFORT TOUCH PEN NDL 31G (pen needle, diabetic) 4MM 31 GAUGE X 5/32" | 2 | |
| COMFORT TOUCH PEN NDL 31G (pen needle, diabetic) 5MM 31 GAUGE X 3/16" | 2 | |
| COMFORT TOUCH PEN NDL 31G (pen needle, diabetic) 6MM 31 GAUGE X 1/4" | 2 | |
| COMFORT TOUCH PEN NDL 31G (pen needle, diabetic) 8MM 31 GAUGE X 5/16" | 2 | |
| COMFORT TOUCH PEN NDL 32G (pen needle, diabetic) 4MM 32 GAUGE X 5/32" | 2 | |
| COMFORT TOUCH PEN NDL 32G (pen needle, diabetic) 5MM 32 GAUGE X 3/16" | 2 | |
| COMFORT TOUCH PEN NDL 32G (pen needle, diabetic) 6MM 32 GAUGE X 1/4" | 2 | |
| COMFORT TOUCH PEN NDL 32G (pen needle, diabetic) 8MM 32 GAUGE X 5/16" | 2 | |
| COMFORT TOUCH PEN NDL 33G (pen needle, diabetic) 4MM 33 GAUGE X 5/32" | 2 | |
| COMFORT TOUCH PEN NDL 33G (pen needle, diabetic) 6MM 33 GAUGE X 1/4" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| COMFORT TOUCH PEN NDL (pen needle, diabetic) 33GX5MM 33 GAUGE X 3/16" | 2 | |
| CURAD GAUZE PADS 2" X 2" 2 X 2 " (gauze bandage) | 1 | GC |
| CURITY GAUZE SPONGES (12 PLY)-200/BAG 2 X 2 " | 1 | GC |
| CURITY GUAZE PADS 1'S(12 PLY) 2 X 2 " (gauze bandage) | 1 | GC |
| DERMACEA 2"X2" GAUZE 12 PLY, USP TYPE VII 2 X 2 " | 1 | GC |
| DERMACEA GAUZE 2"X2" SPONGE 8 PLY 2 X 2 " | 1 | GC |
| DERMACEA NON-WOVEN 2"X2" SPNGE 2 X 2 " | 1 | GC |
| DROPLET 0.5 ML 29GX12.5MM(1/2) 0.5 ML 29 GAUGE X 1/2" | 2 | |
| DROPLET 0.5 ML 30GX12.5MM(1/2) 0.5 ML 30 GAUGE X 1/2" | 2 | |
| DROPLET INS 0.3 ML (insulin syringe-needle u-100) 29GX12.5MM 0.3 ML 29 GAUGE X 1/2" | 2 | |
| DROPLET INS 0.3 ML (insulin syringe-needle u-100) 30GX12.5MM 0.3 ML 30 GAUGE X 1/2" | 2 | |
| DROPLET INS 0.5 ML 30GX6MM(1/2) 0.5ML 30 GAUGE X 15/64" | 2 | |
| DROPLET INS 0.5 ML 30GX8MM(1/2) 0.5 ML 30 GAUGE X 5/16" | 2 | |
| DROPLET INS 0.5 ML 31GX6MM(1/2) 0.5 ML 31 GAUGE X 15/64" | 2 | |
| DROPLET INS 0.5 ML 31GX8MM(1/2) 0.5 ML 31 GAUGE X 5/16" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-------------------------------------|----------------------------|
| DROPLET INS SYR 0.3 ML 30GX6MM 0.3 ML 30 GAUGE X 15/64" | 2 | |
| DROPLET INS SYR 0.3 ML 30GX8MM 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| DROPLET INS SYR 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) 2 | |
| DROPLET INS SYR 0.3 ML 31GX8MM 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| DROPLET INS SYR 1 ML 29GX12.5MM 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | |
| DROPLET INS SYR 1 ML 30GX12.5MM 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | |
| DROPLET INS SYR 1 ML 30GX6MM 1 ML 30 GAUGE X 15/64" | 2 | |
| DROPLET INS SYR 1 ML 30GX8MM 1 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| DROPLET INS SYR 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) 2 | |
| DROPLET INS SYR 1 ML 31GX8MM 1 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| DROPLET MICRON 34G X 9/64" 34 GAUGE X 9/64" | 2 | |
| DROPLET PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | (pen needle, diabetic) 2 | |
| DROPLET PEN NEEDLE 29GX3/8" 29 GAUGE X 3/8" | 2 | |
| DROPLET PEN NEEDLE 30GX5/16" 30 GAUGE X 5/16" | (pen needle, diabetic) 2 | |
| DROPLET PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| DROPLET PEN NEEDLE (pen needle, diabetic) 31GX3/16" 31 GAUGE X 3/16" | 2 | |
| DROPLET PEN NEEDLE (pen needle, diabetic) 31GX5/16" 31 GAUGE X 5/16" | 2 | |
| DROPLET PEN NEEDLE 32GX1/4" (pen needle, diabetic) 32 GAUGE X 1/4" | 2 | |
| DROPLET PEN NEEDLE (pen needle, diabetic) 32GX3/16" 32 GAUGE X 3/16" | 2 | |
| DROPLET PEN NEEDLE (pen needle, diabetic) 32GX5/16" 32 GAUGE X 5/16" | 2 | |
| DROPLET PEN NEEDLE (pen needle, diabetic) 32GX5/32" 32 GAUGE X 5/32" | 2 | |
| DROPSAFE INS SYR 0.3 ML 31G 6MM 0.3 ML 31 GAUGE X 15/64" | 2 | |
| DROPSAFE INS SYR 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | 2 | |
| DROPSAFE INS SYR 0.5 ML 31G 6MM 0.5 ML 31 GAUGE X 15/64" | 2 | |
| DROPSAFE INS SYR 0.5 ML 31G 8MM 0.5 ML 31 GAUGE X 5/16" | 2 | |
| DROPSAFE INSUL SYR 1 ML 31G 6MM 1 ML 31 GAUGE X 15/64" | 2 | |
| DROPSAFE INSUL SYR 1 ML 31G 8MM 1 ML 31 GAUGE X 5/16" | 2 | |
| DROPSAFE INSULN 1 ML 29G 12.5MM 1 ML 29 GAUGE X 1/2" | 2 | |
| DROPSAFE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 2 | |
| DROPSAFE PEN NEEDLE (pen needle, diabetic, safety) 31GX3/16" 31 GAUGE X 3/16" | 2 | |
| DROPSAFE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 2 | |
| DRUG MART ULTRA COMFORT (insulin syringe-needle u-100) SYR 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| EASY CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic, safety) | 2 | |
| EASY CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | |
| EASY CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | |
| EASY COMFORT 0.3 ML 31G 1/2" 0.3 ML 31 X 1/2" | 2 | |
| EASY COMFORT 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| EASY COMFORT 0.3 ML SYRINGE 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| EASY COMFORT 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| EASY COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| EASY COMFORT 0.5 ML 32GX5/16" 1/2 ML 32 GAUGE X 5/16" | 2 | |
| EASY COMFORT 0.5 ML SYRINGE 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| EASY COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| EASY COMFORT 1 ML 32GX5/16" 1 ML 32 GAUGE X 5/16" | 2 | |
| EASY COMFORT INSULIN 1 ML SYR 1 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| EASY COMFORT PEN NDL 31GX1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| EASY COMFORT PEN NDL 31GX3/16" 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| EASY COMFORT PEN NDL 31GX5/16" 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| EASY COMFORT PEN NDL 32GX5/32" 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| EASY COMFORT PEN NDL 33G 4MM 33 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| EASY COMFORT PEN NDL 33G 5MM 33 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| EASY COMFORT PEN NDL 33G 6MM 33 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| EASY COMFORT SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| EASY GLIDE INS 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | |
| EASY GLIDE INS 0.5 ML 31GX6MM 1/2 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | |
| EASY GLIDE INS 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | |
| EASY GLIDE PEN NEEDLE 4MM 33G 33 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| EASY TOUCH 0.3 ML SYR 30GX1/2" 0.3 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| EASY TOUCH 0.5 ML SYR 27GX1/2" 1/2 ML 27 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| EASY TOUCH 0.5 ML SYR 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 2 | |
| EASY TOUCH 0.5 ML SYR 30GX1/2" 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| EASY TOUCH 0.5 ML SYR 30GX5/16 0.5 ML 30 GAUGE X 5/16" | 2 | |
| EASY TOUCH 1 ML SYR 27GX1/2" 1 ML 27 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| EASY TOUCH 1 ML SYR 29GX1/2" 1 ML 29 GAUGE X 1/2" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| EASY TOUCH 1 ML SYR 30GX1/2" 1 ML 30 GAUGE X 1/2" | 2 | |
| EASY TOUCH FLIPLOK 1 ML 27GX0.5 1 ML 27 GAUGE X 1/2" | 2 | |
| EASY TOUCH INSULIN 1 ML 29GX1/2 1 ML 29 GAUGE X 1/2" | 2 | |
| EASY TOUCH INSULIN 1 ML 30GX1/2 1 ML 30 GAUGE X 1/2" | 2 | |
| EASY TOUCH INSULIN SYR 0.3 ML 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| EASY TOUCH INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| EASY TOUCH INSULIN SYR 1 ML 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | |
| EASY TOUCH INSULIN SYR 1 ML RETRACTABLE 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| EASY TOUCH INSULN 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 2 | |
| EASY TOUCH INSULN 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 2 | |
| EASY TOUCH INSULN 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | 2 | |
| EASY TOUCH INSULN 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | 2 | |
| EASY TOUCH INSULN 1 ML 31GX5/16 1 ML 31 GAUGE X 5/16" | 2 | |
| EASY TOUCH INSULN 1 ML 31GX5/16 1 ML 31 GAUGE X 5/16" | 2 | |
| EASY TOUCH LUER LOK INSUL 1 ML (insulin syringe needleless) | 2 | |
| EASY TOUCH PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | |
| EASY TOUCH PEN NEEDLE 30GX5/16 30 GAUGE X 5/16" (pen needle, diabetic) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------------------|------------------------------|------------------------------------|
| EASY TOUCH PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | |
| EASY TOUCH PEN NEEDLE 31GX3/16 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | |
| EASY TOUCH PEN NEEDLE 31GX5/16 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | |
| EASY TOUCH PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | |
| EASY TOUCH PEN NEEDLE 32GX3/16 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | |
| EASY TOUCH PEN NEEDLE 32GX5/32 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | |
| EASY TOUCH SAF PEN NDL 29G 5MM 29 GAUGE X 3/16" | | 2 | |
| EASY TOUCH SAF PEN NDL 29G 8MM 29 GAUGE X 5/16" | | 2 | |
| EASY TOUCH SAF PEN NDL 30G 5MM 30 GAUGE X 3/16" | | 2 | |
| EASY TOUCH SAF PEN NDL 30G 8MM 30 GAUGE X 5/16" | | 2 | |
| EASY TOUCH SYR 0.5 ML 28G 12.7MM 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| EASY TOUCH SYR 0.5 ML 29G 12.7MM 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| EASY TOUCH SYR 1 ML 27G 16MM 1 ML 27 GAUGE X 5/8" | | 2 | |
| EASY TOUCH SYR 1 ML 28G 12.7MM 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| EASY TOUCH SYR 1 ML 29G 12.7MM 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| EASY TOUCH UNI-SLIP SYR 1 ML | (insulin syringe needleless) | 2 | |
| EASYTOUCH SAF PEN NDL 30G 6MM 30 GAUGE X 1/4" | | 2 | |
| EMBRACE PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | |
| EMBRACE PEN NEEDLE 30G 5MM 30 GAUGE X 3/16" | (pen needle, diabetic) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------------|------------------------------|------------------------------------|
| EMBRACE PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 | |
| EMBRACE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | |
| EMBRACE PEN NEEDLE 31G 6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | |
| EMBRACE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | |
| EMBRACE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | |
| EQL INSULIN 0.3 ML SYRINGE SHORT NEEDLE 0.3 ML 30 | (Ultra Comfort Insulin Syringe) | 2 | |
| EQL INSULIN 0.5 ML SYRINGE SHORT NEEDLE 1/2 ML 30 GAUGE | (Ultra Comfort Insulin Syringe) | 2 | |
| EQL INSULIN 1 ML SYRINGE SHORT NEEDLE 1 ML 30 GAUGE X 7/16" | (Ultra Comfort Insulin Syringe) | 2 | |
| FIFTY50 INS 0.5 ML 31GX5/16" SHORT NEEDLE (OTC) 0.5 ML 31 GAUGE X 5/16" | (Advocate Syringes) | 2 | |
| FIFTY50 INS SYR 1 ML 31GX5/16" SHORT NEEDLE (OTC) 1 ML 31 GAUGE X 5/16 | (Advocate Syringes) | 2 | |
| FIFTY50 PEN 31G X 3/16" NEEDLE (OTC) 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | |
| FP INSULIN 1 ML SYRINGE 1 ML 28 GAUGE | (Ultra Comfort Insulin Syringe) | 2 | |
| FREESTYLE PREC 0.5 ML 30GX5/16 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | |
| FREESTYLE PREC 0.5 ML 31GX5/16 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | |
| FREESTYLE PREC 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | |
| FREESTYLE PREC 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| GAUZE PAD TOPICAL BANDAGE 2 X 2 " (gauze bandage) | 1 | GC |
| GNP ULT C 0.3 ML 29GX1/2" (1/2) 1/2 UNIT 0.3 ML 29 GAUGE X 1/2" | 2 | |
| GNP ULTRA COMFORT 0.5 ML SYR 1/2 ML 29 , 1/2 ML 30 GAUGE (insulin syringe-needle u-100) | 2 | |
| GNP ULTRA COMFORT 1 ML SYRINGE 1 ML 28 GAUGE, 1 ML 30 GAUGE X 7/16" (insulin syringe-needle u-100) | 2 | |
| GNP ULTRA COMFORT 1 ML SYRINGE 1 ML 29 GAUGE | 2 | |
| GNP ULTRA COMFORT 3/10 ML SYR 0.3 ML 30 (insulin syringe-needle u-100) | 2 | |
| HEALTHWISE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| HEALTHWISE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| HEALTHWISE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| HEALTHWISE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| HEALTHWISE INS 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | |
| HEALTHWISE INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | |
| HEALTHWISE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| HEALTHWISE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| HEALTHWISE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| HEALTHY ACCENTS PENTIP 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| HEALTHY ACCENTS PENTIP 5MM 31G 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| HEALTHY ACCENTS PENTIP 6MM 31G 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| HEALTHY ACCENTS PENTIP 8MM 31G 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| HEALTHY ACCENTS PENTIP 12MM 29G 29 GAUGE X 1/2" | 2 | |
| INCONTROL PEN NEEDLE 12MM 29G 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | |
| INCONTROL PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| INCONTROL PEN NEEDLE 5MM 31G 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| INCONTROL PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| INCONTROL PEN NEEDLE 8MM 31G 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| INPEN (FOR HUMALOG) BLUE SUBCUTANEOUS INSULIN PEN | 3 | |
| INPEN (NOVOLOG OR FIASP) BLUE SUBCUTANEOUS INSULIN PEN | 3 | |
| INSULIN SYR 0.3 ML 31GX1/4(1/2) 0.3 ML 31 GAUGE X 1/4" (UltiCare Insuln Syr(half unit)) | 2 | |
| INSULIN SYRIN 0.3 ML 30GX1/2" SHORT NEEDLE 0.3 ML 30 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | |
| INSULIN SYRIN 0.5 ML 28GX1/2" (OTC) 1/2 ML 28 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | |
| INSULIN SYRIN 0.5 ML 29GX1/2" (OTC) 0.5 ML 29 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | |
| INSULIN SYRIN 0.5 ML 30GX1/2" SHORT NEEDLE (OTC) 0.5 ML 30 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | |
| INSULIN SYRIN 0.5 ML 30GX5/16" SHORT NEEDLE (OTC) 0.5 ML 30 GAUGE X 5/16" (Advocate Syringes) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| INSULIN SYRINGE 0.5 ML 27G 1/2" (Easy Touch Insulin INNER (OTC) 1/2 ML 27 GAUGE X 1/2" | 2 | |
| INSULIN SYRINGE 0.3 ML 0.3 ML 29 GAUGE (insulin syringe-needle u-100) | 2 | |
| INSULIN SYRINGE 0.3 ML 31GX1/4 0.3 ML 31 GAUGE X 1/4" (Sure Comfort Insulin Syringe) | 2 | |
| INSULIN SYRINGE 0.5 ML 1/2 ML 29 (insulin syringe-needle u-100) | 2 | |
| INSULIN SYRINGE 0.5 ML 31GX1/4 1/2 ML 31 GAUGE X 1/4" (Sure Comfort Insulin Syringe) | 2 | |
| INSULIN SYRINGE 1 ML 1 ML 29 GAUGE | 2 | |
| INSULIN SYRINGE 1 ML 27G 1/2" (Easy Touch Insulin INNER 1 ML 27 GAUGE X 1/2" | 2 | |
| INSULIN SYRINGE 1 ML 28G 1/2" (Comfort EZ Insulin INNER (RX) 1 ML 28 GAUGE X 1/2" | 2 | |
| INSULIN SYRINGE 1 ML 30GX1/2" (BD Eclipse Luer-Lok) (RX) 1 ML 30 GAUGE X 1/2" | 2 | |
| INSULIN SYRINGE 1 ML 30GX5/16" SHORT NEEDLE (Advocate Syringes) (OTC) 1 ML 30 GAUGE X 5/16" | 2 | |
| INSULIN SYRINGE 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" (Sure Comfort Insulin Syringe) | 2 | |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE (Ultilet Insulin Syringe) | 2 | |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 1 ML 29 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 1/2 ML 28 GAUGE (Monoject Syringe) | 2 | |
| INSUPEN 30G ULTRAFIN NEEDLE 30 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| INSUPEN 31G ULTRAFIN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| INSUPEN 32G 6MM PEN NEEDLE (pen needle, diabetic) 32 GAUGE X 1/4" | 2 | |
| INSUPEN 32G 8MM PEN NEEDLE (pen needle, diabetic) 32 GAUGE X 5/16" | 2 | |
| INSUPEN PEN NEEDLE (pen needle, diabetic) 29GX12MM 29 GAUGE X 1/2" | 2 | |
| INSUPEN PEN NEEDLE (pen needle, diabetic) 31GX3/16" 31 GAUGE X 3/16" | 2 | |
| INSUPEN PEN NEEDLE (pen needle, diabetic) 32GX4MM 32 GAUGE X 5/32" | 2 | |
| INSUPEN PEN NEEDLE (pen needle, diabetic) 33GX4MM 33 GAUGE X 5/32" | 2 | |
| LISCO SPONGES 100/BAG 2 X 2 " | 1 | GC |
| LITE TOUCH 31GX1/4" PEN (pen needle, diabetic) NEEDLE 31 GAUGE X 1/4" | 2 | |
| LITE TOUCH INSULIN 0.5 ML (insulin syringe-needle SYR 1/2 ML 28 GAUGE, 1/2 ML 29 u-100) , 1/2 ML 30 GAUGE | 2 | |
| LITE TOUCH INSULIN 1 ML SYR (insulin syringe-needle 1 ML 28 GAUGE, 1 ML 30 GAUGE u-100) X 7/16" | 2 | |
| LITE TOUCH INSULIN 1 ML SYR 1 ML 29 GAUGE | 2 | |
| LITE TOUCH INSULIN SYR 1 ML (insulin syringe-needle 1 ML 31 GAUGE X 5/16 u-100) | 2 | |
| LITE TOUCH PEN NEEDLE 29G (pen needle, diabetic) 29 GAUGE X 1/2" | 2 | |
| LITE TOUCH PEN NEEDLE 31G (pen needle, diabetic) 31 GAUGE X 3/16", 31 GAUGE X 5/16" | 2 | |
| LITETOUCH INS 0.3 ML 29GX1/2" (insulin syringe-needle 0.3 ML 29 GAUGE X 1/2" u-100) | 2 | |
| LITETOUCH INS 0.3 ML (insulin syringe-needle 30GX5/16" 0.3 ML 30 GAUGE X u-100) 5/16" | 2 | |
| LITETOUCH INS 0.3 ML (insulin syringe-needle 31GX5/16" 0.3 ML 31 GAUGE X u-100) 5/16" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------------------|------------------------------|------------------------------------|
| LITETOUCH INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | |
| LITETOUCH SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| LITETOUCH SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| LITETOUCH SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | |
| LITETOUCH SYRIN 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| LITETOUCH SYRIN 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| LITETOUCH SYRIN 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | |
| MAGELLAN INSUL SYRINGE 0.3 ML 0.3 ML 30 X 5/16" | | 2 | |
| MAGELLAN INSUL SYRINGE 0.5 ML 0.5 ML 30 GAUGE X 5/16" | | 2 | |
| MAGELLAN INSULIN SYR 0.3 ML 0.3 ML 29 GAUGE X 1/2" | | 2 | |
| MAGELLAN INSULIN SYR 0.5 ML 0.5 ML 29 GAUGE X 1/2" | | 2 | |
| MAGELLAN INSULIN SYRINGE 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16" | | 2 | |
| MAXICOMFORT II PEN NDL 31GX6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | |
| MAXICOMFORT INS 0.5 ML 27GX1/2" 1/2 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| MAXI-COMFORT INS 0.5 ML 28G 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| MAXICOMFORT INS 1 ML 27GX1/2" 1 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| MAXI-COMFORT INS 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| MAXICOMFORT PEN NDL 29G X 5MM 29 GAUGE X 3/16" | 2 | |
| MAXICOMFORT PEN NDL 29G X 8MM 29 GAUGE X 5/16" | 2 | |
| MICRODOT PEN NEEDLE 31GX6MM 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| MICRODOT PEN NEEDLE 32GX4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| MICRODOT PEN NEEDLE 33GX4MM 33 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| MICRODOT READYGARD NDL 31G 5MM OUTER 31 GAUGE X 3/16" | 2 | |
| MINI PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" (1st Tier Unifine Pentips) | 2 | |
| MINI PEN NEEDLE 32G 5MM 32 GAUGE X 3/16" (CareFine Pen Needle) | 2 | |
| MINI PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" (BD Ultra-Fine Micro Pen Needle) | 2 | |
| MINI PEN NEEDLE 32G 8MM 32 GAUGE X 5/16" (Comfort EZ Pen Needles) | 2 | |
| MINI PEN NEEDLE 33G 4MM 33 GAUGE X 5/32" (Advocate Pen Needle) | 2 | |
| MINI PEN NEEDLE 33G 5MM 33 GAUGE X 3/16" (Comfort EZ Pen Needles) | 2 | |
| MINI PEN NEEDLE 33G 6MM 33 GAUGE X 1/4" (Comfort EZ Pen Needles) | 2 | |
| MINI ULTRA-THIN II PEN NDL 31G STERILE 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| MONOJECT 0.5 ML SYRN 28GX1/2" 1/2 ML 28 GAUGE (insulin syringe-needle u-100) | 2 | |
| MONOJECT 1 ML SYRN 27X1/2" 1 ML 27 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| MONOJECT 1 ML SYRN 28GX1/2" (OTC) 1 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| MONOJECT INSUL SYR U100 (OTC) 0.3 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| MONOJECT INSUL SYR U100 .5ML,29GX1/2" (OTC) 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| MONOJECT INSUL SYR U100 0.5 ML CONVERTS TO 29G (OTC) 1/2 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| MONOJECT INSUL SYR U100 1 ML 1 ML 25 GAUGE X 5/8" (insulin syringe-needle u-100) | 2 | |
| MONOJECT INSUL SYR U100 1 ML 3'S, 29GX1/2" (OTC) 1 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| MONOJECT INSUL SYR U100 1 ML W/O NEEDLE (OTC) (insulin syringes (disposable)) | 2 | |
| MONOJECT INSULIN SYR 0.3 ML (OTC) 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| MONOJECT INSULIN SYR 0.3 ML 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| MONOJECT INSULIN SYR 0.5 ML (OTC) 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| MONOJECT INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| MONOJECT INSULIN SYR 1 ML 3'S (OTC) 1 ML 30 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | |
| MONOJECT INSULIN SYR U-100 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| MONOJECT INSULIN SYR U-100 29 GAUGE X 1/2" | 2 | |
| MONOJECT SYRINGE 0.3 ML 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| MONOJECT SYRINGE 0.5 ML 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| MONOJECT SYRINGE 1 ML 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | |
| NOVOFINE 30 NEEDLE | 2 | |
| NOVOFINE 32G NEEDLES 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| NOVOFINE PLUS PEN NDL 32GX1/6" 32 GAUGE X 1/6" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| NOVOTWIST NEEDLE 32G 5MM 32 GAUGE X 1/5" | 2 | |
| OMNIPOD 5 (G6/LIBRE 2 PLUS) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD 5 G6-G7 INTRO KT(GEN5) SUBCUTANEOUS CARTRIDGE | 3 | QL (1 per 365 days) |
| OMNIPOD 5 G6-G7 PODS (GEN 5) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD 5 INTRO(G6/LIBRE2PLUS) SUBCUTANEOUS CARTRIDGE | 3 | QL (1 per 365 days) |
| OMNIPOD CLASSIC PODS (GEN 3) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD DASH INTRO KIT (GEN 4) SUBCUTANEOUS CARTRIDGE | 3 | QL (1 per 365 days) |
| OMNIPOD DASH PDM KIT (GEN 4) | 3 | QL (1 per 365 days) |
| OMNIPOD DASH PODS (GEN 4) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD GO PODS 10 UNITS/DAY SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD GO PODS 15 UNITS/DAY SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD GO PODS 20 UNITS/DAY SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD GO PODS 25 UNITS/DAY SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD GO PODS 30 UNITS/DAY SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD GO PODS 40 UNITS/DAY SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| OMNIPOD GO PODS SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| PC UNIFINE PENTIPS 8MM NEEDLE SHORT 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| PEN NEEDLE 30G 5MM OUTER 30 GAUGE X 3/16" (Embrace Pen Needle) | 2 | |
| PEN NEEDLE 30G 8MM INNER 30 GAUGE X 5/16" (CareFine Pen Needle) | 2 | |
| PEN NEEDLE 30G X 5/16" 30 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2" (1st Tier Unifine Pentips Plus) | 2 | |
| PEN NEEDLES 12MM 29G 29GX12MM,STRL 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | |
| PEN NEEDLES 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| PEN NEEDLES 6MM 31G 31GX6MM, STRL 31 GAUGE X 1/4" (1st Tier Unifine Pentips) | 2 | |
| PEN NEEDLES 8MM 31G 31GX8MM,STRL,SHORT (OTC) 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| PENTIPS PEN NEEDLE 29G 1/2" 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | |
| PENTIPS PEN NEEDLE 31G 1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| PENTIPS PEN NEEDLE 31GX3/16" MINI, 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| PENTIPS PEN NEEDLE 31GX5/16" SHORT, 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| PENTIPS PEN NEEDLE 32G 1/4" 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| PENTIPS PEN NEEDLE 32GX5/32" 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| PIP PEN NEEDLE 31G X 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| PIP PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| PREVENT PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 2 | |
| PREVENT PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 2 | |
| PRO COMFORT 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| PRO COMFORT 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| PRO COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| PRO COMFORT 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| PRO COMFORT 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| PRO COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| PRO COMFORT PEN NDL 31GX5/16" 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| PRO COMFORT PEN NDL 32G X 1/4" 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| PRO COMFORT PEN NDL 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| PRO COMFORT PEN NDL 5MM 32G 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| PRODIGY INS SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| PRODIGY SYRNG 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| PRODIGY SYRNGE 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| PURE CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic, safety) | 2 | |
| PURE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| PURE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | |
| PURE COMFORT PEN NDL 32G (pen needle, diabetic) 4MM 32 GAUGE X 5/32" | 2 | |
| PURE COMFORT PEN NDL 32G (pen needle, diabetic) 5MM 32 GAUGE X 3/16" | 2 | |
| PURE COMFORT PEN NDL 32G (pen needle, diabetic) 6MM 32 GAUGE X 1/4" | 2 | |
| PURE COMFORT PEN NDL 32G (pen needle, diabetic) 8MM 32 GAUGE X 5/16" | 2 | |
| RAYA SURE PEN NEEDLE 29G 12MM 29 GAUGE X 15/32" | 2 | |
| RAYA SURE PEN NEEDLE 31G (Comfort Touch Pen 4MM 31 GAUGE X 5/32" Needle) | 2 | |
| RAYA SURE PEN NEEDLE 31G 5MM 31 GAUGE X 13/64" | 2 | |
| RAYA SURE PEN NEEDLE 31G 6MM 31 GAUGE X 15/64" | 2 | |
| RELION INS SYR 0.3 ML (BD Veo Insulin Syringe 31GX6MM 0.3 ML 31 GAUGE X UF) 15/64" | 2 | |
| RELION INS SYR 0.5 ML (BD Veo Insulin Syringe 31GX6MM 1/2 ML 31 GAUGE X UF) 15/64" | 2 | |
| RELION INS SYR 1 ML (BD Veo Insulin Syringe 31GX15/64" 1 ML 31 GAUGE X UF) 15/64" | 2 | |
| RELI-ON INSULIN 0.5 ML SYR (Ultilet Insulin Syringe) 1/2 ML 29 | 2 | |
| RELI-ON INSULIN 1 ML SYR 1 ML 29 GAUGE X 7/16" | 2 | |
| RELION MINI PEN 31G X 1/4" (pen needle, diabetic) NDL 31 GAUGE X 1/4" | 2 | |
| RELION NEEDLES NEEDLE 31 (pen needle, diabetic) GAUGE X 1/4" | 2 | |
| RELION PEN NEEDLES NEEDLE (pen needle, diabetic) 32 GAUGE X 5/32" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| SAFESNAP INS SYR UNITS-100 0.3 ML 30GX5/16",10X10 0.3 ML 30 GAUGE X 5/16" | 2 | |
| SAFESNAP INS SYR UNITS-100 0.5 ML 29GX1/2",10X10 0.5 ML 29 GAUGE X 1/2" | 2 | |
| SAFESNAP INS SYR UNITS-100 0.5 ML 30GX5/16",10X10 0.5 ML 30 GAUGE X 5/16" | 2 | |
| SAFESNAP INS SYR UNITS-100 1 ML 28GX1/2",10X10 1 ML 28 GAUGE X 1/2" | 2 | |
| SAFESNAP INS SYR UNITS-100 1 ML 29GX1/2",10X10 1 ML 29 GAUGE X 1/2" | 2 | |
| SAFETY PEN NEEDLE 31G 4MM (Comfort EZ PRO 31 GAUGE X 5/32" Safety Pen Ndl) | 2 | |
| SAFETY PEN NEEDLE 5MM X (pen needle, diabetic, 31G 31 GAUGE X 3/16" safety) | 2 | |
| SAFETY SYRINGE 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | 2 | |
| SECURESAFE PEN NDL 30GX5/16" OUTER 30 GAUGE X 5/16" | 2 | |
| SECURESAFE SYR 0.5 ML 29G 1/2" OUTER 0.5 ML 29 GAUGE X 1/2" | 2 | |
| SECURESAFE SYRNG 1 ML 29G 1/2" OUTER 1 ML 29 GAUGE X 1/2" | 2 | |
| SKY SAFETY PEN NEEDLE 30G 5MM 30 GAUGE X 3/16" | 2 | |
| SKY SAFETY PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | 2 | |
| SM ULT CFT 0.3 ML 31GX5/16(1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | |
| STERILE PADS 2" X 2" 2 X 2 " (gauze bandage) | 1 | GC |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------------------|----------------------------|
| SURE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | |
| SURE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | |
| NEEDLES, INSULIN DISP., SAFETY | (insulin syringe-needle u-100) | 2 |
| SURE COMFORT 0.5 ML SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 |
| SURE COMFORT 1 ML SYRINGE 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 |
| SURE COMFORT 3/10 ML SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 |
| SURE COMFORT 3/10 ML SYRINGE INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 |
| SURE COMFORT 30G PEN NEEDLE 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 |
| SURE COMFORT INS 0.3 ML 31GX1/4 0.3 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 |
| SURE COMFORT INS 0.5 ML 31GX1/4 1/2 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 |
| SURE COMFORT INS 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 |
| SURE COMFORT PEN NDL 29GX1/2" 12.7MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 |
| SURE COMFORT PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 |
| SURE COMFORT PEN NDL 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 |
| SURE COMFORT PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| SURE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| SURE-FINE PEN NEEDLES 12.7MM 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | |
| SURE-FINE PEN NEEDLES 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| SURE-FINE PEN NEEDLES 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| SURE-JECT INSU SYR U100 0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |
| SURE-JECT INSU SYR U100 0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| SURE-JECT INSU SYR U100 1 ML 1 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| SURE-JECT INSUL SYR U100 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | |
| SURE-JECT INSULIN SYRINGE 1 ML 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | |
| TECHLITE 0.3 ML 29GX12MM (1/2) 0.3 ML 29 GAUGE X 1/2" (1/2) 0.3 ML 29 GAUGE X 1/2" | 2 | |
| TECHLITE 0.3 ML 30GX12MM (1/2) 0.3 ML 30 GAUGE X 1/2" (1/2) 0.3 ML 30 GAUGE X 1/2" | 2 | |
| TECHLITE 0.3 ML 30GX8MM (1/2) 0.3 ML 30 GAUGE X 5/16" (1/2) 0.3 ML 30 GAUGE X 5/16" | 2 | |
| TECHLITE 0.3 ML 31GX6MM (1/2) 0.3 ML 31 GAUGE X 15/64" (1/2) 0.3 ML 31 GAUGE X 15/64" | 2 | |
| TECHLITE 0.3 ML 31GX8MM (1/2) 0.3 ML 31 GAUGE X 5/16" (1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | |
| TECHLITE 0.5 ML 29GX12MM (1/2) 0.5 ML 29 GAUGE X 1/2" (1/2) 0.5 ML 29 GAUGE X 1/2" | 2 | |
| TECHLITE 0.5 ML 30GX12MM (1/2) 0.5 ML 30 GAUGE X 1/2" (1/2) 0.5 ML 30 GAUGE X 1/2" | 2 | |
| TECHLITE 0.5 ML 30GX8MM (1/2) 0.5 ML 30 GAUGE X 5/16" (1/2) 0.5 ML 30 GAUGE X 5/16" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| TECHLITE 0.5 ML 31GX6MM (1/2) 0.5 ML 31 GAUGE X 15/64" | 2 | |
| TECHLITE 0.5 ML 31GX8MM (1/2) 0.5 ML 31 GAUGE X 5/16" | 2 | |
| TECHLITE INS SYR 1 ML 29GX12MM 1 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| TECHLITE INS SYR 1 ML 30GX12MM 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| TECHLITE INS SYR 1 ML 30GX8MM 1 ML 30 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | |
| TECHLITE INS SYR 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | |
| TECHLITE INS SYR 1 ML 31GX8MM 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | |
| TECHLITE PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | |
| TECHLITE PEN NEEDLE 29GX3/8" 29 GAUGE X 3/8" | 2 | |
| TECHLITE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| TECHLITE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| TECHLITE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| TECHLITE PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| TECHLITE PEN NEEDLE 32GX5/16" 32 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| TECHLITE PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| TECHLITE PLUS PEN NDL 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| TERUMO INS SYRINGE U100-1 (insulin syringe-needle u-100) ML 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" | 2 | |
| TERUMO INS SYRINGE U100-1 (Thinpro Insulin Syringe) ML 1 ML 30 GAUGE X 3/8" | 2 | |
| TERUMO INS SYRINGE U100-1/2 (insulin syringe-needle u-100) ML 1/2 ML 30 X 3/8" | 2 | |
| TERUMO INS SYRINGE U100-1/3 (insulin syringe-needle u-100) ML 0.3 ML 30 X 3/8" | 2 | |
| TERUMO INS SYRNG U100-1/2 (insulin syringe-needle u-100) ML 0.5 ML 29 GAUGE X 1/2", 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" | 2 | |
| THINPRO INS SYRIN U100-0.3 (insulin syringe-needle u-100) ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 X 3/8" | 2 | |
| THINPRO INS SYRIN U100-0.3 ML 0.3 ML 31 X 3/8" | 2 | |
| THINPRO INS SYRIN U100-0.5 (insulin syringe-needle u-100) ML 0.5 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 X 3/8" | 2 | |
| THINPRO INS SYRIN U100-0.5 ML 0.5 ML 31 X 3/8" | 2 | |
| THINPRO INS SYRIN U100-1 ML (insulin syringe-needle u-100) 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 3/8" | 2 | |
| THINPRO INS SYRIN U100-1 ML 1 ML 31 X 3/8" | 2 | |
| TOPCARE CLICKFINE 31G X 1/4" (pen needle, diabetic) 31 GAUGE X 1/4" | 2 | |
| TOPCARE CLICKFINE 31G X (pen needle, diabetic) 5/16" 31 GAUGE X 5/16" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-------------------------------------|----------------------------|
| TOPCARE ULTRA COMFORT SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) 2 | |
| TRUE CMFRT PRO 0.5 ML 30G 5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| TRUE CMFRT PRO 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| TRUE CMFRT PRO 0.5 ML 32G 5/16" 1/2 ML 32 GAUGE X 5/16" | 2 | |
| TRUE CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic, safety) 2 | |
| TRUE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | |
| TRUE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | |
| TRUE COMFORT 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | 2 | |
| TRUE COMFORT 0.5 ML 30G 5/16" 0.5 ML 30 GAUGE X 5/16" | 2 | |
| TRUE COMFORT 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | 2 | |
| TRUE COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| TRUE COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| TRUE COMFORT PEN NDL 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) 2 | |
| TRUE COMFORT PEN NDL 31GX5MM 31 GAUGE X 3/16" | (pen needle, diabetic) 2 | |
| TRUE COMFORT PEN NDL 31GX6MM 31 GAUGE X 1/4" | (pen needle, diabetic) 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| TRUE COMFORT PEN NDL 32G 5MM 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| TRUE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| TRUE COMFORT PEN NDL 32GX4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| TRUE COMFORT PEN NDL 33G 4MM 33 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| TRUE COMFORT PEN NDL 33G 5MM 33 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| TRUE COMFORT PEN NDL 33G 6MM 33 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| TRUE COMFORT PRO 1 ML 30G 1/2" 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| TRUE COMFORT PRO 1 ML 30G 5/16" 1 ML 30 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | |
| TRUE COMFORT PRO 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | |
| TRUE COMFORT PRO 1 ML 32G 5/16" 1 ML 32 GAUGE X 5/16" | 2 | |
| TRUE COMFORT SFTY 1 ML 30G 1/2" 1 ML 30 GAUGE X 1/2" | 2 | |
| TRUE COMFRT PRO 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| TRUE COMFRT SFTY 1 ML 30G 5/16" 1 ML 30 GAUGE X 5/16" | 2 | |
| TRUE COMFRT SFTY 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16" | 2 | |
| TRUE COMFRT SFTY 1 ML 32G 5/16" 1 ML 32 GAUGE X 5/16" | 2 | |
| TRUEPLUS PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | |
| TRUEPLUS PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| TRUEPLUS PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| TRUEPLUS PEN NEEDLE 31G X 1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| TRUEPLUS PEN NEEDLE (pen needle, diabetic) 32GX5/32" 32 GAUGE X 5/32" | 2 | |
| TRUEPLUS SYR 0.3 ML 29GX1/2" (insulin syringe-needle 0.3 ML 29 GAUGE X 1/2" u-100) | 2 | |
| TRUEPLUS SYR 0.3 ML (insulin syringe-needle 30GX5/16" 0.3 ML 30 GAUGE X u-100) 5/16" | 2 | |
| TRUEPLUS SYR 0.3 ML (insulin syringe-needle 31GX5/16" 0.3 ML 31 GAUGE X u-100) 5/16" | 2 | |
| TRUEPLUS SYR 0.5 ML 28GX1/2" (insulin syringe-needle 1/2 ML 28 GAUGE X 1/2" u-100) | 2 | |
| TRUEPLUS SYR 0.5 ML 29GX1/2" (insulin syringe-needle 0.5 ML 29 GAUGE X 1/2" u-100) | 2 | |
| TRUEPLUS SYR 0.5 ML (insulin syringe-needle 30GX5/16" 0.5 ML 30 GAUGE X u-100) 5/16" | 2 | |
| TRUEPLUS SYR 0.5 ML (insulin syringe-needle 31GX5/16" 0.5 ML 31 GAUGE X u-100) 5/16" | 2 | |
| TRUEPLUS SYR 1 ML 28GX1/2" 1 (insulin syringe-needle ML 28 GAUGE X 1/2" u-100) | 2 | |
| TRUEPLUS SYR 1 ML 29GX1/2" 1 (insulin syringe-needle ML 29 GAUGE X 1/2" u-100) | 2 | |
| TRUEPLUS SYR 1 ML 30GX5/16" (insulin syringe-needle 1 ML 30 GAUGE X 5/16 u-100) | 2 | |
| TRUEPLUS SYR 1 ML 31GX5/16" (insulin syringe-needle 1 ML 31 GAUGE X 5/16 u-100) | 2 | |
| ULTICAR INS 0.3 ML (insulin syr/ndl u100 31GX1/4(1/2) 0.3 ML 31 GAUGE X half mark) 1/4" | 2 | |
| ULTICARE INS 1 ML 31GX1/4" 1 (insulin syringe-needle ML 31 GAUGE X 1/4" u-100) | 2 | |
| ULTICARE INS SYR 0.3 ML 30G (Advocate Syringes) 8MM 0.3 ML 30 GAUGE X 5/16" | 2 | |
| ULTICARE INS SYR 0.3 ML 31G (insulin syringe-needle 6MM 0.3 ML 31 GAUGE X 1/4" u-100) | 2 | |
| ULTICARE INS SYR 0.3 ML 31G (Advocate Syringes) 8MM 0.3 ML 31 GAUGE X 5/16" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|----------------------------------|----------------------------|
| ULTICARE INS SYR 0.5 ML 31G 6MM 1/2 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) 2 | |
| ULTICARE INS SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | |
| ULTICARE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) 2 | |
| ULTICARE PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) 2 | |
| ULTICARE PEN NEEDLE 8MM 31G 31 GAUGE X 5/16" | (pen needle, diabetic) 2 | |
| ULTICARE PEN NEEDLES 12MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) 2 | |
| ULTICARE PEN NEEDLES 4MM 32G MICRO, 32GX4MM 32 GAUGE X 5/32" | (pen needle, diabetic) 2 | |
| ULTICARE PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" | (pen needle, diabetic) 2 | |
| ULTICARE SAFE PEN NDL 30G 8MM 30 GAUGE X 5/16" | 2 | |
| ULTICARE SAFE PEN NDL 5MM 30G 30 GAUGE X 3/16" | 2 | |
| ULTICARE SYR 0.3 ML 29G 12.7MM 0.3 ML 29 GAUGE X 1/2" | (Comfort EZ Insulin Syringe) 2 | |
| ULTICARE SYR 0.3 ML 30GX1/2" 0.3 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | |
| ULTICARE SYR 0.3 ML 31GX5/16" SHORT NDL 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| ULTICARE SYR 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | |
| ULTICARE SYR 0.5 ML 31GX5/16" SHORT NDL 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| ULTICARE SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| ULTIGUARD SAFE 1 ML 30G 12.7MM 1 ML 30 X 1/2" | 2 | |
| ULTIGUARD SAFE PACK 32G 4MM 32 GAUGE X 5/32" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|--------------------------------|----------------------------|
| ULTIGUARD SAFE0.3 ML 30G 12.7MM 0.3 ML 30 X 1/2" | 2 | |
| ULTIGUARD SAFE0.5 ML 30G 12.7MM 1/2 ML 30 X 1/2" | 2 | |
| ULTIGUARD SAFEPACK 1 ML 31G 8MM 1 ML 31 X 5/16" | 2 | |
| ULTIGUARD SAFEPACK 29G 12.7MM 29 GAUGE X 1/2" | 2 | |
| ULTIGUARD SAFEPACK 31G 5MM 31 GAUGE X 3/16" | 2 | |
| ULTIGUARD SAFEPACK 31G 6MM 31 GAUGE X 1/4" | 2 | |
| ULTIGUARD SAFEPACK 31G 8MM 31 GAUGE X 5/16" | 2 | |
| ULTIGUARD SAFEPACK 32G 6MM 32 GAUGE X 1/4" | 2 | |
| ULTIGUARD SAFEPK 0.3 ML 31G 8MM 0.3 ML 31 X 5/16" | 2 | |
| ULTIGUARD SAFEPK 0.5 ML 31G 8MM 1/2 ML 31 X 5/16" | 2 | |
| ULTILET INSULIN SYRINGE 0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 |
| ULTILET INSULIN SYRINGE 0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 |
| ULTILET INSULIN SYRINGE 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 |
| ULTILET PEN NEEDLE 29 GAUGE | | 2 |
| ULTILET PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 |
| ULTRA COMFORT 0.3 ML SYRINGE 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-------------------------------------|----------------------------|
| ULTRA COMFORT 0.5 ML 28GX1/2" CONVERTS TO 29G 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | |
| ULTRA COMFORT 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | |
| ULTRA COMFORT 0.5 ML SYRINGE 1/2 ML 28 GAUGE | (insulin syringe-needle u-100) 2 | |
| ULTRA COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) 2 | |
| ULTRA COMFORT 1 ML SYRINGE 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | |
| ULTRA FLO 0.3 ML 30G 1/2" (1/2) 0.3 ML 30 GAUGE X 1/2" | 2 | |
| ULTRA FLO 0.3 ML 30G 5/16"(1/2) 0.3 ML 30 GAUGE X 5/16" | 2 | |
| ULTRA FLO 0.3 ML 31G 5/16"(1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | |
| ULTRA FLO PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) 2 | |
| ULTRA FLO PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) 2 | |
| ULTRA FLO PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) 2 | |
| ULTRA FLO PEN NEEDLE 33G 4MM 33 GAUGE X 5/32" | (pen needle, diabetic) 2 | |
| ULTRA FLO PEN NEEDLES 12MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) 2 | |
| ULTRA FLO SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | |
| ULTRA FLO SYR 0.3 ML 30G 5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| ULTRA FLO SYR 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | |
| ULTRA FLO SYR 0.5 ML 29G 1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | |
| ULTRA THIN PEN NDL 32G X 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------------------|------------------------------------|
| ULTRACARE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 |
| ULTRACARE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 |
| ULTRACARE INS 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 |
| ULTRACARE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 |
| ULTRACARE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 |
| ULTRACARE INS 1 ML 30G X 5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 |
| ULTRACARE INS 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 |
| ULTRACARE INS 1 ML 31G X 5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 |
| ULTRACARE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 |
| ULTRACARE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 |
| ULTRACARE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 |
| ULTRACARE PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 |
| ULTRACARE PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 |
| ULTRACARE PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 |
| ULTRACARE PEN NEEDLE 33GX5/32" 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 |
| ULTRA-THIN II 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 |
| ULTRA-THIN II INS 0.3 ML 30G 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------------------|------------------------------|------------------------------------|
| ULTRA-THIN II INS 0.3 ML 31G 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | |
| ULTRA-THIN II INS 0.5 ML 29G 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| ULTRA-THIN II INS 0.5 ML 30G 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | |
| ULTRA-THIN II INS 0.5 ML 31G 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | |
| ULTRA-THIN II INS SYR 1 ML 29G 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | |
| ULTRA-THIN II INS SYR 1 ML 30G 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | |
| ULTRA-THIN II PEN NDL 29GX1/2" 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | |
| ULTRA-THIN II PEN NDL 31GX5/16 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | |
| UNIFINE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | |
| UNIFINE PENTIPS 12MM 29G 29GX12MM, STRL 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | |
| UNIFINE PENTIPS 31GX3/16" 31GX5MM,STRL,MINI 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | |
| UNIFINE PENTIPS 32GX1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | |
| UNIFINE PENTIPS 32GX5/32" 32GX4MM, STRL, NANO 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | |
| UNIFINE PENTIPS 33GX5/32" 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | |
| UNIFINE PENTIPS 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | |
| UNIFINE PENTIPS MAX 30GX3/16" 30 GAUGE X 3/16" | (pen needle, diabetic) | 2 | |
| UNIFINE PENTIPS NEEDLES 29G 29 GAUGE | | 2 | |
| UNIFINE PENTIPS PLUS 29GX1/2" 12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 30GX3/16" 30 GAUGE X 3/16" | 2 | |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 31GX1/4" ULTRA SHORT, 6MM 31 GAUGE X 1/4" | 2 | |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 31GX3/16" MINI 31 GAUGE X 3/16" | 2 | |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 31GX5/16" SHORT 31 GAUGE X 5/16" | 2 | |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 32GX5/32" 32 GAUGE X 5/32" | 2 | |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 33GX5/32" 33 GAUGE X 5/32" | 2 | |
| UNIFINE PROTECT 30G 5MM 30 GAUGE X 3/16" | 2 | |
| UNIFINE PROTECT 30G 8MM 30 GAUGE X 5/16" | 2 | |
| UNIFINE PROTECT 32G 4MM 32 GAUGE X 5/32" | 2 | |
| UNIFINE SAFECONTROL 30GX3/16" 30 GAUGE X 3/16" | 2 | |
| UNIFINE SAFECONTROL 30GX5/16" 30 GAUGE X 5/16" | 2 | |
| UNIFINE SAFECONTROL 31G (pen needle, diabetic) 5MM 31 GAUGE X 3/16" | 2 | |
| UNIFINE SAFECONTROL 31G (pen needle, diabetic) 6MM 31 GAUGE X 1/4" | 2 | |
| UNIFINE SAFECONTROL 31G (pen needle, diabetic) 8MM 31 GAUGE X 5/16" | 2 | |
| UNIFINE SAFECONTROL 32G 4MM 32 GAUGE X 5/32" | 2 | |
| UNIFINE ULTRA PEN NDL 31G (pen needle, diabetic) 5MM 31 GAUGE X 3/16" | 2 | |
| UNIFINE ULTRA PEN NDL 31G (pen needle, diabetic) 6MM 31 GAUGE X 1/4" | 2 | |
| UNIFINE ULTRA PEN NDL 31G (pen needle, diabetic) 8MM 31 GAUGE X 5/16" | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| UNIFINE ULTRA PEN NDL 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| VANISHPOINT 0.5 ML 30GX1/2" SY OUTER 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| VANISHPOINT INS 1 ML 30GX3/16" 1 ML 30 GAUGE X 3/16" | 2 | |
| VANISHPOINT U-100 29X1/2 SYR 1 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| VERIFINE INS SYR 1 ML 29G 1/2" 1 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| VERIFINE PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | |
| VERIFINE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| VERIFINE PEN NEEDLE 31G X 6MM 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| VERIFINE PEN NEEDLE 31G X 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| VERIFINE PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | |
| VERIFINE PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| VERIFINE PEN NEEDLE 32G X 5MM 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| VERIFINE PLUS PEN NDL 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | |
| VERIFINE PLUS PEN NDL 31G 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | |
| VERIFINE PLUS PEN NDL 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | |
| VERIFINE PLUS PEN NDL 32G 4MM-SHARPS CONTAINER 32 GAUGE X 5/32" | 2 | |
| VERIFINE SYRING 0.5 ML 29G 1/2" 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | |
| VERIFINE SYRING 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|------------------------------|
| VERIFINE SYRNG 0.3 ML 31G (insulin syringe-needle 5/16" 0.3 ML 31 GAUGE X 5/16" u-100) | 2 | |
| VERIFINE SYRNG 0.5 ML 31G (insulin syringe-needle 5/16" 0.5 ML 31 GAUGE X 5/16" u-100) | 2 | |
| VERSALON ALL PURPOSE SPONGE 25'S,N-STERILE,3PLY 2 X 2 " | 1 | GC |
| V-GO 20 DEVICE | 3 | QL (30 per 30 days) |
| V-GO 30 DEVICE | 3 | QL (30 per 30 days) |
| V-GO 40 DEVICE | 3 | QL (30 per 30 days) |
| Non-Frf | | |
| Non-Frf | | |
| MIPLYFFA ORAL CAPSULE 124 MG, 47 MG, 62 MG, 93 MG | 5 | PA; NDS; QL (90 per 30 days) |
| Preparaciones De Reemplazo | | |
| Preparaciones De Reemplazo | | |
| <i>calcium chloride intravenous syringe 100 mg/ml (10 %)</i> | 2 | |
| <i>d5 % and 0.9 % sodium chloride intravenous parenteral solution</i> | 2 | |
| <i>d5 %-0.45 % sodium chloride intravenous parenteral solution</i> | 2 | |
| <i>electrolyte-148 intravenous parenteral solution</i> | 2 | |
| ISOLYTE S IV SOLUTION-EXCEL SINGLE USE | 4 | |
| ISOLYTE S PH 7.4 INTRAVENOUS PARENTERAL SOLUTION | 4 | |
| ISOLYTE-P IN 5 % DEXTROSE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | |
| <i>klor-con m10 oral tablet,er particles/crystals 10 meq</i> (potassium chloride) | 2 | |
| <i>klor-con m15 oral tablet,er particles/crystals 15 meq</i> (potassium chloride) | 2 | |
| <i>klor-con m20 oral tablet,er particles/crystals 20 meq</i> (potassium chloride) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>magnesium sulfate in d5w intravenous piggyback 1 gram/100 ml</i> | 2 | |
| <i>magnesium sulfate in water intravenous parenteral solution 20 gram/500 ml (4 %), 40 gram/1,000 ml (4 %)</i> | 2 | |
| <i>magnesium sulfate in water intravenous piggyback 2 gram/50 ml (4 %), 4 gram/100 ml (4 %), 4 gram/50 ml (8 %)</i> | 2 | |
| <i>magnesium sulfate injection solution 500 mg/ml (50 %)</i> | 4 | |
| <i>magnesium sulfate injection syringe 500 mg/ml (50 %)</i> | 2 | |
| NORMOSOL-M IN 5 % DEXTROSE INTRAVENOUS PARENTERAL SOLUTION | 4 | |
| PLASMA-LYTE A (electrolyte-a) INTRAVENOUS PARENTERAL SOLUTION | 4 | |
| <i>potassium chloride intravenous solution 2 meq/ml</i> | 1 | PA BvD; GC |
| <i>potassium chloride intravenous solution 2 meq/ml (20 ml)</i> | 2 | PA BvD |
| <i>potassium chloride oral capsule, extended release 10 meq, 8 meq</i> | 2 | |
| <i>potassium chloride oral liquid 20 meq/15 ml, 40 meq/15 ml</i> | 2 | |
| <i>potassium chloride oral tablet extended release 10 meq</i> (Klor-Con 10) | 2 | |
| <i>potassium chloride oral tablet extended release 15 meq</i> | 2 | |
| <i>potassium chloride oral tablet extended release 20 meq</i> (K-Tab) | 2 | |
| <i>potassium chloride oral tablet extended release 8 meq</i> (Klor-Con 8) | 2 | |
| <i>potassium chloride oral tablet,er particles/crystals 10 meq</i> (Klor-Con M10) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>potassium chloride oral tablet,er particles/crystals 15 meq</i> (Klor-Con M15) | 2 | |
| <i>potassium chloride oral tablet,er particles/crystals 20 meq</i> (Klor-Con M20) | 2 | |
| <i>potassium chloride-0.45 % nacl intravenous parenteral solution 20 meq/l</i> | 2 | |
| <i>potassium citrate oral tablet extended release 10 meq (1,080 mg)</i> (Urocit-K 10) | 2 | |
| <i>potassium citrate oral tablet extended release 15 meq</i> (Urocit-K 15) | 2 | |
| <i>potassium citrate oral tablet extended release 5 meq (540 mg)</i> | 2 | |
| <i>sodium chloride 0.45 % intravenous parenteral solution 0.45 %</i> | 2 | |
| <i>sodium chloride 0.9 % intravenous parenteral solution</i> | 2 | |
| <i>sodium chloride 0.9% solution mini-bag, single use</i> | 2 | |
| Productos Para La Tos Y Resfriado | | |
| Productos Para La Tos Y Resfriado | | |
| <i>benzonatate oral capsule 100 mg, 200 mg</i> | 1 | GC; EX |
| Productos Sanguíneos/Modificadores/Expansores De Volumen | | |
| Agentes Hematológicos, Varios | | |
| <i>anagrelide oral capsule 0.5 mg</i> (Agrylin) | 2 | |
| <i>anagrelide oral capsule 1 mg</i> | 2 | |
| CABLIVI INJECTION KIT 11 MG | 5 | PA; NDS; QL (30 per 30 days) |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG | 4 | |
| <i>protamine intravenous solution 10 mg/ml</i> | 2 | |
| <i>tranexamic acid intravenous solution 1,000 mg/10 ml (100 mg/ml)</i> (Cyklokapron) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| <i>tranexamic acid oral tablet 650 mg</i> | 2 | |
| Anticoagulantes | | |
| <i>dabigatran etexilate oral capsule 110 mg, 150 mg, 75 mg</i> (Pradaxa) | 2 | QL (60 per 30 days) |
| ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS) | 3 | |
| ELIQUIS ORAL TABLET 2.5 MG | 3 | QL (60 per 30 days) |
| ELIQUIS ORAL TABLET 5 MG | 3 | QL (74 per 30 days) |
| <i>enoxaparin subcutaneous solution 300 mg/3 ml</i> (Lovenox) | 2 | QL (30 per 30 days) |
| <i>enoxaparin subcutaneous syringe 100 mg/ml, 150 mg/ml</i> (Lovenox) | 2 | QL (60 per 30 days) |
| <i>enoxaparin subcutaneous syringe 120 mg/0.8 ml, 80 mg/0.8 ml</i> (Lovenox) | 2 | QL (48 per 30 days) |
| <i>enoxaparin subcutaneous syringe 30 mg/0.3 ml</i> (Lovenox) | 2 | QL (18 per 30 days) |
| <i>enoxaparin subcutaneous syringe 40 mg/0.4 ml</i> (Lovenox) | 2 | QL (24 per 30 days) |
| <i>enoxaparin subcutaneous syringe 60 mg/0.6 ml</i> (Lovenox) | 2 | QL (36 per 30 days) |
| <i>fondaparinux subcutaneous syringe 10 mg/0.8 ml</i> (Arixtra) | 5 | NDS; QL (24 per 30 days) |
| <i>fondaparinux subcutaneous syringe 2.5 mg/0.5 ml</i> (Arixtra) | 2 | QL (15 per 30 days) |
| <i>fondaparinux subcutaneous syringe 5 mg/0.4 ml</i> (Arixtra) | 5 | NDS; QL (12 per 30 days) |
| <i>fondaparinux subcutaneous syringe 7.5 mg/0.6 ml</i> (Arixtra) | 5 | NDS; QL (18 per 30 days) |
| <i>heparin (porcine) injection cartridge 5,000 unit/ml (1 ml)</i> | 2 | |
| <i>heparin (porcine) injection solution 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml</i> | 2 | |
| <i>heparin, porcine (pf) injection solution 1,000 unit/ml</i> | 2 | |
| <i>heparin, porcine (pf) injection syringe 5,000 unit/0.5 ml, 5,000 unit/ml</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>jantoven oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> (warfarin) | 1 | GC |
| <i>warfarin oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> (Jantoven) | 1 | GC |
| XARELTO DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 15 MG (42)- 20 MG (9) | 3 | |
| XARELTO ORAL SUSPENSION FOR RECONSTITUTION 1 MG/ML | 3 | QL (600 per 30 days) |
| XARELTO ORAL TABLET 10 MG, 20 MG | 3 | QL (30 per 30 days) |
| XARELTO ORAL TABLET 15 MG, 2.5 MG | 3 | QL (60 per 30 days) |
| Inhibidores De Agregación De Plaquetas | | |
| <i>aspirin-dipyridamole oral capsule, er multiphase 12 hr 25-200 mg</i> | 2 | QL (60 per 30 days) |
| BRILINTA ORAL TABLET 60 MG, 90 MG | 3 | |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 2 | |
| <i>clopidogrel oral tablet 75 mg</i> (Plavix) | 1 | GC |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i> | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>pentoxifylline oral tablet extended release 400 mg</i> | 2 | |
| <i>prasugrel oral tablet 10 mg, 5 mg</i> (Effient) | 2 | QL (30 per 30 days) |
| Modificadores De Formación De Sangre | | |
| ALVAIZ ORAL TABLET 18 MG, 36 MG, 54 MG, 9 MG | 5 | PA; NDS; QL (60 per 30 days) |
| CINRYZE INTRAVENOUS RECON SOLN 500 UNIT (5 ML) | 5 | PA; NDS |
| DOPTELET (10 TAB PACK) ORAL TABLET 20 MG | 5 | PA; NDS; QL (60 per 30 days) |
| DOPTELET (15 TAB PACK) ORAL TABLET 20 MG | 5 | PA; NDS; QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| DOPTELET (30 TAB PACK) ORAL TABLET 20 MG | 5 | PA; NDS; QL (60 per 30 days) |
| FULPHILA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5 | PA; NDS |
| GRANIX SUBCUTANEOUS SOLUTION 300 MCG/ML, 480 MCG/1.6 ML | 5 | PA; NDS |
| GRANIX SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5 | PA; NDS |
| HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT | 5 | PA; NDS; QL (30 per 30 days) |
| HAEGARDA SUBCUTANEOUS RECON SOLN 3,000 UNIT | 5 | PA; NDS; QL (20 per 30 days) |
| LEUKINE INJECTION RECON SOLN 250 MCG | 5 | NDS |
| NEULASTA ONPRO SUBCUTANEOUS SYRINGE, W/ WEARABLE INJECTOR 6 MG/0.6 ML | 5 | PA; NDS |
| NIVESTYM INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML | 5 | PA; NDS |
| NIVESTYM SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5 | PA; NDS |
| NYVEPRIA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5 | PA; NDS |
| PROMACTA ORAL POWDER IN PACKET 12.5 MG | 5 | PA; NDS; QL (90 per 30 days) |
| PROMACTA ORAL POWDER IN PACKET 25 MG | 5 | PA; NDS; QL (180 per 30 days) |
| PROMACTA ORAL TABLET 12.5 MG | 5 | PA; NDS; QL (90 per 30 days) |
| PROMACTA ORAL TABLET 25 MG | 5 | PA; NDS; QL (30 per 30 days) |
| PROMACTA ORAL TABLET 50 MG, 75 MG | 5 | PA; NDS; QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| RELEUKO INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML | 5 | PA; NDS |
| RELEUKO SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5 | PA; NDS |
| RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML | 3 | PA; QL (12 per 28 days) |
| RETACRIT INJECTION SOLUTION 40,000 UNIT/ML | 3 | PA; QL (4 per 28 days) |
| UDENYCA AUTOINJECTOR SUBCUTANEOUS AUTO- INJECTOR 6 MG/0.6 ML | 5 | PA; NDS |
| UDENYCA ONBODY SUBCUTANEOUS SYRINGE, W/ WEARABLE INJECTOR 6 MG/0.6 ML | 5 | PA; NDS |
| UDENYCA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5 | PA; NDS |
| ZARXIO INJECTION SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5 | PA; NDS |
| Reemplazo/Modificadores De Enzima | | |
| Reemplazo/Modificadores De Enzima | | |
| CERDELGA ORAL CAPSULE 84 MG | 5 | PA; NDS |
| CREON ORAL CAPSULE,DELAYED RELEASE(DR/EC) 12,000-38,000 - 60,000 UNIT, 24,000-76,000 - 120,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000- 180,000 UNIT, 6,000-19,000 -30,000 UNIT | 3 | |
| GALAFOLD ORAL CAPSULE 123 MG | 5 | PA; NDS; QL (14 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>javygtor oral tablet,soluble 100 mg</i> (sapropterin) | 5 | PA; NDS |
| <i>miglustat oral capsule 100 mg</i> (Yargesa) | 5 | PA; NDS; QL (90 per 30 days) |
| <i>nitisinone oral capsule 10 mg, 2 mg, 20 mg, 5 mg</i> (Orfadin) | 5 | PA; NDS |
| ORFADIN ORAL SUSPENSION 4 MG/ML | 5 | PA; NDS |
| PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 2.5 MG/0.5 ML, 20 MG/ML | 5 | PA; NDS |
| PULMOZYME INHALATION SOLUTION 1 MG/ML | 5 | PA BvD; NDS |
| <i>sapropterin oral tablet,soluble 100 mg</i> (Javygtor) | 5 | PA; NDS |
| STRENSIQ SUBCUTANEOUS SOLUTION 18 MG/0.45 ML, 28 MG/0.7 ML, 40 MG/ML, 80 MG/0.8 ML | 5 | PA; LA; NDS |
| <i>yargesa oral capsule 100 mg</i> (miglustat) | 5 | PA; NDS; QL (90 per 30 days) |
| ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,000-32,000 - 42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT | 3 | |
| Relajantes Musculares Esqueléticos | | |
| Relajantes Musculares Esqueléticos | | |
| <i>baclofen oral tablet 10 mg, 15 mg, 20 mg, 5 mg</i> | 2 | |
| <i>chlorzoxazone oral tablet 500 mg</i> | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>cyclobenzaprine oral tablet 10 mg, 5 mg</i> | 1 | PA-HRM; GC; AGE (Max 64 Years) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>dantrolene oral capsule 100 mg, 50 mg</i> | 2 | |
| <i>dantrolene oral capsule 25 mg</i> (Dantrium) | 2 | |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>revonto intravenous recon soln 20 mg</i> (dantrolene) | 2 | |
| <i>tizanidine oral tablet 2 mg</i> | 2 | |
| <i>tizanidine oral tablet 4 mg</i> (Zanaflex) | 2 | |
| Vitaminas Y Minerales | | |
| Vitaminas Y Minerales | | |
| <i>bal-care dha combo pack 27-1-430 mg</i> | 2 | |
| <i>bal-care dha essential pack 27 mg iron-1 mg -374 mg</i> | 2 | |
| <i>c-nate dha softgel 28 mg iron-1 mg - 200 mg</i> | 2 | |
| <i>completenate tablet chew 29 mg iron-1 mg</i> | 2 | |
| <i>cyanocobalamin (vitamin b-12) injection solution</i> (Dodex) | 1 | GC; EX |
| <i>ergocalciferol (vitamin d2) oral capsule 1,250 mcg (50,000 unit)</i> (Drisdol) | 1 | GC; EX |
| <i>folic acid oral tablet 1 mg</i> | 1 | GC; EX |
| <i>folivane-ob capsule 85-1 mg</i> | 2 | |
| <i>kosher prenatal plus iron tab 30 mg iron- 1 mg</i> | 2 | |
| <i>marnatal-f capsule 60 mg iron-1 mg</i> | 2 | |
| <i>m-natal plus tablet 27 mg iron- 1 mg</i> (pnv,calcium 72-iron-folic acid) | 2 | |
| <i>mynatal advance oral tablet 90-1-50 mg</i> | 2 | |
| <i>mynatal capsule 65 mg iron- 1 mg</i> | 2 | |
| <i>mynatal oral tablet 90-1-50 mg</i> | 2 | |
| <i>mynatal plus captab 65 mg iron- 1 mg</i> | 2 | |
| <i>mynatal-z captab 65 mg iron- 1 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|---------------------------------------|------------------------------------|
| <i>mynate 90 plus oral tablet extended release 90 mg iron-1 mg</i> | 2 | |
| <i>newgen tablet 32-1,000 mg-mcg</i> | 2 | |
| <i>niva-plus tablet 27 mg iron- 1 mg</i> | 2 | |
| <i>obstetrix dha combo pack 29 mg iron- 1,700 mcg dfe</i> | 2 | |
| <i>obstetrix dha oral combo pack,tablet and cap,dr 29 mg iron-1 mg -50 mg</i> | 2 | |
| <i>o-cal prenatal tablet 15 mg iron-1,000 mcg</i> | 2 | |
| <i>pnv 29-1 tablet (rx) 29 mg iron- 1 mg</i> | 2 | |
| <i>pnv prenatal plus multivit tab gluten-free (rx) 27 mg iron- 1 mg</i> | (pnv,calcium 72-iron-folic acid) 2 | |
| <i>pnv-dha + docusate oral capsule 27-1.25-55-300 mg</i> | 2 | |
| <i>pnv-omega softgel 28-1-300 mg</i> | 2 | |
| <i>pr natal 400 combo pack 29-1-400 mg</i> | 2 | |
| <i>pr natal 400 ec combo pack 29-1-400 mg</i> | 2 | |
| <i>pr natal 430 combo pack 29 mg iron-1 mg -430 mg</i> | 2 | |
| <i>pr natal 430 ec combo pack 29-1-430 mg</i> | 2 | |
| <i>prena1 true combo pack 30 mg iron-1.4 mg-300 mg</i> | 2 | |
| <i>prenaissance oral capsule 29-1.25-55-325 mg</i> | 2 | |
| <i>prenaissance plus oral capsule 28-1-50-250 mg</i> | 2 | |
| <i>prenatabs fa tablet 29-1 mg</i> | 2 | |
| <i>prenatal 19 (with docusate) oral tablet 29 mg iron- 1 mg-25 mg</i> | 2 | |
| <i>prenatal 19 chewable tablet 29 mg iron- 1 mg</i> | 2 | |
| <i>prenatal low iron tablet (rx) 27 mg iron- 1 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i> prenatal plus iron tablet (rx) 29 mg iron- 1 mg</i> (pnv,calcium 72-iron,carb-folic) | 2 | |
| <i> prenatal vitamin plus low iron oral tablet 27 mg iron- 1 mg</i> (pnv,calcium 72-iron-folic acid) | 2 | |
| <i> prenatal-u capsule 106.5-1 mg</i> | 2 | |
| <i> preplus ca-fe 27 mg-fa 1 mg tb (rx) 27 mg iron- 1 mg</i> (pnv,calcium 72-iron-folic acid) | 2 | |
| <i> pretab 29 mg-1 mg tablet (rx) 29-1 mg</i> | 2 | |
| <i> r-natal ob softgel 20 mg iron- 1 mg-320 mg</i> | 2 | |
| <i> select-ob chewable caplet 29 mg iron- 1 mg</i> | 2 | |
| <i> select-ob chewable caplet 29 mg iron- 1 mg</i> | 2 | |
| <i> se-natal 19 chewable tablet 29 mg iron- 1 mg</i> | 2 | |
| <i> taron-c dha capsule 35-1-200 mg</i> | 2 | |
| <i> taron-prex prenatal-dha oral capsule 30 mg iron-1.2 mg-55 mg-265 mg</i> | 2 | |
| <i> triveen-duo dha oral combo pack 29-1-400 mg</i> | 2 | |
| <i> virt-c dha softgel (rx) 35-1-200 mg</i> | 2 | |
| <i> virt-nate dha softgel 28 mg iron-1 mg -200 mg</i> | 2 | |
| <i> virt-pn dha softgel (rx) 27 mg iron-1 mg -300 mg</i> | 2 | |
| <i> virt-pn plus softgel (rx) 28-1-300 mg</i> | 2 | |
| <i> vitafof gummies 3.33 mg iron- 0.33 mg</i> | 2 | |
| <i> vitafof nano tablet 18 mg iron- 1 mg</i> | 2 | |
| <i> vitafof-ob+dha combo pack 65-1-250 mg</i> | 2 | |
| <i> vp-ch-pnv oral capsule 30 mg iron-1 mg -50 mg-260 mg</i> | 2 | |
| <i> vp-pnv-dha softgel (rx) 28 mg iron- 1 mg-200 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>zatean-pn dha capsule 27 mg iron-1 mg -300 mg</i> | 2 | |
| <i>zatean-pn plus softgel 28-1-300 mg</i> | 2 | |
| <i>zingiber tablet 1.2 mg-40 mg- 124.1 mg-100 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este document.

ÍNDICE

| | | |
|--|--|--|
| 1ST TIER UNIFINE PENTIPS 142, 143 | ADVOCATE SYRINGES.....143 | <i>amitriptyline</i> 130 |
| 1ST TIER UNIFINE PENTIPS PLUS..... 143 | <i>afirmelle</i> 116 | <i>amlodipine</i> 46 |
| <i>abacavir</i> 136 | AIRSUPRA..... 62, 63 | <i>amlodipine-atorvastatin</i> 47 |
| <i>abacavir-lamivudine</i> 136 | AJOVY AUTOINJECTOR..... 27 | <i>amlodipine-benazepril</i> 47 |
| ABELCET..... 133 | AJOVY SYRINGE..... 27 | <i>amlodipine-olmesartan</i> 47 |
| ABILIFY ASIMTUFII..... 33 | AKEEGA..... 3 | <i>amlodipine-valsartan</i> 47 |
| ABILIFY MAINTENA..... 33 | AKYNZEO (FOSNETUPITANT)..... 28 | <i>amlodipine-valsartan-hcthiazid</i> .. 47 |
| <i>abiraterone</i> 3 | AKYNZEO (NETUPITANT).... 29 | <i>ammonium lactate</i> 68 |
| ABOUTTIME PEN NEEDLE..143 | <i>ala-cort</i> 66 | <i>amoxapine</i> 130 |
| ABRAXANE..... 3 | <i>albendazole</i> 30 | <i>amoxicillin</i> 113 |
| ABRYSVO (PF)..... 88 | <i>albuterol sulfate</i> 63, 64 | <i>amoxicillin-pot clavulanate</i> 113 |
| <i>acamprosate</i> 19 | <i>alclometasone</i> 66 | <i>amphotericin b</i> 133 |
| <i>acarbose</i> 22 | ALCOHOL PADS..... 68 | <i>amphotericin b liposome</i> 133 |
| <i>accutane</i> 68 | ALCOHOL PREP PADS..... 69 | <i>ampicillin</i> 113 |
| <i>acebutolol</i> 42 | ALCOHOL PREP SWABS..... 68 | <i>ampicillin sodium</i> 113 |
| <i>acetaminophen-codeine</i> 103 | ALCOHOL SWABS..... 68 | <i>ampicillin-sulbactam</i> 113 |
| <i>acetazolamide</i> 93 | ALCOHOL WIPES..... 68 | <i>anagrelide</i> 187 |
| <i>acetazolamide sodium</i> 93 | ALECENSA..... 3 | <i>anastrozole</i> 3 |
| <i>acetic acid</i> 94 | <i>alendronate</i> 53 | ANKTIVA..... 3 |
| <i>acetylcysteine</i> 60 | <i>alfuzosin</i> 75 | ANORO ELLIPTA..... 64 |
| <i>acitretin</i> 68 | <i>aliskiren</i> 51 | <i>apomorphine</i> 31 |
| ACTEMRA..... 82 | <i>allopurinol</i> 26, 27 | APONVIE..... 29 |
| ACTEMRA ACTPEN..... 82 | <i>alosetron</i> 52 | <i>apraclonidine</i> 98 |
| ACTHAR..... 79 | <i>alprazolam</i> 20 | <i>aprepitant</i> 29 |
| ACTHAR SELFJECT..... 79, 80 | <i>altavera (28)</i> 116 | APRETUDE..... 136 |
| ACTHIB (PF)..... 88 | ALTRENO..... 71 | <i>apri</i> 116 |
| ACTIMMUNE..... 99 | ALUNBRIG..... 3 | APTIOM..... 125 |
| <i>acyclovir</i> 68, 142 | ALVAIZ..... 189 | APTIVUS..... 136 |
| <i>acyclovir sodium</i> 142 | <i>alyacen 1/35 (28)</i> 116 | AQINJECT PEN NEEDLE..... 144 |
| ADACEL(TDAP | <i>alyacen 7/7/7 (28)</i> 116 | <i>aranelle (28)</i> 116 |
| ADOLESN/ADULT)(PF)..... 88 | <i>alyq</i> 101 | ARCALYST..... 82 |
| <i>adapalene</i> 71 | <i>amabelz</i> 77 | AREXVY (PF)..... 88 |
| <i>adefovir</i> 142 | <i>amantadine hcl</i> 31 | AREXVY ANTIGEN |
| ADEMPAS..... 101 | <i>ambrisentan</i> 101 | COMPONENT..... 88 |
| <i>adrucil</i> 3 | <i>amethia</i> 116 | <i>aripiprazole</i> 33 |
| ADVAIR HFA..... 62 | <i>amiloride</i> 49 | ARISTADA..... 33, 34 |
| ADVOCATE PEN NEEDLE... 144 | <i>amiloride-hydrochlorothiazide</i> .. 49 | ARISTADA INITIO..... 33 |
| | <i>amiodarone</i> 41 | <i>armodafinil</i> 54 |
| | | ARNUITY ELLIPTA..... 62 |

| | | | | | |
|--------------------------------------|-----|-------------------------------------|----------|--|----------|
| <i>ascomp with codeine</i> | 104 | <i>azithromycin</i> | 112 | BD VEO INSULIN SYR | |
| <i>asenapine maleate</i> | 34 | <i>aztreonam</i> | 110 | (HALF UNIT)..... | 146 |
| <i>ashlyna</i> | 116 | <i>azurette (28)</i> | 117 | BD VEO INSULIN SYRINGE | |
| <i>aspirin-dipyridamole</i> | 189 | <i>bacitracin</i> | 94 | UF..... | 146, 147 |
| ASSURE ID DUO PRO SFTY | | <i>bacitracin-polymyxin b</i> | 94 | BELSOMRA..... | 54 |
| PEN NDL..... | 144 | <i>baclofen</i> | 192 | <i>benazepril</i> | 50 |
| ASSURE ID DUO-SHIELD.... | 144 | <i>bal-care dha</i> | 193 | <i>benazepril-hydrochlorothiazide</i> .. | 50 |
| ASSURE ID INSULIN | | <i>bal-care dha essential</i> | 193 | <i>bendamustine</i> | 3 |
| SAFETY..... | 144 | <i>balsalazide</i> | 52 | BENDAMUSTINE..... | 4 |
| ASSURE ID PEN NEEDLE.... | 144 | BALVERSA..... | 3 | BENDEKA..... | 4 |
| ASSURE ID PRO PEN | | <i>balziva (28)</i> | 117 | BENLYSTA..... | 82 |
| NEEDLE..... | 144 | BCG VACCINE, LIVE (PF)..... | 88 | <i>benzonatate</i> | 187 |
| ASTAGRAF XL..... | 82 | BD ALCOHOL SWABS..... | 68 | <i>benztropine</i> | 31 |
| <i>atazanavir</i> | 136 | BD AUTOSHIELD DUO PEN | | BESREMI..... | 82 |
| <i>atenolol</i> | 42 | NEEDLE..... | 145 | <i>betaine</i> | 99 |
| <i>atenolol-chlorthalidone</i> | 42 | BD ECLIPSE LUER-LOK..... | 145 | <i>betamethasone acet,sod phos</i> | 78 |
| <i>atomoxetine</i> | 55 | BD INSULIN SYRINGE..... | 145 | <i>betamethasone dipropionate</i> | 66 |
| <i>atorvastatin</i> | 47 | BD INSULIN SYRINGE | | <i>betamethasone valerate</i> | 66 |
| <i>atovaquone</i> | 30 | (HALF UNIT)..... | 145 | <i>betamethasone, augmented</i> | 66 |
| <i>atovaquone-proguanil</i> | 30 | BD INSULIN SYRINGE SLIP | | BETASERON..... | 56 |
| <i>atropine</i> | 98 | TIP..... | 145 | <i>betaxolol</i> | 42 |
| ATROVENT HFA..... | 64 | BD INSULIN SYRINGE U- | | <i>bethanechol chloride</i> | 75 |
| <i>aubra eq</i> | 117 | 500..... | 145 | <i>bexarotene</i> | 4 |
| AUGTYRO..... | 3 | BD INSULIN SYRINGE | | BEXSERO..... | 88 |
| <i>aurovela 1.5/30 (21)</i> | 117 | ULTRA-FINE..... | 145 | <i>bicalutamide</i> | 4 |
| <i>aurovela 1/20 (21)</i> | 117 | BD NANO 2ND GEN PEN | | BICILLIN L-A..... | 114 |
| <i>aurovela 24 fe</i> | 117 | NEEDLE..... | 145 | BIKTARVY..... | 136 |
| <i>aurovela fe 1.5/30 (28)</i> | 117 | BD SAFETYGLIDE INSULIN | | <i>bisoprolol fumarate</i> | 42 |
| <i>aurovela fe 1-20 (28)</i> | 117 | SYRINGE..... | 145, 146 | <i>bisoprolol-hydrochlorothiazide</i> .. | 42 |
| AUSTEDO..... | 55 | BD SAFETYGLIDE SYRINGE | | <i>bleomycin</i> | 4 |
| AUSTEDO XR..... | 55 | | 146 | <i>blisovi 24 fe</i> | 117 |
| AUSTEDO XR TITRATION | | BD ULTRA-FINE MICRO | | <i>blisovi fe 1.5/30 (28)</i> | 117 |
| KT(WK1-4)..... | 56 | PEN NEEDLE..... | 146 | <i>blisovi fe 1/20 (28)</i> | 117 |
| AUVELITY..... | 130 | BD ULTRA-FINE MINI PEN | | BOOSTRIX TDAP..... | 88, 89 |
| <i>aviane</i> | 117 | NEEDLE..... | 146 | BORDERED GAUZE..... | 147 |
| AVONEX..... | 56 | BD ULTRA-FINE NANO PEN | | <i>bortezomib</i> | 4 |
| <i>ayuna</i> | 117 | NEEDLE..... | 146 | <i>bosentan</i> | 101 |
| AYVAKIT..... | 3 | BD ULTRA-FINE ORIG PEN | | BOSULIF..... | 4 |
| <i>azacitidine</i> | 3 | NEEDLE..... | 146 | BRAFTOVI..... | 4 |
| <i>azathioprine</i> | 82 | BD ULTRA-FINE SHORT | | BREO ELLIPTA..... | 62 |
| <i>azathioprine sodium</i> | 82 | PEN NEEDLE..... | 146 | <i>breyna</i> | 62 |
| <i>azelastine</i> | 98 | | | BREZTRI AEROSPHERE..... | 64 |

| | | | | |
|---|---------|--|---|---------|
| <i>briellyn</i> | 117 | <i>carbidopa-levodopa-</i> | <i>chlorzoxazone</i> | 192 |
| BRILINTA..... | 189 | <i>entacapone</i> | <i>cholestyramine (with sugar)</i> | 47 |
| <i>brimonidine</i> | 93 | CAREFINE PEN NEEDLE..... | <i>cholestyramine light</i> | 47 |
| <i>brimonidine-timolol</i> | 93 | CARETOUCH ALCOHOL | <i>ciclopirox</i> | 133 |
| <i>brinzolamide</i> | 93 | PREP PAD..... | <i>cilostazol</i> | 189 |
| BRIVIACT..... | 125 | CARETOUCH INSULIN | CIMDUO..... | 136 |
| <i>bromfenac</i> | 96, 97 | SYRINGE..... | <i>cimetidine hcl</i> | 71 |
| <i>bromocriptine</i> | 31 | CARETOUCH PEN NEEDLE..... | <i>cinacalcet</i> | 53 |
| BRONCHITOL..... | 60 | <i>carglumic acid</i> | CINQAIR..... | 60 |
| BRUKINSA..... | 4 | <i>carteolol</i> | CINRYZE..... | 189 |
| <i>budesonide</i> | 52, 62 | <i>cartia xt</i> | <i>ciprofloxacin</i> | 115 |
| <i>budesonide-formoterol</i> | 63 | <i>carvedilol</i> | <i>ciprofloxacin hcl</i> | 94, 114 |
| <i>bumetanide</i> | 49 | <i>casprofungin</i> | <i>ciprofloxacin in 5 % dextrose</i> ... | 114 |
| <i>buprenorphine hcl</i> | 19, 104 | CAYSTON..... | <i>ciprofloxacin-dexamethasone</i> | 94 |
| <i>buprenorphine-naloxone</i> | 19 | <i>caziant (28)</i> | <i>citalopram</i> | 130 |
| <i>bupropion hcl</i> | 130 | <i>cefactor</i> | <i>clarithromycin</i> | 112 |
| <i>bupropion hcl (smoking deter)</i> ... | 19 | <i>cefadroxil</i> | CLENPIQ..... | 74 |
| <i>bupirone</i> | 99 | <i>cefazolin</i> | CLICKFINE PEN NEEDLE.... | 148 |
| <i>butalbital-acetaminophen-caff.</i> | 104 | <i>cefazolin in dextrose (iso-os)</i> | <i>clindamycin hcl</i> | 109 |
| <i>butalbital-aspirin-caffeine</i> | 104 | <i>cefdinir</i> | <i>clindamycin in 5 % dextrose</i> | 109 |
| CABENUVA..... | 136 | <i>cefepime</i> | <i>clindamycin pediatric</i> | 109 |
| <i>cabergoline</i> | 31 | <i>cefexime</i> | <i>clindamycin phosphate</i> 70, 108, 109 | |
| CABLIVI..... | 187 | <i>cefotaxime</i> | <i>clindamycin-benzoyl peroxide</i> | 70 |
| CABOMETYX..... | 4 | <i>cefoxitin</i> | CLINIMIX 5%/D15W | |
| <i>cabotegravir</i> | 136 | <i>cefpodoxime</i> | SULFITE FREE..... | 39 |
| <i>caffeine citrate</i> | 56 | <i>cefprozil</i> | CLINIMIX 4.25%/D10W | |
| <i>calcipotriene</i> | 68 | <i>ceftazidime</i> | SULF FREE..... | 39 |
| <i>calcitonin (salmon)</i> | 53 | <i>ceftriaxone</i> | CLINIMIX 4.25%/D5W | |
| <i>calcitriol</i> | 53 | <i>cefuroxime axetil</i> | SULFIT FREE..... | 39 |
| <i>calcium acetate(phosphat bind)</i> .. | 74 | <i>cefuroxime sodium</i> | CLINIMIX 5%- | |
| <i>calcium chloride</i> | 185 | <i>celecoxib</i> | D20W(SULFITE-FREE)..... | 39 |
| CALQUENCE | | <i>cephalexin</i> | CLINIMIX 6%-D5W | |
| (ACALABRUTINIB MAL)..... | 4 | CERDELGA..... | (SULFITE-FREE)..... | 39 |
| <i>camila</i> | 117 | <i>cevimeline</i> | CLINIMIX 8%- | |
| <i>candesartan</i> | 45 | <i>chateal eq (28)</i> | D10W(SULFITE-FREE)..... | 39 |
| <i>candesartan-hydrochlorothiazid</i> | 45 | <i>chloramphenicol sod succinate</i> | CLINIMIX 8%- | |
| CAPLYTA..... | 34 | <i>chlordiazepoxide hcl</i> | D14W(SULFITE-FREE)..... | 39 |
| CAPRELSA..... | 4 | <i>chlorhexidine gluconate</i> | CLINIMIX E 2.75%/D5W | |
| <i>captopril</i> | 51 | <i>chloroquine phosphate</i> | SULF FREE..... | 39 |
| <i>carbamazepine</i> | 125 | <i>chlorothiazide sodium</i> | CLINIMIX E 4.25%/D10W | |
| <i>carbidopa-levodopa</i> | 31, 32 | <i>chlorpromazine</i> | SUL FREE..... | 40 |
| | | <i>chlorthalidone</i> | | |

| | | | | |
|---|---------------------------------------|------------|---|-------------|
| CLINIMIX E 4.25%/D5W | <i>compro</i> | 29 | <i>dasetta 1/35 (28)</i> | 118 |
| SULF FREE..... | <i>constulose</i> | 72 | <i>dasetta 7/7/7 (28)</i> | 118 |
| CLINIMIX E 5%/D15W | COPAXONE..... | 56 | DAURISMO..... | 5 |
| SULFIT FREE..... | COPIKTRA..... | 5 | <i>daysee</i> | 118 |
| CLINIMIX E 5%/D20W | CORLANOR..... | 44 | <i>deblitane</i> | 118 |
| SULFIT FREE..... | CORTROPHIN GEL..... | 80 | <i>decitabine</i> | 5 |
| CLINIMIX E 8%-D10W | COSENTYX..... | 83, 99 | <i>deferasirox</i> | 107, 108 |
| SULFITEFREE..... | COSENTYX (2 SYRINGES)..... | 82 | <i>deferiprone</i> | 108 |
| <i>clobazam</i> | COSENTYX PEN (2 PENS)..... | 82 | DELSTRIGO..... | 137 |
| <i>clobetasol</i> | COSENTYX UNOREADY | | DENG VAXIA (PF)..... | 89 |
| <i>clobetasol-emollient</i> | PEN..... | 83 | <i>denta 5000 plus</i> | 65 |
| <i>clomipramine</i> | COTELLIC..... | 5 | <i>dentagel</i> | 65 |
| <i>clonazepam</i> | CREON..... | 191 | DEPO-SUBQ PROVERA 104.. | 81 |
| <i>clonidine</i> | <i>cromolyn</i> | 60, 72, 98 | DERMACEA..... | 151 |
| <i>clonidine hcl</i> | <i>cryselle (28)</i> | 117 | DERMACEA NON-WOVEN.. | 151 |
| <i>clopidogrel</i> | CURAD GAUZE PAD..... | 151 | DESCOVY..... | 137 |
| <i>clorazepate dipotassium</i> | CURITY ALCOHOL SWABS.. | 69 | <i>desipramine</i> | 130 |
| <i>clotrimazole</i> | CURITY GAUZE..... | 151 | <i>desmopressin</i> | 80 |
| <i>clotrimazole-betamethasone</i> | <i>cyanocobalamin (vitamin b-12)</i> | 193 | <i>desog-e.estradiol/e.estradiol</i> | 118 |
| <i>clozapine</i> | <i>cyclobenzaprine</i> | 192 | <i>desogestrel-ethinyl estradiol</i> | 118 |
| <i>c-nate dha</i> | <i>cyclopentolate</i> | 98 | <i>desoximetasone</i> | 66 |
| COARTEM..... | <i>cyclophosphamide</i> | 5 | <i>desvenlafaxine succinate</i> | 130 |
| COBENFY..... | <i>cyclosporine</i> | 83 | <i>dexamethasone</i> | 78 |
| COBENFY STARTER PACK... 34 | <i>cyclosporine modified</i> | 83 | <i>dexamethasone sodium phos</i> | |
| <i>codeine sulfate</i> | <i>cyproheptadine</i> | 135 | (<i>pf</i>)..... | 78 |
| <i>codeine-butalbital-asa-caff</i> | CYRAMZA..... | 5 | <i>dexamethasone sodium</i> | |
| <i>colchicine</i> | <i>cyred eq</i> | 117 | <i>phosphate</i> | 78, 97 |
| <i>colesevelam</i> | CYSTARAN..... | 98 | <i>dexmethylphenidate</i> | 56 |
| <i>colestipol</i> | <i>d5 % and 0.9 % sodium</i> | | <i>dextroamphetamine sulfate</i> | 56 |
| <i>colistin (colistimethate na)</i> | <i>chloride</i> | 185 | <i>dextroamphetamine-</i> | |
| COMBIVENT RESPIMAT..... | <i>d5 %-0.45 % sodium chloride</i> .. | 185 | <i>amphetamine</i> | 56 |
| COMETRIQ..... | <i>dabigatran etexilate</i> | 188 | <i>dextrose 10 % in water (d10w)</i> ... 40 | |
| COMFORT EZ INSULIN | <i>dalfampridine</i> | 56 | <i>dextrose 5 % in water (d5w)</i> | 40 |
| SYRINGE..... | <i>danazol</i> | 76 | DIACOMIT..... | 125, 126 |
| COMFORT EZ PEN | <i>dantrolene</i> | 193 | <i>diazepam</i> | 20, 21, 126 |
| NEEDLES..... | DANYELZA..... | 5 | <i>diazepam intensol</i> | 20 |
| COMFORT EZ PRO SAFETY | <i>dapsone</i> | 135 | <i>diazoxide</i> | 99 |
| PEN NDL..... | DAPTACEL (DTAP | | <i>diclofenac potassium</i> | 102 |
| COMFORT TOUCH PEN | PEDIATRIC) (PF)..... | 89 | <i>diclofenac sodium</i> | 97, 102 |
| NEEDLE..... | <i>daptomycin</i> | 109 | <i>diclofenac-misoprostol</i> | 102 |
| COMPLERA..... | <i>darunavir</i> | 137 | <i>dicloxacillin</i> | 114 |
| <i>completenate</i> | <i>dasatinib</i> | 5 | <i>dicyclomine</i> | 72 |

| | | | |
|---|----------|--|--|
| <i>didanosine</i> | 137 | DROPLET MICRON PEN | EASY TOUCH SAFETY PEN |
| DIFICID | 112 | NEEDLE | NEEDLE |
| <i>difluprednate</i> | 97 | DROPLET PEN NEEDLE | EASY TOUCH |
| <i>digitek</i> | 44 | | SHEATHLOCK INSULIN |
| <i>digox</i> | 45 | | 152, 153 |
| <i>digoxin</i> | 45 | DROPSAFE ALCOHOL PREP | EASY TOUCH UNI-SLIP |
| <i>dihydroergotamine</i> | 27 | PADS | 157 |
| <i>diltiazem hcl</i> | 43, 44 | DROPSAFE INSULIN | <i>ec-naproxen</i> |
| <i>dilt-xr</i> | 44 | SYRINGE | 102 |
| <i>dimenhydrinate</i> | 29 | DROPSAFE PEN NEEDLE | <i>econazole</i> |
| <i>dimethyl fumarate</i> | 57 | <i>drosiprone-ethinyl estradiol</i> .. | 133 |
| DIPENTUM | 52 | DROXIA | EDARBI |
| <i>diphenhydramine hcl</i> | 135 | <i>droxidopa</i> | 45 |
| <i>diphenoxylate-atropine</i> | 72 | DUAVEE | EDARBYCLOR |
| <i>dipyridamole</i> | 189 | <i>duloxetine</i> | 46 |
| <i>disopyramide phosphate</i> | 41 | DUPIXENT PEN | EDURANT |
| <i>disulfiram</i> | 19 | DUPIXENT SYRINGE | 137 |
| <i>divalproex</i> | 126 | <i>dutasteride</i> | <i>efavirenz</i> |
| <i>dofetilide</i> | 41 | EASY COMFORT ALCOHOL | <i>efavirenz-emtricitabin-tenofov</i> .. |
| <i>donepezil</i> | 21 | PAD | <i>efavirenz-lamivu-tenofov disop</i> .. |
| DOPTELET (10 TAB PACK) .. | 189 | EASY COMFORT INSULIN | EGRIFTA SV |
| DOPTELET (15 TAB PACK) .. | 189 | SYRINGE | <i>electrolyte-148</i> |
| DOPTELET (30 TAB PACK) .. | 190 | EASY COMFORT PEN | 185 |
| <i>dorzolamide</i> | 93 | NEEDLES | ELIGARD |
| <i>dorzolamide-timolol</i> | 94 | | ELIGARD (3 MONTH) |
| <i>dotti</i> | 77 | EASY COMFORT SAFETY | 6 |
| DOVATO | 137 | PEN NEEDLE | ELIGARD (4 MONTH) |
| <i>doxazosin</i> | 41 | | 6 |
| <i>doxepin</i> | 131 | EASY GLIDE INSULIN | ELIGARD (6 MONTH) |
| <i>doxorubicin</i> | 5 | SYRINGE | 6 |
| <i>doxorubicin, peg-liposomal</i> | 5 | EASY GLIDE PEN NEEDLE .. | <i>elinest</i> |
| <i>doxy-100</i> | 115 | | 118 |
| <i>doxycycline hyclate</i> | 115 | EASY TOUCH | ELIQUIS |
| <i>doxycycline monohydrate</i> | 116 | | 188 |
| DRIZALMA SPRINKLE | 131 | EASY TOUCH ALCOHOL | ELIQUIS DVT-PE TREAT |
| <i>dronabinol</i> | 29 | PREP PADS | 30D START |
| <i>droperidol</i> | 29 | | 188 |
| DROPLET INSULIN | | EASY TOUCH FLIPLOCK | ELLA |
| SYR(HALF UNIT) | 151 | INSULIN | 118 |
| DROPLET INSULIN | | SYRINGE | ELMIRON |
| SYRINGE | 151, 152 | EASY TOUCH INSULIN | 99 |
| | | SAFETY SYR | ELREXFIO |
| | | | 6 |
| | | EASY TOUCH INSULIN | <i>eluryng</i> |
| | | SYRINGE | 118 |
| | | | EMBRACE PEN NEEDLE |
| | | EASY TOUCH LUER LOCK | |
| | | INSULIN | 157, 158 |
| | | EASY TOUCH PEN NEEDLE | EMCYT |
| | | | 6 |
| | | | EMEND |
| | | | 29 |
| | | | EMGALITY PEN |
| | | | 27 |
| | | | EMGALITY SYRINGE |
| | | | 27 |
| | | | EMSAM |
| | | | 131 |
| | | | <i>emtricitabine</i> |
| | | | 137 |
| | | | <i>emtricitabine-tenofovir (tdf)</i> |
| | | | 137 |
| | | | EMTRIVA |
| | | | 137 |
| | | | <i>emzahn</i> |
| | | | 118 |
| | | | <i>enalapril maleate</i> |
| | | | 51 |
| | | | <i>enalaprilat</i> |
| | | | 51 |
| | | | <i>enalapril-hydrochlorothiazide</i> |
| | | | 51 |
| | | | ENBREL |
| | | | 83 |

| | | | | | |
|---|----------|--|-----|---|------------|
| ENBREL MINI..... | 83 | <i>eszopiclone</i> | 55 | <i>fesoterodine</i> | 75 |
| ENBREL SURECLICK..... | 83 | <i>ethambutol</i> | 135 | FETZIMA..... | 131 |
| <i>endocet</i> | 104 | <i>ethosuximide</i> | 126 | FIASP FLEXTOUCH U-100 | |
| ENGERIX-B (PF)..... | 89 | <i>ethynodiol diac-eth estradiol</i> ... | 118 | INSULIN..... | 24 |
| ENGERIX-B PEDIATRIC (PF)..... | 89 | <i>etodolac</i> | 102 | FIASP PENFILL U-100 | |
| <i>enilloring</i> | 118 | <i>etonogestrel-ethinyl estradiol</i> ... | 119 | INSULIN..... | 24 |
| <i>enoxaparin</i> | 188 | ETOPOPHOS..... | 6 | FIASP U-100 INSULIN..... | 24 |
| <i>enpresse</i> | 118 | <i>etoposide</i> | 6 | <i>finasteride</i> | 75 |
| <i>enskyce</i> | 118 | <i>etravirine</i> | 137 | <i>fingolimod</i> | 57 |
| <i>entacapone</i> | 32 | EUCRISA..... | 67 | FINTEPLA..... | 126 |
| <i>entecavir</i> | 142 | <i>everolimus (antineoplastic)</i> | 7 | FIRMAGON KIT W | |
| ENTRESTO..... | 46 | <i>everolimus</i> | | DILUENT SYRINGE..... | 7 |
| ENTRESTO SPRINKLE..... | 46 | <i>(immunosuppressive)</i> | 83 | FLEBOGAMMA DIF..... | 83 |
| <i>enulose</i> | 72 | EVOTAZ..... | 137 | <i>flecainide</i> | 41 |
| EPCLUSA..... | 140, 141 | EVRYSDI..... | 99 | <i>floxuridine</i> | 7 |
| EPIDIOLEX..... | 126 | <i>exemestane</i> | 7 | <i>fluconazole</i> | 133 |
| <i>epinastine</i> | 98 | EXKIVITY..... | 7 | <i>fluconazole in nacl (iso-osm)</i> | 133 |
| <i>epinephrine</i> | 45 | EXTENCILLINE..... | 114 | <i>flucytosine</i> | 134 |
| <i>epitol</i> | 126 | EYSUVIS..... | 97 | <i>fludrocortisone</i> | 78 |
| EPIVIR HBV..... | 137 | <i>ezetimibe</i> | 48 | <i>flumazenil</i> | 57 |
| EPKINLY..... | 6 | <i>ezetimibe-simvastatin</i> | 48 | <i>flunisolide</i> | 97 |
| <i>eplerenone</i> | 51 | <i>falmina (28)</i> | 119 | <i>fluocinolone</i> | 67 |
| EPRONTIA..... | 126 | <i>famciclovir</i> | 142 | <i>fluocinolone acetonide oil</i> | 97 |
| ERBITUX..... | 6 | <i>famotidine</i> | 72 | <i>fluocinonide</i> | 67 |
| <i>ergocalciferol (vitamin d2)</i> | 193 | <i>famotidine (pf)</i> | 71 | <i>fluocinonide-emollient</i> | 67 |
| <i>ergoloid</i> | 21 | <i>famotidine (pf)-nacl (iso-os)</i> | 72 | <i>fluoride (sodium)</i> | 65 |
| ERIVEDGE..... | 6 | FANAPT..... | 34 | <i>fluorometholone</i> | 97 |
| ERLEADA..... | 6 | FARXIGA..... | 22 | <i>fluorouracil</i> | 7, 69 |
| <i>erlotinib</i> | 6 | FASENRA..... | 60 | <i>fluoxetine</i> | 131 |
| <i>errin</i> | 118 | FASENRA PEN..... | 60 | <i>fluphenazine decanoate</i> | 35 |
| <i>ertapenem</i> | 110 | <i>febuxostat</i> | 27 | <i>fluphenazine hcl</i> | 35 |
| <i>ery pads</i> | 70 | <i>felbamate</i> | 126 | <i>flurbiprofen</i> | 102 |
| <i>erythromycin</i> | 95, 113 | FEMRING..... | 77 | <i>flurbiprofen sodium</i> | 97 |
| <i>erythromycin ethylsuccinate</i> | 112 | <i>fenofibrate</i> | 48 | <i>fluticasone propionate</i> | 63, 67, 97 |
| <i>erythromycin with ethanol</i> | 70 | <i>fenofibrate micronized</i> | 48 | <i>fluticasone propion-salmeterol</i> ... | 63 |
| <i>escitalopram oxalate</i> | 131 | <i>fenofibrate nanocrystallized</i> | 48 | <i>fluvastatin</i> | 48 |
| <i>esomeprazole magnesium</i> | 71 | <i>fenofibric acid (choline)</i> | 48 | <i>fluvoxamine</i> | 131 |
| <i>esomeprazole sodium</i> | 71 | <i>fentanyl</i> | 104 | <i>folic acid</i> | 193 |
| <i>estarylla</i> | 118 | <i>fentanyl citrate</i> | 104 | <i>folivane-ob</i> | 193 |
| <i>estradiol</i> | 77 | FERRIPROX..... | 108 | <i>fondaparinux</i> | 188 |
| <i>estradiol valerate</i> | 77 | FERRIPROX (2 TIMES A | | <i>fosamprenavir</i> | 137 |
| <i>estradiol-norethindrone acet</i> | 77 | DAY)..... | 108 | <i>fosaprepitant</i> | 29 |

| | | | | | |
|--|-------------|--------------------------------------|--------|---|------------|
| <i>foscarnet</i> | 141 | GILENYA..... | 57 | HEALTHY ACCENTS | |
| <i>fosinopril</i> | 51 | GILOTRIF..... | 7 | UNIFINE PENTIP..... | 159, 160 |
| <i>fosinopril-hydrochlorothiazide</i> ... | 51 | <i>glatiramer</i> | 57 | <i>heather</i> | 119 |
| <i>fosphenytoin</i> | 126 | <i>glatopa</i> | 57 | <i>heparin (porcine)</i> | 188 |
| FOTIVDA..... | 7 | GLEOSTINE..... | 8 | <i>heparin, porcine (pf)</i> | 188 |
| FREESTYLE PRECISION..... | 158 | <i>glimepiride</i> | 26 | HEPLISAV-B (PF)..... | 89 |
| FRUZAQLA..... | 7 | <i>glipizide</i> | 26 | HERCEPTIN HYLECTA..... | 8 |
| FULPHILA..... | 190 | <i>glipizide-metformin</i> | 26 | HERZUMA..... | 8 |
| <i>fulvestrant</i> | 7 | <i>glutamine (sickle cell)</i> | 99 | HIBERIX (PF)..... | 89 |
| <i>furosemide</i> | 50 | <i>glyburide</i> | 26 | HUMIRA..... | 84 |
| FUZEON..... | 137 | <i>glyburide micronized</i> | 26 | HUMIRA PEN..... | 84 |
| FYARRO..... | 7 | <i>glyburide-metformin</i> | 26 | HUMIRA PEN CROHNS-UC- | |
| <i>fyavolv</i> | 77 | <i>glycopyrrolate</i> | 73 | HS START..... | 84 |
| FYCOMPA..... | 126 | <i>glydo</i> | 107 | HUMIRA PEN PSOR- | |
| <i>gabapentin</i> | 126, 127 | GLYXAMBI..... | 22 | UVEITS-ADOL HS..... | 84 |
| GALAFOLD..... | 191 | <i>granisetron (pf)</i> | 29 | HUMIRA(CF)..... | 85 |
| <i>galantamine</i> | 21 | <i>granisetron hcl</i> | 29 | HUMIRA(CF) PEDI CROHNS | |
| <i>gallifrey</i> | 81 | GRANIX..... | 190 | STARTER..... | 84 |
| GAMIFANT..... | 84 | <i>griseofulvin microsize</i> | 134 | HUMIRA(CF) PEN..... | 85 |
| GAMMAGARD LIQUID..... | 84 | <i>guanfacine</i> | 41, 57 | HUMIRA(CF) PEN CROHNS- | |
| GAMMAGARD S-D (IGA < 1 | | GVOKE..... | 99 | UC-HS..... | 84 |
| MCG/ML)..... | 84 | GVOKE HYPOPEN 2-PACK.... | 99 | HUMIRA(CF) PEN | |
| GAMMAPLEX..... | 84 | GVOKE PFS 1-PACK | | PEDIATRIC UC..... | 84 |
| GAMMAPLEX (WITH | | SYRINGE..... | 99 | HUMIRA(CF) PEN PSOR-UV- | |
| SORBITOL)..... | 84 | GVOKE PFS 2-PACK | | ADOL HS..... | 84 |
| GARDASIL 9 (PF)..... | 89 | SYRINGE..... | 99 | HUMULIN R U-500 (CONC) | |
| <i>gatifloxacin</i> | 95 | HAEGARDA..... | 190 | INSULIN..... | 24 |
| GATTEX 30-VIAL..... | 73 | <i>hailey</i> | 119 | HUMULIN R U-500 (CONC) | |
| GAUZE PAD..... | 159 | <i>hailey 24 fe</i> | 119 | KWIKPEN..... | 24 |
| <i>gavilyte-c</i> | 74 | <i>hailey fe 1.5/30 (28)</i> | 119 | <i>hydralazine</i> | 45 |
| <i>gavilyte-g</i> | 74 | <i>hailey fe 1/20 (28)</i> | 119 | <i>hydrochlorothiazide</i> | 50 |
| <i>gavilyte-n</i> | 74 | <i>halobetasol propionate</i> | 67 | <i>hydrocodone-acetaminophen</i> | |
| GAVRETO..... | 7 | <i>haloette</i> | 119 | | 104, 105 |
| <i>gefitinib</i> | 7 | <i>haloperidol</i> | 35 | <i>hydrocodone-ibuprofen</i> | 105 |
| <i>gemfibrozil</i> | 48 | <i>haloperidol decanoate</i> | 35 | <i>hydrocortisone</i> | 52, 67, 78 |
| <i>generlac</i> | 73 | <i>haloperidol lactate</i> | 35 | <i>hydrocortisone butyrate</i> | 67 |
| <i>engraf</i> | 84 | HARVONI..... | 141 | <i>hydrocortisone valerate</i> | 67 |
| <i>gentak</i> | 95 | HAVRIX (PF)..... | 89 | <i>hydrocortisone-acetic acid</i> | 95 |
| <i>gentamicin</i> | 70, 95, 108 | HEALTHWISE INSULIN | | <i>hydromorphone</i> | 105 |
| <i>gentamicin sulfate (ped) (pf)</i> | 108 | SYRINGE..... | 159 | <i>hydromorphone (pf)</i> | 105 |
| <i>gentamicin sulfate (pf)</i> | 109 | HEALTHWISE PEN NEEDLE | 159 | <i>hydroxychloroquine</i> | 31 |
| GENVOYA..... | 137 | | | <i>hydroxyurea</i> | 8 |

| | | | | | |
|----------------------------------|---------|---|--------|-----------------------------------|---------|
| <i>hydroxyzine hcl</i> | 135 | INQOVI..... | 9 | <i>ivermectin</i> | 31 |
| <i>hydroxyzine pamoate</i> | 99, 100 | INREBIC..... | 9 | IWILFIN..... | 9 |
| <i>ibandronate</i> | 53 | <i>insulin asp prt-insulin aspart</i> | 25 | IXCHIQ (PF)..... | 90 |
| IBRANCE..... | 8 | <i>insulin aspart u-100</i> | 25 | IXIARO (PF)..... | 90 |
| <i>ibu</i> | 102 | INSULIN SYR/NDL U100 | | <i>jaimiess</i> | 119 |
| <i>ibuprofen</i> | 103 | HALF MARK..... | 160 | JAKAFI..... | 9 |
| <i>icatibant</i> | 45 | INSULIN SYRINGE..... | 145 | <i>jantoven</i> | 189 |
| <i>iclevia</i> | 119 | INSULIN SYRINGE | | JANUMET..... | 22 |
| ICLUSIG..... | 8 | MICROFINE..... | 145 | JANUMET XR..... | 22 |
| IDHIFA..... | 8 | INSULIN SYRINGE | | JANUVIA..... | 22 |
| <i>ifosfamide</i> | 8 | NEEDLELESS..... | 145 | JARDIANCE..... | 22 |
| ILEVRO..... | 97 | INSULIN SYRINGE-NEEDLE | | <i>jasmiel (28)</i> | 119 |
| <i>imatinib</i> | 8 | U-100 | | <i>javygtor</i> | 192 |
| IMBRUVICA..... | 8 | .. 158, 160, 161, 169, 174, 177, 178 | | JAYPIRCA..... | 9 |
| IMDELLTRA..... | 8 | INSUPEN PEN NEEDLE 161, 162 | | JEMPERLI..... | 9 |
| <i>imipenem-cilastatin</i> | 110 | INTELENCE..... | 138 | <i>jencycla</i> | 119 |
| <i>imipramine hcl</i> | 131 | INTRALIPID..... | 40 | JENTADUETO..... | 22 |
| <i>imiquimod</i> | 69 | INVEGA HAFYERA..... | 35 | JENTADUETO XR..... | 22 |
| IMJUDO..... | 8 | INVEGA SUSTENNA..... | 35, 36 | <i>jinteli</i> | 77 |
| IMLYGIC..... | 9 | INVEGA TRINZA..... | 36 | <i>juleber</i> | 119 |
| IMOVAX RABIES VACCINE | | INVELTYS..... | 97 | JULUCA..... | 138 |
| (PF)..... | 89 | INVIRASE..... | 138 | <i>junel 1.5/30 (21)</i> | 119 |
| IMPAVIDO..... | 31 | IPOL..... | 90 | <i>junel 1/20 (21)</i> | 119 |
| INBRIJA..... | 32 | <i>ipratropium bromide</i> | 64, 98 | <i>junel fe 1.5/30 (28)</i> | 119 |
| <i>incassia</i> | 119 | <i>ipratropium-albuterol</i> | 64 | <i>junel fe 1/20 (28)</i> | 119 |
| INCONTROL ALCOHOL | | <i>irbesartan</i> | 46 | <i>junel fe 24</i> | 120 |
| PADS..... | 69 | <i>irbesartan-hydrochlorothiazide</i> .. | 46 | JUXTAPID..... | 48 |
| INCONTROL PEN NEEDLE.. | 160 | ISENTRESS..... | 138 | JYLAMVO..... | 9 |
| INCRELEX..... | 80 | ISENTRESS HD..... | 138 | JYNNEOS (PF)..... | 90 |
| <i>indapamide</i> | 50 | <i>isibloom</i> | 119 | <i>kalliga</i> | 120 |
| <i>indomethacin</i> | 103 | ISOLYTE S PH 7.4..... | 185 | KALYDECO..... | 60, 61 |
| INFANRIX (DTAP) (PF)..... | 90 | ISOLYTE-P IN 5 % | | <i>kariva (28)</i> | 120 |
| <i>infliximab</i> | 85 | DEXTROSE..... | 185 | <i>kelnor 1/35 (28)</i> | 120 |
| INGREZZA..... | 57 | ISOLYTE-S..... | 185 | <i>kelnor 1/50 (28)</i> | 120 |
| INGREZZA INITIATION | | <i>isoniazid</i> | 135 | KERENDIA..... | 52 |
| PK(TARDIV)..... | 57 | <i>isosorbide dinitrate</i> | 52 | KESIMPTA PEN..... | 57 |
| INGREZZA SPRINKLE..... | 57 | <i>isosorbide mononitrate</i> | 52 | <i>ketoconazole</i> | 134 |
| INLYTA..... | 9 | <i>isosorbide-hydralazine</i> | 52 | <i>ketorolac</i> | 97, 103 |
| INPEN (FOR HUMALOG) | | <i>isradipine</i> | 47 | KEVZARA..... | 85 |
| BLUE..... | 160 | <i>itraconazole</i> | 134 | KEYTRUDA..... | 9 |
| INPEN (NOVOLOG OR | | IV PREP WIPES..... | 69 | KIMMTRAK..... | 9 |
| FIASP) BLUE..... | 160 | <i>ivabradine</i> | 45 | KINERET..... | 85 |

| | | | | | |
|--|-------|---|-------------|---|--------|
| KINRIX (PF)..... | 90 | LEUKERAN..... | 10 | <i>loperamide</i> | 73 |
| <i>kionex (with sorbitol)</i> | 73 | LEUKINE..... | 190 | <i>lopinavir-ritonavir</i> | 138 |
| KISQALI..... | 9, 10 | <i>leuprolide</i> | 10 | LOQTORZI..... | 10 |
| KISQALI FEMARA CO- PACK..... | 9 | <i>leuprolide (3 month)</i> | 10 | <i>lorazepam</i> | 21 |
| KLISYRI..... | 69 | <i>levetiracetam</i> | 127 | LORBRENA..... | 11 |
| <i>klor-con m10</i> | 185 | <i>levobunolol</i> | 94 | <i>loryna (28)</i> | 121 |
| <i>klor-con m15</i> | 185 | <i>levocarnitine</i> | 100 | <i>losartan</i> | 46 |
| <i>klor-con m20</i> | 185 | <i>levocarnitine (with sugar)</i> | 100 | <i>losartan-hydrochlorothiazide</i> | 46 |
| KLOXXADO..... | 19 | <i>levocetirizine</i> | 135 | LOTEMAX..... | 97 |
| KOSELUGO..... | 10 | <i>levofloxacin</i> | 95, 98, 115 | LOTEMAX SM..... | 97 |
| <i>kosher prenatal plus iron</i> | 193 | <i>levofloxacin in d5w</i> | 115 | <i>loteprednol etabonate</i> | 97 |
| KOURZEQ..... | 65 | <i>levonest (28)</i> | 120 | <i>lovastatin</i> | 48 |
| KRAZATI..... | 10 | <i>levonorgest-eth.estradiol-iron</i> .. | 120 | <i>low-ogestrel (28)</i> | 121 |
| KRINTAFEL..... | 31 | <i>levonorgestrel-ethinyl estrad</i> | 120, 121 | <i>loxapine succinate</i> | 36 |
| <i>kurvelo (28)</i> | 120 | <i>levonorg-eth estrad triphasic</i> | 121 | <i>lo-zumandimine (28)</i> | 121 |
| KYNMOBI..... | 32 | <i>levora-28</i> | 121 | <i>lubiprostone</i> | 73 |
| <i>l norgest/e.estradiol-e.estrad</i> | 120 | <i>levothyroxine</i> | 76 | LUMAKRAS..... | 11 |
| <i>labetalol</i> | 42 | LEXIVA..... | 138 | LUMIGAN..... | 94 |
| <i>lacosamide</i> | 127 | LIBERVANT..... | 127 | LUNSUMIO..... | 11 |
| <i>lactulose</i> | 73 | <i>lidocaine</i> | 107 | LUPRON DEPOT..... | 80 |
| <i>lagevrio (eua)</i> | 142 | <i>lidocaine (pf)</i> | 41, 107 | LUPRON DEPOT (3 MONTH) | 11, 80 |
| <i>lamivudine</i> | 138 | <i>lidocaine hcl</i> | 107 | LUPRON DEPOT (4 MONTH). 11 | |
| <i>lamivudine-zidovudine</i> | 138 | <i>lidocaine viscous</i> | 107 | LUPRON DEPOT (6 MONTH). 11 | |
| <i>lamotrigine</i> | 127 | <i>lidocaine-prilocaine</i> | 107 | <i>lurasidone</i> | 36 |
| <i>lanreotide</i> | 80 | <i>linezolid</i> | 109 | <i>lutea (28)</i> | 121 |
| <i>lansoprazole</i> | 72 | <i>linezolid in dextrose 5%</i> | 109 | LYBALVI..... | 36 |
| <i>lapatinib</i> | 10 | LINZESS..... | 73 | <i>lyleq</i> | 121 |
| <i>larin 1.5/30 (21)</i> | 120 | <i>liothyronine</i> | 76 | <i>lyllana</i> | 77 |
| <i>larin 1/20 (21)</i> | 120 | LISCO..... | 162 | LYNPARZA..... | 11 |
| <i>larin 24 fe</i> | 120 | <i>lisinopril</i> | 51 | LYSODREN..... | 11 |
| <i>larin fe 1.5/30 (28)</i> | 120 | <i>lisinopril-hydrochlorothiazide</i> | 51 | LYTGOBI..... | 11 |
| <i>larin fe 1/20 (28)</i> | 120 | LITE TOUCH INSULIN PEN | | <i>lyza</i> | 121 |
| <i>latanoprost</i> | 94 | NEEDLES..... | 162 | MAGELLAN INSULIN | |
| LAZCLUZE..... | 10 | LITE TOUCH INSULIN | | SAFETY SYRNG..... | 163 |
| <i>leflunomide</i> | 85 | SYRINGE..... | 162, 163 | MAGELLAN SYRINGE..... | 163 |
| <i>lenalidomide</i> | 10 | <i>lithium carbonate</i> | 57, 58 | <i>magnesium sulfate</i> | 186 |
| LENTOCILIN S..... | 114 | <i>lithium citrate</i> | 58 | <i>magnesium sulfate in d5w</i> | 186 |
| LENVIMA..... | 10 | LIVALO..... | 48 | <i>magnesium sulfate in water</i> | 186 |
| <i>lessina</i> | 120 | <i>lojaimiess</i> | 121 | <i>malathion</i> | 71 |
| <i>letrozole</i> | 10 | LOKELMA..... | 73 | <i>maraviroc</i> | 138 |
| <i>leucovorin calcium</i> | 100 | LONSURF..... | 10 | MARGENZA..... | 11 |

| | | | | | |
|--|----------|---|--------------|--|----------|
| <i>marlissa (28)</i> | 121 | MENVEO A-C-Y-W-135-DIP (PF)..... | 90 | <i>miglustat</i> | 192 |
| <i>marnatal-f</i> | 193 | <i>mercaptapurine</i> | 12 | <i>mili</i> | 121 |
| MARPLAN..... | 131 | <i>meropenem</i> | 110 | <i>mimvey</i> | 78 |
| MATULANE..... | 11 | <i>merzee</i> | 121 | MINI ULTRA-THIN II..... | 164 |
| MAVENCLAD (10 TABLET PACK)..... | 58 | <i>mesalamine</i> | 52, 53 | <i>minocycline</i> | 116 |
| MAVENCLAD (4 TABLET PACK)..... | 58 | <i>mesna</i> | 100 | <i>minoxidil</i> | 52 |
| MAVENCLAD (5 TABLET PACK)..... | 58 | MESNEX..... | 100 | MIPLYFFA..... | 185 |
| MAVENCLAD (6 TABLET PACK)..... | 58 | <i>metformin</i> | 22 | <i>mirtazapine</i> | 131 |
| MAVENCLAD (7 TABLET PACK)..... | 58 | <i>methadone</i> | 105 | <i>misoprostol</i> | 72 |
| MAVENCLAD (8 TABLET PACK)..... | 58 | <i>methadose</i> | 105 | <i>mitoxantrone</i> | 12 |
| MAVENCLAD (9 TABLET PACK)..... | 58 | <i>methenamine hippurate</i> | 109 | M-M-R II (PF)..... | 90 |
| MAXICOMFORT II PEN NEEDLE..... | 163 | <i>methimazole</i> | 76 | <i>m-natal plus</i> | 193 |
| MAXICOMFORT INSULIN SYRINGE..... | 163 | <i>methocarbamol</i> | 193 | <i>modafinil</i> | 55 |
| MAXI-COMFORT INSULIN SYRINGE..... | 163, 164 | <i>methotrexate sodium</i> | 12 | <i>moexipril</i> | 51 |
| MAXICOMFORT SAFETY PEN NEEDLE..... | 164 | <i>methotrexate sodium (pf)</i> | 12 | <i>molindone</i> | 36 |
| MAYZENT..... | 58 | <i>methoxsalen</i> | 69 | <i>mometasone</i> | 67, 97 |
| MAYZENT STARTER(FOR 1MG MAINT)..... | 58 | <i>methscopolamine</i> | 73 | <i>mondoxyne nl</i> | 116 |
| MAYZENT STARTER(FOR 2MG MAINT)..... | 58 | <i>methsuximide</i> | 127 | MONOJECT INSULIN SAFETY SYRINGE..... | 165 |
| <i>meclizine</i> | 29 | <i>methyldopa</i> | 41 | MONOJECT INSULIN SYRINGE..... | 164, 165 |
| <i>medroxyprogesterone</i> | 81 | <i>methylphenidate hcl</i> | 58, 59 | MONOJECT SYRINGE..... | 164 |
| <i>mefenamic acid</i> | 103 | <i>methylprednisolone</i> | 79 | MONOJECT ULTRA COMFORT INSULIN..... | 180 |
| <i>mefloquine</i> | 31 | <i>methylprednisolone acetate</i> | 79 | <i>mono-lynyah</i> | 121 |
| <i>megestrol</i> | 11, 82 | <i>methylprednisolone sodium succ</i> | 79 | <i>montelukast</i> | 63 |
| MEKINIST..... | 11 | <i>metoclopramide hcl</i> | 73 | <i>morphine</i> | 105 |
| MEKTOVI..... | 12 | <i>metolazone</i> | 50 | MORPHINE..... | 105 |
| <i>meloxicam</i> | 103 | <i>metoprolol succinate</i> | 42 | <i>morphine concentrate</i> | 105 |
| <i>memantine</i> | 21 | <i>metoprolol ta-hydrochlorothiaz</i> .. | 43 | MOUNJARO..... | 23 |
| MENACTRA (PF)..... | 90 | <i>metoprolol tartrate</i> | 43 | MOVANTIK..... | 73 |
| MENQUADFI (PF)..... | 90 | <i>metronidazole</i> | 70, 108, 109 | <i>moxifloxacin</i> | 95, 115 |
| | | <i>metronidazole in nacl (iso-os)</i> .. | 109 | <i>moxifloxacin-sod.ace,sul-water</i> | 115 |
| | | <i>metyrosine</i> | 45 | <i>moxifloxacin-sod.chloride(iso)</i> .. | 115 |
| | | <i>mexiletine</i> | 41 | MRESVIA (PF)..... | 90 |
| | | <i>miconazole-3</i> | 134 | MULTAQ..... | 41 |
| | | MICRODOT INSULIN PEN NEEDLE..... | 164 | <i>mupirocin</i> | 70 |
| | | MICRODOT READYGARD PEN NEEDLE..... | 164 | MVASI..... | 12 |
| | | <i>microgestin fe 1/20 (28)</i> | 121 | <i>mycophenolate mofetil</i> | 85 |
| | | <i>midodrine</i> | 41 | <i>mycophenolate mofetil (hcl)</i> | 85 |
| | | <i>mifepristone</i> | 22 | <i>mycophenolate sodium</i> | 85 |
| | | | | <i>mynatal</i> | 193 |

| | | | | | |
|--|--------|--|---------|---|--------|
| <i>mynatal advance</i> | 193 | NINLARO..... | 12 | NUCALA..... | 61 |
| <i>mynatal plus</i> | 193 | <i>nitazoxanide</i> | 31 | NULOJIX..... | 85 |
| <i>mynatal-z</i> | 193 | <i>nitisinone</i> | 192 | NUPLAZID..... | 36 |
| <i>mynate 90 plus</i> | 194 | <i>nitrofurantoin macrocrystal</i> | 110 | NURTEC ODT..... | 27 |
| MYRBETRIQ..... | 75 | <i>nitrofurantoin monohyd/m-cryst</i> | | NUTRILIPID..... | 40 |
| <i>nabumetone</i> | 103 | | 110 | <i>nyamyc</i> | 134 |
| <i>nafcillin</i> | 114 | <i>nitroglycerin</i> | 52, 100 | <i>nylia 1/35 (28)</i> | 122 |
| <i>naloxone</i> | 19, 20 | <i>niva-plus</i> | 194 | <i>nylia 7/7/7 (28)</i> | 122 |
| <i>naltrexone</i> | 20 | NIVESTYM..... | 190 | <i>nymyo</i> | 122 |
| <i>naproxen</i> | 103 | <i>nizatidine</i> | 72 | <i>nystatin</i> | 134 |
| <i>naratriptan</i> | 27 | NORDITROPIN FLEXPRO..... | 80 | <i>nystatin-triamcinolone</i> | 134 |
| NATACYN..... | 95 | <i>norelgestromin-ethin.estradiol</i> .. | 121 | <i>nystop</i> | 134 |
| <i>nateglinide</i> | 23 | <i>norethindrone (contraceptive)</i> .. | 122 | NYVEPRIA..... | 190 |
| NATPARA..... | 53 | <i>norethindrone acetate</i> | 82 | <i>obstetrix dha</i> | 194 |
| NAYZILAM..... | 127 | <i>norethindrone ac-eth estradiol</i> | | <i>obstetrix dha prenatal duo</i> | 194 |
| <i>neбиволol</i> | 43 | | 78, 122 | <i>o-cal prenatal</i> | 194 |
| <i>necon 0.5/35 (28)</i> | 121 | <i>norethindrone-e.estradiol-iron</i> .. | 122 | OCALIVA..... | 73 |
| <i>nefazodone</i> | 132 | <i>norgestimate-ethinyl estradiol</i> .. | 122 | OCREVUS..... | 59 |
| <i>neomycin</i> | 109 | NORMOSOL-M IN 5 % | | OCREVUS ZUNOVO..... | 59 |
| <i>neomycin-bacitracin-poly-hc</i> | 95 | DEXTROSE..... | 186 | OCTAGAM..... | 85 |
| <i>neomycin-bacitracin-polymyxin</i> .. | 95 | <i>nortrel 0.5/35 (28)</i> | 122 | <i>octreotide acetate</i> | 80, 81 |
| <i>neomycin-polymyxin b gu</i> | 70 | <i>nortrel 1/35 (21)</i> | 122 | ODEFSEY..... | 139 |
| <i>neomycin-polymyxin b-</i> | | <i>nortrel 1/35 (28)</i> | 122 | ODOMZO..... | 12 |
| <i>dexameth</i> | 95 | <i>nortrel 7/7/7 (28)</i> | 122 | OFEV..... | 61 |
| <i>neomycin-polymyxin-gramicidin</i> .. | 95 | <i>nortriptyline</i> | 132 | <i>ofloxacin</i> | 96 |
| <i>neomycin-polymyxin-hc</i> | 95, 96 | NORVIR..... | 139 | OGIVRI..... | 12 |
| <i>neo-polycin</i> | 96 | NOVOFINE 30..... | 165 | OGSIVEO..... | 12 |
| <i>neo-polycin hc</i> | 96 | NOVOFINE 32..... | 165 | OJEMDA..... | 12 |
| NERLYNX..... | 12 | NOVOFINE PLUS..... | 165 | OJJAARA..... | 12 |
| NEULASTA ONPRO..... | 190 | NOVOLIN 70/30 U-100 | | <i>olanzapine</i> | 36 |
| <i>nevirapine</i> | 138 | INSULIN..... | 25 | <i>olmesartan</i> | 46 |
| <i>newgen</i> | 194 | NOVOLIN 70-30 FLEXPEN | | <i>olmesartan-amlodipin-hcthiiazid</i> .. | 46 |
| NEXLETOL..... | 48 | U-100..... | 25 | <i>olmesartan-hydrochlorothiazide</i> .. | 46 |
| NEXLIZET..... | 48 | NOVOLIN N FLEXPEN..... | 25 | <i>olopatadine</i> | 98, 99 |
| <i>niacin</i> | 48, 49 | NOVOLIN N NPH U-100 | | OLUMIANT..... | 85 |
| <i>niacor</i> | 49 | INSULIN..... | 25 | <i>omega-3 acid ethyl esters</i> | 49 |
| <i>nicardipine</i> | 47 | NOVOLIN R FLEXPEN..... | 25 | <i>omeprazole</i> | 72 |
| NICOTROL..... | 20 | NOVOLIN R REGULAR U100 | | OMNIPOD 5 (G6/LIBRE 2 | |
| NICOTROL NS..... | 20 | INSULIN..... | 25 | PLUS)..... | 166 |
| <i>nifedipine</i> | 47 | NOVOTWIST..... | 166 | OMNIPOD 5 G6-G7 INTRO | |
| <i>nikki (28)</i> | 121 | NOXAFIL..... | 134 | KT(GEN5)..... | 166 |
| <i>nilutamide</i> | 12 | NUBEQA..... | 12 | | |

| | | | | | |
|--|-----|---------------------------------------|--------------------|--|----------|
| OMNIPOD 5 G6-G7 PODS (GEN 5)..... | 166 | <i>oseltamivir</i> | 141 | PENBRAYA MENACWY COMPONENT(PF)..... | 91 |
| OMNIPOD 5 INTRO(G6/LIBRE2PLUS)..... | 166 | OSMOLEX ER..... | 32 | PENBRAYA MENB COMPONENT (PF)..... | 91 |
| OMNIPOD CLASSIC PODS (GEN 3)..... | 166 | OTEZLA..... | 86 | <i>penicillamine</i> | 108 |
| OMNIPOD DASH INTRO KIT (GEN 4)..... | 166 | OTEZLA STARTER..... | 86 | <i>penicillin g potassium</i> | 114 |
| OMNIPOD DASH PDM KIT (GEN 4)..... | 166 | <i>oxandrolone</i> | 76 | <i>penicillin g procaine</i> | 114 |
| OMNIPOD DASH PODS (GEN 4)..... | 166 | <i>oxazepam</i> | 21 | <i>penicillin v potassium</i> | 114 |
| OMNIPOD GO PODS..... | 167 | <i>oxcarbazepine</i> | 127 | PENTACEL (PF)..... | 91 |
| OMNIPOD GO PODS 10 UNITS/DAY..... | 166 | OXLUMO..... | 100 | <i>pentamidine</i> | 31 |
| OMNIPOD GO PODS 15 UNITS/DAY..... | 166 | <i>oxybutynin chloride</i> | 75 | PENTIPS PEN NEEDLE..... | 167 |
| OMNIPOD GO PODS 20 UNITS/DAY..... | 166 | <i>oxycodone</i> | 105, 106 | <i>pentoxifylline</i> | 189 |
| OMNIPOD GO PODS 25 UNITS/DAY..... | 166 | <i>oxycodone-acetaminophen</i> | 106 | <i>perindopril erbumine</i> | 51 |
| OMNIPOD GO PODS 30 UNITS/DAY..... | 166 | OXYCONTIN..... | 106 | <i>periogard</i> | 65 |
| OMNIPOD GO PODS 40 UNITS/DAY..... | 166 | <i>oxymorphone</i> | 106 | <i>permethrin</i> | 71 |
| <i>ondansetron</i> | 30 | OZEMPIC..... | 23 | <i>perphenazine</i> | 37 |
| <i>ondansetron hcl</i> | 30 | <i>pacerone</i> | 41 | PERSERIS..... | 37 |
| <i>ondansetron hcl (pf)</i> | 29 | <i>paclitaxel protein-bound</i> | 13 | <i>pfizerpen-g</i> | 114 |
| ONTRUZANT..... | 13 | <i>paliperidone</i> | 37 | <i>phenelzine</i> | 132 |
| ONUREG..... | 13 | PALYNZIQ..... | 192 | <i>phenobarbital</i> | 127, 128 |
| OPDIVO..... | 13 | PANRETIN..... | 69 | <i>phenylephrine hcl</i> | 41 |
| OPDUALAG..... | 13 | <i>pantoprazole</i> | 72 | <i>phenytoin</i> | 128 |
| OPSUMIT..... | 101 | <i>paricalcitol</i> | 54 | <i>phenytoin sodium</i> | 128 |
| <i>oralone</i> | 65 | <i>paroex oral rinse</i> | 65 | <i>phenytoin sodium extended</i> | 128 |
| ORENCIA..... | 86 | <i>paromomycin</i> | 31 | <i>philith</i> | 122 |
| ORENCIA (WITH MALTOSE)..... | 85 | <i>paroxetine hcl</i> | 132 | PIFELTRO..... | 139 |
| ORENCIA CLICKJECT..... | 86 | PAXLOVID..... | 141 | <i>pilocarpine hcl</i> | 65, 94 |
| ORFADIN..... | 192 | <i>pazopanib</i> | 13 | <i>pimecrolimus</i> | 67 |
| ORGOVYX..... | 81 | PEDIARIX (PF)..... | 90 | <i>pimozide</i> | 37 |
| ORLISSA..... | 81 | PEDVAX HIB (PF)..... | 90 | <i>pimtrea (28)</i> | 122 |
| ORKAMBI..... | 61 | <i>peg 3350-electrolytes</i> | 74 | <i>pindolol</i> | 43 |
| ORSERDU..... | 13 | PEGASYS..... | 142 | <i>pioglitazone</i> | 23 |
| | | <i>peg-electrolyte soln</i> | 75 | <i>pioglitazone-metformin</i> | 23 |
| | | PEMAZYRE..... | 13 | PIP PEN NEEDLE..... | 167, 168 |
| | | <i>pemetrexed</i> | 13 | <i>piperacillin-tazobactam</i> | 114 |
| | | <i>pemetrexed disodium</i> | 13 | PIQRAY..... | 13 |
| | | PEMRYDI RTU..... | 13 | <i>pirfenidone</i> | 61 |
| | | PEN NEEDLE..... | 158, 167, 169 | <i>pirmella</i> | 123 |
| | | PEN NEEDLE, DIABETIC | 150, 164, 167, 169 | <i>piroxicam</i> | 103 |
| | | PEN NEEDLE, DIABETIC, SAFETY..... | 170 | PLASMA-LYTE A..... | 186 |
| | | PENBRAYA (PF)..... | 90 | PLEGRIDY..... | 59 |
| | | | | <i>pnv 29-1</i> | 194 |

| | | | | | |
|---|----------|--|---------|--|----------|
| <i>pnv-dha + docusate</i> | 194 | <i>prenatal vitamin plus low iron</i> . | 195 | <i>proparacaine</i> | 99 |
| <i>pnv-omega</i> | 194 | <i>prenatal-u</i> | 195 | <i>propranolol</i> | 43 |
| <i>podofilox</i> | 69 | <i>preplus</i> | 195 | <i>propranolol-hydrochlorothiazid</i> .. | 43 |
| <i>polycin</i> | 96 | <i>pretab</i> | 195 | <i>propylthiouracil</i> | 76 |
| <i>polymyxin b sulfate</i> | 110 | PRETOMANID..... | 135 | PROQUAD (PF)..... | 91 |
| <i>polymyxin b sulf-trimethoprim</i> | 96 | <i>prevalite</i> | 49 | PROSOL 20 %..... | 40 |
| POMALYST..... | 13 | PREVENT DROPSAFE PEN | | <i>protamine</i> | 187 |
| <i>portia 28</i> | 123 | NEEDLE..... | 168 | <i>protriptyline</i> | 132 |
| <i>posaconazole</i> | 134 | PREVYMIS..... | 141 | PULMOZYME..... | 192 |
| <i>potassium chloride</i> | 186, 187 | PREZCOBIX..... | 139 | PURE COMFORT ALCOHOL | |
| <i>potassium chloride-0.45 % nacl</i> | | PREZISTA..... | 139 | PADS..... | 69 |
| | 187 | PRIFTIN..... | 135 | PURE COMFORT PEN | |
| <i>potassium citrate</i> | 187 | PRIMAQUINE..... | 31 | NEEDLE..... | 169 |
| <i>pr natal 400</i> | 194 | <i>primidone</i> | 128 | PURE COMFORT SAFETY | |
| <i>pr natal 400 ec</i> | 194 | PRIORIX (PF)..... | 91 | PEN NEEDLE..... | 168, 169 |
| <i>pr natal 430</i> | 194 | PRIVIGEN..... | 86 | PURIXAN..... | 13 |
| <i>pr natal 430 ec</i> | 194 | PRO COMFORT ALCOHOL | | <i>pyrazinamide</i> | 135 |
| PRALUENT PEN..... | 49 | PADS..... | 69 | <i>pyridostigmine bromide</i> | 100 |
| <i>pramipexole</i> | 32 | PRO COMFORT INSULIN | | <i>pyrimethamine</i> | 31 |
| <i>prasugrel</i> | 189 | SYRINGE..... | 168 | QINLOCK..... | 13 |
| <i>pravastatin</i> | 49 | PRO COMFORT PEN | | QUADRACEL (PF)..... | 91 |
| <i>prazosin</i> | 41 | NEEDLE..... | 168 | <i>quetiapine</i> | 37 |
| <i>prednicarbate</i> | 67 | <i>probenecid</i> | 27 | <i>quinapril</i> | 51 |
| <i>prednisolone</i> | 79 | <i>probenecid-colchicine</i> | 27 | <i>quinapril-hydrochlorothiazide</i> ... | 51 |
| <i>prednisolone acetate</i> | 97 | <i>procainamide</i> | 41, 42 | <i>quinidine gluconate</i> | 42 |
| <i>prednisolone sodium phosphate</i> | | <i>prochlorperazine</i> | 30 | <i>quinidine sulfate</i> | 42 |
| | 79, 98 | <i>prochlorperazine edisylate</i> ... 30, 37 | | <i>quinine sulfate</i> | 31 |
| <i>prednisone</i> | 79 | <i>prochlorperazine maleate</i> | 30 | QULIPTA..... | 27 |
| <i>pregabalin</i> | 128 | <i>procto-pak</i> | 67 | RABAVERT (PF)..... | 91 |
| PREHEVBRIO (PF)..... | 91 | <i>proctosol hc</i> | 68 | <i>rabeprazole</i> | 72 |
| PREMARIN..... | 78 | <i>proctozone-hc</i> | 68 | <i>raloxifene</i> | 78 |
| PREMPHASE..... | 78 | PRODIGY INSULIN | | <i>ramipril</i> | 51 |
| PREMPRO..... | 78 | SYRINGE..... | 168 | <i>ranolazine</i> | 45 |
| <i>prenal true</i> | 194 | <i>progesterone</i> | 82 | <i>rasagiline</i> | 32 |
| <i>prenaissance</i> | 194 | <i>progesterone micronized</i> | 82 | RASUVO (PF)..... | 86 |
| <i>prenaissance plus</i> | 194 | PROGRAF..... | 86 | RAVICTI..... | 73 |
| <i>prenatabs fa</i> | 194 | PROLASTIN-C..... | 61 | RAYALDEE..... | 54 |
| <i>prenatal 19</i> | 194 | PROLIA..... | 54 | <i>reclipsen (28)</i> | 123 |
| <i>prenatal 19 (with docusate)</i> | 194 | PROMACTA..... | 190 | RECOMBIVAX HB (PF)..... | 91 |
| <i>prenatal low iron</i> | 194 | <i>promethazine</i> | 30, 135 | RELENZA DISKHALER..... | 141 |
| <i>prenatal plus</i> | 195 | <i>promethegan</i> | 30 | RELEUKO..... | 191 |
| <i>prenatal plus (calcium carb)</i> | 194 | <i>propafenone</i> | 42 | RELION NEEDLES..... | 169 |

| | | | | | |
|---------------------------------------|--------|-------------------------------------|--------|---|--------|
| RELION PEN NEEDLES..... | 169 | ROZLYTREK..... | 14 | SIGNIFOR..... | 81 |
| <i>repaglinide</i> | 23 | RUBRACA..... | 14 | <i>sildenafil</i> | 101 |
| REPATHA PUSHTRONEX..... | 49 | <i>rufinamide</i> | 128 | <i>sildenafil (pulm.hypertension)</i> .. | 101 |
| REPATHA SURECLICK..... | 49 | RUKOBIA..... | 139 | <i>silver sulfadiazine</i> | 70 |
| REPATHA SYRINGE..... | 49 | RUXIENCE..... | 14 | SIMBRINZA..... | 94 |
| RESTASIS..... | 98 | RYBELSUS..... | 23 | <i>simliya (28)</i> | 123 |
| RESTASIS MULTIDOSE..... | 98 | RYBREVANT..... | 14 | <i>simpesse</i> | 123 |
| RETACRIT..... | 191 | RYDAPT..... | 14 | <i>simvastatin</i> | 49 |
| RETEVMO..... | 14 | RYTELO..... | 14 | <i>sirolimus</i> | 86 |
| RETROVIR..... | 139 | SAFESNAP INSULIN | | SIRTURO..... | 136 |
| <i>revonto</i> | 193 | SYRINGE..... | 170 | SKY SAFETY PEN NEEDLE..... | 170 |
| REXULTI..... | 37 | SAFETY PEN NEEDLE..... | 170 | SKYRIZI..... | 86, 87 |
| REYATAZ..... | 139 | <i>sajazir</i> | 45 | <i>sodium chloride 0.45 %</i> | 187 |
| REZLIDHIA..... | 14 | SANTYL..... | 69 | <i>sodium chloride 0.9 %</i> | 187 |
| REZUROCK..... | 86 | <i>sapropterin</i> | 192 | <i>sodium fluoride-pot nitrate</i> | 65 |
| RHOPRESSA..... | 94 | SAVELLA..... | 60 | <i>sodium oxybate</i> | 55 |
| RIABNI..... | 14 | SCEMBLIX..... | 14, 15 | <i>sodium phenylbutyrate</i> | 73 |
| <i>ribavirin</i> | 142 | <i>scopolamine base</i> | 30 | <i>sodium polystyrene sulfonate</i> | 74 |
| RIDAURA..... | 86 | SECUADO..... | 38 | <i>sodium,potassium,mag sulfates</i> .. | 75 |
| <i>rifabutin</i> | 136 | SECURESAFE INSULIN | | <i>solifenacin</i> | 75 |
| <i>rifampin</i> | 136 | SYRINGE..... | 170 | SOLQUA 100/33..... | 26 |
| <i>rilpivirine</i> | 139 | SECURESAFE PEN NEEDLE..... | 170 | SOLTAMOX..... | 15 |
| <i>riluzole</i> | 59 | <i>select-ob</i> | 195 | SOLU-CORTEF ACT-O-VIAL | |
| <i>rimantadine</i> | 141 | <i>select-ob (folic acid)</i> | 195 | (PF)..... | 79 |
| RINVOQ..... | 86 | <i>selegiline hcl</i> | 32 | SOMATULINE DEPOT..... | 81 |
| RINVOQ LQ..... | 86 | <i>selenium sulfide</i> | 70 | SOMAVERT..... | 81 |
| <i>risedronate</i> | 54 | SELZENTRY..... | 139 | <i>sorafenib</i> | 15 |
| <i>risperidone</i> | 37 | SEMGLEE(INSULIN | | <i>sorine</i> | 43 |
| <i>risperidone microspheres</i> | 37 | GLARGINE-YFGN)..... | 25 | <i>sotalol</i> | 43 |
| <i>ritonavir</i> | 139 | SEMGLEE(INSULIN GLARG- | | <i>sotalol af</i> | 43 |
| RITUXAN HYCELA..... | 14 | YFGN)PEN..... | 25 | SPIRIVA RESPIMAT..... | 64 |
| <i>rivastigmine</i> | 21 | <i>se-natal 19 chewable</i> | 195 | SPIRIVA WITH | |
| <i>rivastigmine tartrate</i> | 21 | SEREVENT DISKUS..... | 64 | HANDIHALER..... | 64 |
| <i>rizatriptan</i> | 27, 28 | SEROSTIM..... | 81 | <i>spironolactone</i> | 50 |
| <i>r-natal ob</i> | 195 | <i>sertraline</i> | 132 | SPRAVATO..... | 132 |
| ROCKLATAN..... | 94 | <i>setlakin</i> | 123 | <i>sprintec (28)</i> | 123 |
| <i>roflumilast</i> | 61 | <i>sevelamer carbonate</i> | 74 | SPRITAM..... | 128 |
| <i>ropinirole</i> | 32 | <i>sevelamer hcl</i> | 74 | SPRYCEL..... | 15 |
| <i>rosadan</i> | 70 | SEZABY..... | 128 | <i>sps (with sorbitol)</i> | 74 |
| <i>rosuvastatin</i> | 49 | <i>sf 5000 plus</i> | 65 | <i>sronyx</i> | 123 |
| ROTARIX..... | 92 | <i>sharobel</i> | 123 | <i>ssd</i> | 70 |
| ROTATEQ VACCINE..... | 92 | SHINGRIX (PF)..... | 92 | <i>stavudine</i> | 139 |

| | | | | | |
|--|----------|--|----------|--|--------|
| STELARA..... | 87 | SYMLINPEN 60..... | 23 | TEFLARO..... | 112 |
| STERILE PADS..... | 170 | SYMPAZAN..... | 128 | <i>telmisartan</i> | 46 |
| STIOLTO RESPIMAT..... | 64 | SYMTUZA..... | 140 | <i>telmisartan-hydrochlorothiazid</i> .. | 46 |
| STIVARGA..... | 15 | SYNAREL..... | 81 | <i>temazepam</i> | 21 |
| STRENSIQ..... | 192 | SYNJARDY..... | 23 | TEMIXYS..... | 140 |
| <i>streptomycin</i> | 109 | SYNJARDY XR..... | 23 | TENIVAC (PF)..... | 92 |
| STRIBILD..... | 139 | SYNRIBO..... | 15 | <i>tenofovir disoproxil fumarate</i> ... | 140 |
| STRIVERDI RESPIMAT..... | 64 | SYRINGE WITH NEEDLE, SAFETY..... | 170 | TEPMETKO..... | 16 |
| <i>subvenite</i> | 128 | TABLOID..... | 15 | <i>terazosin</i> | 75 |
| <i>sucralfate</i> | 72 | TABRECTA..... | 15 | <i>terbinafine hcl</i> | 134 |
| <i>sulfacetamide sodium</i> | 96 | <i>tacrolimus</i> | 68, 87 | <i>terbutaline</i> | 64 |
| <i>sulfacetamide sodium (acne)</i> | 71 | <i>tadalafil (pulm. hypertension)</i> .. | 101 | <i>terconazole</i> | 108 |
| <i>sulfacetamide-prednisolone</i> | 96 | TAFINLAR..... | 15 | <i>teriflunomide</i> | 60 |
| <i>sulfadiazine</i> | 115 | TAGRISSE..... | 15 | <i>teriparatide</i> | 54 |
| <i>sulfamethoxazole-trimethoprim</i> | 115 | TAKHZYRO..... | 100 | TERUMO INSULIN | |
| <i>sulfasalazine</i> | 53 | TALTZ AUTOINJECTOR..... | 87 | SYRINGE..... | 174 |
| <i>sulindac</i> | 103 | TALTZ SYRINGE..... | 87 | <i>testosterone</i> | 76 |
| <i>sumatriptan</i> | 28 | TALVEY..... | 15 | <i>testosterone cypionate</i> | 76 |
| <i>sumatriptan succinate</i> | 28 | TALZENNA..... | 15 | <i>testosterone enanthate</i> | 76 |
| <i>sumatriptan-naproxen</i> | 28 | <i>tamoxifen</i> | 15 | TETANUS,DIPHThERIA | |
| <i>sunitinib malate</i> | 15 | <i>tamsulosin</i> | 75 | TOX PED(PF)..... | 92 |
| SUNLENCA..... | 139, 140 | <i>tarina 24 fe</i> | 123 | <i>tetrabenazine</i> | 60 |
| SUNOSI..... | 55 | <i>tarina fe 1-20 eq (28)</i> | 123 | <i>tetracycline</i> | 116 |
| SURE COMFORT ALCOHOL PREP PADS..... | 69 | <i>taron-c dha</i> | 195 | TEVIMBRA..... | 16 |
| SURE COMFORT INS. SYR. | | <i>taron-prex prenatal-dha</i> | 195 | THALOMID..... | 100 |
| U-100..... | 171 | TASCENSO ODT..... | 60 | <i>theophylline</i> | 65 |
| SURE COMFORT INSULIN | | TASIGNA..... | 15 | THINPRO INSULIN | |
| SYRINGE..... | 171 | <i>tasimelteon</i> | 55 | SYRINGE..... | 174 |
| SURE COMFORT PEN | | <i>tazarotene</i> | 71 | <i>thioridazine</i> | 38 |
| NEEDLE..... | 171, 172 | TAZORAC..... | 71 | <i>thiothixene</i> | 38 |
| SURE COMFORT SAFETY | | <i>taztia xt</i> | 44 | <i>tiadylt er</i> | 44 |
| PEN NEEDLE..... | 171 | TAZVERIK..... | 15 | <i>tiagabine</i> | 129 |
| SURE-FINE PEN NEEDLES.. | 172 | TDVAX..... | 92 | TIBSOVO..... | 16 |
| SURE-JECT INSULIN | | TECHLITE INSULIN | | TICE BCG..... | 16 |
| SYRINGE..... | 172 | SYRINGE..... | 173 | TICOVAC..... | 92 |
| SURE-PREP ALCOHOL PREP | | TECHLITE INSULN | | <i>tigecycline</i> | 116 |
| PADS..... | 69 | SYR(HALF UNIT)..... | 172, 173 | <i>timolol maleate</i> | 43, 94 |
| SUTAB..... | 75 | TECHLITE PEN NEEDLE..... | 173 | <i>tiopronin</i> | 75 |
| <i>syeda</i> | 123 | TECHLITE PLUS PEN | | TIVDAK..... | 16 |
| SYMDEKO..... | 61 | NEEDLE..... | 173 | TIVICAY..... | 140 |
| SYMLINPEN 120..... | 23 | TECVAYLI..... | 16 | TIVICAY PD..... | 140 |
| | | | | <i>tizanidine</i> | 193 |

| | | | | | |
|--|------------|--------------------------------|----------|----------------------------|--------------------|
| <i>tobramycin</i> | 96, 109 | <i>trifluridine</i> | 96 | TRUEPLUS PEN NEEDLE | 176, 177 |
| <i>tobramycin in 0.225 % nacl</i> | 109 | <i>trihexyphenidyl</i> | 33 | TRULICITY..... | 24 |
| <i>tobramycin sulfate</i> | 109 | TRIJARDY XR..... | 24 | TRUMENBA..... | 92 |
| <i>tobramycin-dexamethasone</i> | 96 | TRIKAFTA..... | 61 | TRUQAP..... | 16 |
| <i>tolterodine</i> | 75 | <i>tri-legest fe</i> | 123 | TRUXIMA..... | 16 |
| TOPCARE CLICKFINE..... | 174 | <i>tri-linyah</i> | 123 | TUKYSA..... | 16 |
| TOPCARE ULTRA | | <i>tri-lo-estarylla</i> | 123 | <i>tulana</i> | 124 |
| COMFORT..... | 175 | <i>tri-lo-marzia</i> | 123 | TURALIO..... | 16 |
| <i>topiramate</i> | 129 | <i>tri-lo-mili</i> | 123 | <i>turqoz (28)</i> | 124 |
| <i>toposar</i> | 16 | <i>tri-lo-sprintec</i> | 124 | TWINRIX (PF)..... | 92 |
| <i>toremifene</i> | 16 | <i>trimethoprim</i> | 110 | <i>tyblume</i> | 124 |
| <i>torpenz</i> | 16 | <i>tri-mili</i> | 124 | TYBOST..... | 100 |
| <i>torse mide</i> | 50 | <i>trimipramine</i> | 132 | TYMLOS..... | 54 |
| TOUJEO MAX U-300 | | TRINTELLIX..... | 132 | TYPHIM VI..... | 92 |
| SOLOSTAR..... | 26 | <i>tri-nymyo</i> | 124 | TYSABRI..... | 88 |
| TOUJEO SOLOSTAR U-300 | | <i>tri-sprintec (28)</i> | 124 | UBRELVY..... | 28 |
| INSULIN..... | 26 | TRIUMEQ..... | 140 | UDENYCA..... | 191 |
| TRACLEER..... | 101 | TRIUMEQ PD..... | 140 | UDENYCA AUTOINJECTOR | 191 |
| TRADJENTA..... | 24 | <i>triveen-duo dha</i> | 195 | UDENYCA ONBODY..... | 191 |
| <i>tramadol</i> | 106 | <i>trivora (28)</i> | 124 | ULTICARE..... | 178 |
| <i>tramadol-acetaminophen</i> | 106 | <i>tri-vylibra</i> | 124 | ULTICARE INSULIN | |
| <i>trandolapril</i> | 51 | <i>tri-vylibra lo</i> | 124 | SYRINGE..... | 177, 178 |
| <i>trandolapril-verapamil</i> | 51 | TRIZIVIR..... | 140 | ULTICARE INSULN | |
| <i>tranexamic acid</i> | 187, 188 | TROGARZO..... | 140 | SYR(HALF UNIT)..... | 177 |
| <i>tranylcypromine</i> | 132 | TROPHAMINE 10 %..... | 40 | ULTICARE PEN NEEDLE..... | 178 |
| TRAVASOL 10 %..... | 40 | <i>trospium</i> | 75 | ULTICARE SAFETY PEN | |
| <i>travoprost</i> | 94 | TRUE COMFORT ALCOHOL | | NEEDLE..... | 178 |
| TRAZIMERA..... | 16 | PADS..... | 69 | ULTIGUARD SAFEPACK- | |
| <i>trazodone</i> | 132 | TRUE COMFORT INSULIN | | INSULIN SYR..... | 178, 179 |
| TRECATOR..... | 136 | SYRINGE..... | 175 | ULTIGUARD SAFEPACK- | |
| TRELEGY ELLIPTA..... | 65 | TRUE COMFORT PEN | | PEN NEEDLE..... | 178, 179 |
| TRELSTAR..... | 16 | NEEDLE..... | 175, 176 | ULTILET ALCOHOL SWAB... 70 | |
| TREMFYA..... | 87 | TRUE COMFORT PRO | | ULTILET INSULIN SYRINGE | |
| TREMFYA PEN..... | 87 | ALCOHOL PADS..... | 70 | | 161, 179 |
| <i>tretinoin</i> | 71 | TRUE COMFORT PRO INS | | ULTILET PEN NEEDLE..... | 179 |
| <i>tretinoin (antineoplastic)</i> | 16 | SYRINGE..... | 175, 176 | ULTRA CMFT INS SYR | |
| <i>triamcinolone acetonide</i> .. | 65, 68, 79 | TRUE COMFORT SAFE | | (HALF UNIT)..... | 159, 170 |
| <i>triamterene-hydrochlorothiazid</i> .. | 50 | INSULIN SYRG..... | 175, 176 | ULTRA COMFORT INSULIN | |
| <i>tridacaine ii</i> | 107 | TRUE COMFORT SAFETY | | SYRINGE..... | 153, 159, 179, 180 |
| <i>trientine</i> | 108 | PEN NEEDLE..... | 175 | ULTRA FLO INSUL | |
| <i>tri-estarylla</i> | 123 | TRUEPLUS INSULIN..... | 177 | SYR(HALF UNIT)..... | 180 |
| <i>trifluoperazine</i> | 38 | | | | |

| | | | | |
|--|---|----------|------------------------------|--------|
| ULTRA FLO INSULIN | VANFLYTA..... | 17 | <i>viorele (28)</i> | 124 |
| SYRINGE..... | VANISHPOINT INSULIN | | VIRACEPT..... | 140 |
| 180 | SYRINGE..... | 184 | VIREAD..... | 140 |
| ULTRA FLO PEN NEEDLE... 180 | VANISHPOINT SYRINGE.... | 184 | <i>virt-c dha</i> | 195 |
| ULTRA THIN PEN NEEDLE. 180 | VAQTA (PF)..... | 92, 93 | <i>virt-nate dha</i> | 195 |
| ULTRACARE INSULIN | <i>varenicline</i> | 20 | <i>virt-pn dha</i> | 195 |
| SYRINGE..... | VARIVAX (PF)..... | 93 | <i>virt-pn plus</i> | 195 |
| 181 | VASCEPA..... | 49 | <i>vitafol gummies</i> | 195 |
| ULTRACARE PEN NEEDLE. 181 | VAXCHORA VACCINE..... | 93 | <i>vitafol nano</i> | 195 |
| ULTRA-THIN II (SHORT) | VEGZELMA..... | 17 | <i>vitafol-ob+dha</i> | 195 |
| INS SYR..... | VELCADE..... | 17 | VITRAKVI..... | 17 |
| 181, 182 | <i>velivet triphasic regimen (28)</i> ... | 124 | VIZIMPRO..... | 17 |
| ULTRA-THIN II (SHORT) | VELPHORO..... | 74 | VOCABRIA..... | 140 |
| PEN NDL..... | VELTASSA..... | 74 | <i>volnea (28)</i> | 124 |
| 182 | VEMLIDY..... | 140 | VONJO..... | 17 |
| ULTRA-THIN II INS PEN | VENCLEXTA..... | 17 | VORANIGO..... | 17 |
| NEEDLES..... | VENCLEXTA STARTING | | <i>voriconazole</i> | 135 |
| 182 | PACK..... | 17 | VOSEVI..... | 141 |
| ULTRA-THIN II INSULIN | <i>venlafaxine</i> | 132 | VOWST..... | 101 |
| SYRINGE..... | <i>venlafaxine besylate</i> | 132 | <i>vp-ch-pnv</i> | 195 |
| 182 | <i>verapamil</i> | 44 | <i>vp-pnv-dha</i> | 195 |
| UNIFINE PEN NEEDLE..... | VERIFINE INSULIN | | VRAYLAR..... | 38 |
| 182 | SYRINGE..... | 184, 185 | VUMERITY..... | 60 |
| UNIFINE PENTIPS..... | VERIFINE PEN NEEDLE..... | 184 | VYALEV..... | 33 |
| 167, 182 | VERIFINE PLUS PEN | | <i>vyfemla (28)</i> | 124 |
| UNIFINE PENTIPS | NEEDLE..... | 184 | <i>vylibra</i> | 124 |
| MAXFLOW..... | VERIFINE PLUS PEN | | VYLOY..... | 17 |
| 182 | NEEDLE-SHARP..... | 184 | VYZULTA..... | 94 |
| UNIFINE PENTIPS PLUS | VERQUVO..... | 45 | <i>warfarin</i> | 189 |
| | VERSACLOZ..... | 38 | WEBCOL..... | 70 |
| 182, 183 | VERSALON..... | 185 | WELIREG..... | 17 |
| UNIFINE PENTIPS PLUS | VERZENIO..... | 17 | <i>wera (28)</i> | 124 |
| MAXFLOW..... | <i>vestura (28)</i> | 124 | WINREVAIR..... | 62 |
| 183 | V-GO 20..... | 185 | <i>wixela inhub</i> | 63 |
| UNIFINE PROTECT..... | V-GO 30..... | 185 | XALKORI..... | 17, 18 |
| 183 | V-GO 40..... | 185 | XARELTO..... | 189 |
| UNIFINE SAFECONTROL.... | <i>vienna</i> | 124 | XARELTO DVT-PE TREAT | |
| 183 | <i>vigabatrin</i> | 129 | 30D START..... | 189 |
| UNIFINE SAFECONTROL | <i>vigadrone</i> | 129 | XATMEP..... | 18 |
| PEN NEEDLE..... | <i>vigpoder</i> | 129 | XCOPRI..... | 129 |
| 183 | <i>vilazodone</i> | 132 | XCOPRI MAINTENANCE | |
| UNIFINE ULTRA PEN | <i>vinorelbine</i> | 17 | PACK..... | 129 |
| NEEDLE..... | | | | |
| 183, 184 | | | | |
| UPTRAVI..... | | | | |
| 101 | | | | |
| <i>ursodiol</i> | | | | |
| 74 | | | | |
| UZEDY..... | | | | |
| 38 | | | | |
| <i>valacyclovir</i> | | | | |
| 142 | | | | |
| VALCHLOR..... | | | | |
| 70 | | | | |
| <i>valganciclovir</i> | | | | |
| 142 | | | | |
| <i>valproate sodium</i> | | | | |
| 129 | | | | |
| <i>valproic acid</i> | | | | |
| 129 | | | | |
| <i>valproic acid (as sodium salt)</i> .. | | | | |
| 129 | | | | |
| <i>valsartan</i> | | | | |
| 46 | | | | |
| <i>valsartan-hydrochlorothiazide</i> ... | | | | |
| 46 | | | | |
| VALTOCO..... | | | | |
| 129 | | | | |
| <i>vancomycin</i> | | | | |
| 110 | | | | |

| | | | |
|-----------------------------------|----------|--|-----|
| XCOPRI TITRATION PACK.. | 130 | ZIRGAN..... | 96 |
| XELJANZ..... | 88 | ZOLADEX..... | 19 |
| XELJANZ XR..... | 88 | <i>zoledronic acid</i> | 54 |
| XERMELO..... | 74 | <i>zoledronic acid-mannitol-water</i> .. | 54 |
| XGEVA..... | 54 | ZOLINZA..... | 19 |
| XHANCE..... | 98 | <i>zolmitriptan</i> | 28 |
| XIFAXAN..... | 110 | <i>zolpidem</i> | 55 |
| XIGDUO XR..... | 24 | ZONISADE..... | 130 |
| XIIDRA..... | 98 | <i>zonisamide</i> | 130 |
| XOFLUZA..... | 142 | <i>zovia 1-35 (28)</i> | 125 |
| XOLAIR..... | 62 | ZTALMY..... | 130 |
| XOSPATA..... | 18 | ZTLIDO..... | 107 |
| XPOVIO..... | 18 | <i>zumandimine (28)</i> | 125 |
| XTAMPZA ER..... | 106, 107 | ZURZUVAE..... | 133 |
| XTANDI..... | 18 | ZYDELIG..... | 19 |
| <i>xulane</i> | 124 | ZYKADIA..... | 19 |
| XULTOPHY 100/3.6..... | 26 | ZYLET..... | 96 |
| XYOSTED..... | 77 | ZYNLONTA..... | 19 |
| <i>yargesa</i> | 192 | ZYNYZ..... | 19 |
| YERVOY..... | 18 | ZYPREXA RELPREVV..... | 39 |
| YF-VAX (PF)..... | 93 | | |
| YONSA..... | 18 | | |
| <i>yuvafem</i> | 78 | | |
| <i>zafemy</i> | 125 | | |
| <i>zafirlukast</i> | 63 | | |
| <i>zaleplon</i> | 55 | | |
| <i>zarah</i> | 125 | | |
| ZARXIO..... | 191 | | |
| <i>zatean-pn dha</i> | 196 | | |
| <i>zatean-pn plus</i> | 196 | | |
| ZEGALOGUE | | | |
| AUTOINJECTOR..... | 101 | | |
| ZEGALOGUE SYRINGE..... | 101 | | |
| ZEJULA..... | 18 | | |
| ZELBORAF..... | 18 | | |
| <i>zenatane</i> | 70 | | |
| ZENPEP..... | 192 | | |
| <i>zidovudine</i> | 140 | | |
| <i>zingiber</i> | 196 | | |
| <i>ziprasidone hcl</i> | 38 | | |
| <i>ziprasidone mesylate</i> | 39 | | |
| ZIRABEV..... | 18 | | |